0001802768-23-000029.txt : 20231108 0001802768-23-000029.hdr.sgml : 20231108 20231108090452 ACCESSION NUMBER: 0001802768-23-000029 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231108 DATE AS OF CHANGE: 20231108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Royalty Pharma plc CENTRAL INDEX KEY: 0001802768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39329 FILM NUMBER: 231386250 BUSINESS ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 883-0200 MAIL ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 10-Q 1 rprx-20230930.htm 10-Q rprx-20230930
0001802768December 312023Q3FALSE1259145900018027682023-01-012023-09-300001802768us-gaap:CommonClassAMember2023-11-02xbrli:shares0001802768us-gaap:CommonClassBMember2023-11-0200018027682023-09-30iso4217:USD00018027682022-12-310001802768us-gaap:CommonClassAMember2023-09-30iso4217:USDxbrli:shares0001802768us-gaap:CommonClassAMember2022-12-310001802768us-gaap:CommonClassBMember2023-09-300001802768us-gaap:CommonClassBMember2022-12-310001802768rprx:ClassRRedeemableStockMember2023-09-30iso4217:GBPxbrli:shares0001802768rprx:ClassRRedeemableStockMember2022-12-310001802768rprx:FinancialRoyaltyAssetsMember2023-07-012023-09-300001802768rprx:FinancialRoyaltyAssetsMember2022-07-012022-09-300001802768rprx:FinancialRoyaltyAssetsMember2023-01-012023-09-300001802768rprx:FinancialRoyaltyAssetsMember2022-01-012022-09-300001802768rprx:IntangibleRoyaltyAssetsMember2023-07-012023-09-300001802768rprx:IntangibleRoyaltyAssetsMember2022-07-012022-09-300001802768rprx:IntangibleRoyaltyAssetsMember2023-01-012023-09-300001802768rprx:IntangibleRoyaltyAssetsMember2022-01-012022-09-300001802768rprx:RoyaltyIncomeOtherMember2023-07-012023-09-300001802768rprx:RoyaltyIncomeOtherMember2022-07-012022-09-300001802768rprx:RoyaltyIncomeOtherMember2023-01-012023-09-300001802768rprx:RoyaltyIncomeOtherMember2022-01-012022-09-3000018027682023-07-012023-09-3000018027682022-07-012022-09-3000018027682022-01-012022-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-06-300001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2023-06-300001802768rprx:DeferredSharesMember2023-06-300001802768us-gaap:AdditionalPaidInCapitalMember2023-06-300001802768us-gaap:RetainedEarningsMember2023-06-300001802768us-gaap:NoncontrollingInterestMember2023-06-300001802768us-gaap:TreasuryStockCommonMember2023-06-3000018027682023-06-300001802768us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001802768us-gaap:CommonClassAMember2023-07-012023-09-300001802768us-gaap:RetainedEarningsMember2023-07-012023-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-07-012023-09-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-07-012023-09-300001802768rprx:DeferredSharesMember2023-07-012023-09-300001802768us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001802768us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-09-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-300001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2023-09-300001802768rprx:DeferredSharesMember2023-09-300001802768us-gaap:AdditionalPaidInCapitalMember2023-09-300001802768us-gaap:RetainedEarningsMember2023-09-300001802768us-gaap:NoncontrollingInterestMember2023-09-300001802768us-gaap:TreasuryStockCommonMember2023-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-06-300001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2022-06-300001802768rprx:DeferredSharesMember2022-06-300001802768us-gaap:AdditionalPaidInCapitalMember2022-06-300001802768us-gaap:RetainedEarningsMember2022-06-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001802768us-gaap:NoncontrollingInterestMember2022-06-300001802768us-gaap:TreasuryStockCommonMember2022-06-3000018027682022-06-300001802768us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001802768us-gaap:CommonClassAMember2022-07-012022-09-300001802768us-gaap:RetainedEarningsMember2022-07-012022-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-07-012022-09-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-07-012022-09-300001802768rprx:DeferredSharesMember2022-07-012022-09-300001802768us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300001802768us-gaap:TreasuryStockCommonMember2022-07-012022-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-09-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-09-300001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2022-09-300001802768rprx:DeferredSharesMember2022-09-300001802768us-gaap:AdditionalPaidInCapitalMember2022-09-300001802768us-gaap:RetainedEarningsMember2022-09-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300001802768us-gaap:NoncontrollingInterestMember2022-09-300001802768us-gaap:TreasuryStockCommonMember2022-09-3000018027682022-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-12-310001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2022-12-310001802768rprx:DeferredSharesMember2022-12-310001802768us-gaap:AdditionalPaidInCapitalMember2022-12-310001802768us-gaap:RetainedEarningsMember2022-12-310001802768us-gaap:NoncontrollingInterestMember2022-12-310001802768us-gaap:TreasuryStockCommonMember2022-12-310001802768us-gaap:NoncontrollingInterestMember2023-01-012023-09-300001802768us-gaap:CommonClassAMember2023-01-012023-09-300001802768us-gaap:RetainedEarningsMember2023-01-012023-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-01-012023-09-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-01-012023-09-300001802768rprx:DeferredSharesMember2023-01-012023-09-300001802768us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001802768us-gaap:TreasuryStockCommonMember2023-01-012023-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-12-310001802768rprx:ClassRRedeemableStockMemberus-gaap:CommonStockMember2021-12-310001802768rprx:DeferredSharesMember2021-12-310001802768us-gaap:AdditionalPaidInCapitalMember2021-12-310001802768us-gaap:RetainedEarningsMember2021-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001802768us-gaap:NoncontrollingInterestMember2021-12-310001802768us-gaap:TreasuryStockCommonMember2021-12-3100018027682021-12-310001802768us-gaap:NoncontrollingInterestMember2022-01-012022-09-300001802768us-gaap:CommonClassAMember2022-01-012022-09-300001802768us-gaap:RetainedEarningsMember2022-01-012022-09-300001802768us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-09-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-01-012022-09-300001802768rprx:DeferredSharesMember2022-01-012022-09-300001802768us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-09-300001802768us-gaap:TreasuryStockCommonMember2022-01-012022-09-300001802768rprx:ExchangeOfferMemberrprx:LegacyInvestorsPartnershipsMember2020-02-112020-02-11xbrli:pure0001802768rprx:RoyaltyPharmaInvestmentsOldRPIMemberrprx:ExchangeOfferMember2020-02-110001802768rprx:RoyaltyPharmaCollectionTrustMember2020-02-110001802768rprx:RoyaltyPharmaCollectionTrustMemberrprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember2020-02-110001802768rprx:RoyaltyPharmaInvestmentsOldRPIMember2022-12-310001802768rprx:RoyaltyPharmaInvestmentsOldRPIMember2023-09-30rprx:noncontrolling_interest0001802768rprx:RoyaltyPharmaInvestmentsOldRPIMemberrprx:LegacyInvestorsPartnershipsMember2023-09-300001802768us-gaap:FinanceReceivablesMemberus-gaap:CustomerConcentrationRiskMemberrprx:VertexMember2023-01-012023-09-300001802768us-gaap:FinanceReceivablesMemberus-gaap:CustomerConcentrationRiskMemberrprx:VertexMember2022-01-012022-12-3100018027682022-01-072022-01-07rprx:trancherprx:payment0001802768us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberrprx:DevelopmentFundingBondMember2021-06-022021-06-020001802768rprx:MorphoSysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-06-022021-06-020001802768rprx:DevelopmentFundingBondMember2022-09-012022-09-300001802768rprx:DevelopmentFundingBondMember2022-01-012022-09-300001802768rprx:MorphoSysMember2022-09-012022-09-300001802768rprx:MorphoSysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-09-012022-09-300001802768us-gaap:PreferredStockMember2023-09-300001802768rprx:FundingCommitmentsMember2023-09-300001802768us-gaap:PreferredStockMember2022-12-310001802768rprx:FundingCommitmentsMember2022-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-09-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-09-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-09-300001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2022-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2022-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2022-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2022-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768us-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768rprx:RoyaltyInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768rprx:RoyaltyInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768rprx:RoyaltyInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768rprx:RoyaltyInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768rprx:RoyaltyInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768rprx:RoyaltyInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768rprx:RoyaltyInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768rprx:RoyaltyInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100018027682022-01-012022-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2023-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2023-06-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2023-06-300001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2023-06-300001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2023-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2023-07-012023-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2023-07-012023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2023-07-012023-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2023-07-012023-09-300001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2023-07-012023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2023-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2023-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2023-09-300001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2022-06-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-06-300001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2022-06-300001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2022-07-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2022-07-012022-09-300001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2022-07-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2022-07-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2022-07-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-07-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2022-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2022-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2022-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2022-09-300001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2022-09-300001802768us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberrprx:DevelopmentFundingBondMember2022-07-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2022-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2022-12-310001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-12-310001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2022-12-310001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2022-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2023-01-012023-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2023-01-012023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2023-01-012023-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2023-01-012023-09-300001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2021-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2021-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2021-12-310001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2021-12-310001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2021-12-310001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2022-01-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2022-01-012022-09-300001802768us-gaap:RoyaltyMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-01-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberrprx:DerivativeAssetMember2022-01-012022-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2022-01-012022-09-300001802768us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberrprx:DevelopmentFundingBondMember2022-01-012022-09-300001802768rprx:CytokineticsCommercialLaunchFundingMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-09-300001802768rprx:CytokineticsCommercialLaunchFundingMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310001802768us-gaap:FairValueMeasurementsRecurringMember2023-03-012023-03-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001802768rprx:CysticFibrosisFranchiseMember2023-09-300001802768rprx:TysabriMember2023-09-300001802768rprx:TrelegyMember2023-09-300001802768rprx:TremfyaMember2023-09-300001802768rprx:EvrysdiMember2023-09-300001802768rprx:XtandiMember2023-09-300001802768rprx:OtherFinancialRoyaltyAssetMember2023-09-300001802768rprx:SeltorexantOlpasiranPelacarsenAndKarXTMember2023-09-300001802768rprx:CysticFibrosisFranchiseMember2022-12-310001802768rprx:TysabriMember2022-12-310001802768rprx:TrelegyMember2022-12-310001802768rprx:TremfyaMember2022-12-310001802768rprx:ImbruvicaMember2022-12-310001802768rprx:XtandiMember2022-12-310001802768rprx:OtherFinancialRoyaltyAssetMember2022-12-310001802768rprx:LegacyInvestorsPartnershipsMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsMember2023-07-012023-09-300001802768rprx:LegacyInvestorsPartnershipsMember2023-01-012023-09-300001802768rprx:LegacyInvestorsPartnershipsMember2022-07-012022-09-300001802768rprx:LegacyInvestorsPartnershipsMember2022-01-012022-09-300001802768rprx:AvillionEntitiesMember2023-07-012023-09-300001802768rprx:AvillionEntitiesMember2023-01-012023-09-300001802768rprx:AvillionEntitiesMember2022-07-012022-09-300001802768rprx:AvillionEntitiesMember2022-01-012022-09-300001802768rprx:AvillionIMember2023-01-012023-09-300001802768rprx:AvillionIMember2022-01-012022-09-300001802768rprx:AvillionIIMemberrprx:MerckAssetPhaseIIClinicalTrialMember2022-06-300001802768rprx:AvillionIIMember2023-01-012023-01-310001802768rprx:AvillionIIMember2023-03-012023-03-310001802768rprx:AvillionEntitiesMember2023-09-300001802768rprx:AvillionEntitiesMember2022-12-310001802768rprx:CytokineticsMember2023-01-012023-09-300001802768rprx:CytokineticsMember2022-01-012022-09-300001802768rprx:TheravanceBiopharmaIncMember2022-01-012022-09-300001802768rprx:PointSevenFivePercentSeniorNotesDue2023Memberus-gaap:UnsecuredDebtMember2023-09-300001802768rprx:PointSevenFivePercentSeniorNotesDue2023Memberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001802768rprx:PointSevenFivePercentSeniorNotesDue2023Memberus-gaap:UnsecuredDebtMember2022-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointTwoZeroPercentSeniorNotesDue2025Member2023-09-300001802768us-gaap:UnsecuredDebtMemberrprx:OnePointTwoZeroPercentSeniorNotesDue2025Member2023-01-012023-09-300001802768us-gaap:UnsecuredDebtMemberrprx:OnePointTwoZeroPercentSeniorNotesDue2025Member2022-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2023-09-300001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2023-01-012023-09-300001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2022-12-310001802768rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Memberus-gaap:UnsecuredDebtMember2023-09-300001802768rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Memberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001802768rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Memberus-gaap:UnsecuredDebtMember2022-12-310001802768rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Memberus-gaap:UnsecuredDebtMember2023-09-300001802768rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Memberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001802768rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Memberus-gaap:UnsecuredDebtMember2022-12-310001802768rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Memberus-gaap:UnsecuredDebtMember2023-09-300001802768rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Memberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001802768rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Memberus-gaap:UnsecuredDebtMember2022-12-310001802768rprx:ThreePointFiveFivePercentSeniorNotesDue2050Memberus-gaap:UnsecuredDebtMember2023-09-300001802768rprx:ThreePointFiveFivePercentSeniorNotesDue2050Memberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001802768rprx:ThreePointFiveFivePercentSeniorNotesDue2050Memberus-gaap:UnsecuredDebtMember2022-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeFiveZeroPercentDue2051Member2023-09-300001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeFiveZeroPercentDue2051Member2023-01-012023-09-300001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeFiveZeroPercentDue2051Member2022-12-310001802768us-gaap:SeniorNotesMember2021-07-260001802768us-gaap:SeniorNotesMemberrprx:SeniorNotesDue2051Member2021-07-260001802768us-gaap:UnsecuredDebtMemberrprx:TheNotesMember2020-09-020001802768us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:UnsecuredDebtMemberrprx:TheNotesMember2020-09-022020-09-020001802768us-gaap:UnsecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberrprx:TheNotesMember2020-09-022020-09-020001802768us-gaap:UnsecuredDebtMemberrprx:TheNotesMember2023-09-012023-09-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:UnsecuredDebtMemberrprx:TheNotesMember2023-09-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:UnsecuredDebtMemberrprx:TheNotesMember2022-12-310001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2022-10-312022-10-310001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2022-10-310001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2023-09-300001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2022-12-310001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2023-10-012023-10-310001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberrprx:OvernightBankFundingRateMember2022-10-312022-10-310001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberus-gaap:FederalFundsPurchasedMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2022-10-312022-10-310001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberrprx:SecuredOvernightFinancingRateSOFRMember2022-10-312022-10-310001802768us-gaap:UnsecuredDebtMemberrprx:TheNotesMember2023-09-30rprx:classrprx:vote0001802768rprx:ClassRRedeemableStockMember2023-01-012023-09-300001802768us-gaap:CommonClassAMember2023-03-310001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2023-06-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2023-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2023-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2023-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2023-07-012023-09-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2023-07-012023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2023-07-012023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2023-07-012023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2023-09-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2022-06-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2022-07-012022-09-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2022-07-012022-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-07-012022-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-07-012022-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2022-09-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2022-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2022-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2022-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2023-01-012023-09-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2023-01-012023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2023-01-012023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2023-01-012023-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2021-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2021-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2021-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2021-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:LegacyInvestorsPartnershipsMember2022-01-012022-09-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2022-01-012022-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-01-012022-09-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-01-012022-09-300001802768rprx:RPHoldingsMemberrprx:ContinuingInvestorsPartnershipMember2023-09-300001802768rprx:RoyaltyPharmaPlcMember2023-09-300001802768rprx:RPHoldingsMemberrprx:ContinuingInvestorsPartnershipMember2022-09-300001802768rprx:RoyaltyPharmaPlcMember2022-09-300001802768rprx:A2020EquityIncentivePlanMemberus-gaap:CommonClassAMember2020-06-150001802768rprx:ContinuingNonControllingInterestsMember2023-07-012023-09-300001802768rprx:ContinuingNonControllingInterestsMember2022-07-012022-09-300001802768rprx:ContinuingNonControllingInterestsMember2023-01-012023-09-300001802768rprx:ContinuingNonControllingInterestsMember2022-01-012022-09-300001802768rprx:LegacyNonControllingInterestsMember2023-07-012023-09-300001802768rprx:LegacyNonControllingInterestsMember2022-07-012022-09-300001802768rprx:LegacyNonControllingInterestsMember2023-01-012023-09-300001802768rprx:LegacyNonControllingInterestsMember2022-01-012022-09-300001802768us-gaap:RelatedPartyMemberrprx:OperatingAndPersonnelPaymentsMember2023-09-300001802768us-gaap:RelatedPartyMemberrprx:OperatingAndPersonnelPaymentsMember2023-01-012023-09-300001802768us-gaap:RelatedPartyMemberrprx:OperatingAndPersonnelPaymentsMember2023-07-012023-09-300001802768us-gaap:RelatedPartyMemberrprx:FormerOperatingAndPersonnelPaymentsMember2022-07-012022-09-300001802768us-gaap:RelatedPartyMemberrprx:FormerOperatingAndPersonnelPaymentsMember2022-01-012022-09-300001802768us-gaap:RelatedPartyMemberrprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember2023-09-300001802768us-gaap:RelatedPartyMemberrprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember2022-12-310001802768us-gaap:RelatedPartyMemberrprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember2023-09-300001802768us-gaap:RelatedPartyMemberrprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember2022-12-310001802768rprx:BristolMyersSquibbMemberrprx:AssignmentAgreementBenefitOfPaymentStreamMember2017-12-082017-12-080001802768rprx:BristolMyersSquibbMemberrprx:AssignmentAgreementFundingObligationsMember2017-12-082017-12-080001802768us-gaap:RelatedPartyMemberrprx:BristolMyersSquibbMember2023-09-300001802768us-gaap:RelatedPartyMemberrprx:BristolMyersSquibbMember2022-12-310001802768rprx:AgreementWithMSCIMember2021-04-162021-04-160001802768rprx:AgreementWithMSCIMember2022-01-012022-12-310001802768rprx:AgreementWithMSCIMember2023-01-012023-09-300001802768us-gaap:RelatedPartyMemberrprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember2023-01-012023-09-300001802768us-gaap:RelatedPartyMemberus-gaap:TreasuryStockCommonMemberrprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember2023-09-300001802768us-gaap:RelatedPartyMemberus-gaap:NoncontrollingInterestMemberrprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember2023-09-300001802768us-gaap:RelatedPartyMemberus-gaap:NoncontrollingInterestMemberrprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember2022-12-310001802768rprx:PTCTherapeuticsIncMemberrprx:RochesEvrysdiMemberus-gaap:SubsequentEventMember2023-10-012023-10-310001802768rprx:PTCTherapeuticsIncMemberus-gaap:SubsequentEventMember2023-10-012023-10-310001802768srt:MaximumMemberrprx:PTCTherapeuticsIncMemberus-gaap:SubsequentEventMember2023-10-012023-10-310001802768srt:MinimumMemberrprx:PTCTherapeuticsIncMemberus-gaap:SubsequentEventMember2023-10-012023-10-310001802768rprx:PTCTherapeuticsIncMemberus-gaap:SubsequentEventMember2023-10-012023-10-310001802768rprx:TevaPharmaceuticalsInternationalGMBHMemberus-gaap:SubsequentEventMember2023-11-012023-11-300001802768rprx:TerranceCoyneMember2023-07-012023-09-300001802768rprx:TerranceCoyneMember2023-09-300001802768rprx:MarshallUristMember2023-07-012023-09-300001802768rprx:MarshallUristMember2023-09-300001802768rprx:RoryRiggsMember2023-07-012023-09-300001802768rprx:RoryRiggsMember2023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_________ to __________
Commission file number 001-39329
Royalty Pharma plc
(Exact name of registrant as specified in its charter)
England and Wales
98-1535773
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
110 East 59th Street
New York, New York 10022
(Address of principal executive offices and zip code)

(212) 883-0200
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Class A ordinary shares, par value $0.0001RPRXThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒   No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer  
☐
Smaller reporting company
☐
Emerging growth company
☐
                
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ☐     No  ☒




As of November 2, 2023, Royalty Pharma plc had 444,886,039 Class A ordinary shares outstanding and 152,546,046 Class B ordinary shares outstanding.

ROYALTY PHARMA PLC

INDEX

PART I.FINANCIAL INFORMATION
Item 1.Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 (unaudited)
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022 (unaudited)
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2023 and 2022 (unaudited)
Condensed Consolidated Statements of Shareholders’ Equity for the three and nine months ended September 30, 2023 and 2022 (unaudited)
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 (unaudited)
Notes to Condensed Consolidated Financial Statements (unaudited)
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3.Quantitative and Qualitative Disclosures About Market Risk
Item 4.Controls and Procedures
PART II.OTHER INFORMATION
Item 1.Legal Proceedings
Item 1A.Risk Factors
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.Defaults Upon Senior Securities
Item 4.Mine Safety Disclosures
Item 5.Other Information
Item 6.Exhibits



















Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains statements reflecting our views about our future performance that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “target,” “forecast,” “guidance,” “goal,” “predicts,” “project,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of the numerous risks outlined in Part II under Item 1A. under “Risk Factors.”

These risks and uncertainties include factors related to, among other topics:

•sales risks of biopharmaceutical products on which we receive royalties;
•the ability of RP Management, LLC (the “Manager”) to locate suitable assets for us to acquire;
•uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;
•the assumptions underlying our business model;
•our ability to successfully execute our royalty acquisition strategy;
•our ability to leverage our competitive strengths;
•actual and potential conflicts of interest with the Manager and its affiliates;
•the ability of the Manager or its affiliates to attract and retain highly talented professionals;
•the effect of changes to tax legislation and our tax position; and
•the risks, uncertainties and other factors we identify elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the U.S. Securities and Exchange Commission (“SEC”).

Although we believe the expectations reflected in the forward-looking statements are reasonable, any of those expectations could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Quarterly Report on Form 10-Q should not be regarded as a representation by us that our plans and business objectives will be achieved. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform our prior statements to actual results or revised expectations.





PART 1.     FINANCIAL INFORMATION
Item 1.         CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
(Unaudited)
 As of September 30, As of December 31,
20232022
Assets
Current assets
Cash and cash equivalents$936,448 $1,710,751 
Marketable securities— 24,421 
Financial royalty assets742,160 691,319 
Accrued royalty receivable16,360 16,830 
Available for sale debt securities5,300 1,300 
Other royalty income receivable21,553 19,767 
Other current assets6,784 90,520 
Total current assets1,728,605 2,554,908 
Financial royalty assets, net13,230,474 13,493,106 
Equity securities144,342 112,348 
Available for sale debt securities353,600 226,300 
Equity method investments378,291 397,175 
Other assets20,212 29,629 
Total assets$15,855,524 $16,813,466 
Liabilities and shareholders’ equity
Current liabilities
Distributions payable to legacy non-controlling interests$101,711 $94,803 
Accounts payable and accrued expenses13,627 7,906 
Interest payable12,595 54,162 
Current portion of long-term debt— 997,512 
Other current liabilities— 12,400 
Total current liabilities127,933 1,166,783 
Long-term debt6,131,194 6,118,810 
Other liabilities11,300 2,500 
Total liabilities6,270,427 7,288,093 
Commitments and contingencies
Shareholders’ equity
Class A ordinary shares, $0.0001 par value; issued and outstanding: 2023–445,843 and 2022–443,166
45 44 
Class B ordinary shares, $0.000001 par value; issued and outstanding: 2023–152,546 and 2022–164,058
— — 
Class R redeemable shares, £1 par value; issued and outstanding: 2023–50 and 2022–50
63 63 
Deferred shares, $0.000001 par value; issued and outstanding: 2023–382,837 and 2022–371,325
— — 
Additional paid-in capital4,006,758 3,666,160 
Retained earnings2,134,680 1,964,689 
Non-controlling interests3,446,175 3,897,223 
Treasury interests(2,624)(2,806)
Total shareholders’ equity9,585,097 9,525,373 
Total liabilities and shareholders’ equity$15,855,524 $16,813,466 

See accompanying notes to these unaudited condensed consolidated financial statements.
1



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Income and other revenues
Income from financial royalty assets$508,657 $551,682 $1,674,689 $1,578,555 
Revenue from intangible royalty assets252 1,073 597 37,196 
Other royalty income27,404 20,708 83,200 55,716 
Total income and other revenues536,313 573,463 1,758,486 1,671,467 
Operating expenses
Provision for changes in expected cash flows from financial royalty assets277,137 305,061 637,169 595,396 
Research and development funding expense50,500 25,500 51,500 126,606 
Amortization of intangible assets— — — 5,670 
General and administrative expenses57,234 50,692 190,563 154,075 
Total operating expenses, net384,871 381,253 879,232 881,747 
Operating income151,442 192,210 879,254 789,720 
Other expense/(income)
Equity in losses/(earnings) of equity method investees5,222 3,251 (28,614)2,117 
Interest expense46,033 46,977 139,932 141,006 
Losses/(gains) on derivative financial instruments8,680 (25,785)2,290 (97,590)
(Gains)/losses on equity securities(1,541)(5,168)(31,994)22,970 
Gains on available for sale debt securities(7,300)(44,243)(122,500)(97,985)
Interest income(23,436)(14,034)(65,791)(34,482)
Other non-operating expense, net1,707 10,798 3,429 13,590 
Total other expense/(income), net29,365 (28,204)(103,248)(50,374)
Consolidated net income before tax122,077 220,414 982,502 840,094 
Income tax expense— — — — 
Consolidated net income122,077 220,414 982,502 840,094 
Net income attributable to non-controlling interests49,963 77,763 342,008 341,178 
Net income attributable to Royalty Pharma plc$72,114 $142,651 $640,494 $498,916 
Earnings per Class A ordinary share:
     Basic$0.16 $0.32 $1.43 $1.14 
     Diluted$0.16 $0.32 $1.43 $1.14 
Weighted average Class A ordinary shares outstanding:
     Basic448,439 439,293 448,162 436,542 
     Diluted601,138 607,226 604,717 607,209 
See accompanying notes to these unaudited condensed consolidated financial statements.
2



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
(Unaudited)

For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Consolidated net income$122,077 $220,414 $982,502 $840,094 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 13,050 — 24,000 
Reclassification of unrealized gains on available for sale debt securities— (7,111)— (24,053)
Other comprehensive income/(loss):$— $5,939 $— $(53)
Comprehensive income$122,077 $226,353 $982,502 $840,041 
Comprehensive income attributable to non-controlling interests49,963 80,161 342,008 341,109 
Comprehensive income attributable to Royalty Pharma plc$72,114 $146,192 $640,494 $498,932 

See accompanying notes to these unaudited condensed consolidated financial statements.

3



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands, except per share amounts)
(Unaudited)


Class A
Ordinary Shares		Class B
Ordinary Shares		Class R
Redeemable Shares		Deferred SharesAdditional Paid-in CapitalRetained EarningsNon-Controlling InterestsTreasury InterestsTotal Shareholders’ Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at June 30, 2023450,352$46 152,896$— 50$63 382,487$— $4,031,242 $2,252,945 $3,532,019 $(2,629)$9,813,686 
Contributions— — — — — — — — — — 2,850 — 2,850 
Distributions— — — — — — — — — — (120,198)— (120,198)
Dividends ($0.20 per Class A ordinary share)
— — — — — — — — — (89,751)— — (89,751)
Other exchanges350 — (350)— — — 350 — 18,454 — (18,459)5 — 
Share-based compensation and related issuances of Class A ordinary shares3 — — — — — — — 581 — — — 581 
Repurchases of Class A ordinary shares(4,862)(1)— — — — — — (43,519)(100,628)— — (144,148)
Net income— — — — — — — — — 72,114 49,963 — 122,077 
Balance at September 30, 2023445,843$45 152,546$— 50$63 382,837$— $4,006,758 $2,134,680 $3,446,175 $(2,624)$9,585,097 

Class A
Ordinary Shares		Class B
Ordinary Shares		Class R Redeemable SharesDeferred SharesAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive IncomeNon-Controlling InterestsTreasury InterestsTotal Shareholders’ Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at June 30, 2022437,139$44 170,081$— 50$63 365,302$— $3,570,585 $2,446,132 $13,177 $4,380,938 $(2,752)$10,408,187 
Contributions— — — — — — — — — — — 2,970 — 2,970 
Distributions— — — — — — — — — — — (137,880)— (137,880)
Dividends ($0.19 per Class A ordinary share)
— — — — — — — — — (83,809)— — — (83,809)
Other exchanges3,963 — (3,963)— — — 3,963 — 61,736 — 186 (61,886)(36)— 
Share-based compensation and related issuances of Class A ordinary shares2 — — — — — — — 582 — — — — 582 
Net income— — — — — — — — — 142,651 — 77,763 — 220,414 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— — — — — — — — — — 7,781 5,269 — 13,050 
Reclassification of unrealized gains on available for sale debt securities— — — — — — — — — — (4,240)(2,871)— (7,111)
Balance at September 30, 2022441,104$44 166,118$— 50$63 369,265$— $3,632,903 $2,504,974 $16,904 $4,264,303 $(2,788)$10,416,403 

See accompanying notes to these unaudited condensed consolidated financial statements.
4



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands, except per share amounts)
(Unaudited)

Class A
Ordinary Shares		Class B
Ordinary Shares		Class R
Redeemable Shares		Deferred SharesAdditional Paid-in CapitalRetained EarningsNon-Controlling InterestsTreasury InterestsTotal Shareholders’ Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at December 31, 2022443,166 $44 164,058 $— 50 $63 371,325 $— $3,666,160 $1,964,689 $3,897,223 $(2,806)$9,525,373 
Contributions— — — — — — — — — — 9,690 — 9,690 
Distributions— — — — — — — — — — (386,590)— (386,590)
Dividends ($0.60 per Class A ordinary share)
— — — — — — — — — (268,989)— — (268,989)
Other exchanges11,512 2 (11,512)— — — 11,512 — 415,972 — (416,156)182 — 
Share-based compensation and related issuances of Class A ordinary shares54 — — — — — — — 1,740 — — — 1,740 
Repurchases of Class A ordinary shares(8,889)(1)— — — — — — (77,114)(201,514)— — (278,629)
Net income— — — — — — — — — 640,494 342,008 — 982,502 
Balance at September 30, 2023445,843$45 152,546$— 50$63 382,837$— $4,006,758 $2,134,680 $3,446,175 $(2,624)$9,585,097 

Class A
Ordinary Shares		Class B
Ordinary Shares		Class R
Redeemable Shares		Deferred SharesAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive IncomeNon-Controlling InterestsTreasury InterestsTotal Shareholders’ Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at December 31, 2021432,963 $43 174,213 $— 50 $63 361,170 $— $3,507,533 $2,255,179 $16,491 $4,471,951 $(2,715)$10,248,545 
Contributions— — — — — — — — — — — 9,173 — 9,173 
Distributions— — — — — — — — — — — (433,822)— (433,822)
Dividends ($0.57 per Class A ordinary share)
— — — — — — — — — (249,121)— — — (249,121)
Other exchanges8,095 1 (8,095)— — — 8,095 — 123,783 — 397 (124,108)(73)— 
Share-based compensation and related issuances of Class A ordinary shares46 — — — — — — — 1,587 — — — — 1,587 
Net income— — — — — — — — — 498,916 — 341,178 — 840,094 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— — — — — — — — — — 14,262 9,738 — 24,000 
Reclassification of unrealized gains on available for sale debt securities— — — — — — — — — — (14,246)(9,807)— (24,053)
Balance at September 30, 2022441,104$44 166,118$— 50$63 369,265$— $3,632,903 $2,504,974 $16,904 $4,264,303 $(2,788)$10,416,403 

See accompanying notes to these unaudited condensed consolidated financial statements.
5



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
For the Nine Months Ended September 30,
20232022
Cash flows from operating activities:
Cash collections from financial royalty assets$2,454,054 $1,843,899 
Cash collections from intangible royalty assets1,067 72,406 
Other royalty cash collections84,275 51,607 
Distributions from equity method investees18,823 33,316 
Interest received63,135 10,556 
Development-stage funding payments - ongoing(1,500)(1,606)
Development-stage funding payments - upfront and milestone(50,000)(125,000)
Payments for operating and professional costs(188,839)(141,653)
Interest paid(165,841)(169,476)
Net cash provided by operating activities2,215,174 1,574,049 
Cash flows from investing activities:
Distributions from equity method investees39,225 — 
Investments in equity method investees(10,550)(9,896)
Purchases of equity securities— (62,785)
Proceeds from equity securities— 46,158 
Purchases of available for sale debt securities— (393,737)
Proceeds from available for sale debt securities— 46,875 
Purchases of marketable securities— (234,869)
Proceeds from sales and maturities of marketable securities24,391 676,705 
Acquisitions of financial royalty assets(1,113,283)(1,491,399)
Acquisitions of other financial assets— (21,215)
Milestone payments(12,400)— 
Net cash used in investing activities(1,072,617)(1,444,163)
Cash flows from financing activities:
Distributions to legacy non-controlling interests - royalty receipts(284,637)(322,726)
Distributions to legacy non-controlling interests - other— (2,335)
Distributions to continuing non-controlling interests(95,045)(110,964)
Dividends to shareholders(268,989)(249,121)
Repurchases of Class A ordinary shares(274,559)— 
Contributions from legacy non-controlling interests - R&D455 971 
Contributions from non-controlling interests - other5,915 4,869 
Repayment of long-term debt(1,000,000)— 
Net cash used in financing activities(1,916,860)(679,306)
Net change in cash and cash equivalents(774,303)(549,420)
Cash and cash equivalents, beginning of period1,710,751 1,541,048 
Cash and cash equivalents, end of period$936,448 $991,628 
See accompanying notes to these unaudited condensed consolidated financial statements.

6
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1. Organization and Purpose

Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the initial public offering (“IPO”) of our Class A ordinary shares. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.

We control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our condensed consolidated financial statements.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management vehicle, and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”). RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”) and Royalty Pharma plc. Prior to the Exchange Offer (defined below), Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

RP Management, LLC (the “Manager”), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the “Management Agreement”).

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Exchange Offer

We consummated an exchange offer on February 11, 2020 (the “Exchange Offer”) to facilitate the IPO. Through the Exchange Offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. Following the Exchange Offer, we became the indirect owner of an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”). We are entitled to 82% of the economics of Old RPI’s wholly-owned subsidiary RPI Finance Trust, a Delaware statutory trust (“RPIFT”), and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust.

2. Summary of Significant Accounting Policies

Basis of Preparation and Use of Estimates

The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2022, included in our Annual Report on Form 10-K.

7
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.

Basis of Consolidation

The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interests in our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

In 2022, we became an indirect owner of an 82% economic interest in Royalty Pharma Investments ICAV (“RPI ICAV”), which previously was owned directly by Old RPI.

We report four non-controlling interests: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the “legacy non-controlling interests”). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of RP Holdings Class B Interests (the “continuing non-controlling interests”) and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain performance conditions are met.

All intercompany transactions and balances have been eliminated in consolidation.

Reclassification

Certain prior period amounts have been reclassified to conform to the current period presentation.

Concentrations of Credit Risk

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of September 30, 2023 and December 31, 2022 were held with Bank of America, State Street, Scotiabank, Citibank, TD Bank, DNB Bank and U.S. Bank. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson & Johnson, Merck & Co., Pfizer, Astellas, Novartis and Gilead. As of September 30, 2023 and December 31, 2022, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, represented the largest individual marketer and payor of our royalties, accounting for 31% of our current portion of financial royalty assets.

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.
8
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Significant Accounting Policies

There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2022.

3. Available for Sale Debt Securities

Cytokinetics Commercial Launch Funding

On January 7, 2022, we entered into a long-term funding agreement, which was later amended in 2022, with Cytokinetics, Incorporated (“Cytokinetics”). We agreed to provide funding of up to $300 million (“Cytokinetics Commercial Launch Funding”) in five tranches. The initial tranche of $50 million was funded upon closing. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). Because the regulatory milestones for the second and third tranches were not met, $75 million of the optional funding is no longer available. For tranches one, four and five, we expect to receive a return of 1.9 times the amount drawn over 34 consecutive quarterly payments beginning on the last business day of the seventh quarter following the quarter of the funding date of each tranche. As of September 30, 2023, $125 million of the optional $200 million remained available under the Cytokinetics Funding Commitments.

We elected the fair value option to account for the Cytokinetics Commercial Launch Funding as it most accurately reflects the nature of the funding arrangement. The funded Cytokinetics Commercial Launch Funding is recorded within Available for sale debt securities on the condensed consolidated balance sheets. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within Other liabilities on the condensed consolidated balance sheets. The changes in the fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within Gains on available for sale debt securities in the condensed consolidated statements of operations.

MorphoSys Development Funding Bonds

On June 2, 2021, we announced a long-term strategic funding agreement with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc. which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350 million of capital (“Development Funding Bonds”), of which MorphoSys was required to draw a minimum of $150 million. In September 2022, we funded $300 million of the Development Funding Bonds, which represents $150 million in additional funding above the minimum funding commitment (“Additional Funding”), and settled our forward commitment. We expect to receive a return of 2.2 times the funded amount of the Development Funding Bonds, payable on a quarterly basis over nine years, with the first payment beginning in the fourth quarter of 2024.

We elected the fair value option to account for the Development Funding Bonds as it most accurately reflects the nature of the instruments. The Development Funding Bonds are recorded within Available for sale debt securities on the condensed consolidated balance sheets. The changes in the fair value of the Development Funding Bonds are recorded within Gains on available for sale debt securities in the condensed consolidated statements of operations.
9
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

The table below summarizes our available for sale debt securities recorded at fair value as of September 30, 2023 and December 31, 2022 (in thousands):

CostUnrealized(Losses)/GainsFair Value Current AssetsNon-Current AssetsNon-Current LiabilitiesTotal
As of September 30, 2023
Debt securities (1)$359,400 $(500)$358,900 $5,300 $353,600 $— $358,900 
Funding commitments (2)(7,300)(4,000)(11,300)— — (11,300)(11,300)
Total available for sale debt securities$352,100 $(4,500)$347,600 $5,300 $353,600 $(11,300)$347,600 
As of December 31, 2022
Debt securities (1)$359,400 $(131,800)$227,600 $1,300 $226,300 $— $227,600 
Funding commitments (2)(9,400)6,900 (2,500)— — (2,500)(2,500)
Total available for sale debt securities$350,000 $(124,900)$225,100 $1,300 $226,300 $(2,500)$225,100 
(1)The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amount funded.
(2)Related to Cytokinetics Funding Commitments for which related tranches remain available as of respective balance sheet dates. The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.

4. Fair Value Measurements and Financial Instruments

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):
As of September 30, 2023As of December 31, 2022
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Money market funds (1)$605,422 $— $— $605,422 $5,068 $— $— $5,068 
Marketable securities
Certificates of deposit— — — — — 11,501 — 11,501 
U.S. government securities— — — — — 12,920 — 12,920 
Available for sale debt securities (2)— — 5,300 5,300 — — 1,300 1,300 
Derivative instruments (3)— — — — — — 86,150 86,150 
Total current assets$605,422 $— $5,300 $610,722 $5,068 $24,421 $87,450 $116,939 
Equity securities140,170 — 4,172 144,342 103,876 — 8,472 112,348 
Available for sale debt securities (2)— — 353,600 353,600 — — 226,300 226,300 
Derivative instruments (3)— — — — — — 10,460 10,460 
Royalty at fair value (4)— — 16,331 16,331 — — 14,500 14,500 
Total non-current assets$140,170 $— $374,103 $514,273 $103,876 $— $259,732 $363,608 
Liabilities:
Funding commitments (5)— — (11,300)(11,300)— — (2,500)(2,500)
Total non-current liabilities$— $— $(11,300)$(11,300)$— $— $(2,500)$(2,500)
(1)Recorded within Cash and cash equivalents on the condensed consolidated balance sheets.
(2)Reflects the fair value of the funded portions of the Development Funding Bonds and the Cytokinetics Commercial Launch Funding.
(3)Reflects the fair value of the Milestone Acceleration Option (defined below) which was recorded within Other current assets and Other assets on the condensed consolidated balance sheets. As of December 31, 2022, the fair value for the current portion of the derivative instruments related to the intranasal indication of zavegepant which settled in March 2023 when the U.S. Food and Drug Administration (“FDA”) approved Zavzpret and the fair value of the non-current portion of the derivative instruments related to the oral indication of zavegepant.
(4)Recorded within Other assets on the condensed consolidated balance sheets. See Note 7–Non-Consolidated Affiliates for additional discussion.
(5)Related to the fair value of the Cytokinetics Funding Commitments recorded within Other liabilities on the condensed consolidated balance sheets.

10
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

For the third quarter and first nine months of 2023, we recognized gains of $1.5 million and $32.0 million, respectively, on equity securities still held as of September 30, 2023. For the third quarter and first nine months of 2022, we recognized losses of $0.9 million and $27.7 million, respectively, on equity securities still held as of September 30, 2023.

The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands):

For the Three Months Ended September 30, 2023
Equity SecuritiesDebt SecuritiesFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$5,718 $348,800 $(8,500)$8,680 $16,583 
Losses on equity securities(1,546)— — — — 
Losses on derivative financial instruments— — — (8,680)— 
Gains/(losses) on available for sale debt securities included in earnings
— 10,100 (2,800)— — 
Other non-operating expense
— — — — (252)
Balance at the end of the period$4,172 $358,900 $(11,300)$— $16,331 

For the Three Months Ended September 30, 2022
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 
Purchases— 314,579 — — — — 
Losses on initial recognition (1)— (8,800)— — — — 
Losses on equity securities(10,489)— — — — — 
Gains on derivative financial instruments— — — — 25,790 — 
Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)
— 13,050 — — — — 
Gains/(losses) on available for sale debt securities included in earnings— 14,200 40,643 (1,800)— — 
Other non-operating expense— — — — — (7,278)
Settlement (2)
— 2,427 (2,427)— — — 
Redemptions— (15,625)— — — — 
Balance at the end of the period$18,296 $682,831 $66,316 $(9,900)$97,590 $13,937 
(1)Represents the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million.
(2)Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares.

For the Nine Months Ended September 30, 2023
Equity SecuritiesDebt SecuritiesFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$8,472 $227,600 $(2,500)$96,610 $14,500 
Losses on equity securities(4,300)— — — — 
Losses on derivative financial instruments— — — (2,290)— 
Gains/(losses) on available for sale debt securities included in earnings— 131,300 (8,800)— — 
Other non-operating income— — — — 1,831 
Settlement (1)— — — (94,320)— 
Balance at the end of the period$4,172 $358,900 $(11,300)$— $16,331 
(1)Represents the fair value of the Milestone Acceleration Option (defined below) attributable to the intranasal indication of zavegepant which was settled when the FDA approved Zavzpret in March 2023.

11
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

For the Nine Months Ended September 30, 2022
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$43,013 $253,700 $16,700 $— $— $— 
Purchases28,785 393,737 — — — 21,215 
Gains/(losses) on initial recognition (1)— 600 — (9,400)— — 
Losses on equity securities(12,810)— — — — — 
Gains on derivative financial instruments— — — — 97,590 — 
Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)— 24,000 — — — — 
Gains/(losses) on available for sale debt securities included in earnings
— 44,400 62,885 (500)— — 
Other non-operating expense— — — — — (7,278)
Settlements (2)
— 13,269 (13,269)— — — 
Transfer out of Level 3 (3)
(40,692)— — — — — 
Redemptions— (46,875)— — — — 
Balance at the end of the period$18,296 $682,831 $66,316 $(9,900)$97,590 $13,937 
(1)Represents purchase price allocation to arrive at the appropriate fair value on initial recognition. Amounts also reflect the initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million.
(2)Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares.
(3)Related to the expiration of the transfer restriction on BioCryst common stock.

Valuation Inputs for Recurring Fair Value Measurements

Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements as of September 30, 2023 and December 31, 2022 in the fair value hierarchy.

ApiJect Investment

We estimated the fair value of the equity securities and revenue participation right that we acquired from ApiJect Holdings, Inc. (“ApiJect”), a private company, as of September 30, 2023 and December 31, 2022 by utilizing a discounted cash flow calculation using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 7–Non-Consolidated Affiliates for additional discussion.

Cytokinetics Commercial Launch Funding and Cytokinetics Funding Commitments

We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of September 30, 2023 and December 31, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding require significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.
12
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

We estimated the fair value of the Cytokinetics Funding Commitments as of September 30, 2023 and December 31, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty’s assumed cost of debt, which would impact Cytokinetics’ decision to exercise its option to draw on each respective tranche. As of September 30, 2023 and December 31, 2022, this methodology incorporates Level 3 fair value measurements and inputs, including an assumed risk-adjusted discount rate of 15.4% and 13.5%, respectively, and an assumed interest rate volatility of 32.5% and 30.0%, respectively. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

MorphoSys Development Funding Bonds

We estimated the fair value of the Development Funding Bonds as of September 30, 2023 and December 31, 2022 based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 fair value inputs. Our estimate of the risk adjusted discount rates could reasonably be different than the discount rates selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

Milestone Acceleration Option

On August 7, 2020, we entered into an expanded funding agreement with Biohaven to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. Following Pfizer’s acquisition of Biohaven on October 2, 2022, which was a change of control event, we elected to accelerate the payment of the zavegepant milestone payments, if triggered, into a lump sum amount (“Milestone Acceleration Option”). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven. In March 2023, the FDA approved Zavzpret (zavegepant), a calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults, which triggered a milestone payment of $475 million that we received in the same month and resulted in a partial settlement of the derivative instrument.

We estimated the fair value of the Milestone Acceleration Option as of December 31, 2022 using the “with-and-without” methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rate which was primarily based on Pfizer’s cost of debt and management’s estimated probabilities of achieving the success-based milestones. Assessing the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate and the probabilities of achieving marketing approval could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

Other Financial Instruments

As of September 30, 2023, we did not have any financial instruments recorded at fair value using Level 2 inputs. As of December 31, 2022, financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consisted of certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that provide quoted market prices in active markets for similar securities or observable inputs for their pricing without applying significant adjustments.

13
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Financial Assets Not Measured at Fair Value

Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products which are estimated using sell-side equity research analysts’ consensus sales forecasts. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments, are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are presented below (in thousands):

As of September 30, 2023As of December 31, 2022
Fair ValueCarrying Value, netFair ValueCarrying Value, net
Financial royalty assets, net$17,356,414 $13,230,474 $17,314,094 $13,493,106 

5. Financial Royalty Assets

Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are as follows (in thousands):
As of September 30, 2023
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,304,675 $— $5,304,675 
Tysabri
(3)
1,557,167 (356,280)1,200,887 
Trelegy2029-20301,237,514 (65,715)1,171,799 
Tremfya2031-2032927,465 (151,563)775,902 
Evrysdi
2030-2035 (4)
772,667 — 772,667 
Xtandi2027-2028939,653 (296,160)643,493 
Other2024-20416,375,151 (2,125,113)4,250,038 
Total$17,114,292 $(2,994,831)$14,119,461 
Less: Cumulative allowance for credit losses (Note 6)(146,827)
Total current and non-current financial royalty assets, net$13,972,634 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key U.S. patents on Evrysdi expire in 2035. Our royalty will end when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

As of September 30, 2023, the balance of $14.0 billion for total current and non-current financial royalty assets, net included $562.1 million in unapproved financial royalty assets held at cost related to olpasiran, pelacarsen, KarXT and seltorexant.

14
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

As of December 31, 2022
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (4)
Cystic fibrosis franchise
2037 (2)
$5,333,535 $(10,908)$5,322,627 
Tysabri
(3)
1,683,441 (212,283)1,471,158 
Trelegy2029-20301,284,054 (24,126)1,259,928 
Tremfya2031-2032894,160 — 894,160 
Imbruvica2027-20321,436,969 (660,703)776,266 
Xtandi2027-20281,009,168 (235,625)773,543 
Other2024-20415,134,980 (1,332,815)3,802,165 
Total$16,776,307 $(2,476,460)$14,299,847 
Less: Cumulative allowance for credit losses (Note 6)(115,422)
Total current and non-current financial royalty assets, net$14,184,425 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

6. Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets

The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets on the condensed consolidated balance sheets and includes the following:

•the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products which are estimated by sell-side equity research analysts’ consensus sales forecasts,
•the write-off of cumulative allowance at the end of a royalty asset’s life which only impacts the condensed consolidated balance sheets, and
•the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.

The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):

Activity for the Period
Balance at December 31, 2022 (1)$(2,591,882)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(860,242)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets254,478 
Write-off of cumulative allowance87,393 
Current period provision for credit losses, net (2)(31,405)
Balance at September 30, 2023$(3,141,658)
(1)Includes $115.4 million related to cumulative allowance for credit losses.
(2)The provision expense for credit losses was primarily related to the additions of Adstiladrin and Skytrofa to our portfolio of financial royalty assets with limited protective rights.

15
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

7. Non-Consolidated Affiliates

We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities over which we have elected the fair value option.

ApiJect

In April 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for such investments. We are also required to purchase additional common stock from ApiJect if certain milestones are achieved. The fair value of our equity investment in ApiJect is recorded within Equity securities and the change in fair value is recorded within (Gains)/losses on equity securities. The fair value of the revenue participation right is recorded within Other assets and the change in fair value is recorded within Other non-operating expense, net. No amounts were due from ApiJect as of September 30, 2023.

The Legacy SLP Interest

In connection with the Exchange Offer, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is accounted for under the equity method as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI and RPI ICAV.

The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. Equity in earnings from the Legacy SLP Interest is recorded within Equity in losses/(earnings) of equity method investees. We recorded a loss allocation of $2.3 million and an income allocation of $0.6 million in the third quarter and first nine months of 2023, respectively. We recorded a loss allocation of $2.1 million and an income allocation of $7.2 million in the third quarter and first nine months of 2022, respectively. We collected cash receipts from the Legacy SLP Interest of $4.8 million and $9.7 million in the third quarter and first nine months of 2023, respectively. We collected cash receipts from the Legacy SLP Interest of $5.8 million and $19.9 million in the third quarter and first nine months of 2022, respectively.

The Avillion Entities

We account for our partnership interests in Avillion Financing I, LP and its related entities (“Avillion I”) and BAv Financing II, LP and its related entities (“Avillion II” and, together with Avillion I, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. Equity in earnings from the Avillion Entities is recorded within Equity in losses/(earnings) of equity method investees. During the third quarter of 2023 and first nine months of 2023, we recorded a loss allocation of $3.0 million and an income allocation of $28.0 million, respectively. We recorded loss allocations of $1.2 million and $9.3 million in the third quarter and first nine months of 2022, respectively.

On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.6 million and $13.4 million in the first nine months of 2023 and 2022, respectively.

16
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

In May 2018, RPIFT entered into an agreement with Avillion II, which was amended in July 2021 and June 2022, to fund a total of $150 million over multiple years for a portion of the costs of Phase 2 and 3 clinical trials to advance Airsupra, formerly known as PT027, which was approved by the FDA in January 2023. Avillion II is a party to a co-development agreement with AstraZeneca to develop Airsupra for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments. In January 2023, AstraZeneca notified Avillion II that it elected to pay a fee of $80 million to Avillion II to exercise an option to commercialize Airsupra in the United States. In March 2023, we received our pro rata portion of the exercise fee of $34.8 million from Avillion II.

Our maximum exposure to loss at any particular reporting date is limited to the carrying value of our equity method investments plus the unfunded commitments. As of September 30, 2023 and December 31, 2022, we had unfunded commitments related to the Avillion Entities of $18.3 million and $28.8 million, respectively.

8. Research & Development (“R&D”) Funding Expense

R&D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the first nine months of 2023 and 2022, we did not enter into any new ongoing R&D funding arrangements.

We recognized R&D funding expense of $50.5 million and $51.5 million in the third quarter and first nine months of 2023, respectively. We recognized R&D funding expense of $25.5 million and $126.6 million in the third quarter and first nine months of 2022, respectively. The R&D funding expense in 2023 was primarily related to a $50.0 million clinical milestone payment that was triggered under the agreement with Cytokinetics. During the first nine months of 2022, R&D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0 million and $25.0 million to acquire royalties on development-stage product candidates from Cytokinetics and Theravance Biopharma, Inc., respectively.

9. Borrowings

Our borrowings as of September 30, 2023 and December 31, 2022 consisted of the following (in thousands):

Type of BorrowingDate of IssuanceMaturityAs of September 30, 2023As of December 31, 2022
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)
9/20209/2023$— $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)
9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)
9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)
9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)
7/20219/2031600,000 600,000 
$1,000,000, 3.30% (issued at 95.556% of par)
9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)
9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)
7/20219/2051700,000 700,000 
Unamortized debt discount and issuance costs(168,806)(183,678)
Total debt carrying value6,131,194 7,116,322 
Less: Current portion of long-term debt— (997,512)
Total long-term debt$6,131,194 $6,118,810 

Senior Unsecured Notes

Interest on each series of the $1.3 billion senior unsecured notes issued in 2021 (the “2021 Notes”) accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.
17
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Interest on each series of the $6.0 billion senior unsecured notes issued in 2020 (the “2020 Notes”) accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.13% and 2.50%, respectively.

The 2020 Notes and the 2021 Notes (the “Notes”) may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly-owned subsidiary. We are required to comply with certain covenants under our Notes and as of September 30, 2023, we were in compliance with all applicable covenants.

In September 2023, we repaid $1.0 billion of senior unsecured notes upon maturity.

As of September 30, 2023 and December 31, 2022, the fair value of our outstanding Notes using Level 2 inputs was approximately $4.6 billion and $5.7 billion, respectively.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the “Credit Agreement”). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Revolving Credit Facility has a maturity date of October 31, 2027. As of September 30, 2023 and December 31, 2022, there were no outstanding borrowings under the Revolving Credit Facility. In October 2023, we drew $350.0 million on the Revolving Credit Facility to fund a portion of our acquisition of additional royalties on Roche’s Evrysdi.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds rate plus 0.5% and (3) Term SOFR plus 1% or (b) Daily SOFR, Term SOFR, the Alternative Currency Term Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuate during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.

The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. The Credit Agreement includes customary covenants for credit facilities of this type that limit our ability to engage in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of September 30, 2023, RP Holdings was in compliance with these covenants.

18
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Principal Payments on the Notes

The future principal payments for our borrowings as of September 30, 2023 over the next five years and thereafter are as follows (in thousands):

YearPrincipal Payments
Remainder of 2023$— 
2024— 
20251,000,000 
2026— 
20271,000,000 
Thereafter4,300,000 
Total (1)$6,300,000 
(1)Excludes unamortized debt discount and issuance costs of $168.8 million as of September 30, 2023, which are amortized through interest expense over the remaining life of the underlying debt obligations.

10. Shareholders’ Equity

Capital Structure

We have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up. As of September 30, 2023, we have 445,843 thousand Class A ordinary shares and 152,546 thousand Class B ordinary shares outstanding.

An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of September 30, 2023, we have 382,837 thousand deferred shares outstanding.

In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.

Class A Ordinary Share Repurchases

In March 2023, our board of directors authorized a share repurchase program under which we may repurchase up to $1.0 billion of our Class A ordinary shares. The authorization for the share repurchase program expires on June 23, 2027 and repurchases may be made in the open market or in privately negotiated transactions. Amounts paid to repurchase shares in excess of the par value are allocated between Additional paid-in capital and Retained earnings. We began repurchasing our Class A ordinary shares in April 2023. In the first nine months of 2023, we repurchased and retired 8,889 thousand shares at a cost of approximately $278.6 million.

19
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Non-Controlling Interests

The changes in the balances of our four non-controlling interests for the third quarter and first nine months of 2023 and 2022 are as follows (in thousands):

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
June 30, 2023$1,420,864 $(103)$2,111,258 $— $3,532,019 
Contributions1,413 — 1,437 — 2,850 
Distributions(88,112)(848)(31,238)— (120,198)
Other exchanges— — (18,459)— (18,459)
Net income25,623 285 24,055 — 49,963 
September 30, 2023$1,359,788 $(666)$2,087,053 $— $3,446,175 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
June 30, 2022$1,716,186 $8,882 $2,655,870 $— $4,380,938 
Contributions1,570 — 1,400 — 2,970 
Distributions(95,084)(4,175)(38,621)— (137,880)
Other exchanges— — (61,886)— (61,886)
Net income21,432 1,935 54,396 — 77,763 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities2,294 — 2,975 — 5,269 
Reclassification of unrealized gains on available for sale debt securities(1,250)— (1,621)— (2,871)
September 30, 2022$1,645,148 $6,642 $2,612,513 $— $4,264,303 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2022$1,527,887 $(597)$2,369,933 $— $3,897,223 
Contributions6,614 — 3,076 — 9,690 
Distributions(286,674)(4,755)(95,161)— (386,590)
Other exchanges— — (416,156)— (416,156)
Net income111,961 4,686 225,361 — 342,008 
September 30, 2023$1,359,788 $(666)$2,087,053 $— $3,446,175 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2021$1,809,269 $13,528 $2,649,154 $— $4,471,951 
Contributions4,964 — 4,209 — 9,173 
Distributions(302,670)(20,188)(110,964)— (433,822)
Other exchanges— — (124,108)— (124,108)
Net income133,595 13,302 194,281 — 341,178 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities4,218 — 5,520 — 9,738 
Reclassification of unrealized gains on available for sale debt securities(4,228)— (5,579)— (9,807)
September 30, 2022$1,645,148 $6,642 $2,612,513 $— $4,264,303 

20
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

The Continuing Investors Partnerships hold a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests held by them. As the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares, the Continuing Investors Partnerships’ ownership in RP Holdings decreases. We operate and control the business affairs of RP Holdings through our ownership of RP Holdings Class A Interests and RP Holdings Class B Interests. In connection with our repurchase of Class A ordinary shares, RP Holdings also began to retire RP Holdings Class A Interests held by us which reduces our ownership in RP Holdings. The change in RP Holdings ownership between the Continuing Investors Partnerships and us as a result of (1) the exchanges of RP Holding Class B Interests for Class A ordinary shares and (2) retirement of RP Holdings Class A Interests is reflected through Other exchanges in the above tables and in our condensed consolidated statements of shareholders’ equity.

As of September 30, 2023, the Continuing Investors Partnerships owned approximately 25% of RP Holdings with the remaining 75% owned by Royalty Pharma plc. As of September 30, 2022, the Continuing Investors Partnerships owned approximately 27% of RP Holdings with the remaining 73% owned by Royalty Pharma plc.

RP Holdings Class C Special Interest Held by EPA Holdings

EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest. We do not expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met. Similarly, we do not expect any material income to be allocated to EPA Holdings until such performance conditions are met.

Dividends

The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the first nine months of 2023, we declared and paid three quarterly cash dividends of $0.20 per Class A ordinary share for an aggregate amount of $269.0 million to holders of our Class A ordinary shares.

2020 Independent Directors Equity Incentive Plan

On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors.

RSU Activity and Share-based Compensation

We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of General and administrative expenses in the condensed consolidated statements of operations. In the third quarter and first nine months of 2023 and 2022, respectively, we did not recognize material share-based compensation expense.

21
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

11. Earnings per Share

For the third quarter and first nine months of 2023 and 2022, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.

The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the third quarter and first nine months of 2023 and 2022 (in thousands, except per share amounts):

For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Numerator
Consolidated net income$122,077 $220,414 $982,502 $840,094 
Less: Net income attributable to continuing non-controlling interests24,055 54,396 225,361 194,281 
Less: Net income attributable to legacy non-controlling interests25,908 23,367 116,647 146,897 
Net income attributable to Royalty Pharma plc - basic72,114 142,651 640,494 498,916 
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 24,055 54,396 225,361 194,281 
Net income attributable to Royalty Pharma plc - diluted$96,169 $197,047 $865,855 $693,197 
Denominator
Weighted average Class A ordinary shares outstanding - basic448,439 439,293 448,162 436,542 
Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares152,691 167,927 156,541 170,651 
Unvested RSUs8 6 14 16 
Weighted average Class A ordinary shares outstanding - diluted601,138 607,226 604,717 607,209 
Earnings per Class A ordinary share - basic$0.16 $0.32 $1.43 $1.14 
Earnings per Class A ordinary share - diluted$0.16 $0.32 $1.43 $1.14 



22
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

12. Indirect Cash Flow

Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):
For the Nine Months Ended September 30,
20232022
Cash flow from operating activities:
Consolidated net income$982,502 $840,094 
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from financial royalty assets(1,674,689)(1,578,555)
Provision for changes in expected cash flows from financial royalty assets637,169 595,396 
Amortization of intangible assets— 5,670 
Amortization of debt discount and issuance costs15,658 16,026 
Losses/(gains) on derivative financial instruments2,290 (97,590)
(Gains)/losses on equity securities(31,994)22,970 
Equity in (earnings)/losses of equity method investees(28,614)2,117 
Distributions from equity method investees18,823 33,316 
Share-based compensation1,740 1,587 
Interest income accretion— (24,053)
Gains on available for sale debt securities(122,500)(97,985)
Other3,263 3,443 
Changes in operating assets and liabilities:
Cash collected on financial royalty assets2,454,054 1,843,899 
Accrued royalty receivable470 37,574 
Other royalty income receivable(669)(4,108)
Other current assets(2,412)8,253 
Accounts payable and accrued expenses1,650 10,492 
Interest payable(41,567)(44,497)
Net cash provided by operating activities$2,215,174 $1,574,049 

13. Commitments and Contingencies

Cytokinetics Funding Commitments

As of September 30, 2023, $125 million of the optional $200 million remained available under the Cytokinetics Funding Commitments. Additionally, Cytokinetics is required to draw $50 million if a certain contingency is met.

Other Commitments

We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 7–Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments (defined below) over the life of the Management Agreement as described in Note 14–Related Party Transactions.

Indemnifications

In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.

23
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Legal Proceedings

We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of September 30, 2023 and December 31, 2022. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.

14. Related Party Transactions

The Manager

The Manager is the investment manager of Royalty Pharma plc and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.

In connection with the Exchange Offer (discussed in Note 1–Organization and Purpose), the Manager entered into the Management Agreement with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. Additionally, we also pay certain costs and expenses of the Manager.

Total operating and personnel payments incurred, including the amounts attributable to Old RPI, are recognized within General and administrative expenses in the condensed consolidated statements of operations. During the third quarter and first nine months of 2023, total operating and personnel payments incurred, including the amounts attributable to Old RPI, were $43.0 million and $154.9 million, respectively. During the third quarter and first nine months of 2022, total operating and personnel payments incurred, including the amounts attributable to Old RPI, were $40.6 million and $117.8 million, respectively.

Distributions Payable to Legacy Non-Controlling Interests

The distributions payable to legacy non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPI ICAV and RPSFT’s non-controlling interest in RPCT. The distributions payable to legacy non-controlling interests include the following (in thousands):

As of September 30, 2023As of December 31, 2022
Payable to Legacy Investors Partnerships
$98,439 $87,522 
Payable to RPSFT
3,272 7,281 
Total distributions payable to legacy non-controlling interests$101,711 $94,803 

Acquisition from Bristol Myers Squibb

In November 2017, RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly-owned subsidiary of BioPharma Credit PLC (“BPCR”), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.
24
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

As of September 30, 2023 and December 31, 2022, the financial royalty asset of $82.6 million and $103.4 million, respectively, on the condensed consolidated balance sheets represented only our right to the future payment streams acquired from BMS.

Other Transactions

Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to develop thematic life sciences indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of both September 30, 2023 and December 31, 2022. The financial impact associated with this transaction has not been material to date.

In connection with the Exchange Offer, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI and RPI ICAV. Refer to Note 7–Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.

RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million was recorded as treasury interests, of which $1.6 million and $1.5 million were held by non-controlling interests as of September 30, 2023 and December 31, 2022, respectively.

Each Continuing Investor Partnership pays a pro rata portion based on its ownership percentage of RP Holdings of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.

15. Subsequent Events

In October 2023, we acquired additional royalties on Roche’s Evrysdi, an approved product for the treatment of spinal muscular atrophy, from PTC Therapeutics, Inc (“PTC”) for $1.0 billion upfront. Until December 31, 2025, PTC has an option to sell its remaining royalties for $500 million less royalties received in five equal tranches. If PTC exercises its options for fewer than three tranches, we have an option to acquire half of PTC’s remaining royalties for $250 million less royalties received until March 31, 2026.


25

Item 2.         MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations, cash flows and other changes in financial condition. MD&A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes to our consolidated financial statements included in our Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Special Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q and in Part II, Item 1A. Risk Factors.

Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the initial public offering (“IPO”) of our Class A ordinary shares on June 16, 2020. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.

Business Overview

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties or milestones, and indirectly when we acquire existing royalties from the original innovators.

Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development (“R&D”) costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.

We classify our royalty acquisitions by the approval status of the therapy at the time of acquisition:

•Approved Products – We acquire royalties in approved products that generate predictable cash flows and may offer upside potential from unapproved indications. Since inception in 1996 through 2022, we have deployed $17.0 billion of cash to acquire royalties, milestones and related assets on approved products. From 2012 through 2022, we have deployed $12.1 billion to acquire royalties, milestones and related assets on approved products.

•Development-Stage Product Candidates – We acquire royalties on development-stage product candidates that have demonstrated strong clinical proof of concept. From 2012, when we began acquiring royalties on development-stage product candidates, through 2022, we have deployed $8.3 billion to acquire royalties, milestones and related assets on development-stage product candidates.

While we classify our acquisitions in these two broad categories, several of our approved product transactions are driven by the long-term expanded potential of these existing commercial products in indications that are unapproved at the time of acquisition. Similarly, some of our development-stage product candidate transactions are specifically related to indications that are unapproved at the time of acquisition, on products that are already approved and commercialized in other indications.

26

We acquire product royalties in ways that can be tailored to the needs of our partners through a variety of structures:

•Third-party Royalties – Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.

•Synthetic Royalties – Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales by the developer or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing R&D for biopharmaceutical companies in exchange for future royalties and milestones if the product or indication we are funding is approved.

•Launch and Development Capital – Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company. The funding of launch and development capital is generally reflected on our statements of cash flows as Purchases of available for sale debt securities.

•Mergers and Acquisitions (“M&A”) Related – We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities such as our strategic alliance with MSCI Inc. (“MSCI”) to develop thematic life science indexes.

Background and Format of Presentation

We consummated an exchange offer on February 11, 2020 (the “Exchange Offer”) to facilitate our IPO. Through the Exchange Offer, investors which represented 82% of the aggregate limited partnership interests in the various partnerships (the “Legacy Investors Partnerships”) that owned Royalty Pharma Investments, an Irish unit trust (“Old RPI”) exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in RPI US Partners 2019, LP, a Delaware limited partnership, or RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”).

We operate and control the business affairs of Royalty Pharma Holdings Ltd (“RP Holdings”). We include RP Holdings and its subsidiaries in our condensed consolidated financial statements. RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV, which is an Irish collective asset management vehicle and is the successor to Old RPI.

Following the Exchange Offer, we became the indirect owner of an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust. We are entitled to 82% of the economics of Old RPI’s wholly-owned subsidiary RPI Finance Trust, a Delaware statutory trust, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly-owned by Royalty Pharma Select, an Irish unit trust.

In 2022, we became the indirect owner of an 82% economic interest in Royalty Pharma Investments ICAV (“RPI ICAV”), which was previously owned directly by Old RPI.

27

Understanding Our Financial Reporting

Most of the royalties we acquire are treated as investments in cash flow streams and are classified as financial assets measured under the effective interest method in accordance with generally accepted accounting principles in the United States (“GAAP”). Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset.

The measurement of income from our financial royalty assets requires significant judgments and estimates, including management’s judgment in forecasting the expected future cash flows of the underlying royalties and the expected duration of the financial royalty asset. Our cash flow forecasts are updated each reporting period primarily using sell-side equity research analysts’ consensus sales estimates for each of the products in which we own royalties. We then calculate our expected royalty receipts by applying our royalty terms to these consensus sales forecasts. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly in the income statement as non-cash provision expense. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reverse the provision expense previously recorded in part or in full by recording a non-cash credit to the provision.

As a result of the non-cash charges associated with applying the effective interest method accounting methodology to our financial royalty assets, our condensed consolidated income statement activity can be volatile and unpredictable. Small declines in sell-side equity research analysts’ consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise and shortly after, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expense in our condensed consolidated income statements. Over the course of 10 quarters, we continued to recognize non-cash provision expense as a result of these changes in forecasts, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty, resulting in the reversal of the remaining $1.10 billion cumulative allowance. The recognition of the associated non-cash provision income of $1.10 billion in 2019 was not tied to royalty receipts, but rather to the increase in sales forecasts. This example illustrates the volatility caused by our accounting model in our condensed consolidated income statements.

We believe there is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets. Further, income from financial royalty assets and the provision for changes in expected cash flows related to these financial royalty assets can be volatile and unpredictable.

Our operating performance is a function of our liquidity as our operations have historically been financed primarily with cash flows generated by our royalties. We use the cash generated by our existing royalties to fund investments in new royalties. Given the importance of cash flows and their predictability to management’s operation of the business, management uses total royalty receipts as a key measure of our operating performance. Total royalty receipts refer to the summation of the following line items from our GAAP consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees. Total royalty receipts are an important input for our non-GAAP liquidity measures. Management believes that analyzing our non-GAAP financial results alongside our GAAP financial results is critical for investors to understand management’s ability to execute on its strategy and the business’s future growth potential. Refer to the section titled “Liquidity and Capital Resources” for additional discussion of management’s use of non-GAAP measures as supplemental financial measures.

28

Portfolio Overview

Our portfolio consists of royalties on more than 35 marketed therapies and 11 development-stage product candidates. The therapies in our portfolio address therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology and diabetes, and are delivered to patients across both primary and specialty care settings. The table below includes royalty receipts for the third quarter and first nine months of 2023 and 2022 by product in order of contribution to total royalty receipts for the first nine months of 2023 (in thousands).

Royalty Receipts
RoyaltiesMarketer(s)Therapeutic AreaFor the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Cystic fibrosis franchise (1)
VertexRare disease$237,902 $207,882 $660,673 $591,733 
Zavzpret milestone (2)
PfizerNeurology— — 475,000 — 
TysabriBiogenNeurology86,704 91,252 256,932 281,819 
ImbruvicaAbbVie, Johnson & JohnsonCancer62,174 74,391 193,895 241,943 
TrelegyGSKRespiratory58,240 42,720 143,111 42,720 
PromactaNovartisHematology54,122 50,067 142,406 132,679 
XtandiPfizer, AstellasCancer47,119 45,717 131,366 141,100 
TremfyaJohnson & JohnsonImmunology27,194 21,409 81,117 68,062 
Cabometyx/CometriqExelixis, Ipsen, TakedaCancer17,294 14,612 48,234 40,523 
EvrysdiRocheRare disease15,749 9,602 46,318 26,933 
Farxiga/Onglyza AstraZenecaDiabetes10,478 11,522 32,274 32,336 
PrevymisMerck & Co.Infectious disease15,343 11,052 29,157 25,174 
TrodelvyGileadCancer11,058 6,496 28,137 17,428 
SpinrazaBiogenNeurology15,253 — 27,815 — 
ErleadaJohnson & JohnsonCancer8,959 5,586 22,390 15,305 
OrladeyoBioCrystRare disease7,776 6,265 21,130 15,456 
CrysvitaUltragenyx, Kyowa KirinRare disease4,679 5,241 15,696 14,887 
Nurtec ODT/Biohaven payment (3)PfizerNeurology6,218 20,459 15,659 59,549 
EmgalityLillyNeurology4,903 4,657 14,350 13,845 
Other products (4)46,241 74,974 211,784 286,611 
Total royalty receipts$737,406 $703,904 $2,597,444 $2,048,103 
(1)The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(2)Related to a $475.0 million milestone payment that we received in the first quarter of 2023 following the U.S. Food and Drug Administration (“FDA”) approval of Zavzpret.
(3)In 2022, amounts include the $15.6 million quarterly redemption payments related to the Series A Biohaven Preferred Shares (presented as Proceeds from available for sale debt securities on the condensed consolidated statements of cash flows). The Series A Biohaven Preferred Shares were fully redeemed in October 2022 following Pfizer’s acquisition of Biohaven. The remaining amounts are related to royalty receipts from Nurtec ODT.
(4)Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion I, for which receipts are presented as Distributions from equity method investees in the operating section of the condensed consolidated statements of cash flows), Cimzia, Entyvio, IDHIFA, Januvia, Janumet, Other DPP-IVs, Lexiscan, Nesina, and Soliqua. Other products also include distributions from the Legacy SLP Interest (defined below) which are presented as Distributions from equity method investees in both the investing and operating section of the condensed consolidated statements of cash flows. In the first nine months of 2023, we received $34.8 million from our joint venture investee, Avillion II, for our pro rata portion of the $80 million fee paid by AstraZeneca to exercise the option to commercialize Airsupra in the United States (presented as Distributions from equity method investees in the investing section of the condensed consolidated statements of cash flows).

29

Key Developments and Upcoming Events Relating to Our Portfolio

Recent key developments related to products in our portfolio are discussed below:

Commercial Products

•Tysabri. In September 2023, Sandoz announced that the European Commission granted marketing authorization for biosimilar Tyruko for relapsing forms of multiple sclerosis. This follows FDA approval of biosimilar Tyruko in August 2023.

•Evrysdi. In August 2023, Roche announced that the European Commission approved Evrysdi for babies under two months old with spinal muscular atrophy.

•Cabometyx. In August 2023, Exelixis and Ipsen announced that Cabometyx in combination with atezolizumab compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer in the Phase 3 CONTACT-02 trial demonstrated a statistically significant improvement in progression-free survival (PFS) at the primary analysis. At a prespecified interim analysis for the primary endpoint of overall survival (OS) that occurred at the same time as the primary analysis of PFS, a trend toward improvement of OS was observed. The trial will continue to the next analysis of OS.

•Trodelvy. In July 2023, Gilead announced the European Commission approved Trodelvy as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer.

•Cystic fibrosis franchise. In July 2023, Vertex announced the European Commission approved the label extension of Orkambi for the treatment of children with cystic fibrosis ages 1 to less than 2 years old.

Development-Stage Product Candidates

•Trontinemab. In October 2023, at the Clinical Trials on Alzheimer’s Disease medical conference, Roche presented interim results of a phase 1b/2a study for trontinemab, a novel Brainshuttle Amyloid β antibody for the treatment of Alzheimer’s disease. This study demonstrated that trontinemab rapidly reduces amyloid plaque reduction in patients with Alzheimer’s disease.

•KarXT. In September 2023, Karuna Therapeutics announced the submission of its New Drug Application to the FDA for KarXT for the treatment of schizophrenia.

•Aficamten. In September 2023, Cytokinetics announced the start of ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The initiation of ACACIA-HCM triggered a $50 million milestone payment to Cytokinetics in September 2023.

Understanding Our Results of Operations

We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us and which are attributable to:

1. The Legacy Investors Partnerships’ ownership of approximately 18% of Old RPI and RPI ICAV. The value of this non-controlling interest will decline over time as the assets in Old RPI and RPI ICAV expire.

2. A de minimis interest in RPCT held by RPSFT. The value of this non-controlling interest was substantially eliminated as of December 31, 2022.

The Legacy Investors Partnership together with RPSFT are referred to as the “legacy non-controlling interests.” The legacy non-controlling interests are the only historical non-controlling interests that existed prior to our IPO.

30

Additionally, following the consummation of our IPO, we also report non-controlling interests related to:

3. The Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of RP Holdings Class B Interests was approximately 25% as of September 30, 2023. RP Holdings Class B Interests are exchangeable into Class A ordinary shares. As the Continuing Investors Partnerships conduct exchanges, the Continuing Investors Partnerships’ ownership in RP Holdings decreases and the value of this non-controlling interest decreases. Additionally, RP Holdings began to retire RP Holdings Class A Interests held by us in connection with our repurchase of Class A ordinary shares. As RP Holdings retires RP Holding Class A Interests, our ownership in RP Holdings decreases and the value of this non-controlling interest increases.

The Continuing Investors Partnerships are referred to as the “continuing non-controlling interests.”

4. RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”).

EPA Holdings is entitled to receive equity distributions through its RP Holdings Class C Special Interest (“Equity Performance Awards”). Equity Performance Awards owed to EPA Holdings will be recognized as an equity transaction when the obligation becomes due and will impact the income allocated to non-controlling interest related to the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions are met, which we do not expect to occur until the mid-2020s.

The results of operations of RP Holdings, Old RPI, RPI ICAV and RPCT are consolidated into our financial statements.

Total income and other revenues

Total income and other revenues is primarily comprised of interest income from our financial royalty assets, royalty income generally arising from successful commercialization of products developed through R&D funding arrangements, and a declining contribution of royalty revenue from our intangible royalty assets for which patent rights have materially expired. Most of our royalties are classified as financial assets as our ownership rights are generally protective and passive in nature. In instances in which we acquire a royalty that does include more substantial rights or ownership of the underlying intellectual property, we classify such royalties as intangible assets.

We recognize interest income related to our financial royalty assets. Royalty revenue solely relates to our intangible royalty assets from our DPP-IV products. Our royalties on DPP-IV products have substantially ended in the first quarter of 2022 and we do not expect any material revenue in the future periods. For the third quarter of 2023 and 2022 and the first nine months of 2023 and 2022, the royalty payors that accounted for greater than 10% of our total income and other revenues are shown in the table below:

For the Three Months Ended September 30,For the Nine Months Ended September 30,
Royalty PayorRoyalty2023202220232022
VertexCystic fibrosis franchise41 %35 %36 %36 %
AbbVieImbruvica*13 %*15 %
*Represents less than 10%.

31

Income from financial royalty assets

Our financial royalty assets represent investments in cash flow streams with yield components that most closely resemble loans measured at amortized cost under the effective interest method. We calculate the effective interest rate using forecasted expected cash flows to be received over the life of the royalty asset relative to the initial acquisition price. Interest income is recognized at the effective rate of return over the expected life of the asset, which is calculated at the end of each reporting period and applied prospectively. As changes in sell-side equity research analysts’ consensus sales estimates are updated on a quarterly basis, the effective rate of return changes. For example, if sell-side equity research analysts’ consensus sales forecasts increase, the yield to derive income on a financial royalty asset will increase and result in higher income for subsequent periods.

Variables affecting the recognition of interest income from financial royalty assets under the prospective effective interest method include any one of the following: (1) additional acquisitions, (2) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus sales forecasts, (3) regulatory approval of additional indications which leads to new cash flow streams, (4) changes to the estimated duration of the royalty (e.g., patent expiration date) and (5) changes in amounts and timing of projected royalty receipts and milestone payments. Our financial royalty assets are directly linked to sales of underlying pharmaceutical products whose life cycle typically peaks at a point in time, followed frequently by declining sales trends due to the entry of generic competition, resulting in natural declines in the asset balance and periodic interest income over the life of our royalties. The recognition of interest income from royalties requires management to make estimates and assumptions around many factors, including those impacting the variables noted above.

Revenue from intangible royalty assets

Revenue from intangible royalty assets is derived from sales of Januvia, Janumet and other DPP-IV products by our licensees. Our royalties on Januvia and Janumet expired in the first quarter of 2022. Our royalties on other DPP-IV products have also substantially ended and we do not expect any material revenue from the other DPP-IV products in the future periods.

Other royalty income

Other royalty income primarily includes income from financial royalty assets that have been fully amortized and income from synthetic royalties and milestones arising out of R&D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectability concerns, which, if resolved, may result in future cash collections when no financial royalty asset remains. Similarly, we may continue to collect royalties on a fully amortized financial royalty asset beyond the estimated duration. In each scenario where a financial royalty asset has been fully amortized, income from such royalty is recognized as Other royalty income. Other royalty income also includes income from royalties that are recorded at fair value on our condensed consolidated balance sheets.

Provision for changes in expected cash flows from financial royalty assets

The Provision for changes in expected future cash flows from financial royalty assets includes the following:

•non-cash expense or income related to the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows; and
•non-cash expense or income related to the provision for current expected credit losses, which reflects the activity for the period, primarily due to new financial royalty assets with limited protective rights and changes to cash flow estimates for financial royalty assets with limited protective rights.

As discussed above, income is accreted on our financial royalty assets using the effective interest method. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly in the income statement through the line item Provision for changes in expected cash flows from financial royalty assets. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reduce the cumulative allowance previously established for a financial royalty asset for the incremental increase in the present value of cash flows expected to be collected. This results in provision income (i.e., a credit to the provision).

32

The same variables and management’s estimates affecting the recognition of interest income on our financial royalty assets noted above also directly impact the provision.

R&D funding expense

R&D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. It includes development-stage funding payments that are made upfront or upon pre-approval milestones, and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties.

General and administrative expenses

General and administrative (“G&A”) expenses include primarily Operating and Personnel Payments (defined below), legal expenses, other expenses for professional services and share-based compensation. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&A expenses on an ongoing basis.

Under the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments, which is Adjusted Cash Receipts (a non-GAAP measure as further discussed in the section titled “Liquidity and Capital Resources”), for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter.

The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in G&A expenses, are calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investors Partnerships) during the previous twelve calendar months.

Equity in losses/(earnings) of equity method investees

Equity in losses/(earnings) of equity method investees primarily includes the results of our share of income or loss from the following non-consolidated affiliates:

1. Legacy SLP Interest. In connection with the Exchange Offer, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) in exchange for issuing shares in our subsidiary. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and a performance income allocation on a similar basis. As the Legacy Investors Partnerships no longer participate in investment opportunities, the value of the Legacy SLP Interest is expected to decline over time.

2. The Avillion Entities. The Avillion Entities (as defined below) partner with global biopharmaceutical companies to perform R&D in exchange for success-based milestones or royalties if products are commercialized. Our investments in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II” and together with Avillion I, the “Avillion Entities”) are accounted for using the equity method.

Other income, net

Other income, net primarily includes the changes in fair market value of our equity securities, derivative instruments and available for sale debt securities, including related forwards and funding commitments, and interest income.

33

Net income attributable to non-controlling interests

The net income attributable to non-controlling interests includes income attributable to the legacy non-controlling interests and the continuing non-controlling interests. As the Legacy Investors Partnerships and RPSFT no longer participate in investment opportunities, the related net income attributable to the legacy non-controlling interests is expected to decline over time as the assets held by RPCT, Old RPI and RPI ICAV mature.

Net income attributable to the continuing non-controlling interests includes RP Holdings Class B Interests held by the Continuing Investors Partnerships and will include net income attributable to the RP Holdings Class C Special Interest held by EPA Holdings once certain performance conditions have been met. Future net income attributable to the non-controlling interest related to RP Holdings Class B Interests held by the Continuing Investors Partnerships will decline over time if the investors who indirectly own RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares.

Net income attributable to non-controlling interests above can fluctuate significantly from period to period, primarily driven by volatility in the income statement activity of the respective underlying entity as a result of the non-cash charges associated with applying the effective interest accounting methodology to our financial royalty assets as described in section titled “Understanding Our Financial Reporting.”

Results of Operations

The comparison of our historical results of operations for the third quarter and first nine months of 2023 and 2022 is as follows (in thousands):

For the Three Months Ended September 30,ChangeFor the Nine Months Ended September 30,Change
20232022$ % 20232022$ %
Income and other revenues
Income from financial royalty assets$508,657 $551,682 $(43,025)(7.8)%$1,674,689 $1,578,555 $96,134 6.1 %
Revenue from intangible royalty assets252 1,073 (821)(76.5)%597 37,196 (36,599)(98.4)%
Other royalty income27,404 20,708 6,696 32.3 %83,200 55,716 27,484 49.3 %
Total income and other revenues536,313 573,463 (37,150)(6.5)%1,758,486 1,671,467 87,019 5.2 %
Operating expenses
Provision for changes in expected cash flows from financial royalty assets277,137 305,061 (27,924)(9.2)%637,169 595,396 41,773 7.0 %
Research and development funding expense50,500 25,500 25,000 98.0 %51,500 126,606 (75,106)(59.3)%
Amortization of intangible assets— — — n/a— 5,670 (5,670)(100.0)%
General and administrative expenses57,234 50,692 6,542 12.9 %190,563 154,075 36,488 23.7 %
Total operating expenses, net384,871 381,253 3,618 0.9 %879,232 881,747 (2,515)(0.3)%
Operating income151,442 192,210 (40,768)(21.2)%879,254 789,720 89,534 11.3 %
Other expense/(income)
Equity in losses/(earnings) of equity method investees5,222 3,251 1,971 60.6 %(28,614)2,117 (30,731)*
Interest expense46,033 46,977 (944)(2.0)%139,932 141,006 (1,074)(0.8)%
Other income, net(21,890)(78,432)56,542 (72.1)%(214,566)(193,497)(21,069)10.9 %
Total other expense/(income), net29,365 (28,204)57,569 *(103,248)(50,374)(52,874)105.0 %
Consolidated net income122,077 220,414 (98,337)(44.6)%982,502 840,094 142,408 17.0 %
Net income attributable to non-controlling interests49,963 77,763 (27,800)(35.7)%342,008 341,178 830 0.2 %
Net income attributable to Royalty Pharma plc$72,114 $142,651 $(70,537)(49.4)%$640,494 $498,916 $141,578 28.4 %
*Percentage change is not meaningful.

34

Total income and other revenues

Income from financial royalty assets

Income from financial royalty assets by top products for the third quarter and first nine months of 2023 and 2022 is as follows, in order of contribution to income for the first nine months of 2023 (in thousands):

For the Three Months Ended September 30,ChangeFor the Nine Months Ended September 30,Change
20232022$ % 20232022$ %
Cystic fibrosis franchise$218,938 $203,383 $15,555 7.6 %$631,813 $599,504 $32,309 5.4 %
Zavzpret— — — n/a153,649 — 153,649 n/a
Imbruvica38,463 76,251 (37,788)(49.6)%136,785 244,515 (107,730)(44.1)%
Tysabri42,682 54,029 (11,347)(21.0)%130,658 157,953 (27,295)(17.3)%
Tremfya36,937 30,493 6,444 21.1 %114,422 72,309 42,113 58.2 %
Trelegy32,234 25,582 6,652 26.0 %96,571 25,582 70,989 *
Other products139,403 161,944 (22,541)(13.9)%410,791 478,692 (67,901)(14.2)%
Total income from financial royalty assets$508,657 $551,682 $(43,025)(7.8)%$1,674,689 $1,578,555 $96,134 6.1 %
*Percentage change is not meaningful.

Three months ended September 30, 2023 and 2022

Income from financial royalty assets decreased by $43.0 million, or 7.8%, in the third quarter of 2023 compared to the third quarter of 2022, primarily due to declines in sell-side equity research analysts’ consensus sales forecasts for Imbruvica and Tysabri. The decrease was partially offset by the strong performances of the cystic fibrosis franchise, Trelegy and Tremfya as well as income related to recently acquired assets, such as Spinraza, which was acquired in the first quarter of 2023.

Nine months ended September 30, 2023 and 2022

Income from financial royalty assets increased by $96.1 million, or 6.1%, in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by the FDA approval of Pfizer’s Zavzpret in March 2023. This FDA approval resulted in our receipt of a $475.0 million milestone payment and $153.6 million of interest income recognized in the first quarter of 2023. The difference between the milestone payment and interest income is attributable to the derecognition of the related financial royalty asset and the settlement of the related derivative instrument. Income from recently acquired assets, primarily Trelegy, contributed to the increase, partially offset by declines in sell-side equity research analysts’ consensus sales forecasts for Imbruvica and Tysabri.

Revenue from intangible royalty assets

Three months ended September 30, 2023 and 2022

Revenue from intangible royalty assets was relatively flat in the third quarter of 2023 compared to the third quarter of 2022.

Nine months ended September 30, 2023 and 2022

Revenue from intangible royalty assets decreased by $36.6 million, or 98.4%, in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by the maturity of our royalties on Januvia and Janumet in the first quarter of 2022.

35

Other royalty income

Three months ended September 30, 2023 and 2022

Other royalty income increased by $6.7 million, or 32.3%, in the third quarter of 2023 compared to the third quarter of 2022, primarily driven by growth in the ongoing product launch of Trodelvy that arose from our R&D funding agreement with Immunomedics.

Nine months ended September 30, 2023 and 2022

Other royalty income increased by $27.5 million, or 49.3% in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by income from fully amortized financial royalty assets which was reflected as Income from financial royalty assets in the first nine months of 2022 and growth of Trodelvy.

Provision for changes in expected cash flows from financial royalty assets

Provision activity is a combination of income and expense items. The provision breakdown by royalty asset (exclusive of the provision for current expected credit losses) based on the largest contributors to each period’s provision income or expense (in thousands) is as follows:

For the Three Months Ended September 30, 2023For the Three Months Ended September 30, 2022
RoyaltyRoyalty
Tysabri$145,004 Imbruvica$133,750 
Xtandi52,705 Tysabri119,691 
Tremfya45,873 Xtandi73,063 
Tazverik6,606 Tazverik46,804 
Crysvita(11,467)Cystic fibrosis franchise(54,609)
Other8,504 Other41,976 
Total provision, exclusive of provision for credit losses247,225 Total provision, exclusive of provision for credit losses360,675 
Provision for current expected credit losses29,912 Provision for current expected credit losses(55,614)
Total provision$277,137 Total provision$305,061 
For the Nine Months Ended September 30, 2023For the Nine Months Ended September 30, 2022
RoyaltyRoyalty
Imbruvica$231,453 Imbruvica $314,044 
Tremfya151,563 Tazverik 124,975 
Tysabri143,998 Tysabri 103,073 
Xtandi60,536 Xtandi 54,116 
Evrysdi(46,077)Cystic fibrosis franchise (48,636)
Other64,291 Other166,397 
Total provision, exclusive of provision for credit losses605,764 Total provision, exclusive of provision for credit losses713,969 
Provision for current expected credit losses31,405 Provision for current expected credit losses(118,573)
Total provision$637,169 Total provision$595,396 

Three months ended September 30, 2023 and 2022

In the third quarter of 2023, we recorded provision expense of $277.1 million, comprised of $247.2 million in provision expense for changes in expected cash flows and $29.9 million in provision expense for current expected credit losses. We recorded provision expense for changes in expected cash flows primarily related to Tysabri, Xtandi and Tremfya due to declines in sell-side equity research analysts’ consensus sales forecasts. The provision expense for credit losses was primarily driven by the additions of Skytrofa and Adstiladrin to our portfolio of financial royalty assets with limited protective rights.

36

In the third quarter of 2022, we recorded provision expense of $305.1 million, comprised of $360.7 million in provision expense for changes in expected cash flows and $55.6 million in provision income for current expected credit losses. We recorded provision expense for changes in expected cash flows primarily related to Imbruvica, Tysabri, Xtandi and Tazverik due to significant declines in sell-side equity research analysts’ consensus sales forecasts, which was partially offset by provision income for the cystic fibrosis franchise due to an increase in sell-side equity research analysts’ consensus sales forecasts. The provision income for credit losses was primarily driven by a change in the payor for a particular product.

Nine months ended September 30, 2023 and 2022

In the first nine months of 2023, we recorded provision expense of $637.2 million, comprised of $605.8 million in provision expense for changes in expected cash flows and $31.4 million in provision expense for current expected credit losses. We recorded provision expense for changes in expected cash flows for Imbruvica, Tremfya and Tysabri primarily due to declines in sell-side equity research analysts’ consensus sales forecasts. The provision expense for credit losses was primarily driven by the additions of Skytrofa and Adstiladrin to our portfolio of financial royalty assets with limited protective rights.

In the first nine months of 2022, we recorded provision expense of $595.4 million, comprised of $714.0 million in provision expense for changes in expected cash flows and $118.6 million in provision income for current expected credit losses. We recorded provision expense for changes in expected cash flows for Imbruvica, Tazverik and Tysabri primarily due to significant declines in sell-side equity research analysts’ consensus forecasts. The provision income for credit losses was primarily driven by a significant decrease in current expected credit losses related to Tazverik as a result of the decline in the financial asset value as well as a change in the payor for a particular product.

R&D funding expense

Three months ended September 30, 2023 and 2022

R&D funding expense increased by $25.0 million, or 98.0%, in the third quarter of 2023 as compared to the third quarter of 2022. In the third quarter of 2023, we recognized R&D funding expense of $50.0 million related to a clinical milestone payment that was triggered under the agreement with Cytokinetics, Incorporated (“Cytokinetics”). In the third quarter of 2022, we recognized R&D funding expense of $25.0 million to acquire a royalty on a development-stage product from Theravance Biopharma, Inc (“Theravance”).

Nine months ended September 30, 2023 and 2022

R&D funding expense decreased by $75.1 million, or 59.3%, for the first nine months of 2023 as compared to the first nine months of 2022. In the first nine months of 2023, we recognized R&D funding expense of $50.0 million related to a clinical milestone payment that was triggered under the agreement with Cytokinetics. In the first nine months of 2022, we recognized R&D funding expense of $125.0 million to acquire royalties and milestones on development-stage products from Cytokinetics and Theravance.

G&A expenses

Three months ended September 30, 2023 and 2022

G&A expenses increased by $6.5 million, or 12.9%, in the third quarter of 2023 as compared to the third quarter of 2022, primarily driven by higher Operating and Personnel Payments due to increased cash receipts from royalty investments.

Nine months ended September 30, 2023 and 2022

G&A expenses increased by $36.5 million, or 23.7%, in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by higher Operating and Personnel Payments due to increased cash receipts from royalty investments, specifically the $475.0 million Zavzpret milestone payment received in the first quarter of 2023.

37

Equity in losses/(earnings) of equity method investees

Three months ended September 30, 2023 and 2022

Equity in losses of equity method investees was relatively flat in the third quarter of 2023 as compared to the third quarter of 2022.

Nine months ended September 30, 2023 and 2022

Equity in earnings of equity method investees was $28.6 million in the first nine months of 2023 compared to equity in losses of equity method investees of $2.1 million in the first nine months of 2022, primarily driven by an income allocation from the Avillion Entities of $28.0 million in the first nine months of 2023 as compared to a loss allocation of $9.3 million in the first nine months of 2022. The income allocation in the first nine months of 2023 from the Avillion Entities was primarily driven by an $80 million payment the Avillion Entities received related to AstraZeneca’s election to exercise an option to commercialize Airsupra in the United States.

Interest expense

Three months ended September 30, 2023 and 2022

Interest expense was relatively flat in the third quarter of 2023 as compared to the third quarter of 2022. In September 2023, we repaid $1.0 billion of senior unsecured notes. The weighted average coupon rate on our senior unsecured notes outstanding as of September 30, 2023 and 2022 was 2.48% and 2.24%, respectively.

Nine months ended September 30, 2023 and 2022

Interest expense was relatively flat in the first nine months of 2023 compared to the first nine months of 2022.

Refer to the “Liquidity and Capital Resources” section for additional discussion of debt financing arrangements.

Other income, net

Three months ended September 30, 2023 and 2022

Other income, net of $21.9 million in the third quarter of 2023 was primarily comprised of $23.4 million of interest income earned on cash held in banks and money market funds.

Other income, net of $78.4 million in the third quarter of 2022 was primarily comprised of $44.2 million of gains on available for sale debt securities and $25.8 million of gains on the milestone acceleration option derivative financial instrument, primarily driven by the estimated high probability of a change of control event for Biohaven.

Nine months ended September 30, 2023 and 2022

Other income, net of $214.6 million in the first nine months of 2023 was primarily comprised of $122.5 million of gains on available for sale debt securities, $65.8 million of interest income earned on cash held in banks and money market funds and $32.0 million of gains on equity securities. The gains on available for sale debt securities were primarily driven by the change in fair value of the Development Funding Bonds.

Other income, net of $193.5 million in the first nine months of 2022 was primarily comprised of $98.0 million of gains on available for sale debt securities and $97.6 million of gains on the milestone acceleration option derivative financial instrument, both driven by the estimated high probability of a change of control event for Biohaven.

38

Net income attributable to non-controlling interests

Three months ended September 30, 2023 and 2022

Net income attributable to the Legacy Investors Partnerships increased by $4.2 million in the third quarter of 2023 as compared to the third quarter of 2022, primarily driven by higher net income attributable to Old RPI and RPI ICAV.

Net income attributable to the Continuing Investors Partnerships decreased by $30.3 million in the third quarter of 2023 as compared to the third quarter of 2022, primarily driven by lower net income attributable to RP Holdings in the third quarter of 2023 and a decline in the Continuing Investors Partnerships’ ownership of RP Holdings resulting from the exchanges by investors in the Continuing Investors Partnerships who indirectly own RP Holdings Class B Interests for our Class A ordinary shares.

Net income attributable to RPSFT decreased by $1.7 million in the third quarter of 2023 as compared to the third quarter of 2022 in line with our expectation as the assets held by RPCT mature.

Nine months ended September 30, 2023 and 2022

Net income attributable to the Legacy Investors Partnerships decreased by $21.6 million in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by lower net income attributable to Old RPI.

Net income attributable to the Continuing Investors Partnerships increased by $31.1 million in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by higher net income attributable to RP Holdings as a result of increased interest income related to the FDA approval of Zavzpret in March 2023. This was partially offset by exchanges by investors in the Continuing Investors Partnerships who indirectly own RP Holdings Class B Interests for our Class A ordinary shares, which resulted in a decline in the Continuing Investors Partnerships’ ownership of RP Holdings.

Net income attributable to RPSFT decreased by $8.6 million in the first nine months of 2023 compared to the first nine months of 2022 in line with our expectations as the underlying assets mature.

Investments Overview

Ongoing investment in new royalties is fundamental to the long-term prospects of our business. New investments provide a source of growth for our royalty receipts, supplementing growth within our existing portfolio and offsetting declines for royalties on products that have lost market exclusivity. We evaluate an array of royalty acquisition opportunities on a continuous basis and expect to continue to make acquisitions in the ordinary course of our business. We have established a strong track record of identifying, evaluating and investing in royalties tied to leading products across therapeutic areas and treatment modalities. We invest in approved products and development-stage product candidates that have generated robust proof of concept data. We invest in these therapies through the purchase of royalties, milestones and related assets, by making hybrid investments and by acquiring businesses with significant existing royalty assets or the potential for the creation of such assets.

During the first nine months of 2023, we invested $1.2 billion in royalties, milestones and related assets. While volatility exists in the total amount of our new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods. Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold.

Summary of Royalty Acquisition Activities

•In October 2023, we acquired additional royalties on Roche’s Evrysdi, an approved product for the treatment of spinal muscular atrophy, from PTC Therapeutics, Inc. (“PTC”) for an upfront payment of $1 billion. Until December 31, 2025, PTC has an option to sell its remaining royalties for $500 million less royalties received in five equal tranches. If PTC exercises its options for fewer than three tranches, we have an option to acquire half of PTC’s remaining royalties for $250 million less royalties received until March 31, 2026.

39

•In September 2023, we acquired a royalty interest in Skytrofa from Ascendis Pharma A/S for an upfront payment of $150 million. Skytrofa is approved for the treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone.

•In August 2023, we acquired a royalty interest in Adstiladrin from Ferring Pharmaceuticals for an upfront payment of $300 million and a $200 million additional milestone payment contingent on certain manufacturing goals. Adstiladrin is approved for the treatment of adult patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

•In June 2023, we acquired an incremental royalty interest in Erleada from the Regents of the University of California for an upfront payment of $59 million. Erleada is approved for the treatment of prostate cancer and is marketed by Johnson & Johnson.

•In March 2023, we acquired a royalty interest in KarXT from PureTech Health plc for an upfront payment of $100 million and up to $400 million in milestone payments contingent on the achievement of certain regulatory and commercial milestones. KarXT is in Phase 3 development by Karuna Therapeutics for the treatment of psychiatric and neurological conditions, including schizophrenia as a monotherapy and adjunctive therapy and psychosis in Alzheimer’s disease.

•In January 2023, we acquired royalty interests in Spinraza and pelacarsen from Ionis Pharmaceuticals, Inc. for an upfront payment of $500 million and committed up to $625 million in additional payments contingent upon the achievement of certain pelacarsen milestones. Spinraza is approved for the treatment of spinal muscular atrophy and pelacarsen is in Phase 3 development by Novartis for the treatment of cardiovascular disease.

•In November 2022, we acquired a royalty interest in olpasiran from Arrowhead Pharmaceuticals for an upfront payment of $250 million and certain contingent clinical, regulatory, and sales-based milestones of up to $160 million. Olpasiran is currently in Phase 3 development for the treatment of atherosclerotic cardiovascular disease and is licensed to Amgen.

•In October 2022, we entered into a R&D funding agreement with MSD International Business GmbH (“Merck”) to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia. We funded $50 million upon closing, and if Merck decides to proceed with Phase 3, we have the option to fund up to an additional $375 million. In exchange, we are eligible to receive milestone payments associated with certain regulatory approvals as well as royalties on annual worldwide sales of any approved product.

•In July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy for an upfront payment of $1.31 billion and up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine.

•In June 2022, we acquired an ex-U.S. royalty interest in Gavreto from Blueprint Medicines for an upfront payment of $175 million and contingent sales-based milestones up to $165 million. During the fourth quarter of 2022, we impaired our financial royalty asset related to Gavreto and recorded a non-cash impairment charge of $182.1 million.

•In April 2022, we acquired common stock and a revenue participation right from ApiJect Holdings, Inc. for $50 million.

40

•In January 2022, we acquired a royalty interest in aficamten, a development-stage product for obstructive hypertrophic cardiomyopathy (“oHCM”), for an upfront payment of $50 million and two additional contingent $50 million payments, which are triggered upon the initiation of potential pivotal clinical trials for oHCM and nHCM, respectively. In February 2022, one of the $50 million contingent milestone payments was triggered following Cytokinetics’ announcement that it initiated the clinical trial for oHCM. In September 2023, Cytokinetics announced the start of ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with symptomatic nHCM. The initiation of ACACIA-HCM triggered a $50 million milestone payment to Cytokinetics in September 2023. Additionally, we entered into a funding agreement to provide Cytokinetics long-term capital of up to $300 million (“Cytokinetics Commercial Launch Funding”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil, both development-stage products. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50 million that was funded upon closing. In June 2022, we amended the funding agreement to increase the required draw amount and further amended the funding agreement in December 2022 to extend the draw periods and increase the repayment terms of the second and third tranche. Both tranches two and three became unavailable for draw due to the regulatory milestones not being met by March 31, 2023.

Liquidity and Capital Resources

Overview

Our primary source of liquidity is cash provided by operations. For the first nine months of 2023 and 2022, we generated $2.2 billion and $1.6 billion, respectively, in Net cash provided by operating activities. We believe that our existing capital resources, cash provided by operating activities and access to our undrawn Revolving Credit Facility (defined below) will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&D funding arrangements, and to meet our debt service obligations for the foreseeable future. We have historically operated at a low level of fixed operating costs. Our primary cash operating expenses, other than R&D funding commitments, include interest expense, our Operating and Personnel Payments, and legal and professional fees.

As of September 30, 2023, our cash and cash equivalents totaled $936.4 million. We did not hold any marketable securities as of September 30, 2023. As of December 31, 2022, our cash and cash equivalents and marketable securities totaled $1.7 billion and $24.4 million, respectively. We intend to fund short-term and long-term financial obligations as they mature through cash and cash equivalents, sales of marketable securities, future cash flows from operations or the issuance of additional debt. Our ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the sales of the underlying pharmaceutical products in which we hold royalties, deterioration in our key financial ratios or credit ratings, or other material unfavorable changes in business conditions. Currently, we believe that we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives.

We have access to substantial sources of funds in the capital markets and we may, from time to time, seek additional capital through a combination of additional debt or equity financings. In September 2023, we repaid $1.0 billion of senior unsecured notes upon maturity. As of September 30, 2023 and December 31, 2022, the par values of our total outstanding borrowings were $6.3 billion and $7.3 billion, respectively. Additionally, we have a Revolving Credit Facility which provides for borrowing capacity of up to $1.5 billion. In October 2023, we drew $350 million on the Revolving Credit Facility, resulting in a remaining borrowing capacity of $1.15 billion under the Revolving Credit Facility. A summary of our borrowing activities, balances and compliance with certain debt covenants under various financing arrangements is included in Note 9–Borrowings of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

We have historically funded our acquisition program through operating cash flows, equity contributions and debt. Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high conversion of our Adjusted Cash Receipts to Adjusted Cash Flow (refer to section below titled “Sources of Capital” for further discussion). We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and our acquisition program through cash flow and issuances of equity and debt. In the past, we have supplemented our available cash and cash equivalents on hand with attractive debt capital to fund certain strategic acquisitions.

41

Our ability to satisfy our working capital needs, debt service and other obligations, and to comply with the financial covenants under our financing agreements depends on our future operating performance and cash flow, which are in turn subject to prevailing economic conditions and other factors, many of which are beyond our control.

Cash Flows

The following table and analysis of cash flow changes presents a summary of our cash flow activity for the first nine months of 2023 and 2022 (in thousands):

For the Nine Months Ended September 30,
20232022Change
Cash provided by (used in):
     Operating activities$2,215,174 $1,574,049 $641,125 
     Investing activities(1,072,617)(1,444,163)371,546 
     Financing activities(1,916,860)(679,306)(1,237,554)

Analysis of Cash Flow Changes

Operating Activities

Cash provided by operating activities increased by $641.1 million in the first nine months of 2023 compared to the first nine months of 2022, driven by an increase in cash collections from financial royalty assets of $610.2 million, including a $475.0 million milestone payment related to Zavzpret, and lower development-stage funding payments in the first nine months of 2023. The increase was partially offset by lower cash collections from intangible assets of $71.3 million, as our royalty receipts on Januvia, Janumet and other DPP-IVs substantially ended in the second quarter of 2022, and higher payments for operating and professional costs.

Investing Activities

Cash used in investing activities decreased by $371.5 million in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by a $378.1 million decrease in cash used for acquisitions of financial royalty assets and a decrease of $346.9 million from purchases of and redemptions from available for sale securities in 2022 that did not occur in 2023. Lower net cash provided by marketable securities of $417.4 million partially offset the decrease in cash used in investing activities in the first nine months of 2023 compared to the first nine months of 2022.

Financing Activities

Cash used in financing activities increased by $1.2 billion in the first nine months of 2023 compared to the first nine months of 2022 primarily driven by $1.0 billion in debt repayment and $274.6 million in repurchases of Class A ordinary shares. The increase was partially offset by lower distributions of royalty receipts to legacy non-controlling interests as royalties jointly owned by the Legacy Investors Partnerships and RPSFT are maturing.

Sources of Capital

Our business model is different from that of traditional operating companies in the biopharmaceutical industry. We use the cash generated by existing royalties to fund investments in new royalties and believe that each of our non-GAAP measures represent sources of capital that are critical for investors to understand our business and to evaluate management’s ability to execute on our strategy. Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are each presented as non-GAAP liquidity measures that are supplemental to our GAAP measures.

42

Adjusted Cash Receipts and Adjusted Cash Flow reflect management’s ability to successfully operate the business by generating capital to fund investments in royalty-generating assets, debt repayments, dividends and other discretionary investments. Our non-GAAP measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are most directly comparable to the GAAP measure Net cash provided by operating activities. Each of our non-GAAP measures are calculated using inputs directly from our GAAP statements of cash flows.

Adjusted Cash Receipts enables investors to better analyze our liquidity and long-term growth prospects by providing a more granular presentation of the underlying cash generation of its royalty investments. Adjusted Cash Receipts is a measure calculated with inputs directly from the statements of cash flows and includes total royalty receipts: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from equity method investees, and (iv) Proceeds from available for sale debt securities; less Distributions to legacy non-controlling interests - royalty receipts, which represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to the Legacy Investors Partnerships and RPSFT.

Adjusted EBITDA is an important non-GAAP used by our lenders to assess our ability to meet our financial covenants. Adjusted EBITDA is calculated as Adjusted Cash Receipts less Payments for operating and professional costs. The definition of Adjusted EBITDA is the same as the definition of consolidated EBITDA in the Credit Agreement (defined below). We believe the covenants in the Credit Agreement related to consolidated EBITDA are material terms of the Credit Agreement. Refer to the Senior Unsecured Revolving Credit Facility section below for additional discussion of the Credit Agreement calculation of Adjusted EBITDA.

Our operating performance is a function of our liquidity. Adjusted Cash Flow provides meaningful information about our operating performance because one of our core business strategies is to generate consistent cash flows that can be redeployed into new royalty investments. Adjusted Cash Flow is defined as core cash collections less cash charges, including net interest paid, and reflects management’s ability to successfully operate the business and generate cash flow. Tracking Adjusted Cash Flow over time helps to identify underlying trends in the business and permits management and investors to better understand our performance. Management uses Adjusted Cash Flow for decision-making purposes related to the funding of investments in royalty-generating assets, debt repayments, dividends and other discretionary investments.

Adjusted Cash Flow is calculated as Adjusted Cash Receipts less (1) Payments for operating and professional costs (2) Development-stage funding payments - ongoing, (3) Development-stage funding payments - upfront and milestone, (4) Interest paid, net of Interest received, (5) Investments in equity method investees and (6) Other (including Derivative collateral posted, net of Derivative collateral received, and Termination payments on derivative instruments) plus (1) Contributions from legacy non-controlling interests - R&D, all directly reconcilable to the statements of cash flows.

The non-GAAP measures used in this Quarterly Report on Form 10-Q have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of our results as reported under GAAP. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP measures as supplements to GAAP measures and by presenting the reconciliations of the non-GAAP measures to their most comparable GAAP measures, in each case being Net cash provided by operating activities.

To reconcile Adjusted Cash Receipts, we start with Net cash provided by operating activities and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), which are cash inflows that management believes are derived from royalties and form part of our core business strategy, (2) Distributions from equity method investees, which are classified as cash inflows from investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments, (5) Payments for operating and professional costs, (6) Payments for rebates and (7) Termination payments on derivative instruments, and to deduct (1) Distributions to legacy non-controlling interests - royalty receipts and (2) Derivative collateral posted or (received), net, both of which are excluded when management assesses its operating performance through cash collections, or Adjusted Cash Receipts.

43

To reconcile Adjusted EBITDA, we start with Net cash provided by operating activities and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), (2) Distributions from equity method investees, which are classified as cash inflows from investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments and (5) Termination payments on derivative instruments, and to deduct (1) Distributions to legacy non-controlling interests - royalty receipts and (2) Derivative collateral posted or (received), net.

To reconcile Adjusted Cash Flow, we start with Net cash provided by operating activities and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), (2) Distributions from equity method investees classified as cash inflows from investing activities and (3) Contributions from legacy non-controlling interests - R&D, and to deduct (1) Distributions to legacy non-controlling interests - royalty receipts and (2) Investments in equity method investees. This is intended to present an Adjusted Cash Flow measure that is representative of cash generated from the broader business strategy of acquiring royalty-generating assets that is available for reinvestment and for discretionary purposes.

(in thousands)For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Cash flow data (GAAP basis)
Net cash provided by/(used in):
Operating activities$573,520 $538,827 $2,215,174 $1,574,049 
Investing activities(450,658)(1,425,150)(1,072,617)(1,444,163)
Financing activities(1,359,491)(230,086)(1,916,860)(679,306)
Net cash provided by operating activities (GAAP)$573,520 $538,827 $2,215,174 $1,574,049 
Adjustments:
Proceeds from available for sale debt securities (1), (2)— 15,625 — 46,875 
Distributions from equity method investees (2)4,458 — 39,225 — 
Interest paid, net (2)53,967 75,302 102,706 158,920 
Development-stage funding payments - ongoing (3)500 500 1,500 1,606 
Development-stage funding payments - upfront and milestone (3)50,000 25,000 50,000 125,000 
Payments for operating and professional costs54,961 48,650 188,839 141,653 
Distributions to legacy non-controlling interests - royalty receipts (2)(100,246)(107,183)(284,637)(322,726)
Adjusted Cash Receipts (non-GAAP)$637,160 $596,721 $2,312,807 $1,725,377 
Net cash provided by operating activities (GAAP)$573,520 $538,827 $2,215,174 $1,574,049 
Adjustments:
Proceeds from available for sale debt securities (1), (2)— 15,625 — 46,875 
Distributions from equity method investees (2) 4,458 — 39,225 — 
Interest paid, net (2)53,967 75,302 102,706 158,920 
Development-stage funding payments - ongoing (3)500 500 1,500 1,606 
Development-stage funding payments - upfront and milestone (3)50,000 25,000 50,000 125,000 
Distributions to legacy non-controlling interests - royalty receipts (2)(100,246)(107,183)(284,637)(322,726)
Adjusted EBITDA (non-GAAP) (4)$582,199 $548,071 $2,123,968 $1,583,724 
Net cash provided by operating activities (GAAP)$573,520 $538,827 $2,215,174 $1,574,049 
Adjustments:
Proceeds from available for sale debt securities (1), (2)— 15,625 — 46,875 
Distributions from equity method investees (2) 4,458 — 39,225 — 
Contributions from legacy non-controlling interests - R&D (2)88 240 455 971 
Investments in equity method investees (2), (5)(3,984)(6,846)(10,550)(9,896)
Distributions to legacy non-controlling interests - royalty receipts (2)(100,246)(107,183)(284,637)(322,726)
Adjusted Cash Flow (non-GAAP)$473,836 $440,663 $1,959,667 $1,289,273 
44

(1)In 2022, amounts related to the quarterly redemptions of the Series A Biohaven Preferred Shares are presented as Proceeds from available for sale debt securities on the condensed consolidated statements of cash flows.
(2)The table below shows the line item for each adjustment and the direct location for such line item on the condensed consolidated statements of cash flows.
Reconciling Adjustment
Condensed Consolidated Statements
of Cash Flows Classification
Interest paid, net
Operating activities (Interest paid less Interest received)
Distributions from equity method investeesInvesting activities
Investments in equity method investeesInvesting activities
Proceeds from available for sale debt securitiesInvesting activities
Distributions to legacy non-controlling interests - royalty receiptsFinancing activities
Contributions from legacy non-controlling interests - R&DFinancing activities
(3)Our lenders consider all payments made to support R&D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing development-stage funding payments and upfront and milestone development-stage funding payments are reported as R&D funding expense in net income and are added back in aggregate to Net cash provided by operating activities to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for development-stage funding payments.
(4)Refer to the discussion of our Senior Unsecured Revolving Credit Facility below for additional discussion of the Credit Agreement calculation of Adjusted EBITDA.
(5)Our lenders consider all payments to fund our operating joint ventures that are performing R&D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.

45

The table below includes the royalty receipts and non-GAAP financial results for the third quarter and first nine months of 2023 and 2022 by product in order of contribution to total royalty receipts for the first nine months of 2023 (in thousands).

For the Three Months Ended September 30,For the Nine Months Ended September 30,
Nine Months Year-to-Date Change
2023202220232022$ %
Cystic fibrosis franchise (1)
$237,902 $207,882 $660,673 $591,733 $68,940 11.7 %
Zavzpret milestone (2)
— — 475,000 — 475,000 n/a
Tysabri86,704 91,252 256,932 281,819 (24,887)(8.8)%
Imbruvica62,174 74,391 193,895 241,943 (48,048)(19.9)%
Trelegy58,240 42,720 143,111 42,720 100,391 *
Promacta54,122 50,067 142,406 132,679 9,727 7.3 %
Xtandi47,119 45,717 131,366 141,100 (9,734)(6.9)%
Tremfya27,194 21,409 81,117 68,062 13,055 19.2 %
Cabometyx/Cometriq17,294 14,612 48,234 40,523 7,711 19.0 %
Evrysdi15,749 9,602 46,318 26,933 19,385 72.0 %
Farxiga/Onglyza 10,478 11,522 32,274 32,336 (62)(0.2)%
Prevymis15,343 11,052 29,157 25,174 3,983 15.8 %
Trodelvy11,058 6,496 28,137 17,428 10,709 61.4 %
Spinraza15,253 — 27,815 — 27,815 n/a
Erleada8,959 5,586 22,390 15,305 7,085 46.3 %
Orladeyo7,776 6,265 21,130 15,456 5,674 36.7 %
Crysvita4,679 5,241 15,696 14,887 809 5.4 %
Nurtec ODT/Biohaven payment (3)6,218 20,459 15,659 59,549 (43,890)(73.7)%
Emgality4,903 4,657 14,350 13,845 505 3.6 %
Other products (4)46,241 74,974 211,784 286,611 (74,827)(26.1)%
Total royalty receipts$737,406 $703,904 $2,597,444 $2,048,103 $549,341 26.8 %
Distributions to legacy non-controlling interests - royalty receipts(100,246)(107,183)(284,637)(322,726)38,089 (11.8)%
Adjusted Cash Receipts (non-GAAP)$637,160 $596,721 $2,312,807 $1,725,377 $587,430 34.0 %
Payments for operating and professional costs(54,961)(48,650)(188,839)(141,653)(47,186)33.3 %
Development-stage funding payments - ongoing(500)(500)(1,500)(1,606)106 (6.6)%
Development-stage funding payments - upfront and milestone(50,000)(25,000)(50,000)(125,000)75,000 (60.0)%
Interest paid, net(53,967)(75,302)(102,706)(158,920)56,214 (35.4)%
Investments in equity method investees(3,984)(6,846)(10,550)(9,896)(654)6.6 %
Contributions from legacy non-controlling interests - R&D88 240 455 971 (516)(53.1)%
Adjusted Cash Flow (non-GAAP)$473,836 $440,663 $1,959,667 $1,289,273 $670,394 52.0 %
Weighted average Class A ordinary shares outstanding - diluted601,138607,226604,717607,209
*Percentage change is not meaningful
(1)The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(2)Related to a $475.0 million milestone payment that we received in the first quarter of 2023 following the FDA approval of Zavzpret.
(3)In 2022, amounts include the $15.6 million quarterly redemption payments related to the Series A Biohaven Preferred Shares (presented as Proceeds from available for sale debt securities on the condensed consolidated statements of cash flows). The Series A Biohaven Preferred Shares were fully redeemed in October 2022 following Pfizer’s acquisition of Biohaven. The remaining amounts are related to royalty receipts from Nurtec ODT.
(4)Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion I, for which receipts are presented as Distributions from equity method investees in the operating section of the condensed consolidated statements of cash flows), Cimzia, Entyvio, IDHIFA, Januvia, Janumet, Other DPP-IVs, Lexiscan, Nesina and Soliqua. Other products also include distributions from the Legacy SLP Interest which are presented as Distributions from equity method investees in both the investing and operating section of the condensed consolidated statements of cash flows. In the first nine months of 2023, we received $34.8 million from our joint venture investee, Avillion II, for our pro rata portion of the $80 million fee paid by AstraZeneca to exercise the option to commercialize Airsupra in the United States (presented as Distributions from equity method investees in the investing section of the condensed consolidated statements of cash flows).
46

Adjusted Cash Receipts (non-GAAP)

Adjusted Cash Receipts increased by $587.4 million to $2.3 billion in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by a $475.0 million milestone payment that we received following the FDA’s approval of Zavzpret in March 2023, royalty receipts from newly acquired royalties, an increase in royalty receipts from the strong performance of the cystic fibrosis franchise and a decrease in distributions of royalty receipts to legacy non-controlling interests due to maturing royalties jointly owned by the Legacy Investors Partnerships and RPSFT. The increase in cash receipts was partially offset by a decline in royalty receipts from maturing royalties, primarily Januvia, Janumet and other DPP-IVs, as well as a decrease in royalty receipts from Imbruvica. Additionally, we received redemption payments related to Series A Biohaven Shares in the first nine months of 2022 for which there was no comparable activity in the first nine months of 2023 as the Series A Biohaven Preferred Shares were fully redeemed in October 2022.

Below we discuss the key drivers of total royalty receipts.

•Cystic fibrosis franchise – Royalty receipts from the cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, which are marketed by Vertex for patients with certain mutations causing cystic fibrosis, increased by $68.9 million in the first nine months of 2023 compared to the first nine months of 2022. The increase was primarily driven by the rapid uptake of Kaftrio outside the United States and the continued performance of Trikafta in the United States, including their uptake in younger age groups.

•Zavzpret milestone – We received a $475.0 million milestone payment in the first nine months of 2023 following FDA approval of Zavzpret (zavegepant), a calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults, which is marketed by Pfizer.

•Tysabri – Royalty receipts from Tysabri, which is marketed by Biogen for the treatment of multiple sclerosis, decreased by $24.9 million in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by pricing pressure, competition and channel dynamics.

•Imbruvica – Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson & Johnson for the treatment of blood cancers and chronic graft versus host disease, decreased by $48.0 million in the first nine months of 2023 compared to the first nine months of 2022. Imbruvica continues to be unfavorably impacted by increased competition and the cumulative impact of a suppressed chronic lymphocytic leukemia market.

•Trelegy – Royalty receipts from Trelegy, which is marketed by GSK for the maintenance treatment of chronic obstructive pulmonary disease and asthma, were $143.1 million in the first nine months of 2023, primarily driven by strong patient demand globally and the growth of the single inhaler triple therapy market. We acquired the Trelegy royalty in the third quarter of 2022.

•Promacta – Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia purpura (ITP) and aplastic anemia, increased by $9.7 million in the first nine months of 2023 compared to the first nine months of 2022. This growth was primarily driven by increased use in chronic ITP and further uptake as first-line and/or second-line treatment for severe aplastic anemia.

•Xtandi – Royalty receipts from Xtandi, which is marketed by Pfizer and Astellas for the treatment of prostate cancer, decreased by $9.7 million in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by underperformance in the United States, offset by the sales performance in established markets.

•Tremfya – Royalty receipts from Tremfya, which is marketed by Johnson & Johnson for the treatment of plaque psoriasis and active psoriatic arthritis, increased by $13.1 million in the first nine months of 2023 compared to the first nine months of 2022, primarily due to market growth and continued market share gains, which were partially offset by an unfavorable prior period adjustment taken by Johnson & Johnson, patient mix and rebates.

47

•Cabometyx/Cometriq – Royalty receipts from Cabometyx/Cometriq, which is marketed by Exelixis, Ipsen and Takeda, increased by $7.7 million in the first nine months of 2023 compared to the first nine months of 2022, primarily due to the uptake of Cabometyx in combination with Opdivo as a first-line treatment for patients with advanced renal cell carcinoma.

•Spinraza – Royalty receipts from Spinraza, which is marketed by Biogen for the treatment of spinal muscular atrophy, were $27.8 million in the first nine months of 2023, primarily driven by growth outside the United States, offset by fewer new patient starts and channel dynamics in the United States. We acquired the Spinraza royalty in the first quarter of 2023.

•Nurtec ODT/Biohaven payment – Royalty receipts from Nurtec ODT, which is marketed by Pfizer for the acute and preventative treatment of migraine, increased by $3.0 million in the first nine months of 2023 compared to the first nine months of 2022, primarily driven by demand growth. In the first nine months of 2022, we also received $46.9 million in redemption payments related to the Series A Biohaven Preferred Shares. The Series A Biohaven Preferred Shares were fully redeemed in October 2022 following Pfizer’s acquisition of Biohaven.

•Other products – Royalty receipts from other products decreased by $74.8 million in the first nine months of 2023 compared to the first nine months of 2022, driven by a decline in royalty receipts from maturing royalties, primarily Januvia, Janumet and other DPP-IVs, and from Lexiscan due to generic competition. The decrease was partially offset by a $34.8 million receipt from our joint venture investee, Avillion II, for our pro rata portion of the $80 million fee paid by AstraZeneca to exercise the option to commercialize Airsupra in the United States.

Distributions to legacy non-controlling interests - royalty receipts

Distributions of royalty receipts to legacy non-controlling interests decreased by $38.1 million to $284.6 million in the first nine months of 2023 compared to the first nine months of 2022, which positively impacted Adjusted Cash Receipts. The decrease in distributions to non-controlling interests is primarily due to maturing royalties jointly owned by the Legacy Investors Partnerships and RPSFT.

Adjusted Cash Flow (non-GAAP)

Adjusted Cash Flow increased by $670.4 million to $2.0 billion in the first nine months of 2023 compared to the first nine months of 2022, primarily for the same reasons noted above in “Adjusted Cash Receipts.” The increase was further driven by lower development-stage funding payments. In the first nine months of 2023, we made a $50.0 million clinical milestone payment that was triggered under the agreement with Cytokinetics. In the first nine months of 2022, we paid $125.0 million to acquire royalties on development-stage product candidates from Cytokinetics and Theravance. The increase was partially offset by payments for operating and professional costs which increased in the first nine months of 2023 as our Operating and Personnel Payments are primarily comprised of a fixed percentage of 6.5% of cash receipts from our royalties, which is Adjusted Cash Receipts.

48

Borrowings

Our borrowings as of September 30, 2023 and December 31, 2022 consisted of the following (in thousands):

Date of IssuanceMaturityAs of September 30, 2023As of December 31, 2022
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)9/20209/2023$— $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)7/20219/2031600,000 600,000 
$1,000,000, 3.30% (issued at 95.556% of par)9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)7/20219/2051700,000 700,000 
Total senior unsecured debt6,300,000 7,300,000 
Unamortized debt discount and issuance costs(168,806)(183,678)
Total long-term debt, including current portion6,131,194 7,116,322 
Less: Current portion of long-term debt— (997,512)
Total long-term debt$6,131,194 $6,118,810 

Senior Unsecured Notes

On July 26, 2021, we issued $1.3 billion of senior unsecured notes (the “2021 Notes”) with a weighted average coupon rate of 2.80%. On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the “2020 Notes”) with a weighted average coupon rate of 2.13%. We refer to the 2020 Notes and 2021 Notes, collectively, as the “Notes.” The Notes require semi-annual interest payments. Indentures governing the Notes contain certain covenants with which we were in compliance as of September 30, 2023.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the “Credit Agreement”). The Credit Agreement amended and restated the credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Revolving Credit Facility has a maturity date of October 31, 2027. The Credit Agreement contains certain customary covenants which we were in compliance with as of September 30, 2023. In October 2023, we drew $350 million on the Revolving Credit Facility to fund a portion of our acquisition of additional royalties on Roche’s Evrysdi, resulting a remaining borrowing capacity of $1.15 billion under the Revolving Credit Facility.

The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. Our definition of Adjusted EBITDA is the same as the definition of consolidated EBITDA in the Credit Agreement.

49

Adjusted EBITDA, which is the same as our definition of consolidated EBITDA in the Credit Agreement, is a non-GAAP measure that is a key component of certain material covenants contained within the Credit Agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our Credit Agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity. Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for the analysis of our results as reported under GAAP. The table below is a tabular calculation of Adjusted EBITDA, defined in our Credit Agreement as consolidated EBITDA for the third quarter and first nine months of 2023 and 2022 (in thousands):

For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Total royalty receipts$737,406 $703,904 $2,597,444 $2,048,103 
Distributions to legacy non-controlling interests - royalty receipts(100,246)(107,183)(284,637)(322,726)
Adjusted Cash Receipts (non-GAAP)637,160 596,721 2,312,807 1,725,377 
Payments for operating and professional costs(54,961)(48,650)(188,839)(141,653)
Adjusted EBITDA (non-GAAP)
$582,199 $548,071 $2,123,968 $1,583,724 

Uses of Capital

Acquisitions of Royalties

We acquire product royalties in ways that can be tailored to the needs of our partners through a variety of structures:

•Third-party Royalties – Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.

•Synthetic Royalties – Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales by the developer or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing R&D, for biopharmaceutical companies, in exchange for future royalties and milestones if the product or indication we are funding is approved.

•Launch and Development Capital – Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company. The funding of launch and development capital is generally reflected on our statements of cash flows as Purchases of available for sale debt securities.

•M&A Related – We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities such as our strategic alliance with MSCI to develop thematic life sciences indexes.

50

Distributions to Shareholders

We paid dividends to holders of our Class A ordinary shares of $269.0 million and $249.1 million in the first nine months of 2023 and 2022, respectively. We do not have a legal obligation to pay a quarterly dividend or dividends at any specified rate or at all.

Class A Ordinary Share Repurchases

In March 2023, our board of directors authorized a share repurchase program under which we may repurchase up to $1.0 billion of our Class A ordinary shares. The authorization for the share repurchase program expires on June 23, 2027. Share repurchases may be made in the open market or in privately negotiated transactions. In the first nine months of 2023, we repurchased 8,889 thousand shares at a cost of approximately $278.6 million.

Other Funding Arrangements

In January 2022, we entered into a long-term funding agreement, which was amended later in the same year, with Cytokinetics. We agreed to provide funding of up to $300 million (“Cytokinetics Commercial Launch Funding”) in five tranches. The initial tranche of $50 million was funded upon closing. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). The regulatory milestones for the second and third tranches were not met and as such $75 million of the optional funding is no longer available. As of September 30, 2023, $125 million of the optional $200 million remains available under the Cytokinetics Funding Commitments.

We may have other funding arrangements where we are contractually obligated to fund R&D activities performed by our development partners. We also have funding arrangements related to our equity method investments in the Avillion Entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development under such funding arrangements is considered committed capital, which approximates $30.3 million as of September 30, 2023.

We also have certain milestone payments that are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. These contingent milestone payments are not considered contractual obligations. In the first nine months of 2023, we made a $12.4 million sales-based milestone payment related to Erleada and a $50.0 million milestone payment to Cytokinetics which was triggered following the initiation of the first pivotal clinical trial in nHCM. In the first nine months of 2022, we made a $50 million milestone payment to Cytokinetics which was triggered following the initiation of the first pivotal clinical trial in oHCM.

Debt Service

In September 2023, we repaid $1.0 billion of senior unsecured notes upon maturity. As of September 30, 2023, the future principal and interest payments under our Notes over the next five years and thereafter are as follows (in thousands):

YearPrincipal PaymentsInterest Payments
Remainder of 2023$— $— 
2024— 156,350 
20251,000,000 156,350 
2026— 144,350 
20271,000,000 144,350 
Thereafter4,300,000 1,925,900 
Total (1)$6,300,000 $2,527,300 
(1)Excludes unamortized debt discount and issuance costs of $168.8 million as of September 30, 2023, which are amortized through interest expense over the remaining life of the underlying debt obligations.

51

Operating and Personnel Payments

Under the Management Agreement, we pay quarterly Operating and Personnel Payments equal to 6.5% of the cash receipts from royalty investments, which is Adjusted Cash Receipts, for such quarter and 0.25% of our security investments under GAAP as of the end of each quarter. Because the Operating and Personnel Payments are determined based on cash receipts, the amounts are variable. The payment for our Operating and Personnel Payment is the most significant component of Payments for operating and professional costs presented on the statements of cash flows. Additionally, the expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&A expenses on an ongoing basis.

Guarantor Financial Information

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary (the “Guarantor Subsidiary”). Our remaining subsidiaries (the “Non-Guarantor Subsidiaries”) do not guarantee the Notes. Under the terms of the indenture governing the Notes, Royalty Pharma plc and the Guarantor Subsidiary each fully and unconditionally, jointly and severally, guarantee the payment of interest, principal and premium, if any, on the Notes. As of September 30, 2023, the par value and carrying value of the total outstanding and guaranteed Notes was $6.3 billion and $6.1 billion, respectively.

The following financial information presents summarized combined balance sheet information as of September 30, 2023 and December 31, 2022 and summarized combined statement of operations information for the first nine months of 2023 for Royalty Pharma plc and RP Holdings. All intercompany balances and transactions between Royalty Pharma plc and RP Holdings are eliminated in the presentation of the combined financial statements. RP Holdings’ most significant asset is its investment in operating subsidiaries, which has been eliminated in the table below to exclude investments in Non-Guarantor Subsidiaries. Our operating subsidiaries hold the majority of our cash and cash equivalents, marketable securities and financial royalty assets. As a result, our ability to make required payments on the Notes depends on the performance of our operating subsidiaries and their ability to distribute funds to us. There are no material restrictions on distributions from the operating subsidiaries. Amounts presented below do not represent our total consolidated amounts as of September 30, 2023 and December 31, 2022 or for the first nine months of 2023 (in thousands).

Summarized Combined Balance Sheets
As of September 30, 2023As of December 31, 2022
Current assets$52,477 $92,805 
Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries32,584 14,744 
Current intercompany notes receivable due from Non-Guarantor Subsidiaries— 269,617 
Non-current assets 3,243 4,033 
Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries1,890,582 1,986,906 
Current liabilities18,268 1,053,942 
Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries3,195 14,744 
Current intercompany notes payable due to Non-Guarantor Subsidiaries— 269,617 
Non-current liabilities6,130,293 6,118,022 
Non-current intercompany notes payable due to Non-Guarantor Subsidiaries1,557,693 1,655,842 
Summarized Combined Statement of OperationsFor the Nine Months Ended September 30, 2023
Interest income on intercompany notes receivable due from Non-Guarantor Subsidiaries
$64,393 
Other income7,029 
Operating expenses154,753 
Interest expense on intercompany notes due to Non-Guarantor Subsidiaries
35,005 
Net loss 118,336 

52

Critical Accounting Policies and Use of Estimates

The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as they have the most significant impact on our financial condition and results of operations and require the most difficult, subjective, or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of income and expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Our most critical accounting policies relate to our financial royalty assets. Similarly, the most significant judgments and estimates applied by management are associated with the measurement of our financial royalty assets at amortized cost using the prospective effective interest method. The application of the prospective approach to calculate interest income from our financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. There have been no material changes to our critical accounting policies and estimates as described in our Annual Report on Form 10-K.
53

Item 3.         QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4.         CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were, in design and operation, effective to the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the third quarter of 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.

PART II.     OTHER INFORMATION

Item 1.         LEGAL PROCEEDINGS

For a description of our legal proceedings, refer to Note 13–Commitments and Contingencies, which is incorporated herein by reference.

Item 1A.    RISK FACTORS

Described below are certain risks that we believe apply to our business. You should carefully consider the following information about these risks, together with the other information contained in this Quarterly Report on Form 10-Q, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our condensed consolidated financial statements and related notes. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business.

Summary of Risk Factors

Our business is subject to a number of risks, including risks that may adversely affect our business, financial condition and results of operations. These risks are discussed more fully below and include, but are not limited to, risks related to:

54

Risks Relating to Our Business

•sales risks of biopharmaceutical products on which we receive royalties;
•the growth of the royalty market;
•the ability of the Manager to identify suitable assets for us to acquire;
•uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;
•potential strategic acquisitions of biopharmaceutical companies;
•our use of leverage in connection with our capital deployment;
•our ability to leverage our competitive strengths;
•marketers of products that generate our royalties are outside of our control and are responsible for development, pursuit of ongoing regulatory approval, commercialization, manufacturing and marketing;
•governmental regulation of the biopharmaceutical industry;
•interest rate risk, foreign exchange fluctuations and inflation;
•our reliance on the Manager for all services we require and key members of the Manager’s senior advisory team;
•actual and potential conflicts of interest with the Manager and its affiliates;
•the ability of the Manager or its affiliates to attract and retain highly talented professionals;
•the assumptions underlying our business model;
•our reliance on a limited number of products;
•the competitive nature of the biopharmaceutical industry;
Risks Relating to Our Organization and Structure

•our organizational structure, including our status as a holding company;
Risks Relating to Our Class A Ordinary Shares

•volatility of the market price of our Class A ordinary shares;
•our incorporation under English law;
Risks Relating to Taxation

•the effect of changes to tax legislation and our tax position; and
General Risk Factors

•the impact of COVID-19, or the future outbreak of any other infectious or contagious diseases, on our operations.
55

Risks Relating to Our Business

Biopharmaceutical products are subject to sales risks.

Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, changes in the marketer’s strategic priorities, obsolescence, lack of acceptance by government healthcare programs and private insurance plans, loss of patent protection, government regulations, the impact of the COVID-19 global pandemic or other factors, and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals, declining sales or litigation. As a result, payments of our royalties may be reduced or cease. In addition, these payments may be delayed, causing our near-term financial performance to be weaker than expected.

The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business.

We have been able to grow our business over time by primarily acquiring royalties. However, we may not be able to identify and acquire a sufficient number of royalties, or royalties of sufficient scale, to invest the full amount of capital that may be available to us in the future, or at our targeted amount and rate of deployment, which could prevent us from executing our growth strategy and negatively impact our results of operations. Changes in the royalty market, including its structure, participants and growth rate, changes in preferred methods of financing and capital raising in the biopharmaceutical industry, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire royalties, fewer royalties (or fewer royalties of significant scale) being available, or increased competition for royalties. Even if we continue to acquire royalties, they may not generate a meaningful return for a period of several years, if at all, due to numerous factors including the structure of the transaction, or circumstances relating to the underlying products. As a result, we may not be able to continue to grow as we have in the past, or at all.

Acquisitions of royalties on development-stage biopharmaceutical product candidates are subject to a number of uncertainties.

We may acquire more royalties on development-stage product candidates that have not yet received marketing approval by any regulatory authority. There can be no assurance that the FDA, the Medicines and Healthcare products Regulatory Agency (“MHRA”), the European Medicines Agency (“EMA”), Pharmaceuticals and Medical Devices Agency (“PMDA”) or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. For example, in June 2021, we acquired from MorphoSys the right to receive royalties and certain milestone payments on gantenerumab, an anti-amyloid-beta monoclonal antibody that was in Phase 3 development for Alzheimer’s disease by Roche. Subsequently on November 30, 2022, Roche stated that it would discontinue clinical trials of gantenerumab after the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer’s disease did not meet their primary endpoint of slowing clinical decline. As a result, we concluded that a non-cash impairment charge of $273.6 million related to the financial royalty asset associated with gantenerumab was required.

If the FDA, MHRA, the EMA, PMDA or other regulatory authority approves a development-stage product candidate that generates our royalties, the labeling, packaging, manufacturing, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, including for certain patient populations, and could include withdrawal of the product from the market. Uncertainty relating to development-stage product candidates also make it more difficult to develop precise and accurate assumptions for our internal models relating to any such development-stage product candidate, which can result in reduced royalties compared to estimates.

In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or R&D programs. If other product developers introduce and market products that are more effective, safer or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in diminished returns, or potentially reduced royalties for us, adversely affecting our results of operations.

56

Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could adversely affect our business, financial condition and results of operations.

While we believe that we can evaluate the likelihood of a development-stage product candidate’s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success.

Our strategy of acquiring royalty interests in development-stage product candidates, including by co-funding clinical development and acquiring securities of biopharmaceutical companies, is subject to risks and uncertainties.

We intend to continue to provide capital to innovators to co-fund clinical development of a product candidate in exchange for a share of the future revenues of that asset and when we do so, we do not control its clinical development. In these situations, the innovators may not complete activities on schedule or in accordance with our expectations or in compliance with applicable laws and regulations. Failure by one or more of these third parties to meet their obligations or our expectations, comply with applicable laws or regulations or any disruption in the relationships between us and these third parties, could delay or prevent the development, approval, manufacturing or commercialization of the development-stage product candidate for which we have provided funding.

We seek to further expand our market opportunity by acquiring securities issued by biopharmaceutical companies. Where we may acquire equity securities as all or part of the consideration for business development activities, the value of those securities will fluctuate, and may depreciate in value. We will likely not control the company in which we acquire securities, and as a result, we may have limited ability to determine its management, operational decisions and policies. Further, while we may seek to mitigate the risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. In addition, as a result of our activities we receive material non-public information about other companies from time to time. Where such information relates to a company whose equity securities we hold, we may be delayed or prevented from selling such securities when we would otherwise choose to do so, and such delay or prohibition may result in a loss or reduced gain on such securities.

We may undertake strategic acquisitions of biopharmaceutical companies with significant royalty assets. Our failure to realize expected benefits of such acquisitions or our incurrence of unanticipated liabilities, could adversely affect our business, financial condition and results of operations.

We may acquire companies with significant royalty assets or where we believe we could create significant synthetic royalties. These acquired or created royalty assets may not perform as we project. Moreover, the acquisition of operating biopharmaceutical companies will result in the assumption of, or exposure to, liabilities of the acquired business that are not inherent in our other royalty acquisitions, such as direct exposure to product liability claims, high fixed costs and an expansion of our operations and expense structure, thereby potentially decreasing our profitability. The diversion of our management’s attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our on-going business operations. Despite our business, financial and legal due diligence efforts, we have limited experience in assessing acquisition opportunities, and we ultimately may be unsuccessful in ascertaining or evaluating all risks associated with such acquisitions. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or products, which may result in dilution for shareholders or the incurrence of indebtedness. As a result, our acquisition of biopharmaceutical companies could adversely affect our business, financial condition and results of operations.
57

We use leverage in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us.

We use borrowed funds to finance a significant portion of our deployed capital. The use of leverage creates an opportunity for an increased return but also increases the risk of loss if our assets do not generate sufficient income to us. The interest expense and other costs incurred in connection with such borrowings may not be covered by our cash flow. In addition, leverage may inhibit our operating flexibility and reduce cash flow available for dividends to our shareholders. The level of our indebtedness could limit our ability to respond to changing business conditions. The various agreements relating to our borrowings may impose operating and financial restrictions on us which could affect the number and size of the royalties that we may pursue. Therefore, no assurance can be given that we will be able to take advantage of favorable conditions or opportunities as a result of any restrictive covenants under our indebtedness. There can also be no assurance that additional debt financing, either to replace or increase existing debt financing, will be available when needed or, if available, will be obtainable on terms that are commercially reasonable. Additional risks related to our leverage include:
• our royalties may be used as collateral for our borrowings;
• in the event of a default under secured borrowings, if any, one or more of our creditors or their assignees could obtain control of our royalties and, in the event of a distressed sale, these creditors could dispose of these royalties for significantly less value than we could realize for them;
• we have to comply with various financial covenants in the agreements that govern our debt, including requirements to maintain certain leverage ratios and coverage ratios, which may affect our ability to achieve our business objectives;
• our ability to pay dividends to our shareholders may be restricted; and
• to the extent that interest rates at which we borrow increase, our borrowing costs will increase and our leveraging strategy will become more costly, which could lead to diminished net profits.
We do not employ our own personnel and are entirely dependent upon the Manager for all the services we require.
Because we are “externally managed,” we do not employ our own personnel, but instead depend upon the Manager, its executive officers and its employees for all of the services we require. The Manager selects and manages the acquisition of royalties and similar payment streams that meet our investment criteria and provides all our other administrative services. Accordingly, our success is dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Management Agreement has an initial term of ten years, after which it can be renewed for an additional term of three years, unless either we or the Manager provide notice of non-renewal 180 days prior the expiration of the initial term or renewal term. The Manager may not be removed during the initial or any renewal term without cause. While our Management Agreement requires its executives to devote substantially all their time to managing us and any legacy vehicles related to RPI or Old RPI unless otherwise approved by the board of directors, such resources may prove to be inadequate to meet our needs.
The success of our business depends upon key members of the Manager’s senior advisory team who may not continue to work for the Manager.
We depend on the expertise, skill and network of business contacts of the advisory professionals of the Manager, who evaluate, negotiate, structure, execute, monitor and service our assets in accordance with the terms of the Management Agreement. Our future success depends to a significant extent on the continued service and coordination of the advisory professionals of the Manager, particularly Mr. Legorreta. Pursuant to the Management Agreement, executives of the Manager must devote substantially all of their business time to managing us, unless otherwise approved by the board of directors. Despite this, Mr. Legorreta and other key advisory professionals may have other demands on their time, and we cannot assure you that they will continue to be actively involved in our business. Each of these individuals is an employee of the Manager and is not subject to an employment contract with us. The departure of any of these individuals or competing demands on their time could adversely affect our business, financial condition and results of operations.

58

The key advisory professionals of the Manager have relationships with participants in the biopharmaceutical industry, financial institutions and other advisory professionals, which we rely upon to source potential asset acquisition opportunities. If the key advisory professionals of the Manager fail to maintain such relationships, or to develop new relationships with other sources, we may not be able to grow our portfolio. In addition, we can offer no assurance that these relationships, even if maintained, will generate asset acquisition opportunities for us in the future.
There can be no assurance that the policies and procedures we have established to mitigate conflicts of interest will be effective in doing so.
Pursuant to the Management Agreement, the Manager cannot manage another entity that invests in or acquires royalties other than any legacy vehicle related to RPI or Old RPI. Every executive of our Manager is subject to a non-compete agreement that is effective for 18 months following termination of their employment with the Manager for any reason. We are a beneficiary of these agreements. In addition, executives of the Manager must devote substantially all of their time to managing us and any legacy vehicle related to RPI or Old RPI, unless otherwise approved by the board of directors. Despite this, the ability of our Manager and its officers and employees to engage in other business activities, subject to the terms of our Management Agreement, may reduce the amount of time our Manager, its officers or other employees spend managing us.
Furthermore, there could be conflicts of interest between us and our advisory personnel. For instance, Mr. Legorreta, our Chief Executive Officer, is also a co-founder of and has significant influence over Pharmakon Advisors, which shares physical premises with the Manager. Pharmakon manages BioPharma Credit PLC (LSE: BPCR) and other investment vehicles that collectively are leading providers of debt capital to the biopharmaceutical industry. Mr. Legorreta has a substantial investment in BioPharma Credit. In addition, Mr. Legorreta serves as the chairperson of the board of directors of ProKidney Corp. and he has founded and participates in foundations that receive and provide medical research funding. Even though he has the involvement with Pharmakon, BioPharma Credit PLC, ProKidney Corp. and the foundations described above, Mr. Legorreta does not have any material constraints on the time he has available to devote to us and the Manager. From time to time, the Manager and Pharmakon may pursue similar investment opportunities for their respective clients, although we believe that actual conflicts of interest are rare due to the differing investment strategies of Pharmakon and us, and the fact that royalty holders, rather than Pharmakon and us, determine the type of transaction they seek. Under arrangements with Pharmakon, the Manager subleases office space to Pharmakon, and the parties may provide research, business development, legal, compliance, financial and administrative services to one another. The Manager and Pharmakon reimburse each other to the extent that one of them provides materially more services to the other than they receive in return. In consideration of the support provided to Pharmakon by the Manager, certain employees of the Manager receive compensation from Pharmakon.
In addition, the structure of our Manager’s compensation arrangements may have unintended consequences. We have agreed to pay our Manager or its affiliates quarterly operating and personnel expenses (the “Operating and Personnel Payments”), a portion of which is based on the mark-to-market value of security investments, including equity securities and derivative financial instruments, at the end of each quarter and is payable to the Manager regardless of whether we realize any gain on the security investments when sold. Consequently, the Manager may be incentivized to have us make security investments regardless of our expected gain on such investments, which may not align with our or our shareholders’ interests.
To service our indebtedness and meet our other ongoing liquidity needs, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control. If we cannot generate the required cash, we may not be able to make the required payments under our indebtedness.
As of September 30, 2023, our total principal amount of senior unsecured notes outstanding was $6.3 billion. In addition, we have up to $1.5 billion of available revolving commitments under our unsecured revolving credit facility (the “Revolving Credit Facility”). Except for RP Holdings, our subsidiaries that do not guarantee the senior unsecured notes will have no obligation, contingent or otherwise, to pay amounts due under the senior unsecured notes or to make any funds available to pay those amounts, whether by dividend, distribution, loan or other payment. We cannot assure you that our business will generate sufficient cash flow from operations to enable us to pay our indebtedness or to fund our other liquidity needs.
Absent sufficient cash flow and the ability to refinance, we could also be forced to sell assets to make up for any shortfall in our payment obligations. However, the terms of the agreements that govern our existing outstanding debt limit, our and our subsidiaries’ ability to sell assets and also restrict the use of proceeds from such a sale. Accordingly, we may not be able to sell assets quickly enough or for sufficient amounts to enable us to meet our obligations on our indebtedness.

59

Our business is subject to interest rate, foreign exchange and inflation risk.
We are subject to interest rate fluctuation exposure through any borrowings under our Revolving Credit Facility and our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. In addition, the discontinuation, modification or other reform of the London Interbank Offered Rate (“LIBOR”), or the replacement of LIBOR with a different reference rate, such as the Secured Overnight Financing Rate (“SOFR”), could create uncertainty regarding the nature of potential changes to and future utilization of specific reference rates, require us to amend certain agreements or increase our interest expense. To the extent that interest rates generally increase, our borrowing costs will increase and our leveraging strategy will become more costly, leading to diminished net profits.
Certain products pay royalties in currencies other than U.S. dollars, which creates foreign currency risk primarily with respect to the Euro, Canadian dollar, British pound, Swiss franc and Japanese yen, as our functional and reporting currency is the U.S. dollar. In addition, our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. We are also subject to foreign exchange rate risk caused by significant events with macroeconomic impacts, including, but not limited to, the Russia-Ukraine war, COVID-19 pandemic and actions taken by central banks to counter inflation. Changes in the value of currencies relative to the U.S. dollar, or high inflation in countries using a currency other than the U.S. dollar, can impact our revenues, costs and expenses and our financial guidance.
Information about the biopharmaceutical products underlying the royalties we buy available to us may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited.
We may have limited information concerning the products generating the royalties we are evaluating for acquisition. Often, the information we have regarding products following our acquisition of a royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by marketers of the products or others or the nature or amount of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual cash flow from a royalty may be significantly lower than our estimates.
Our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.
Our business model is based on multiple-year internal and external forecasts regarding product sales and numerous product-specific assumptions in connection with each royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding product sales or competition, patent expirations, exclusivity terms, license terms or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be, and in the past have been, adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. The risks relating to these assumptions may be exacerbated for development-stage product candidates due to the uncertainties around their development, labeling, regulatory approval, commercialization timing, manufacturing and supply, competing products or related factors. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us royalties may also prove, and in the past have proven, to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate expected returns or returns in line with our historical financial performance or in the time periods we expect or at all, which could adversely affect our financial condition and results of operation.
We make assumptions regarding the royalty duration for terms that are not contractually fixed, and a shortened royalty term could result in a reduction in the effective interest rate, a decline in income from royalties, significant reductions in royalty payments compared to expectations, or a permanent impairment.
In accordance with generally accepted accounting principles in the United States (“GAAP”), we classify most royalty assets that we acquire as financial assets that are measured at amortized cost using the prospective effective interest method described in ASC 835-30. The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount, net of any purchased receivables. A critical component of such forecast is our assumptions regarding duration of the royalty.
60

The royalty duration is important for purposes of accurately measuring interest income over the life of a royalty. In making assumptions around the royalty duration for terms that are not contractually fixed, we consider the strength of existing patent protection, expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product.
The duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as patent expiration dates, regulatory exclusivity, years from first commercial sale of the patent-protected product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations.
If an unexpected shortening of a royalty term were to occur, it could result in a reduction in the effective interest rate, a decline in income from royalties, and a significant reduction in royalty payments compared to expectations, or a permanent impairment.
Most of our royalties are classified as financial assets that are measured at amortized cost using the effective interest method as a result of which our GAAP results of operations can be volatile and unpredictable.
In accordance with GAAP, most of the royalty assets we acquire are treated as investments in cash flow streams and are thus classified as financial assets. Under this classification, our financial royalty assets are treated as having a yield component that resembles loans measured at amortized cost under the effective interest accounting methodology. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset.
As a result of the non-cash charges associated with the application of the effective interest method accounting methodology, our income statement activity in respect of many of our royalties can be volatile and unpredictable. Small declines in sell-side equity research analysts’ consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise, which is classified as a financial royalty asset. Beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expenses to the income statement and build up a corresponding cumulative allowance which reduced the gross balance for this financial royalty asset. Over the course of 10 quarters, we recognized non-cash provision expenses as a result of these changes in forecasts, including a non-cash expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income in 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by recognizing non-cash provision income of $1.10 billion in 2019 as a result of an increase in sell-side equity research analysts’ consensus sales forecasts associated with the Trikafta approval. The financial statement impact caused by the application of the effective interest accounting methodology could result in a negative perception of our results in a given period.
Our reliance on a limited number of products may adversely affect our business, financial condition and results of operation.
While our current asset portfolio includes royalties relating to over 35 marketed products and 11 development-stage product candidates, the top five product franchises accounted for 66% of our royalty receipts in the first nine months of 2023 (excluding receipt from Zavzpret milestone payment). In addition, our asset portfolio may not be fully diversified by geographic region or other criteria. Any significant deterioration in the cash flows from the top products in our asset portfolio could adversely affect our business, financial condition and results of operations.
61

We face competition in acquiring royalties and locating suitable royalties to acquire.
There are a limited number of suitable and attractive opportunities to acquire high-quality royalties available in the market. Therefore, competition to acquire such royalties is intense and may increase. We compete with other potential acquirers for these opportunities, including companies that market the products on which royalties are paid, financial institutions and others. These competitors may be able to access lower cost capital, may be larger than us, may have relationships that provide them access to opportunities before us, or may be willing to acquire royalties for lower projected returns than we are.
Biopharmaceutical products are subject to substantial competition.
The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product’s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a royalty will not be rendered obsolete or non-competitive by new or alternate products or improvements on which we are not entitled to a royalty made to existing products, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our royalties.
Competitive factors affecting the market position and success of each product include:
•effectiveness;
•safety and side effect profile;
•price, including third-party insurance reimbursement policies;
•timing, introduction and marketer support of the product;
•efficacy and execution of marketing and commercialization strategy;
•market acceptance;
•manufacturing, supply and distribution;
•governmental regulation, including price caps;
•availability of lower-cost generics or biosimilars;
•intellectual property protection and exclusivity;
•treatment innovations that eliminate or minimize the need for a product; and
•product liability claims.
Products for which we have a royalty receivable or other interest may be rendered obsolete or non-competitive by new or alternate products, including generics or biosimilars, improvements on existing products, marketing or commercialization strategies, or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies, products on which we have a royalty may become unattractive to commercialize or obsolete. If a product’s market acceptance is diminished or it is withdrawn from the market, continuing payments with respect to biopharmaceutical products, including royalty payments and payments of interest on and repayment of the principal, may not be made on time or at all, which may affect our ability to realize the benefits of the royalty receivable or other interest in such product and may result in us incurring asset impairment charges. Further, any product for which we have a royalty receivable or other interest that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Many approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. Any of these developments could adversely affect products for which we have a royalty, and consequently could adversely affect our business, financial condition and results of operations.
62

Marketers of products that generate our royalties are outside of our control.
In the case of our royalty receivables, our cash flow consists primarily of payments supported by royalties paid by marketers. These marketers may have interests that are different from our interests. For example, these marketers may be motivated to maximize income by allocating resources to other products and, in the future, may decide to focus less attention on the products generating our royalties or by allocating resources to develop products that do not generate royalties to us. There can be no assurance that any marketer or person with whom the marketer has a working relationship has adequate resources or motivation to continue to produce, market and sell the products generating our royalties. Aside from any limited audit rights relating to the activities of the marketers that we may have in certain circumstances pursuant to the terms of our arrangements with the licensor, we do not have oversight rights with respect to the marketers’ operations and do not have rights allowing us to direct their operations or strategy nor do our agreements contain performance standards for their operations. The calculation of the royalty payments is subject to and dependent upon the adequacy and accuracy of our counterparties’ sales and accounting functions.
While we may be able to receive certain information relating to sales of products through the exercise of audit rights and review of royalty reports we receive from the licensor, such information may be received many months following our recognition of the royalty revenue, may require us to adjust our royalty revenues in later periods and may require expense on our part.
We have limited information on the marketers’ operations. We will not have the right to review or receive certain information relating to products that the marketers may have, including the results of any studies conducted by the marketers or others, or complaints from doctors or users of products. The market performance of the products generating our royalties may therefore be diminished by any number of factors relating to the marketers that are outside of our control.
The marketers of biopharmaceutical products are, generally, entirely responsible for the ongoing regulatory approval, commercialization, manufacturing and marketing of products.
Generally, the holders of royalties on products have granted exclusive regulatory approval, commercialization, manufacturing and marketing rights to the marketers of such products. The marketers have full control over those efforts and sole discretion to determine the extent and priority of the resources they will commit to their program for a product. Accordingly, the successful commercialization of a product depends on the marketer’s efforts and is beyond our control. If a marketer does not devote adequate resources to the ongoing regulatory approval, commercialization and manufacture of a product, or if a marketer engages in illegal or otherwise unauthorized practices, the product’s sales may not generate sufficient royalties, or the product’s sales may be suspended, and consequently, could adversely affect our business. In addition, if marketers of biopharmaceutical products decide to discontinue product programs or we believe the commercial prospects of assets have been reduced, we may recognize material non-cash impairment charges related to the financial royalty asset associated with those programs or assets.
License agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our royalties.
License agreements relating to the products generating our royalties may be terminated, which may adversely affect sales of such products and therefore the payments we receive. For example, under certain license agreements, marketers retain the right to unilaterally terminate the agreements with the licensors. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate its license agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of any such termination, a licensor may no longer receive all of the payments it expected to receive from the licensee and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license agreement that has been terminated.
63

In addition, license agreements may fail to provide significant protection for the licensor in case of the licensee’s failure to perform or in the event of disputes. License agreements which relate to the products underlying our royalties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what the licensor believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee’s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our royalties and adversely affect our business, financial condition and results of operations. If a marketer were to default on its obligations under a license agreement, the licensor’s remedy may be limited either to terminating certain licenses related to certain countries or to generally terminate the license agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor and we may be required to rely on the resources and willingness of the licensor to enforce its rights against the licensee.
In any of these situations, if the expected payments under the license agreements do not materialize, this could result in a significant loss to us and adversely affect our business, financial condition and results of operations.
The insolvency of a marketer could adversely affect our receipt of cash flows on the related royalties that we hold.
If a marketer were to become insolvent and seek to reorganize under Chapter 11 of Title 11 of the U.S. Code, as amended, or the Bankruptcy Code, or liquidate under Chapter 7 of the Bankruptcy Code (or foreign equivalent), such event could delay or impede the payment of the amounts due under a license agreement, pending a resolution of the insolvency proceeding. Any unpaid royalty payments due for the period prior to the filing of the bankruptcy proceeding would be unsecured claims against the marketer, which might not be paid in full or at all. While royalty payments due for periods after the filing may qualify as administrative expenses entitled to a higher priority, the actual payment of such post-filing royalty payments could be delayed for a substantial period of time and might not be in the full amount due under the license agreement. The licensor would be prevented by the automatic stay from taking any action to enforce its rights without the permission of the bankruptcy court. In addition, the marketer could elect to reject the license agreement, which would require the licensor to undertake a new effort to market the applicable product with another distributor. Such proceedings could adversely affect the ability of a payor to make payments with respect to a royalty, and could consequently adversely affect our business, financial condition and results of operations.
Unsuccessful attempts to acquire new royalties could result in significant costs and negatively impact subsequent attempts to locate and acquire other assets.
The investigation of each specific target royalty and the negotiation, drafting and execution of relevant agreements, disclosure and other documents requires substantial management time and attention and results in substantial costs for accountants, attorneys and others. If a decision is made not to complete a specific acquisition, the costs incurred for the proposed transaction would not be recoverable from a third party. Furthermore, even if an agreement is reached relating to a specific target asset, we may fail to consummate the acquisition for any number of reasons, including, in the case of an acquisition of a royalty through a business combination with a public company, approval by the target company’s public shareholders. Multiple unsuccessful attempts to acquire new royalties could hurt our reputation, result in significant costs and an inefficient use of the Manager’s time. The opportunity cost of diverting management and financial resources could negatively impact our ability to locate and acquire other assets.
The products that generate our royalties are subject to uncertainty related to healthcare reimbursement policies, managed care considerations, pricing pressures and the regulation of the healthcare industry.
In both U.S. and non-U.S. markets, sales of biopharmaceutical products, and the success of such products, depends in part on governmental regulation and the availability and extent of coverage and reimbursement from third-party payors, including government healthcare programs in addition to private insurance plans.
64

In the United States, pharmaceutical product pricing is subject to enhanced government regulation, public scrutiny and calls for reforms. For example, in August 2022, President Biden signed into law the Inflation Reduction Act (“IRA”), which includes significant drug pricing provisions, including (i) inflation rebates, where drug manufacturers must pay a rebate to the government if the prices of their covered single-source drugs and biologics rise faster than the rate of inflation; (ii) Medicare Part D redesign where beneficiaries’ out-of-pocket costs are capped, payment obligation for initial coverage is redistributed with drug manufacturers paying 10% on all drugs and the coverage gap is eliminated, as well as requiring Part D plans to pay a larger portion of the catastrophic phase with drug manufacturers covering 20% of the costs; and (iii) Medicare negotiation, which requires the Department of Health and Human Services (“HHS”) to negotiate prices for certain drugs covered by Medicare Part B and Part D through a drug price negotiation program. In October 2022, President Biden signed an executive order that instructs HHS to consider whether to select for testing new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs. In addition, the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the “ACA”) was enacted by Congress in March 2010 and established a major expansion of healthcare coverage, financed in part by a number of new rebates, discounts and taxes that had a significant effect on the expenses and profitability on the companies that manufacture the products that generate our royalties. These companies and their products face uncertainty due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the IRA and the ACA.
Other U.S. federal or state legislative or regulatory action or policy efforts could adversely affect the healthcare industry, including, among others, additional transparency and limitations related to product pricing, review the relationship between pricing and manufacturer patient programs, general budget control actions, changes in patent laws, the importation of prescription drugs from outside the United States at prices that are regulated by governments of various foreign countries, revisions to reimbursement of biopharmaceutical products under government programs, restrictions on U.S. direct-to-consumer advertising or limitations on interactions with healthcare professionals. No assurances can be provided that these laws and regulations will not adversely affect our business, financial condition and results of operations.
The growth of large managed care organizations and prescription benefit managers, as well as the prevalence of generic substitution, has hindered price increases for prescription drugs. Continued intense public scrutiny of the price of drugs, together with government and payor dynamics, may limit the ability of producers and marketers to set or adjust the price of products based on their value. There can be no assurance that new or proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable the producer or marketer of such product to maintain price levels sufficient to realize an appropriate return. These pricing pressures may adversely affect our current royalties and the attractiveness of future acquisitions of royalties.
Outside the United States, numerous major markets, including the EU, Japan and China, have pervasive government regulation of healthcare and government involvement in funding healthcare, and, in that regard, fix the pricing and reimbursement of pharmaceutical products. Consequently, in those markets, the products generating our royalties are subject to government decision-making and budgetary actions.
In addition, many of the products in our portfolio benefit from regulatory exclusivity. If, in an effort to regulate pricing, regulatory exclusivity is not maintained, our business, financial condition and results of operations may be adversely impacted.
The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of the royalties that we hold.
In an effort to contain the U.S. federal deficit, the biopharmaceutical industry could be considered a potential source of savings via legislative proposals. Government action to reduce U.S. federal spending on entitlement programs, including Medicare, Medicaid or other publicly funded or subsidized health programs, or to lower drug spending, may affect payment for the products that generate our royalties. These and any other cost controls or any significant additional taxes or fees that may be imposed on the biopharmaceutical industry as part of deficit reduction efforts could reduce cash flows from our royalties and therefore adversely affect our business, financial condition and results of operations.
65

Sales of products that generate our royalties are subject to regulatory approvals and actions in the United States and foreign jurisdictions that could harm our business.
The procedures to approve biopharmaceutical products for commercialization vary among countries and can involve additional testing and time. Such procedures may include on-site inspections by regulatory authorities at clinical trial sites or manufacturing facilities, which inspections may be delayed by travel restrictions imposed in response to the COVID-19 pandemic or other pandemics. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and many include additional risks, such as pricing approval.
There can be no assurance that any of these regulatory approvals will be granted or not be revoked or restricted in a manner that would adversely affect the sales of such products and on the ability of payors to make payments with respect to such royalties to us.
The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies.
The manufacture of products generating our royalties is typically complex and is highly regulated. In particular, biopharmaceutical products are manufactured in specialized facilities that require the approval of, and ongoing regulation by, the FDA in the United States and, if manufactured outside of the United States, both the FDA and non-U.S. regulatory agencies, such as the MHRA and the EMA. With respect to a product, to the extent that operational standards set by such agencies are not adhered to, manufacturing facilities may be closed or production interrupted until such time as any deficiencies noted by such agencies are remedied. Any such closure or interruption may interrupt, for an indefinite period of time, the manufacture and distribution of a product and therefore the cash flows from the related biopharmaceutical asset may be significantly less than expected.
In addition, manufacturers of a product may rely on third parties for selected aspects of product development, such as packaging or to supply bulk raw material used in the manufacture of such product. In the United States, the FDA requires that all suppliers of pharmaceutical bulk materials and all manufacturers of pharmaceuticals for sale in or from the United States adhere to the FDA’s current “Good Manufacturing Practice” regulations and guidelines and similar requirements that exist in jurisdictions outside the United States. Licensees generally rely on a small number of key, highly specialized suppliers, manufacturers and packagers. Any interruptions, however minimal, in the operation of these manufacturing and packaging facilities could adversely affect production and product sales and therefore adversely affect our business, financial condition and results of operations.
Product liability claims may diminish the returns on biopharmaceutical products.
The developer, manufacturer or marketer of a product could become subject to product liability claims. A product liability claim, regardless of its merits, could adversely affect the sales of the product and the amount of any related royalty payments, and consequently, could adversely affect the ability of a payor to make payments with respect to a royalty.
Although we believe that we will not bear responsibility in the event of a product liability claim against the developer, manufacturer, marketer or other seller of the product that generates our royalty, such claims could adversely affect our business, financial condition and results of operations due to the lower than expected cash flows from the royalty.
We are typically not involved in maintaining, enforcing and defending patent rights on products that generate our royalties.
Our right to receive royalties generally depends on the existence of valid and enforceable claims of registered or issued patents in the United States and elsewhere in the world. The products on which we receive payments are dependent on patent protection and on the fact that the manufacturing, marketing and selling of such products do not infringe, misappropriate or otherwise violate intellectual property rights of third parties. Typically, we have no ability to control the prosecution, maintenance, enforcement or defense of patent rights, but must rely on the willingness and ability of our partners or their marketers to do so. There can be no assurance that these third parties will vigorously prosecute, maintain, enforce or defend such rights. Even if such third parties seek to prosecute, maintain, enforce or defend such rights, they may not be successful.
66

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation. Furthermore, changes in patent laws or interpretation of patent laws in the United States and in other jurisdictions could increase the uncertainties surrounding the successful prosecution of patent applications and the successful enforcement or defense of issued patents by our partners, all of which could diminish the value of patent protection relating to the biopharmaceutical assets. As a result, the issuance, scope, validity, enforceability and commercial value of the patent rights of our partners and their marketers are highly uncertain. In addition, such third parties’ pending and future patent applications may not result in patents being issued which protect their products, development-stage product candidates and technologies or which effectively prevent others from commercializing competitive products, development-stage product candidates and technologies. Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance.
Even if the patent applications our partners and their marketers license or own do issue as patents, they may not issue in a form that will provide them with any meaningful protection, prevent competitors or other third parties from competing with them or otherwise provide them with any competitive advantage. Competitors or other third parties may be able to circumvent patents of our partners and their marketers by developing similar or alternative products in a non-infringing manner. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit the ability of our partners and their marketers from preventing others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of their products, development-stage product candidates and technologies.
Any loss or reduction in the scope or duration of patent protection for any product that generates our royalties, or any failure to successfully prosecute, maintain, enforce or defend any patents that protect any such product may result in a decrease in the sales of such product and any associated royalties payable to us. Any such event would adversely affect the ability of the payor to make payments of royalties to us or may otherwise reduce the value of our royalty interest, and could consequently adversely affect our business, financial condition and results of operations. In cases where our contractual arrangements with our partner permit us to do so, we could participate in patent suits brought by third parties but this could result in substantial litigation costs, divert management’s attention from our core business and there can be no assurance that such suits would be successful.
The existence of third-party patents in relation to products may result in additional costs for the marketer and reduce the amount of royalties paid to us.
The commercial success of a product depends, in part, on avoiding infringement, misappropriation or other violations of the intellectual property rights and proprietary technologies of others. Third-party issued patents or patent applications claiming subject matter necessary to manufacture and market a product could exist or issue in the future. Such third-party patents or patent applications may include claims directed to the composition, manufacturing, mechanism of action or other unique features of a product. There can be no assurance that a license would be available to marketers for such subject matter if such infringement were to exist or, if offered, would be offered on reasonable or commercially feasible terms. Without such a license, it may be possible for third parties to assert infringement or other intellectual property claims against the marketer of such product based on such patents or other intellectual property rights.
Even if the marketer was able to obtain a license, it could be non-exclusive, thereby giving its competitors and other third parties access to the same technologies. In addition, if a marketer of a product that generates our royalties is required to obtain a license from a third party, the marketer may, in some instances, have the right to offset the licensing and royalty payments to such third party against royalties that would be owed to our partner, which may ultimately reduce the value of our royalty interest. An adverse outcome in infringement or other intellectual property-related proceedings could subject a marketer to significant liabilities to third parties, require disputed rights to be licensed from third parties or require the marketer to cease or modify its manufacturing, marketing and distribution of any affected product, any of which could reduce the amount of cash flow generated by the affected products and any associated royalties payable to us and therefore adversely affect our business, financial condition and results of operations.
67

Disclosure of trade secrets of marketers of products could negatively affect the competitive position of the products underlying our biopharmaceutical assets.
The marketers of the products that generate our royalties depend, in part, on trade secrets, know-how and technology, which are not protected by patents, to maintain the products’ competitive position. This information is typically protected through confidentiality agreements with parties that have access to such information, such as collaborative partners, licensors, employees and consultants. Any of these parties may breach the agreements and disclose the confidential information or competitors might independently develop or learn of the information in some other way, which could harm the competitive position of the products and therefore reduce the amount of cash flow generated by our royalty interest.
The internal computer systems of our counterparties may fail or suffer security breaches, which could result in a significant disruption of their ability to operate their business effectively, adversely affect the cash flow generated by the related biopharmaceutical products, and adversely affect our business, financial condition and results of operations.
The internal computer systems and cloud-based computing services of our counterparties and those of their current and any future collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We have been subject to cyber-based attacks and unauthorized access in the past. If such an event were to occur in the future and cause interruptions in their operations, it could result in a disruption of their development and commercialization programs and business operations, whether due to a loss of trade secrets or other proprietary information or other similar disruptions. To the extent that any disruption or security breach were to result in a loss of, or damage to, a counterparties’ data or applications, or inappropriate disclosure of confidential or proprietary information, our partners’ operations may be harmed and the development and commercialization of their products, development-stage product candidates and technologies could be delayed. Such an event may reduce the amount of cash flow generated by the related biopharmaceutical products and therefore adversely affect our business, financial condition and results of operations.
Our ability to pay periodic dividends to our shareholders or make share repurchases may be limited by applicable provisions of English law and contractual restrictions and obligations.
Under English law, we will only be able to declare dividends, make distributions or repurchase shares (other than out of the proceeds of a new issuance of shares for that purpose) out of profits available for distribution. Profits available for distribution are accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of our distributable reserves is a cumulative calculation. We may be profitable in a single financial year but unable to pay a dividend or make share repurchases if our accumulated, realized profits do not offset all previous years’ accumulated, realized losses. Additionally, we may only make a distribution if our net assets are not less than the amount of our aggregate called-up share capital and distributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate.
Subject to the terms of our indebtedness or other contractual obligations, the approval and payment of any interim dividends are at the sole discretion of our board of directors, which may change our dividend policy at any time and the payment of any final dividends will be subject to majority approval by holders of our Class A ordinary shares and Class B ordinary shares and in each case will be paid out of profits available for that purpose under English law. Our Articles of Association authorize the board of directors to approve interim dividends without shareholder approval to the extent that such dividends appear justified by profits available for such purpose. The board of directors may also recommend final dividends be approved and declared by shareholders at an annual general meeting. No such dividend may exceed the amount recommended by the board of directors.
There can be no assurance that any dividends, whether quarterly or otherwise, will or can be paid or that any shares will or can be repurchased. Whether we pay dividends to our shareholders or make share repurchases depends on a number of factors, including among other things, general economic and business conditions, our strategic plans and prospects, our business and acquisition opportunities, our financial condition and results of operations, working capital requirements and anticipated cash needs, contractual restrictions and obligations, including fulfilling our current and future capital commitments, legal, tax and regulatory restrictions, other restrictions and implications on the payment of dividends by us to our shareholders or making any share repurchases and such other factors as our board of directors may deem relevant.
A shareholder who receives a distribution under circumstances where he or she knows or has reasonable grounds for believing that the distribution is unlawful in the circumstances is obliged to repay such distribution (or that part of it, as the case may be) to us.
68

If we were determined to be an investment company under the U.S. Investment Company Act of 1940, applicable restrictions could make it impractical for us to continue our business as contemplated and could adversely affect our business, financial condition and results of operations.
We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities; or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test.
We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, as interpreted by the SEC staff, requires each such subsidiary to invest at least 55% of its assets in “notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,” which we refer to as the ICA Exception Qualifying Assets.
In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalty interests that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below.
To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term investment securities does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder.
If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to our predecessor or otherwise restricts the conclusions in the SEC staff’s no-action letter such that royalty interests are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our ceasing to qualify for an exemption from registration as an investment company could materially and adversely affect the value of our Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares.
69

The equity performance awards payable to an affiliate of the Manager may create incentives that are not fully aligned with the interests of our shareholders.
Subject to certain conditions, at the end of each fiscal quarter, an affiliate of the Manager is entitled to a distribution in the form of equity from RP Holdings in respect of each portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such portfolio)) for such portfolio for the applicable measuring period (the “Equity Performance Awards”). The right to Equity Performance Awards may create an incentive for the Manager to make riskier or more speculative asset acquisitions. In addition, the Manager may cause us to incur more debt, finance additional asset acquisitions or otherwise use more leverage in connection with asset acquisitions, as generally the use of leverage can increase the rate of return on an investment and therefore our profits. Under certain circumstances, the use of borrowed money may pose higher risks for our business or increase the likelihood of default, which would disfavor our shareholders. In addition, there is no correlation between our profits and the obligation of our board of directors to pay dividends to shareholders. Consequently, shareholders may receive limited or no dividends while an affiliate of the Manager remains entitled to Equity Performance Awards based on our Net Economic Profit. In addition, even though Equity Performance Awards are payable on a portfolio-by-portfolio basis (with portfolios comprised of investments made during sequential two-year periods) in order to reduce the risks that affiliates of the Manager will be paid Equity Performance Awards on individual investments even though our overall portfolio of investments is not performing well, Equity Performance Awards may nevertheless be payable to affiliates of the Manager when our overall portfolio of investments is not performing as well as the individual portfolios that are used as the basis for measuring the Equity Performance Awards.
Our board of directors may make decisions with respect to the cash generated from our operations that may result in no dividends paid to our shareholders or no repurchases made of our ordinary shares.
Our board of directors is under no obligation to pay dividends, make distributions or repurchase our ordinary shares and it may decide to use cash to fund asset acquisitions or operations in lieu of paying dividends, making distributions or repurchasing our ordinary shares. We will pay Equity Performance Awards to an affiliate of the Manager based on our Net Economic Profit regardless of whether any dividends are paid to our shareholders or any ordinary shares are repurchased. Our board of directors’ decisions with respect to our cash may result in no dividends to our shareholders and no ordinary shares repurchased. Furthermore, our board of directors’ decisions with respect to dividends or repurchases of ordinary shares may adversely affect the market price of our Class A ordinary shares. In the event that we generate positive income, but pay limited or no dividends, holders of Class A ordinary shares may, if they have made certain elections for U.S. federal income tax purposes with respect to their Class A ordinary shares, have a tax liability on our income in excess of the actual cash dividends received by such holders. If our board of directors decides to approve limited or no dividends or repurchases of ordinary shares, the primary remedy for holders of Class A ordinary shares will be to sell their shares at the prevailing market price, including at a loss, which may be low due to unfavorable or inconsistent dividends or repurchases of our ordinary shares.
The royalties that we acquire may fall outside the biopharmaceutical industry, and any such assets, and the cash flows therefrom, may not resemble the assets in our current portfolio.
We have discretion as to the types of assets that we may acquire. While we expect the Manager to acquire assets that primarily fall within the biopharmaceutical industry, we are not obligated to do so and may acquire other types of assets that are peripheral to or outside of the biopharmaceutical industry. Consequently, our asset acquisitions in the future, and the cash flows from such assets, may not resemble those of the assets in our current portfolio. There can be no assurance that assets acquired in the future will have returns similar to the returns expected of the assets in our current portfolio or be profitable at all.
The Manager may be the subject of a change of control resulting in a disruption in our operations that could adversely affect our business, financial condition and results of operations.
There could be a change of control of the Manager and, in such a case, the new controlling party may have a different philosophy, employ less experienced advisory professionals, be unsuccessful in identifying asset acquisition opportunities or have a track record that is not as successful as that of the Manager prior to such a change of control. If the foregoing were to occur, we could experience difficulty in making new asset acquisitions, and the value of our existing assets, our business, financial condition and results of operations could materially suffer.
70

The Manager’s liability is limited under the Management Agreement, and we have agreed to indemnify the Manager against certain liabilities. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable.
The Manager does not assume any responsibility other than to render the services called for under the Management Agreement. The Manager and its affiliates (including RPI EPA Holdings, LP (“EPA Holdings”)) and their respective officers, directors, equity holders, members, employees, agents and partners, and any other person who is entitled to indemnification (each, an “Indemnitee”) is not liable to us, any subsidiary of ours, our directors, our shareholders or any subsidiary’s shareholders or partners for acts or omissions performed in accordance with to the Management Agreement, except those resulting from acts constituting fraud, bad faith, willful misconduct, gross negligence (as interpreted under New York law) and a material breach of the Management Agreement that is not cured or a violation of applicable securities laws.
In addition, to the fullest extent permitted by law, we have agreed to indemnify the Indemnitees from and against any and all claims, liabilities, damages, losses, penalties, actions, judgments, costs and expenses (including amounts paid in satisfaction of judgments, in compromises and settlements, as fines and penalties and legal or other costs and reasonable expenses of investigating or defending against any claim or alleged claim) of any nature whatsoever, known or unknown, liquidated or unliquidated that are incurred by any Indemnitee or to which such Indemnitee may be subject by reason of its activities on behalf of us or any of our subsidiaries to the extent that such Indemnitee’s conduct did not constitute fraud, bad faith, willful misconduct, gross negligence (as interpreted under New York law), material breach of the Management Agreement that is not cured or a violation of applicable securities laws. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable.
Operational risks may disrupt our businesses, result in losses or limit our growth.
We rely heavily on the Manager’s financial, accounting, information and other data processing systems and cloud computing services, as well as those of our current and future collaborators, contractors or consultants. Such systems are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, pandemics, such as the COVID-19 pandemic, terrorism, war and telecommunication and electrical failures. If any of these events occur and such systems do not operate properly or are disabled or if there is any unauthorized disclosure of data, whether as a result of tampering, a breach of network security systems, a cyber-incident or attack or otherwise, we could suffer substantial financial loss, increased costs, a disruption of our business, loss of trade secrets or other proprietary information, liability to us, regulatory intervention or reputational damage.
Furthermore, federal, state and international laws and regulations relating to data privacy and protection, such as the European Union’s General Data Protection Regulation, which took effect in May 2018, and the California Consumer Privacy Act, which took effect in January 2020, can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts or data privacy and protection compliance efforts fail. In addition, we operate a business that is highly dependent on information systems and technology. The Manager’s information systems and technology may not continue to be able to accommodate our growth, and the cost of maintaining such systems may increase. Such a failure to accommodate growth, or an increase in costs related to such information systems, could adversely affect our business, financial condition and results of operations.
A disaster or a disruption in the public infrastructure that supports our business, including a disruption involving electronic communications or other services used by us or third parties with whom we conduct business, could adversely affect our ability to continue to operate our business without interruption. Our disaster recovery programs and those of the Manager may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse us for our losses, if at all.
In addition, sustaining our growth may require us or the Manager to commit additional management, operational and financial resources to identify new professionals to join the team and to maintain appropriate operational and financial systems to adequately support expansion. Due to the fact that the market for hiring talented professionals is competitive, we may not be able to grow at the pace we desire.
71

We are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.
Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010 (“Bribery Act”), the U.S. Foreign Corrupt Practices Act of 1977, as amended the (“FCPA”), the U.S. domestic bribery statute contained in 18 U.S.C. §201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and the marketers of products that generate our royalties operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.
We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the “Trade Control laws.”
There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by the United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations.
Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the business practices of the marketers of products that generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the marketers of products that generate are royalties are found to be in violation of any of these laws or any other governmental regulations, we or marketers of products that generate our royalties may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or marketers of products that generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations.
The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.
72

The EU directive on alternative investment fund managers (the “AIFM Directive”) may significantly increase our compliance costs.
The AIFM Directive has been implemented into the national law of the majority of member states of the European Economic Area and the United Kingdom (each an “AIFM state”). The AIFM Directive sets out minimum conditions related to the marketing of interests in alternative investment funds (such as our Class A ordinary shares) in the AIFM states and may impact our ability to attract investors in the AIFM states and may significantly increase our and the Manager’s compliance costs. Such conditions include requirements for us to register with the competent authority in the relevant AIFM state in order to market the Class A ordinary shares to investors, requirements to file periodic reports with the competent authority in the relevant AIFM state and requirements to comply with disclosure and reporting obligations in respect of investors in the relevant AIFM state. Such reports and disclosures may become publicly available. While such conditions are met in relation to the AIFM states where our Class A ordinary shares will be marketed, there can be no guarantee that this will continue to be the case. The AIFM Directive does not, however, prohibit an investor in such AIFM state from subscribing for our Class A ordinary shares at their own initiative in circumstances where such Class A ordinary shares have not been marketed in such AIFM state and we may issue our Class A ordinary shares to such investors, as long as they have provided us and the Manager with representations that they have done so at their own initiative.
In each AIFM state, our Class A ordinary shares may only be offered to investors in accordance with local measures implementing the AIFM Directive. Investors, together with any person making or assisting in the decision to invest in us, who are situated, domiciled or who have a registered office, in an AIFM state where our Class A ordinary shares are not being offered pursuant to private placement rules implementing the AIFM Directive may invest, or effect an investment in our Class A ordinary shares, but only in circumstances where they do so at their own initiative. Any investor acquiring our Class A ordinary shares at their own initiative in such AIFM state should note that as we have not been registered for marketing in that AIFM state, no reports will be filed with the competent authority in the relevant AIFM state by or in respect of us and no investor shall be entitled to receive any disclosure or report that is mandated in respect of an alternative investment fund being marketed pursuant to the AIFM Directive.
The United Kingdom implemented the AIFM Directive through the Alternative Investment Managers Regulations 2013 and the Financial Conduct Authority’s Handbook. Following the United Kingdom’s withdrawal the European Union and the expiration of the transitional period, the rules applicable to the marketing of interests in alternative investment funds in the United Kingdom and the other AIFM states remained largely aligned. However, there are now areas of divergence which are likely to grow as the United Kingdom seeks to adopt a new post-Brexit financial services regulatory regime. Such divergence may make it more time consuming and complex for us to market our Class A ordinary shares to investors in the United Kingdom and other AIFM states which, in turn, may significantly increase our and the Manager’s compliance costs.
Risks Relating to Our Organization and Structure
We are a holding company with no operations and rely on our subsidiaries to provide us with the funds necessary to meet our financial obligations and to pay dividends.
We are a holding company with no material direct operations. Our principal asset is our controlling equity interest in RP Holdings. As a result, we are dependent on loans, dividends and other payments from our subsidiaries to generate the funds necessary to meet our financial obligations and to pay dividends or make distributions to our shareholders. Our subsidiaries are legally distinct from us and may be prohibited or restricted from providing loans, paying dividends or otherwise making funds available to us under certain conditions. If the cash we receive from our subsidiaries is insufficient for us to fund our financial obligations, we may be required to raise cash through the incurrence of debt, the issuance of equity or the sale of assets to fund. However, there is no assurance that we would be able to raise cash by these means. If the ability of any of our subsidiaries to pay dividends or make distributions or payments to us is materially restricted by regulatory or legal requirements, bankruptcy or insolvency, or our need to maintain our financial strength ratings, or is limited due to operating results or other factors, it could adversely affect our ability to meet our financial obligations and to pay dividends or make distributions to our shareholders.
Our structure will result in tax distributions as a result of the RP Holdings Class C Special Interest.
RP Holdings is treated as a partnership for U.S. federal income tax purposes and has owners that are subject to U.S. federal income taxation. RP Holdings is required to make cash distributions, or tax distributions, to the direct owner or beneficial owners of the RP Holdings Class C Special Interest, calculated using an assumed tax rate that is generally uniform for all recipients regardless of their tax status. Funds used by RP Holdings to satisfy its tax distribution obligations will not be available for reinvestment in our business.
73

Risks Relating to Our Ordinary Shares
The market price of our Class A ordinary shares has been and may in the future be volatile, which could cause the value of our shareholders’ investment to decline.
The market price of our Class A ordinary shares has been and may be volatile and could be subject to wide fluctuations. Securities markets worldwide experience significant price and volume fluctuations. Market volatility, as well as general economic, market or political conditions, could reduce the market price of Class A ordinary shares in spite of our operating performance. In addition to the factors discussed in this Quarterly Report on Form 10-Q, our operating results could be below the expectations of public market analysts and investors due to a number of potential factors, including:
• market conditions in the broader stock market in general, or in our industry in particular;
• variations in our quarterly operating results or dividends to shareholders;
• additions or departures of key management personnel at the Manager;
• timing and rate of capital deployment, including relative to estimates;
• changes in our portfolio mix or acquisition strategy;
• failure to meet analysts’ earnings estimates;
• publication of research reports about our industry;
• third-party healthcare reimbursement policies and practices;
• litigation and government investigations;
• changes or proposed changes in laws or regulations or differing interpretations or enforcement thereof affecting our business;
• no results, or projected results, from marketers of products that generate our royalties;
• results from, and any delays to, the clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets or other issues relating to such products, including regulatory approval or commercialization;
• adverse market reaction to any indebtedness that we may incur or securities we may issue in the future;
• changes in market valuations of similar companies or speculation in the press or investment community;
• announcements by our competitors of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures or capital commitments;
• economic and political conditions or events, such as the COVID-19 pandemic, inflation and rising interest rates and global conflicts, including the Russia-Ukraine war; and
• adverse publicity about us or the industries in which we participate or individual scandals.
These and other factors may cause the market price of and demand for our Class A ordinary shares to fluctuate significantly, which may limit or prevent our shareholders from reselling their Class A ordinary shares at or above the purchase price.
Stock markets in general have from time to time experienced extreme price and volume fluctuations, including in recent months. In addition, in the past, following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against public companies. This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.
74

Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act.
Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for resolving all shareholder complaints other than shareholder complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for resolving any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act. This choice of forum provision may limit a shareholder’s ability to bring a claim in a judicial forum that such shareholder finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits. If a court were to find either choice of forum provision contained in our Articles of Association to be inapplicable or unenforceable, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition.
U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or members of senior management and the experts named herein.
We are a public limited company with our registered office in England and our subsidiaries are incorporated in various jurisdictions, including jurisdictions outside the United States. One of our directors is not a resident of the United States, and a substantial portion of our assets and the assets of this director are located outside the United States. As a result, it may be difficult for investors to effect service of process on this director in the United States or to enforce judgments obtained in U.S. courts against us or this director based on the civil liability provisions of the U.S. securities laws or otherwise. Even if shareholders are successful in bringing an action of this kind, the laws of England may render shareholders unable to enforce a judgment against our assets or the assets of our directors and executive officers. In addition, it is doubtful whether English courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in the United Kingdom. An award for monetary damages under the U.S. securities laws would likely be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. As a result of the above, shareholders may have more difficulty in protecting their interest through actions against our management, directors or other shareholders than they would as shareholders of a U.S. public company.
The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.
We are incorporated under English law. The rights of our shareholders are governed by English law, including the provisions of the Companies Act 2006 (the “U.K. Companies Act”), and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations.
The U.K. City Code on Takeovers and Mergers (the “Takeover Code”) applies, among other things, to an offer for a public company whose registered office is in the United Kingdom (or the Channel Islands or the Isle of Man) and whose securities are not admitted to trading on a regulated market in the United Kingdom (or the Channel Islands or the Isle of Man) if the company is considered by the Panel on Takeovers and Mergers (the “Takeover Panel”) to have its place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the “residency test.” Under the Takeover Code, the Takeover Panel will determine whether we have our place of central management and control in the United Kingdom by looking at various factors, including the structure of our board of directors, the functions of the directors and where they are resident.
Given that our central management and control is situated outside the United Kingdom (or the Channel Islands or the Isle of Man), we do not anticipate that we will be subject to the Takeover Code. However, if at the time of a takeover offer, the Takeover Panel determines that we have our place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man), we would be subject to a number of rules and restrictions, including but not limited to the following: (i) our ability to enter into deal protection arrangements with a bidder would be extremely limited; (ii) we might not, without the approval of our shareholders, be able to perform certain actions that could have the effect of frustrating an offer, such as issuing shares or carrying out acquisitions or disposals; and (iii) we would be obliged to provide equality of information to all bona fide competing bidders.
75

Under English law, and whether or not we are subject to the Takeover Code, an offeror for us that has acquired (i) 90% in value of; and (ii) 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for us is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i) approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting; and (ii) approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting.
As an English public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.
We are a public limited company incorporated under the laws of England and Wales. English law provides that a board of directors may only allot shares (or rights to subscribe for or convert into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and valid for a maximum period of five years, each as specified in the articles of association or relevant shareholder resolution. We have obtained authority from our shareholders to allot additional shares for a period expiring on May 31, 2025, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period).
English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). We have obtained authority from our shareholders to disapply preemptive rights for a period expiring on May 31, 2025, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).
English law prohibits us from repurchasing our shares by way of “off market purchases” without the prior approval of shareholders by ordinary resolution (i.e., majority of votes cast by our shareholders), and other formalities. Such approval may be for a maximum period of up to five years but may be sought more frequently. English law prohibits us from conducting “on market purchases” as our shares are listed on the NASDAQ and will not be traded on a recognized investment exchange in the United Kingdom.
Our shareholders approved the authorization of certain “off market purchases” that will expire five years from June 23, 2022 unless renewed by our shareholders prior to the expiration date. We cannot assure shareholders that situations will not arise where such shareholder approval requirements for any of these actions would deprive our shareholders of substantial capital management benefits.
The United Kingdom’s withdrawal from the European Union and differing regulatory regimes may have a negative effect on global economic conditions, financial markets and our business, which could reduce the market price of our Class A ordinary shares.
The withdrawal of the United Kingdom from the European Union (commonly referred to as “Brexit”) took effect on January 31, 2020. On December 30, 2020, the United Kingdom passed legislation giving effect to a trade and cooperation agreement, with the EU, which became effective on May 1, 2021. The trade and cooperation agreement covers the general objectives and framework of the relationship between the United Kingdom and the European Union, including as it related to trade, transport, visas, judicial, law enforcement and security matters, and provides for continued participation in community programs and mechanisms for dispute resolution. Notably, under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the United Kingdom and the European Union. Currently, the United Kingdom has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012, as amended. The regulatory regime in the United Kingdom therefore mostly aligns with EU regulations, however it is possible that these regimes will diverge in future as the trade and cooperation agreement does not provide for mutual recognition of U.K. and EU pharmaceutical legislation. Brexit and its related effects could adversely affect our operations and the market price of our Class A ordinary shares.
76

If our Class A ordinary shares are not eligible for continued deposit and clearing within the facilities of DTC, then transactions in our securities may be disrupted.
The facilities of The Depository Trust Company (“DTC”) are a widely-used mechanism that allow for rapid electronic transfers of securities between the participants in the DTC system, which include many banks and brokerage firms. While our Class A ordinary shares are eligible for deposit and clearing within the DTC system, DTC has discretion to cease to act as a depository and clearing agency for our Class A ordinary shares, including to the extent that any changes in U.K. law change the stamp duty or stamp duty reserve tax (“SDRT”) position in relation to the Class A ordinary shares. If DTC determined that the Class A ordinary shares were not eligible for continued deposit and clearance within its facilities, our Class A ordinary shares may not be eligible for continued listing on the NASDAQ and trading in the Class A ordinary shares would be disrupted. While we would pursue alternative arrangements to preserve our listing and maintain trading, any such disruption could adversely affect the market price of our Class A ordinary shares and our access to the capital markets.
The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members.
As a public company, we are subject to the reporting requirements of the Exchange Act, the requirements of the U.S. Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”), and the requirements of the U.K. Companies Act and, if applicable, the Takeover Code. The requirements of these rules and regulations increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources.
We are obligated to file with the SEC annual and quarterly information and other reports that are specified in the Exchange Act, and therefore will need to have the ability to prepare financial statements that are compliant with all SEC reporting requirements on a timely basis. In addition, we are subject to other reporting and corporate governance requirements, including certain requirements of Nasdaq and certain provisions of the Sarbanes-Oxley Act and the regulations promulgated thereunder, which will impose significant compliance obligations upon us.
We are required to comply with Section 404 of the Sarbanes-Oxley Act, which requires management assessments of the effectiveness of internal control over financial reporting and disclosure controls and procedures. If we are unable to maintain effective internal control over financial reporting or disclosure controls and procedures, our ability to record, process and report financial information accurately and to prepare financial statements within required time periods could be adversely affected, which could subject us to regulatory consequences, including sanctions by the SEC, negatively affect investor confidence in our financial statements, restrict access to capital markets and adversely impact the market price of our Class A ordinary shares.
Our compliance with the requirements under the Exchange Act, the Sarbanes-Oxley Act, the U.K. Companies Act and, if applicable, the Takeover Code and the rules and regulations thereunder increases our legal and financial compliance costs and makes some activities more time consuming and costly. These rules and regulations have made it more difficult and more expensive for us to obtain directors’ and officers’ liability insurance, and we may in the future be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We may not be able to predict or estimate accurately the amount of additional costs we may incur or the timing of such costs.
77

Risks Relating to Taxation
Our structure involves complex provisions of tax law for which no clear precedent or authority may be available. Our structure also is subject to potential legislative, judicial or administrative change and differing interpretations, possibly on a retroactive basis.
Our tax treatment, including Irish, U.K. and U.S. federal income tax treatment, depends in some instances on determinations of fact and interpretations of complex provisions of applicable tax law for which no clear precedent or authority may be available. You should be aware that our tax position is not free from doubt, and that applicable tax rules are generally subject to ongoing review by legislative and administrative bodies and relevant tax authorities, as well as by the Organization for Economic Co-operation and Development (“OECD”), which is continuously considering recommendations for changes to existing tax rules. Furthermore, over 130 member jurisdictions of the G20/OECD Inclusive Framework have joined the Two-Pillar Solution to Address the Tax Challenges of the Digitalization of the Economy as part of the OECD’s base erosion and profit sharing project (“BEPS”), which includes a reallocation of taxing rights among market jurisdictions and a global minimum tax rate of 15%. As proposals to change tax laws and the implementation of the BEPS framework remain subject to further negotiation, we are currently unable to predict the extent to which any changes to tax laws, statutes, rules, regulations or ordinances will occur and, if so, the ultimate impact on our business. These review processes could result in revised interpretations of established concepts, statutory changes, revisions to regulations and other modifications and interpretations. No ruling will be sought from the relevant tax authority regarding any of the tax issues discussed herein, and no assurance can be given that the relevant tax authorities will not challenge any of our tax positions and that such challenge would not succeed. If any such position is successfully challenged, our tax liabilities could materially increase, which would adversely affect our profitability and cash flows.
There have been significant changes both made and proposed to international tax laws that increase the complexity, burden and cost of tax compliance for all multinational companies. We expect to continue to monitor these and other developments in international tax law.
We could be liable for significant taxes due to changes in our eligibility for certain income tax treaty benefits or challenges to our tax positions with respect to the application of income tax treaties.
Our subsidiaries expect to receive revenue from both U.S. and non-U.S. sources. We expect that our subsidiaries generally will be eligible for benefits under the applicable income tax treaties between Ireland and the jurisdictions where income is sourced. However, no assurances can be provided in this regard, and it is possible that a taxing authority could successfully assert that any of our subsidiaries does not qualify for treaty benefits as a result of its failure to satisfy the applicable requirements to be eligible to claim treaty benefits. If a taxing authority were to challenge our position regarding the application of an applicable income tax treaty, we could become subject to increased withholding taxes, and such taxes could be significant.
Specifically, with respect to certain U.S.-source income, we expect that our subsidiaries will be eligible for benefits under the U.S.-Ireland income tax treaty (the “Treaty”), and, under that Treaty, will not be subject to any U.S. withholding taxes on such U.S.-source payments. Our current treaty position with respect to U.S.-source payments relies in part on U.S. citizens or tax residents (as defined for purposes of the Treaty) owning, directly or indirectly, at least 50% of the beneficial interest in, or at least 50% of the aggregate vote and value of, each of our subsidiaries that earns U.S.-source income. Our treaty position is based on the current U.S. status of the majority of the existing indirect investors in RP Holdings and Old RPI. Subject to certain exceptions, the existing indirect U.S. investors in RP Holdings have the right to exchange their interests for our publicly traded Class A ordinary shares. Such publicly traded Class A ordinary shares could be further transferred on the public market to other persons. Therefore, it is possible that over time U.S. persons will own indirectly in the aggregate less than 50% of the interests in our subsidiaries. We currently expect that our Class A ordinary shares and other existing indirect interests in RP Holdings and Old RPI in the aggregate will continue to be owned in sufficient amount by U.S. citizens or tax residents, and that we will be able to establish such ownership, for purposes of satisfying the 50% ownership requirement under the Treaty. However, there is no assurance that RP Holdings and Old RPI will continue to be owned directly or indirectly by sufficient U.S. citizens or residents or that we will be able to establish to the IRS’ satisfaction such ownership for purposes of satisfying the 50% U.S. ownership requirement under the Treaty. It is possible that if the indirect U.S. ownership in our subsidiaries becomes lower than 50% (or we cannot establish such ownership) we may in the future be able to qualify for another applicable exemption from U.S. withholding under the Treaty, but there can be no assurance in this regard. A substantial portion of our revenue is, and is expected to continue to be, derived from U.S.-source royalties. Therefore, if our subsidiaries failed to qualify for an exemption from U.S. withholding tax under the Treaty (by satisfying either the 50% U.S. ownership requirement or an alternative Treaty exemption) and such royalties were subject to a 30% U.S. withholding tax, our financial position, profitability and cash flows could be adversely affected.
78

Furthermore, on August 25, 2016, the Irish Department of Finance announced that, in the context of the publication by the United States Treasury Department of a revised U.S. Model Income Tax Convention in February 2016, discussions have begun with the United States Treasury on updating certain elements of the Treaty. It is at this time not clear what elements of the Treaty may be updated, or when any such updates would go into effect. However, certain elements of the revised U.S. Model Income Tax Convention could, if included in an update to the Treaty, result in our subsidiaries being unable to qualify for the benefits of the Treaty or eliminate or reduce the benefits of the Treaty that otherwise would have been available to us. If our subsidiaries are unable to qualify for the benefits of the Treaty, or if any benefits of the Treaty that otherwise would have been available to us are eliminated or reduced, then all or a portion of our income may become subject to increased withholding taxes, and such taxes could be very significant and materially and adversely affect our financial position, profitability and cash flows.
If our subsidiaries are considered to be engaged in a U.S. trade or business, we could be liable for significant U.S. taxation.
In general, if a foreign corporation, such as Royalty Pharma plc, is considered to be engaged in a U.S. trade or business, such corporation’s share of any income that is effectively connected with such U.S. trade or business will be subject to regular U.S. federal income taxation (currently imposed at a maximum rate of 21%) on a net basis and, potentially, an additional 30% U.S. “branch profits” tax on distributions attributable to income that is effectively connected with such U.S. trade or business. In addition, it is possible that such corporation could be subject to taxation on a net basis by state or local jurisdictions within the United States. We intend to conduct our activities, through our subsidiaries, such that no income realized by us will be effectively connected with the conduct of a U.S. trade or business or otherwise subject to regular U.S. federal income taxation on a net basis. If we are able to conduct our activities in this way, income or gains realized by us will not be subject to U.S. net federal income taxation. However, no assurance can be provided in this regard. The proper characterization of our income and gains for U.S. tax purposes is not certain, and it is possible that all or a portion of our income and gains could be characterized as income that is “effectively connected” with the conduct of a U.S. trade or business. If our income and gains were characterized as effectively connected with a U.S. trade or business, we would be subject to significant U.S. taxes plus interest and possible penalties, and our financial position, cash flows and profitability could be materially and adversely affected.
We expect to operate, and expect that RP Holdings will operate, so as to be treated solely as a resident of the U.K. for tax purposes, but changes to our management and organizational structure or to the tax residency laws of other jurisdictions where we operate may cause the relevant tax authorities to treat us or RP Holdings as also being a resident of another jurisdiction for tax purposes.
Under current U.K. tax law, a company that is incorporated in the U.K. is regarded as resident for tax purposes in the U.K. unless (i) it is concurrently treated as resident for tax purposes in another jurisdiction (applying the rules of that other jurisdiction for determining tax residency) that has a double tax treaty with the U.K. and (ii) there is a residency tie-breaker provision in that tax treaty which allocates tax residence to that other jurisdiction.
Based upon our anticipated management and organizational structure, we believe that we and RP Holdings should be regarded as tax resident solely in the U.K. However, because this analysis is highly factual and may depend on future changes in our management and organizational structure, as well as future changes in the tax residency laws of other jurisdictions where we operate, there can be no assurance regarding the determination of our tax residence in the future.
As U.K. tax resident companies, we and RP Holdings will be subject to U.K. corporation tax on our worldwide taxable profits and gains. Should we (or RP Holdings) be treated as resident in a jurisdiction other than the U.K., we (or RP Holdings, as applicable) could be subject to taxation in that jurisdiction and may be required to comply with a number of material and formal tax obligations, including withholding tax or reporting obligations provided under the relevant tax law, which could result in additional costs and expenses.
79

We believe that we should not be subject to material U.K. corporation tax in respect of certain profits of our non-U.K. tax resident subsidiaries as a result of the U.K.’s “controlled foreign companies” rules but it cannot be guaranteed that this will continue to be the case.
As U.K. tax resident companies, we and RP Holdings will be subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. The types of profits of a Controlled Foreign Company that can potentially be subject to a U.K. corporation tax charge under the U.K. CFC Rules include business profits of the Controlled Foreign Company that are attributable to assets or risks that are managed by activities in the U.K., or certain finance profits of the Controlled Foreign Company that arise from capital or other assets contributed, directly or indirectly, to the Controlled Foreign Company from a connected U.K. tax resident company.
Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We and RP Holdings will therefore be required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets or our financing arrangements, however no assurances can be given that this will continue to be the case. The U.K. CFC Rules are highly complex and fact-dependent, and changes to, or adverse interpretations of, these rules, or changes in the future activities of RPI or other non-U.K. companies in which we hold an interest, directly or indirectly, may alter this position and could impact our group’s effective tax rate.
We believe that dividends received by us and RP Holdings should be exempt from U.K. corporation tax, but it cannot be guaranteed that this will continue to be the case.
U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. However, a number of conditions must be met in order for such dividends to qualify for this tax exemption, including (in respect of dividends paid by RPI, which are tax resident in Ireland) conditions relating to the application of Irish tax law. As such, it cannot be guaranteed that these conditions for the U.K. tax exemption in respect of distributions will continue at all times to be satisfied. If distributions received by us or by RP Holdings were not to fall within an exempt class, such distributions would likely be subject to U.K. corporation tax at the then prevailing corporation tax rate.
Even where distributions fall within an exempt class, certain anti-avoidance and recharacterization rules may also apply. For instance, if RPI were to constitute an “offshore fund” for U.K. tax purposes that has at any time in an accounting period more than 60% by market value of its investments in debt securities, money placed at interest (other than cash awaiting investment), certain contracts for differences, or in holdings in other offshore funds with, broadly, more than 60% of their investments similarly invested, RP Holdings’ shareholding in RPI may be subject to U.K. corporation tax as a deemed “loan relationship”, with the result that dividends received by RP Holdings from RPI could be subject to U.K. tax as deemed interest and RP Holdings may be subject to U.K. corporation tax on increases in the fair market value of its shareholding in RPI. The term “offshore fund” is defined for U.K. tax purposes through a characteristics-based approach and, broadly, can include arrangements constituted by a non-U.K. resident body corporate in which a reasonable investor would expect to be able to realize their investment entirely, or almost entirely, by reference to net asset value. We believe and have been advised that RP Holdings’ shareholding in RPI should not fall within these rules, however no guarantee can be offered that this will continue to be the case. Changes to, or adverse interpretations of, the offshore funds rules, or changes in the nature of our investments, may alter this position and could impact our group’s effective rate.

80

We expect to be classified as a PFIC for U.S. federal income tax purposes, which could subject U.S. holders of our Class A ordinary shares to adverse U.S. federal income tax consequences. Distributions that we pay to individual and other non-corporate U.S. holders will not be eligible for taxation at reduced rates, which could potentially adversely affect the value of our Class A ordinary shares.

We generally expect that our income, which consists primarily of passive income, and our assets, which consist primarily of assets that produce passive income, will result in our treatment as a PFIC for the current taxable year and future taxable years. We intend to annually furnish U.S. holders a “PFIC Annual Information Statement” with the information required to allow shareholders to make a qualified electing fund (“QEF”) election for United States federal income tax purposes on our website. U.S. holders who do not make a QEF election with respect to us or a mark-to-market election with respect to our Class A ordinary shares will be subject to potentially material adverse tax consequences, including (i) the treatment of any gain on disposition of our Class A ordinary shares as ordinary income and (ii) the application of a deferred interest charge on such gain and the receipt of certain distributions on our Class A ordinary shares. In addition, regardless of whether a QEF or mark-to-market election is made with respect to us, U.S. holders will be required to file an annual report on IRS Form 8621 containing such information with respect to its interest in a PFIC as the IRS may require. Failure to file IRS Form 8621 for each applicable taxable year may result in substantial penalties and result in audit by the IRS. Further, if we are a PFIC for any taxable year during which a U.S. holder owns our Class A ordinary shares, we generally would continue to be treated as a PFIC with respect to that U.S. holder for all succeeding years during which such person holds our Class A ordinary shares, even if we ceased to meet the threshold requirements for PFIC status, unless the U.S. holder makes a special “purging” election on IRS Form 8621. The effect of these adverse tax consequences could adversely affect our U.S. shareholders and make investment in our Class A ordinary shares less attractive to U.S. investors.

Distributions made to non-corporate U.S. holders will not be eligible for taxation at reduced tax rates generally applicable to dividends paid by certain U.S. corporations and “qualified foreign corporations” because of our status as a PFIC. The more favorable rates applicable to qualifying corporate dividends could cause individuals to perceive investment in our Class A ordinary shares to be less attractive than investment in the shares of other corporations because of our PFIC status, and this perception could adversely affect the value of our Class A ordinary shares.

General Risk Factors

Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.
We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. We have been subject to these attacks in the past and expect to be subject to them in the future. There can be no assurance that we will be successful in preventing cyber-attacks or mitigating their effects. Any cyber-attack or destruction or loss of data could adversely affect our business. In addition, we may suffer reputational harm or face litigation as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures.
Changes in the application of accounting standards issued by the U.S. Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements.
Our financial statements are prepared in accordance with GAAP, which are periodically revised, interpreted or expanded. From time to time, we are required to adopt new or revised accounting standards issued by recognized authoritative bodies. It is possible that future accounting standards we are required to adopt may require changes to the current accounting treatment that we apply to our consolidated financial statements and may require us to make significant changes to our systems. Such changes could adversely affect our financial condition and results of operations.
81

COVID-19, or the future outbreak of any other infectious or contagious diseases, could adversely affect our results of operations, financial condition and cash flows.
The outbreak of COVID-19 and its variants has severely impacted global economic activity and caused significant volatility and negative pressure in financial markets. COVID-19 and other future health outbreaks and pandemics could lead to quarantines, mandating business and school closures and restricting travel, or trigger global economic slowdowns or global recessions. COVID-19 or another pandemic could adversely affect us due to, among other factors:
• a general decline in business activity;
• the destabilization of the markets could negatively impact our partners in the biopharmaceutical industry and the sales of products generating our royalties;
• difficulty accessing the capital and credit markets on favorable terms, or at all, and a severe disruption and instability in the global financial markets, or deteriorations in credit and financing conditions which could affect our access to capital necessary to fund business operations or address maturing liabilities on a timely basis;
• the potential negative impact on the health of our Manager’s highly qualified personnel, especially if a significant number of them are impacted;
• a deterioration in our ability to ensure business continuity during a disruption;
• interruptions, shortages, delivery delays and potential discontinuation of supply to our partners, which could (i) delay the clinical trials of the development-stage product candidates underlying our assets and result in a loss of our market share for products generating our royalties or development-stage product candidates underlying our assets, if approved, and (ii) hinder our partners’ ability to timely distribute products generating our royalties and satisfy customer demand;
• travel restrictions, shelter-in-place policies or restrictions and other disruptions, which could cause or continue to cause delays and other direct impacts at our partners’ manufacturing sites, which could impact the ability of our partners to manufacture development-stage product candidates underlying our biopharmaceutical assets and products generating our royalties; and
• potential interruptions to our partners’ clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets, including: (i) the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns; (ii) changes in hospital or research institution policies or government regulations, which could delay or adversely impact our partners’ ability to conduct their clinical trials; and (iii) pauses to or delays of trial procedures (particularly any procedures that may be deemed non-essential), patient dosing, shipment of our partners’ development-stage product candidates, distribution of clinical trial materials, study monitoring, site inspections and data analysis due to reasons related to the pandemic, each of which could cause or continue to cause a disruption or delay to the development or the approval of development-stage product candidates underlying our biopharmaceutical assets.
To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Nevertheless, COVID-19 and other future health outbreaks and pandemics present material uncertainty which could adversely affect our results of operations, financial condition and cash flows.
Legal claims and proceedings could adversely affect our business.
We may be subject to a wide variety of legal claims and proceedings. Regardless of their merit, these claims can require significant time and expense to investigate and defend. Since litigation is inherently uncertain, there is no guarantee that we will be successful in defending ourselves against such claims or proceedings, or that our assessment of the materiality of these matters, including any reserves taken in connection therewith, will be consistent with the ultimate outcome of such matters. The resolution of, or increase in the reserves taken in connection with, one or more of these matters could adversely affect our business, financial condition and results of operations.
82

ESG matters and any related reporting obligations may impact our business.
U.S. and international regulators, investors and other stakeholders are increasingly focused on ESG matters. For example, new U.S. and international laws and regulations relating to ESG matters, including human capital, diversity, sustainability, climate change and cybersecurity, are under consideration or being adopted, which may include specific, target-driven disclosure requirements or obligations. Our response will require additional investments and implementation of new practices and reporting processes, all entailing additional compliance risk. In addition, we have announced a number of ESG initiatives and goals, which will require ongoing investment, and there is no assurance that we will achieve any of these goals or that our initiatives will achieve their intended outcomes. Perceptions of our efforts to achieve these goals often differ widely and present risks to our reputation. Any harm to our reputation resulting from our failure or perceived failure to meet such goals could impact employee retention, the willingness of our partners to do business with us, or investors’ willingness to purchase or hold our ordinary shares, any of which could adversely affect our business, financial condition and results of operations. In addition, our ability to implement some initiatives or achieve some goals is dependent on external factors. For example, our ability to meet certain sustainability goals or initiatives may depend in part on third-party collaboration, mitigation innovations or the availability of economically feasible solutions.

Item 2.        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

Share repurchase activities of our Class A ordinary shares during the third quarter of 2023 are as follows (in thousands, except per share amounts):

PeriodsTotal Number of Shares PurchasedAverage Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced ProgramMaximum Dollar Value of Shares that May Yet Be Purchased Under the Program (1)
July 1, 2023 - July 31, 20231,296 $31.03 1,296 $825,319 
August 1, 2023 - August 31, 20231,252 30.50 1,252 787,130 
September 1, 2023 - September 30, 20232,314 28.42 2,314 721,371 
Total4,862 29.65 4,862 
(1)On March 27, 2023, we announced our board of directors authorized a share repurchase program under which we may repurchase up to $1.0 billion of our Class A ordinary shares. The share repurchase program expires on June 23, 2027. The share repurchase program does not obligate us to acquire a minimum amount of our Class A ordinary shares. Under the share repurchase program, Class A ordinary shares may be repurchased in privately negotiated or open market transactions, including under plans complying with Rule 10b5-1 under the Exchange Act.

Item 3.         DEFAULTS UPON SENIOR SECURITIES

Not applicable.

Item 4.        MINE SAFETY DISCLOSURES

Not applicable.

83

Item 5.         OTHER INFORMATION

Rule 10b5-1 Trading Arrangements

The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the third quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
Name and TitleActionAdoption/ Termination
Date
Scheduled Expiration Date of Trading Plan (1)
Maximum Shares Subject to Trading Plan
Terrance Coyne
Executive Vice President & Chief Financial Officer
TerminationSeptember 12, 2023June 13, 2024
900,000 (2)
Marshall Urist
Executive Vice President, Research and Investments
AdoptionSeptember 29, 2023December 29, 2023
46,667
Rory Riggs
Director
AdoptionSeptember 29, 2023December 31, 2024
470,000
(1)A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2)As of the termination date of this Rule 10b5-1 trading plan, 150,000 Class A ordinary shares had been sold under its terms.
84

Item 6.         EXHIBITS

The following exhibits are filed as a part of this Quarterly Report on Form 10-Q:


* Filed or furnished herewith
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ROYALTY PHARMA PLC
(Registrant)
/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer
Date: November 8, 2023
/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer
Date: November 8, 2023
85
 EX-31.1 2 rprx-20230930ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Pablo Legorreta, certify that:
1.    I have reviewed this Quarterly Report on Form 10-Q of Royalty Pharma plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2023
/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer

2
    
 EX-31.2 3 rprx-20230930ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Terrance Coyne, certify that:
1.    I have reviewed this Quarterly Report on Form 10-Q of Royalty Pharma plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2023

/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer

2
    
 EX-32 4 rprx-20230930ex32.htm EX-32 Document

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with Royalty Pharma plc’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”), Pablo Legorreta, the Chief Executive Officer and Terrance Coyne, the Chief Financial Officer of Royalty Pharma plc, each does hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that to his knowledge:
1.    the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Royalty Pharma plc.

Date: November 8, 2023
/s/ Pablo Legorreta
Name: Pablo Legorreta
Chief Executive Officer
/s/ Terrance Coyne
Name: Terrance Coyne
Chief Financial Officer

 EX-101.SCH 5 rprx-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Organization and Purpose link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Available for Sale Debt Securities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair Value Measurements and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Financial Royalty Assets link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Non-Consolidated Affiliates link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Research & Development ("R&D") Funding Expense link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Indirect Cash Flow link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Available for Sale Debt Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Financial Royalty Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Indirect Cash Flow (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Organization and Purpose (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Available for Sale Debt Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Estimated Fair Values Based on Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Financial Royalty Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Non-Consolidated Affiliates (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Research & Development ("R&D") Funding Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Borrowings - Summary of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Borrowings - Summary of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Borrowings - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Borrowings - Summary of Repayments of Debt by Year (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Shareholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Indirect Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rprx-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 rprx-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 rprx-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Gains/(losses) on available for sale debt securities included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Milestone payments Payments For Milestones Payments For Milestones Net income attributable to non-controlling interests Less: net income attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Proceeds from available for sale debt securities Proceeds from Sale of Debt Securities, Available-for-Sale Financing Receivable, Allowance for Credit Loss [Roll Forward] Financing Receivable, Allowance for Credit Loss [Roll Forward] Statistical Measurement [Domain] Statistical Measurement [Domain] Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Summary of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block] Research and development funding expense Research and Development Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Financial royalty assets, net Financing Receivable, after Allowance for Credit Loss, Noncurrent RPSFT Royal Pharmacy Select Finance Trust [Member] Royal Pharmacy Select Finance Trust RP Holdings RP Holdings [Member] RP Holdings Contributions Noncontrolling Interest, Increase from Contributions Noncontrolling Interest, Increase from Contributions Funding agreement amount Funding Agreement Amount Funding Agreement Amount All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] RPCT Royalty Pharma Collection Trust [Member] Royalty Pharma Collection Trust Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Borrowings Debt Disclosure [Text Block] Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Revolving Credit Facility Revolving Credit Facility [Member] Contributions from non-controlling interests - other Proceeds From Noncontrolling Interests, Other Proceeds From Noncontrolling Interests, Other Equity Method Investments and Joint Ventures [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Old RPI Royalty Pharma Investments (Old RPI) [Member] Royalty Pharma Investments (Old RPI) Transfer out of level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Research and Development [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Total other expense/(income), net Nonoperating Income (Expense) Commitments and contingencies Commitments and Contingencies The Notes The Notes [Member] The Notes Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Derivative instruments, current Derivative Asset, Current Required amount to be drawn Long Term Funding Partnership, Covenant, Required Amount Long Term Funding Partnership, Covenant, Required Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Requisite service period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Ownership [Axis] Ownership [Axis] Other royalty income receivable Increase (Decrease) In Other Royalty Income Receivable Increase (Decrease) In Other Royalty Income Receivable Customer [Axis] Customer [Axis] Current liabilities Liabilities, Current [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Dividends Dividends, Cash Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted (in dollars per share) Earnings per Class A ordinary share - diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Cystic fibrosis franchise Cystic Fibrosis Franchise [Member] Cystic Fibrosis Franchise Treasury interests Treasury Stock, Value Supplemental Cash Flow Elements [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Research & Development ("R&D") Funding Expense Research, Development, and Computer Software Disclosure [Text Block] Acquisitions of financial royalty assets Payments to Acquire Finance Receivables Trading Symbol Trading Symbol Investments in equity method investees Payments to Acquire Equity Method Investments Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Summary of Cumulative Allowance for Changes in Expected Cash Flows Financing Receivable, Allowance for Credit Loss [Table Text Block] Maximum consolidated leverage ratio following qualifying material acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Fair value of outstanding notes Long-Term Debt, Fair Value Debt Securities Debt Securities [Member] Net income attributable to Royalty Pharma plc Net Income (Loss) Net Income (Loss) Long term funding partnership, number of tranches Long Term Funding Partnership, Number of Tranches Long Term Funding Partnership, Number of Tranches Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Interest payable Interest Payable, Current Liabilities and shareholders’ equity Liabilities and Equity [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Repurchases of Class A ordinary shares Stock Repurchased During Period, Value Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Available for Sale Debt Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Shareholders’ equity Equity, Attributable to Parent [Abstract] Unrealized(Losses)/Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Avillion II Avillion II [Member] Avillion II Summary of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Amounts of transaction, related parties Related Party Transaction, Amounts of Transaction Cost Debt Securities, Available-For-Sale, Amortized Cost, Adjustment Debt Securities, Available-For-Sale, Amortized Cost, Adjustment Executive Category: Executive Category [Axis] Class B Ordinary Shares Common Class B [Member] Summary of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Payable to Legacy Investors Partnerships Royalty Distribution Payable to Legacy Investors Partnerships [Member] Royalty Distribution Payable to Legacy Investors Partnerships Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Carrying Value, net Reported Value Measurement [Member] 2020 Equity Incentive Plan 2020 Equity Incentive Plan [Member] 2020 Equity Incentive Plan Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Certificates of deposit Certificates of Deposit [Member] 2025 Long-Term Debt, Maturity, Year Two Measurement Basis [Axis] Measurement Basis [Axis] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Denominator Weighted Average Number of Shares Outstanding, Basic [Abstract] Local Phone Number Local Phone Number Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Remainder of 2023 Long-Term Debt, Maturity, Remainder of Fiscal Year Unrealized gains on available for sale debt securities Unrealized gains on available for sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Frequency [Axis] Measurement Frequency [Axis] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt instrument, term (in years) Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Aggregate royalty amount when patents cease Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents Financing receivable, unapproved financial assets held at cost Financing Receivable, Unapproved Financial Assets Held At Cost Financing Receivable, Unapproved Financial Assets Held At Cost Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Summary of Borrowings Schedule of Long-Term Debt Instruments [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Credit Loss, Financial Instrument [Text Block] Unamortized discount and loan issuance costs on long-term debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Repayment of debt Repayments of Senior Debt Milestone payment received Milestone Payment Received Milestone Payment Received Changes in operating assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] Revenues Revenues Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Class R Redeemable Shares Class R Redeemable Stock [Member] Class R Redeemable Stock Option to acquire retained royalties, amount Option To Acquire Retained Royalties, Amount Option To Acquire Retained Royalties, Amount Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type Award Type [Axis] Exchange Offer Exchange Offer [Member] Exchange Offer Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Seltorexant, Olpasiran, Pelacarsen and KarXT Seltorexant, Olpasiran, Pelacarsen And KarXT [Member] Seltorexant, Olpasiran, Pelacarsen And KarXT Payments for royalties Payments for Royalties Overnight Bank Funding Rate Overnight Bank Funding Rate [Member] Overnight Bank Funding Rate Trading Arrangement: Trading Arrangement [Axis] Related Party Transactions Related Party Transactions Disclosure [Text Block] Distributions to legacy non-controlling interests - royalty receipts Payments To Noncontrolling Interests, Royalty Receipts Payments To Noncontrolling Interests, Royalty Receipts Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Interest received Proceeds from Interest Received Unamortized debt discount and issuance costs Debt Instrument, Unamortized Discount Accrued royalty receivable Accrued Royalty Receivable Accrued Royalty Receivable 2026 Long-Term Debt, Maturity, Year Three Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Restatement Determination Date Restatement Determination Date Proceeds exercise fee Proceeds From Exercise Fee Proceeds From Exercise Fee Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Royalty Pharma plc Royalty Pharma plc [Member] Royalty Pharma plc Cytokinetics Commercial Launch Funding Cytokinetics Commercial Launch Funding [Member] Cytokinetics Commercial Launch Funding Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Equity, Attributable to Noncontrolling Interest [Roll Forward] Continuing Investors Partnerships Continuing Investors Partnership [Member] Continuing Investors Partnership Merck Asset - Phase II Clinical Trial Merck Asset - Phase II Clinical Trial [Member] Merck Asset - Phase II Clinical Trial Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Weighted average Class A ordinary shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Interest income accretion Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss) Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss) Common stock, issued (in shares) Common Stock, Shares, Issued Security Exchange Name Security Exchange Name Total debt carrying value Long-Term Debt Financial royalty assets Financing Receivable, after Allowance for Credit Loss, Current Assignment Agreement - Benefit of Payment Stream Assignment Agreement - Benefit of Payment Stream [Member] Assignment Agreement - Benefit of Payment Stream Operating and personnel payments incurred Selling, General and Administrative Expense 2027 Long-Term Debt, Maturity, Year Four Employee Stock Option Employee Stock Option [Member] Financial Royalty Assets Financial Royalty Assets [Member] Financial Royalty Assets Long term funding partnership, expected payment Long Term Funding Partnership, Expected Payment Long Term Funding Partnership, Expected Payment Number of consecutive quarterly payments Number Of Consecutive Quarterly Payments Number Of Consecutive Quarterly Payments Class A Ordinary Shares Common Class A [Member] Total operating expenses, net Costs and Expenses Evrysdi Evrysdi [Member] Evrysdi Deferred Shares Deferred Shares [Member] Deferred Shares Maximum Maximum [Member] Other non-operating income (expense) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Non-Operating Income (Loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Non-Operating Income (Loss) Comprehensive income attributable to Royalty Pharma plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Former Operating and Personnel Payments Former Operating and Personnel Payments [Member] Former Operating and Personnel Payments Summary of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Redemption price, percentage Debt Securities, Available-For-Sale, Redemption Price, Multiple Debt Securities, Available-For-Sale, Redemption Price, Multiple Tabular List, Table Tabular List [Table Text Block] Period of return (in years) Collaborative Arrangement, Rights and Obligations, Period of Return Collaborative Arrangement, Rights and Obligations, Period of Return Number of noncontrolling interests created Number Of Noncontrolling Interests Created Number Of Noncontrolling Interests Created Entity Address, Address Line One Entity Address, Address Line One Teva Pharmaceuticals International GMBH Teva Pharmaceuticals International GMBH [Member] Teva Pharmaceuticals International GMBH Subsequent Event [Table] Subsequent Event [Table] Ownership percentage (as a percent) Subsidiary, Ownership Percentage, Parent Other Other Noncash Income (Expense) Basis of Preparation Basis of Accounting, Policy [Policy Text Block] Purchases of available for sale debt securities Payments to Acquire Debt Securities, Available-for-Sale Related party, rate (as percent) Related Party Transaction, Rate Subsequent Event Subsequent Event [Member] Customer Concentration Risk Customer Concentration Risk [Member] Other current liabilities Other Liabilities, Current Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Variable Rate [Axis] Variable Rate [Axis] Cytokinetics Cytokinetics [Member] Cytokinetics Income Statement [Abstract] Trelegy Trelegy [Member] Trelegy Title of 12(b) Security Title of 12(b) Security Two Point One Five Zero Percent Senior Notes Due 2031 Two Point One Five Zero Percent Senior Notes Due 2031 [Member] Two Point One Five Zero Percent Senior Notes Due 2031 Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Quarterly payments to affiliates, percent of security investment (as percent) Rate, Value Of Security Investments Rate, Value Of Security Investments Related Party [Domain] Related Party, Type [Domain] Comprehensive income attributable to non-controlling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Other exchanges (in shares) Stockholders' Equity, Other Shares Terrance Coyne [Member] Terrance Coyne Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Noncontrolling interest (as percent) Subsidiary, Ownership Percentage, Noncontrolling Owner Purchases of equity securities Payments To Acquire Equity Securities, FN-NI Payments To Acquire Equity Securities, FN-NI Share-based compensation and related issuances of Class A ordinary shares Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other current assets Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Maximum commitment to fund collaborative arrangement Collaborative Arrangement Rights And Obligations, Maximum Commitment To Fund Collaborative Arrangement Rights And Obligations, Maximum Commitment To Fund Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Distributions to continuing non-controlling interests Payments to Noncontrolling Interests Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Summary of Financial Royalty Assets, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Point Seven Five Percent Senior Notes Due 2023 Point Seven Five Percent Senior Notes Due 2023 [Member] Point Seven Five Percent Senior Notes Due 2023 Other Commitments [Domain] Other Commitments [Domain] Equity method investments Equity Method Investments Purchases of marketable securities Payments to Acquire Marketable Securities Statistical Measurement [Axis] Statistical Measurement [Axis] Other current assets Increase (Decrease) in Other Current Assets Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Three Point Three Five Zero Percent Due 2051 Three Point Three Five Zero Percent Due 2051 [Member] Three Point Three Five Zero Percent Due 2051 Payment of capital Collaborative Arrangement, Rights and Obligations, Payment of Capital Collaborative Arrangement, Rights and Obligations, Payment of Capital Total Shareholder Return Amount Total Shareholder Return Amount Marshall Urist [Member] Marshall Urist Repurchases of Class A ordinary shares Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Avillion Entities Avillion Entities [Member] Avillion Entities Summary of Balance Of Non-controlling Interests Schedule of Stockholders Equity [Table Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Senior Unsecured Revolving Credit Facility Senior Unsecured Revolving Credit Facility [Member] Senior Unsecured Revolving Credit Facility Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Fair Value Debt Securities, Available-for-Sale, Adjustment Debt Securities, Available-for-Sale, Adjustment Debt issued as a percent of par value (as percent) Debt Instrument, Issuance As A Percent Of Par Debt Instrument, Issuance As A Percent Of Par Three Point Five Five Percent Senior Notes Due 2050 Three Point Five Five Percent Senior Notes Due 2050 [Member] Three Point Five Five Percent Senior Notes Due 2050 Development-stage funding payments - upfront and milestone Payments For Upfront Development Stage Funding Payments For Upfront Development Stage Funding Debt issued, amount Debt Instrument, Face Amount Gain (loss) on equity securities still held Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Long term funding partnership, optional amount unavailable Long Term Funding Partnership, Optional Amount Unavailable Long Term Funding Partnership, Optional Amount Unavailable Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Minimum consolidated coverage ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Exercise fee, pro rata amount Proceeds From Exercise Fee, Pro Rata Amount Proceeds From Exercise Fee, Pro Rata Amount Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Interest payable Increase (Decrease) in Interest Payable, Net Number of votes per share Common Stock, Voting Rights, Number Of Votes Common Stock, Voting Rights, Number Of Votes Common stock, outstanding (in shares) Common shares outstanding (in shares) Common Stock, Shares, Outstanding Earnings per Class A ordinary share: Earnings Per Share, Basic [Abstract] Losses/(gains) on derivative financial instruments Gains (losses) on derivative financial instruments Gain (Loss) on Derivative Instruments, Net, Pretax Other expense/(income) Other Income and Expenses [Abstract] PEO PEO [Member] Senior Notes Due 2051 Senior Notes Due 2051 [Member] Senior Notes Due 2051 Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other exchanges Stockholders' Equity, Other Long term funding partnership, additional payments, aggregate amount Long Term Funding Partnership, Additional Payments, Aggregate Amount Long Term Funding Partnership, Additional Payments, Aggregate Amount Beginning balance (in shares) Ending balance (in shares) Shares, outstanding (in shares) Shares, Outstanding Maximum consolidated leverage ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Asset Class [Domain] Asset Class [Domain] Legacy non-controlling interests Legacy Non Controlling Interests [Member] Legacy Non Controlling Interests Current portion of Financial royalty assets Financing Receivable [Member] Common stock, par value (in dollars/pounds per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Payable to RPSFT Royalty Distribution Payable to RP Select Finance Trust [Member] Royalty Distribution Payable to RP Select Finance Trust Funding Commitments Funding Commitments [Member] Funding Commitments Write-off of cumulative allowance Financing Receivable Change In Present Value, Write-off Cumulative Allowance Financing Receivable Change In Present Value, Write-off Cumulative Allowance Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Customer [Domain] Customer [Domain] Net income attributable to Royalty Pharma plc - basic Net Income (Loss) Available to Common Stockholders, Basic Debt Instrument [Axis] Debt Instrument [Axis] Stock repurchased and retired value during the period Stock Repurchased and Retired During Period, Value Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Credit Facility [Axis] Credit Facility [Axis] Deferred stock, par value (in dollars per share) Deferred Shares, Par or Stated Value Per Share Deferred Shares, Par or Stated Value Per Share Summary of Repayments of Debt by Year Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Interest rate volatility (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Organization and Purpose Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Shareholders' Equity Shareholders' Equity and Share-Based Payments [Text Block] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Redeemable stock, redemption price (in pound per share) Redeemable Stock, Redemption Price Per Share Redeemable Stock, Redemption Price Per Share Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Equity method investment, unfunded commitments Equity Method Investments, Unfunded Commitments Equity Method Investments, Unfunded Commitments Dividends to shareholders Dividends to shareholders Payment Of Dividends To Shareholders Payment Of Dividends To Shareholders Provision for changes in expected cash flows from financial royalty assets Provision for changes in expected cash flows from financial royalty assets Provision for Other Credit Losses Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Exchange offering, ownership percentage Sale of Stock, Percentage of Ownership before Transaction Debt Disclosure [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Earnings Per Share [Abstract] Quarterly payments to affiliates, percent of adjusted cash receipts (as percent) Rate, Adjusted Cash Receipts Rate, Adjusted Cash Receipts Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock Common Stock, Value, Issued Redemption price (as percent) Debt Instrument, Redemption Price, Percentage U.S. government securities US Government Debt Securities [Member] General and administrative expenses General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Financial royalty assets, net Financing Receivables, Fair Value Disclosure Financing Receivables, Fair Value Disclosure Theravance Biopharma, Inc. Theravance Biopharma, Inc. [Member] Theravance Biopharma, Inc. Contributions from legacy non-controlling interests - R&D Proceeds From Noncontrolling Interests, Research And Development Proceeds From Noncontrolling Interests, Research And Development Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Development fund bond Development Funding Bond [Member] Development fund bond Total current assets Assets, Current Interest income Investment Income, Net Debt securities Preferred Stock [Member] Marketable securities Debt Securities, Trading Equity Securities Equity Securities [Member] All Individuals All Individuals [Member] Royalty Investments Royalty Investments [Member] Royalty Investments Bristol-Myers Squibb Bristol-Myers Squibb [Member] Bristol-Myers Squibb Other non-operating expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Intangible Royalty Assets Intangible Royalty Assets [Member] Intangible Royalty Assets Beginning balance Ending balance Financing Receivable, Allowance for Credit Loss Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Other liabilities Other Liabilities Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Stock repurchase program, authorized repurchase amount Stock Repurchase Program, Authorized Amount Repurchases of Class A ordinary shares (in shares) Stock Repurchased During Period, Shares Gains/(losses) on initial recognition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition PEO Name PEO Name Concentration risk (as percent) Concentration Risk, Percentage Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Financial Royalty Assets Financing Receivables [Text Block] Percentage of net economic profit Share Based Compensation Arrangement By Share Based Payment Award, Covenant, Percentage of Net Economic Profit Share Based Compensation Arrangement By Share Based Payment Award, Covenant, Percentage of Net Economic Profit MorphoSys MorphoSys [Member] MorphoSys Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Forwards Forward Contracts [Member] Class of Stock [Axis] Class of Stock [Axis] Non-Consolidated Affiliates Equity Method Investments and Joint Ventures Disclosure [Text Block] Installment repayments, percentage of amount drawn Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Available for sale debt securities Available for sale debt securities, current Debt Securities, Available-for-Sale, Current Unrealized gains on available for sale debt securities included in other comprehensive income/(loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Acquisitions of other financial assets Payments to Acquire Other Investments Upon occurrence of a change of control triggering event Debt Instrument, Redemption, Period Three [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Debt instrument, stated rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Federal Funds Rate Federal Funds Purchased [Member] Statement of Financial Position [Abstract] Total current and non-current financial royalty assets, net Total current and non-current financial royalty assets, net Financing Receivable, after Allowance for Credit Loss Quarterly conversion basis (in shares) Common Stock, Quarterly Conversion Basis Common Stock, Quarterly Conversion Basis Settlement Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Number of noncontrolling interests Number Of Noncontrolling Interests Number Of Noncontrolling Interests Available for sale debt securities, liabilities current Debt Securities, Available For Sale, Liability, Current Debt Securities, Available For Sale, Liability, Current Cash collected on financial royalty assets Increase (Decrease) In Cash Collections On Financing Receivables Increase (Decrease) In Cash Collections On Financing Receivables Avillion I Avillion I [Member] Avillion I Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Other Other Financial Royalty Asset [Member] Other Financial Royalty Asset Concentration Risk Type [Axis] Concentration Risk Type [Axis] EPA Holdings EPA Holdings [Member] EPA Holdings Subsequent Events [Abstract] Consolidated net income before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Cash collections from intangible royalty assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Number of tranches Number Of Tranches Number Of Tranches Level 2 Fair Value, Inputs, Level 2 [Member] Other Royalty Income Royalty Income, Other [Member] Royalty Income, Other Entity Emerging Growth Company Entity Emerging Growth Company Weighted average effective interest rate (as percent) Debt Instrument, Interest Rate, Effective Percentage Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Fair value asset liability recurring basis still held unrealized gain loss statement of income extensible list not disclosed flag Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Share-based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Available for sale debt securities Available for sale debt securities, noncurrent Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Derivative Instruments Derivative Asset [Member] Derivative Asset Earnings per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Royalty at Fair Value Royalty [Member] Derivative financial instruments Derivative Asset, Noncurrent Number of limited partnership interest acquired (in shares) Number of Partnership Interests Acquired Number of Partnership Interests Acquired Document Fiscal Year Focus Document Fiscal Year Focus Weighted average coupon rate (as percent) Debt, Weighted Average Interest Rate Total shareholders’ equity Beginning balance Ending balance Shareholders' equity Equity, Including Portion Attributable to Noncontrolling Interest Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Minimum Minimum [Member] Receivables [Abstract] Distributions from equity method investees Distributions from equity method investees Proceeds from Equity Method Investment, Distribution Exercise Price Award Exercise Price Xtandi Xtandi [Member] Xtandi Dividends declared and paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Other comprehensive income/(loss): Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Net carrying value, before cumulative allowance for credit losses Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Equity securities Equity Securities, FV-NI, Noncurrent Debt issuance costs Debt Issuance Costs, Gross Consolidated net income Consolidated net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Cash collections from financial royalty assets Proceeds From Cash Collections From Royalties Received On Financing Receivables Proceeds From Cash Collections From Royalties Received On Financing Receivables Retained Earnings Retained Earnings [Member] Current portion of long-term debt Less: Current portion of long-term debt Long-Term Debt, Current Maturities Long term funding partnership, amount Long Term Funding Partnership, Amount Long Term Funding Partnership, Amount Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and shareholders’ equity Liabilities and Equity Cost Debt Securities, Available-for-Sale, Amortized Cost Deferred shares, $0.000001 par value; issued and outstanding: 2023–382,837 and 2022–371,325 Deferred Shares, Value, Issued Deferred Shares, Value, Issued Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Risk-adjusted discount rate (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic (in dollars per share) Earnings per Class A ordinary share - basic (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Option to sell retained royalties, amount Option To Sell Retained Royalties, Amount Option To Sell Retained Royalties, Amount Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Vertex Vertex [Member] Vertex Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Net income attributable to Royalty Pharma plc - diluted Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Basis of Consolidation Consolidation, Policy [Policy Text Block] Rory Riggs [Member] Rory Riggs Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Unsecured Debt Unsecured Debt [Member] Deferred stock, outstanding (in shares) Deferred Shares, Shares, Outstanding Deferred Shares, Shares, Outstanding Termination Date Trading Arrangement Termination Date Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Fair Value Debt Securities, Available-for-Sale Document Information [Table] Document Information [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized(Losses)/Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Losses on equity securities Equity Securities, FV-NI, Gain (Loss) RPSFT Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member] Legacy Investors Partnerships and Royalty Pharma Select Finance Trust Initial term (in years) Related Party Transaction, Initial Term Related Party Transaction, Initial Term Total Long-Term Debt, Gross Adjustments to reconcile consolidated net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Compensation Amount Outstanding Recovery Compensation Amount Tysabri Tysabri [Member] Tysabri Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Development-stage funding payments - ongoing Payments For Ongoing Development Stage Funding Payments For Ongoing Development Stage Funding Roche’s Evrysdi Roche’s Evrysdi [Member] Roche’s Evrysdi Long term funding partnership, initial payment Long Term Funding Partnership, Initial Payment Long Term Funding Partnership, Initial Payment Other Commitments [Axis] Other Commitments [Axis] Additional paid-in capital Additional Paid in Capital Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Document Information [Line Items] Document Information [Line Items] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Indirect Cash Flow Cash Flow, Supplemental Disclosures [Text Block] Cumulative allowance for changes in expected cash flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Gross Carrying Value Financing Receivable, before Allowance for Credit Loss Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Insider Trading Arrangements [Line Items] Distributions from equity method investees Proceeds from Equity Method Investment, Distribution, Return of Capital 2024 Long-Term Debt, Maturity, Year One Related Party [Axis] Related Party, Type [Axis] Prior to the applicable par call date Debt Instrument, Redemption, Period One [Member] Share-based compensation and related issuances of Class A ordinary shares (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Award Timing Method Award Timing Method [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Unvested RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements (Gains)/losses on equity securities (Gains)/losses on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Non-controlling interests Equity, Attributable to Noncontrolling Interest One Point Seven Five Percent Senior Notes Due 2027 One Point Seven Five Percent Senior Notes Due 2027 [Member] One Point Seven Five Percent Senior Notes Due 2027 Document Period End Date Document Period End Date Proceeds from lines of credit Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Summary of Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Credit Loss [Abstract] PTC Therapeutics, Inc. PTC Therapeutics, Inc. [Member] PTC Therapeutics, Inc. Deferred stock, issued (in shares) Deferred Shares, Shares, Issued Deferred Shares, Shares, Issued Distributions payable to legacy non-controlling interests Distributions Payable To Legacy Non-Controlling Interests, Current Distributions Payable To Legacy Non-Controlling Interests, Current Repayment of long-term debt Repayments of Long-Term Debt Treasury Interests Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Liabilities: Liabilities, Fair Value Disclosure [Abstract] Gains/(losses) on available for sale debt securities included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Income tax expense Income Tax Expense (Benefit) Other royalty cash collections Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Class B ordinary shares exchangeable for Class A ordinary shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Allowance for Credit Loss, Writeoff Fair Value Measurements and Financial Instruments Fair Value Disclosures [Text Block] One Point Two Zero Percent Senior Notes Due 2025 One Point Two Zero Percent Senior Notes Due 2025 [Member] One Point Two Zero Percent Senior Notes Due 2025 Name Trading Arrangement, Individual Name Current period provision for credit losses, net Financing Receivable, Credit Loss, Expense (Reversal) Continuing non-controlling interests Continuing Non Controlling Interests [Member] Continuing Non Controlling Interests Equity [Abstract] Reclassification of unrealized gains on available for sale debt securities Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Income from financial royalty assets Increase (Decrease) In Financial Royalty Assets Increase (Decrease) In Financial Royalty Assets Total non-current assets Assets, Fair Value Disclosure, Noncurrent Assets, Fair Value Disclosure, Noncurrent Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Losses/(gains) on derivative financial instruments Unrealized Gain (Loss) on Derivatives Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Agreement with MSCI Agreement with MSCI [Member] Agreement with MSCI Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Assets: Assets, Fair Value Disclosure [Abstract] Stock repurchased and retired during period (in shares) Stock Repurchased and Retired During Period, Shares Credit Facility [Domain] Credit Facility [Domain] Two Point Two Zero Percent Senior Notes Due 2030 Two Point Two Zero Percent Senior Notes Due 2030 [Member] Two Point Two Zero Percent Senior Notes Due 2030 Distributions to legacy non-controlling interests - other Payments To Noncontrolling Interests, Other Payments To Noncontrolling Interests, Other Basis spread on variable rate (as percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Numerator Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Percent calculated for operating and personal payment Operating and Personal Payment Calculation, Percent Operating and Personal Payment Calculation, Percent Imbruvica Imbruvica [Member] Imbruvica Diluted (in shares) Weighted average Class A ordinary shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Cytokinetics Funding Commitment Cytokinetics Funding Commitment [Member] Cytokinetics Funding Commitment Other commitment Other Commitment Available for sale debt securities, liabilities noncurrent Available for sale debt securities, liabilities noncurrent Debt Securities, Available For Sale, Liability, Noncurrent Debt Securities, Available For Sale, Liability, Noncurrent Operating expenses Operating Expenses [Abstract] Number of classes of stock Number Of Classes Of Voting Stock Number Of Classes Of Voting Stock Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Gains on available for sale debt securities Gains on available for sale debt securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Proceeds from equity securities Proceeds From Issuance Of Equity Securities, FN-NI Proceeds From Issuance Of Equity Securities, FN-NI Redemptions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Equity in losses/(earnings) of equity method investees Equity in losses/(earnings) of equity method investees Equity in (earnings)/losses of equity method investees Income (Loss) from Equity Method Investments Amount calculated for operating and personal payment Operating and Personal Payment Calculation, Amount Operating and Personal Payment Calculation, Amount Cover [Abstract] Subsequent Events Subsequent Events [Text Block] Fair Value, Recurring Fair Value, Recurring [Member] Acquisition Of Limited Partnership Interests In Affiliate Acquisition Of Limited Partnership Interests In Affiliate [Member] Acquisition Of Limited Partnership Interests In Affiliate Non-NEOs Non-NEOs [Member] Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Operating and Personnel Payments Operating and Personnel Payments [Member] Operating and Personnel Payments Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Other royalty income receivable Other Royalty Income Receivable, Current Other Royalty Income Receivable, Current Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Assignment Agreement - Funding Obligations Assignment Agreement - Funding Obligations [Member] Assignment Agreement - Funding Obligations Tremfya Tremfya [Member] Tremfya Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted average Class A ordinary shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Operating income Operating Income (Loss) Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Cumulative allowance for credit losses Cumulative allowance for credit losses Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Total current assets Assets, Fair Value Disclosure, Current Assets, Fair Value Disclosure, Current Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Accumulated Other Comprehensive Income AOCI Including Portion Attributable to Noncontrolling Interest [Member] Legacy Investors Partnerships Legacy Investors Partnerships [Member] Legacy Investors Partnerships Accrued royalty receivable Increase (Decrease) In Accrued Royalty Receivable Increase (Decrease) In Accrued Royalty Receivable Number of dividend payments Number Of Dividend Payments Number Of Dividend Payments Payments for operating and professional costs Payments For Operating Costs and Professional Services Payments For Operating Costs and Professional Services Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Fair Value Estimate of Fair Value Measurement [Member] Other comprehensive income/(loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Three Point Three Zero Percent Senior Notes Due 2040 Three Point Three Zero Percent Senior Notes Due 2040 [Member] Three Point Three Zero Percent Senior Notes Due 2040 Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Outstanding borrowings Long-Term Line of Credit Summary of Available for Sale Debt Securities Debt Securities, Available-for-Sale [Table Text Block] Non-Controlling Interests Noncontrolling Interest [Member] EX-101.PRE 9 rprx-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 02, 2023
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-39329  
Entity Registrant Name Royalty Pharma plc  
Entity Incorporation, State or Country Code X0  
Entity Tax Identification Number 98-1535773  
Entity Address, Address Line One 110 East 59th Street  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10022  
City Area Code 212  
Local Phone Number 883-0200  
Title of 12(b) Security Class A ordinary shares, par value $0.0001  
Trading Symbol RPRX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001802768  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Class A Ordinary Shares    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   444,886,039
Class B Ordinary Shares    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   152,546,046
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 936,448 $ 1,710,751
Marketable securities 0 24,421
Financial royalty assets 742,160 691,319
Accrued royalty receivable 16,360 16,830
Available for sale debt securities 5,300 1,300
Other royalty income receivable 21,553 19,767
Other current assets 6,784 90,520
Total current assets 1,728,605 2,554,908
Financial royalty assets, net 13,230,474 13,493,106
Equity securities 144,342 112,348
Available for sale debt securities 353,600 226,300
Equity method investments 378,291 397,175
Other assets 20,212 29,629
Total assets 15,855,524 16,813,466
Current liabilities    
Distributions payable to legacy non-controlling interests 101,711 94,803
Accounts payable and accrued expenses 13,627 7,906
Interest payable 12,595 54,162
Current portion of long-term debt 0 997,512
Other current liabilities 0 12,400
Total current liabilities 127,933 1,166,783
Long-term debt 6,131,194 6,118,810
Other liabilities 11,300 2,500
Total liabilities 6,270,427 7,288,093
Commitments and contingencies
Shareholders’ equity    
Deferred shares, $0.000001 par value; issued and outstanding: 2023–382,837 and 2022–371,325 0 0
Additional paid-in capital 4,006,758 3,666,160
Retained earnings 2,134,680 1,964,689
Non-controlling interests 3,446,175 3,897,223
Treasury interests (2,624) (2,806)
Total shareholders’ equity 9,585,097 9,525,373
Total liabilities and shareholders’ equity 15,855,524 16,813,466
Class A Ordinary Shares    
Shareholders’ equity    
Common stock 45 44
Class B Ordinary Shares    
Shareholders’ equity    
Common stock 0 0
Class R Redeemable Shares    
Shareholders’ equity    
Common stock $ 63 $ 63
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
shares in Thousands
Sep. 30, 2023
$ / shares
shares
Sep. 30, 2023
£ / shares
shares
Dec. 31, 2022
$ / shares
shares
Dec. 31, 2022
£ / shares
shares
Deferred stock, par value (in dollars per share) | $ / shares $ 0.000001   $ 0.000001  
Deferred stock, issued (in shares) 382,837 382,837 371,325 371,325
Deferred stock, outstanding (in shares) 382,837 382,837 371,325 371,325
Class A Ordinary Shares        
Common stock, par value (in dollars/pounds per share) | $ / shares $ 0.0001   $ 0.0001  
Common stock, issued (in shares) 445,843 445,843 443,166 443,166
Common stock, outstanding (in shares) 445,843 445,843 443,166 443,166
Class B Ordinary Shares        
Common stock, par value (in dollars/pounds per share) | $ / shares $ 0.000001   $ 0.000001  
Common stock, issued (in shares) 152,546 152,546 164,058 164,058
Common stock, outstanding (in shares) 152,546 152,546 164,058 164,058
Class R Redeemable Shares        
Common stock, par value (in dollars/pounds per share) | £ / shares   £ 1   £ 1
Common stock, issued (in shares) 50 50 50 50
Common stock, outstanding (in shares) 50 50 50 50
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues $ 536,313 $ 573,463 $ 1,758,486 $ 1,671,467
Operating expenses        
Provision for changes in expected cash flows from financial royalty assets 277,137 305,061 637,169 595,396
Research and development funding expense 50,500 25,500 51,500 126,606
Amortization of intangible assets 0 0 0 5,670
General and administrative expenses 57,234 50,692 190,563 154,075
Total operating expenses, net 384,871 381,253 879,232 881,747
Operating income 151,442 192,210 879,254 789,720
Other expense/(income)        
Equity in losses/(earnings) of equity method investees 5,222 3,251 (28,614) 2,117
Interest expense 46,033 46,977 139,932 141,006
Losses/(gains) on derivative financial instruments 8,680 (25,785) 2,290 (97,590)
(Gains)/losses on equity securities (1,541) (5,168) (31,994) 22,970
Gains on available for sale debt securities (7,300) (44,243) (122,500) (97,985)
Interest income (23,436) (14,034) (65,791) (34,482)
Other non-operating expense, net 1,707 10,798 3,429 13,590
Total other expense/(income), net 29,365 (28,204) (103,248) (50,374)
Consolidated net income before tax 122,077 220,414 982,502 840,094
Income tax expense 0 0 0 0
Consolidated net income 122,077 220,414 982,502 840,094
Net income attributable to non-controlling interests 49,963 77,763 342,008 341,178
Net income attributable to Royalty Pharma plc $ 72,114 $ 142,651 $ 640,494 $ 498,916
Earnings per Class A ordinary share:        
Basic (in dollars per share) $ 0.16 $ 0.32 $ 1.43 $ 1.14
Diluted (in dollars per share) $ 0.16 $ 0.32 $ 1.43 $ 1.14
Weighted average Class A ordinary shares outstanding:        
Basic (in shares) 448,439 439,293 448,162 436,542
Diluted (in shares) 601,138 607,226 604,717 607,209
Financial Royalty Assets        
Revenues $ 508,657 $ 551,682 $ 1,674,689 $ 1,578,555
Intangible Royalty Assets        
Revenues 252 1,073 597 37,196
Other Royalty Income        
Revenues $ 27,404 $ 20,708 $ 83,200 $ 55,716
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Consolidated net income $ 122,077 $ 220,414 $ 982,502 $ 840,094
Other comprehensive income/(loss):        
Unrealized gains on available for sale debt securities 0 13,050 0 24,000
Reclassification of unrealized gains on available for sale debt securities 0 (7,111) 0 (24,053)
Other comprehensive income/(loss): 0 5,939 0 (53)
Comprehensive income 122,077 226,353 982,502 840,041
Comprehensive income attributable to non-controlling interests 49,963 80,161 342,008 341,109
Comprehensive income attributable to Royalty Pharma plc $ 72,114 $ 146,192 $ 640,494 $ 498,932
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Class R Redeemable Shares
Common Stock
Class A Ordinary Shares
Common Stock
Class B Ordinary Shares
Common Stock
Class R Redeemable Shares
Deferred Shares
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income
Non-Controlling Interests
Treasury Interests
Beginning balance (in shares) at Dec. 31, 2021     432,963 174,213 50 361,170          
Beginning balance at Dec. 31, 2021 $ 10,248,545   $ 43 $ 0 $ 63 $ 0 $ 3,507,533 $ 2,255,179 $ 16,491 $ 4,471,951 $ (2,715)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Contributions 9,173                 9,173  
Distributions (433,822)                 (433,822)  
Dividends (249,121)             (249,121)      
Other exchanges (in shares)     8,095 (8,095)   8,095          
Other exchanges 0   $ 1       123,783   397 (124,108) (73)
Share-based compensation and related issuances of Class A ordinary shares (in shares)     46                
Share-based compensation and related issuances of Class A ordinary shares 1,587           1,587        
Net income 840,094             498,916   341,178  
Other comprehensive income/(loss):                      
Unrealized gains on available for sale debt securities 24,000               14,262 9,738  
Reclassification of unrealized gains on available for sale debt securities (24,053)               (14,246) (9,807)  
Ending balance (in shares) at Sep. 30, 2022     441,104 166,118 50 369,265          
Ending balance at Sep. 30, 2022 10,416,403   $ 44 $ 0 $ 63 $ 0 3,632,903 2,504,974 16,904 4,264,303 (2,788)
Beginning balance (in shares) at Jun. 30, 2022     437,139 170,081 50 365,302          
Beginning balance at Jun. 30, 2022 10,408,187   $ 44 $ 0 $ 63 $ 0 3,570,585 2,446,132 13,177 4,380,938 (2,752)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Contributions 2,970                 2,970  
Distributions (137,880)                 (137,880)  
Dividends (83,809)             (83,809)      
Other exchanges (in shares)     3,963 (3,963)   3,963          
Other exchanges 0           61,736   186 (61,886) (36)
Share-based compensation and related issuances of Class A ordinary shares (in shares)     2                
Share-based compensation and related issuances of Class A ordinary shares 582           582        
Net income 220,414             142,651   77,763  
Other comprehensive income/(loss):                      
Unrealized gains on available for sale debt securities 13,050               7,781 5,269  
Reclassification of unrealized gains on available for sale debt securities (7,111)               (4,240) (2,871)  
Ending balance (in shares) at Sep. 30, 2022     441,104 166,118 50 369,265          
Ending balance at Sep. 30, 2022 10,416,403   $ 44 $ 0 $ 63 $ 0 3,632,903 2,504,974 $ 16,904 4,264,303 (2,788)
Beginning balance (in shares) at Dec. 31, 2022     443,166 164,058 50 371,325          
Beginning balance at Dec. 31, 2022 9,525,373   $ 44 $ 0 $ 63 $ 0 3,666,160 1,964,689   3,897,223 (2,806)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Contributions 9,690                 9,690  
Distributions (386,590)                 (386,590)  
Dividends (268,989)             (268,989)      
Other exchanges (in shares)     11,512 (11,512)   11,512          
Other exchanges 0   $ 2       415,972     (416,156) 182
Share-based compensation and related issuances of Class A ordinary shares (in shares)     54                
Share-based compensation and related issuances of Class A ordinary shares 1,740           1,740        
Repurchases of Class A ordinary shares (in shares)     (8,889)                
Repurchases of Class A ordinary shares (278,629)   $ (1)       (77,114) (201,514)      
Net income 982,502             640,494   342,008  
Other comprehensive income/(loss):                      
Unrealized gains on available for sale debt securities 0                    
Reclassification of unrealized gains on available for sale debt securities 0                    
Ending balance (in shares) at Sep. 30, 2023   50 445,843 152,546 50 382,837          
Ending balance at Sep. 30, 2023 9,585,097   $ 45 $ 0 $ 63 $ 0 4,006,758 2,134,680   3,446,175 (2,624)
Beginning balance (in shares) at Jun. 30, 2023     450,352 152,896 50 382,487          
Beginning balance at Jun. 30, 2023 9,813,686   $ 46 $ 0 $ 63 $ 0 4,031,242 2,252,945   3,532,019 (2,629)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Contributions 2,850                 2,850  
Distributions (120,198)                 (120,198)  
Dividends (89,751)             (89,751)      
Other exchanges (in shares)     350 (350)   350          
Other exchanges 0           18,454     (18,459) 5
Share-based compensation and related issuances of Class A ordinary shares (in shares)     3                
Share-based compensation and related issuances of Class A ordinary shares $ 581           581        
Repurchases of Class A ordinary shares (in shares) (4,862)                    
Repurchases of Class A ordinary shares $ (144,148)   $ (1)       (43,519) (100,628)      
Net income 122,077             72,114   49,963  
Other comprehensive income/(loss):                      
Unrealized gains on available for sale debt securities 0                    
Reclassification of unrealized gains on available for sale debt securities 0                    
Ending balance (in shares) at Sep. 30, 2023   50 445,843 152,546 50 382,837          
Ending balance at Sep. 30, 2023 $ 9,585,097   $ 45 $ 0 $ 63 $ 0 $ 4,006,758 $ 2,134,680   $ 3,446,175 $ (2,624)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Parenthetical) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dividends declared and paid (in dollars per share)     $ 0.20  
Class A Ordinary Shares        
Dividends declared and paid (in dollars per share) $ 0.20 $ 0.19 $ 0.60 $ 0.57
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Cash collections from financial royalty assets $ 2,454,054 $ 1,843,899
Cash collections from intangible royalty assets 1,067 72,406
Other royalty cash collections 84,275 51,607
Distributions from equity method investees 18,823 33,316
Interest received 63,135 10,556
Development-stage funding payments - ongoing (1,500) (1,606)
Development-stage funding payments - upfront and milestone (50,000) (125,000)
Payments for operating and professional costs (188,839) (141,653)
Interest paid (165,841) (169,476)
Net cash provided by operating activities 2,215,174 1,574,049
Cash flows from investing activities:    
Distributions from equity method investees 39,225 0
Investments in equity method investees (10,550) (9,896)
Purchases of equity securities 0 (62,785)
Proceeds from equity securities 0 46,158
Purchases of available for sale debt securities 0 (393,737)
Proceeds from available for sale debt securities 0 46,875
Purchases of marketable securities 0 (234,869)
Proceeds from sales and maturities of marketable securities 24,391 676,705
Acquisitions of financial royalty assets (1,113,283) (1,491,399)
Acquisitions of other financial assets 0 (21,215)
Milestone payments (12,400) 0
Net cash used in investing activities (1,072,617) (1,444,163)
Cash flows from financing activities:    
Distributions to legacy non-controlling interests - royalty receipts (284,637) (322,726)
Distributions to legacy non-controlling interests - other 0 (2,335)
Distributions to continuing non-controlling interests (95,045) (110,964)
Dividends to shareholders (268,989) (249,121)
Repurchases of Class A ordinary shares (274,559) 0
Contributions from legacy non-controlling interests - R&D 455 971
Contributions from non-controlling interests - other 5,915 4,869
Repayment of long-term debt (1,000,000) 0
Net cash used in financing activities (1,916,860) (679,306)
Net change in cash and cash equivalents (774,303) (549,420)
Cash and cash equivalents, beginning of period 1,710,751 1,541,048
Cash and cash equivalents, end of period $ 936,448 $ 991,628
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Purpose
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Purpose Organization and Purpose
Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the initial public offering (“IPO”) of our Class A ordinary shares. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.

We control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our condensed consolidated financial statements.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management vehicle, and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”). RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”) and Royalty Pharma plc. Prior to the Exchange Offer (defined below), Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

RP Management, LLC (the “Manager”), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the “Management Agreement”).

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Exchange Offer

We consummated an exchange offer on February 11, 2020 (the “Exchange Offer”) to facilitate the IPO. Through the Exchange Offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. Following the Exchange Offer, we became the indirect owner of an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”). We are entitled to 82% of the economics of Old RPI’s wholly-owned subsidiary RPI Finance Trust, a Delaware statutory trust (“RPIFT”), and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Preparation and Use of Estimates

The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2022, included in our Annual Report on Form 10-K.
The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.

Basis of Consolidation

The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interests in our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

In 2022, we became an indirect owner of an 82% economic interest in Royalty Pharma Investments ICAV (“RPI ICAV”), which previously was owned directly by Old RPI.

We report four non-controlling interests: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the “legacy non-controlling interests”). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of RP Holdings Class B Interests (the “continuing non-controlling interests”) and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain performance conditions are met.

All intercompany transactions and balances have been eliminated in consolidation.

Reclassification

Certain prior period amounts have been reclassified to conform to the current period presentation.

Concentrations of Credit Risk

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of September 30, 2023 and December 31, 2022 were held with Bank of America, State Street, Scotiabank, Citibank, TD Bank, DNB Bank and U.S. Bank. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson & Johnson, Merck & Co., Pfizer, Astellas, Novartis and Gilead. As of September 30, 2023 and December 31, 2022, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, represented the largest individual marketer and payor of our royalties, accounting for 31% of our current portion of financial royalty assets.

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.
Significant Accounting Policies

There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2022.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Available for Sale Debt Securities
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Available for Sale Debt Securities Available for Sale Debt Securities
Cytokinetics Commercial Launch Funding

On January 7, 2022, we entered into a long-term funding agreement, which was later amended in 2022, with Cytokinetics, Incorporated (“Cytokinetics”). We agreed to provide funding of up to $300 million (“Cytokinetics Commercial Launch Funding”) in five tranches. The initial tranche of $50 million was funded upon closing. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). Because the regulatory milestones for the second and third tranches were not met, $75 million of the optional funding is no longer available. For tranches one, four and five, we expect to receive a return of 1.9 times the amount drawn over 34 consecutive quarterly payments beginning on the last business day of the seventh quarter following the quarter of the funding date of each tranche. As of September 30, 2023, $125 million of the optional $200 million remained available under the Cytokinetics Funding Commitments.

We elected the fair value option to account for the Cytokinetics Commercial Launch Funding as it most accurately reflects the nature of the funding arrangement. The funded Cytokinetics Commercial Launch Funding is recorded within Available for sale debt securities on the condensed consolidated balance sheets. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within Other liabilities on the condensed consolidated balance sheets. The changes in the fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within Gains on available for sale debt securities in the condensed consolidated statements of operations.

MorphoSys Development Funding Bonds

On June 2, 2021, we announced a long-term strategic funding agreement with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc. which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350 million of capital (“Development Funding Bonds”), of which MorphoSys was required to draw a minimum of $150 million. In September 2022, we funded $300 million of the Development Funding Bonds, which represents $150 million in additional funding above the minimum funding commitment (“Additional Funding”), and settled our forward commitment. We expect to receive a return of 2.2 times the funded amount of the Development Funding Bonds, payable on a quarterly basis over nine years, with the first payment beginning in the fourth quarter of 2024.

We elected the fair value option to account for the Development Funding Bonds as it most accurately reflects the nature of the instruments. The Development Funding Bonds are recorded within Available for sale debt securities on the condensed consolidated balance sheets. The changes in the fair value of the Development Funding Bonds are recorded within Gains on available for sale debt securities in the condensed consolidated statements of operations.
The table below summarizes our available for sale debt securities recorded at fair value as of September 30, 2023 and December 31, 2022 (in thousands):

CostUnrealized(Losses)/GainsFair Value Current AssetsNon-Current AssetsNon-Current LiabilitiesTotal
As of September 30, 2023
Debt securities (1)$359,400 $(500)$358,900 $5,300 $353,600 $— $358,900 
Funding commitments (2)(7,300)(4,000)(11,300)— — (11,300)(11,300)
Total available for sale debt securities$352,100 $(4,500)$347,600 $5,300 $353,600 $(11,300)$347,600 
As of December 31, 2022
Debt securities (1)$359,400 $(131,800)$227,600 $1,300 $226,300 $— $227,600 
Funding commitments (2)(9,400)6,900 (2,500)— — (2,500)(2,500)
Total available for sale debt securities$350,000 $(124,900)$225,100 $1,300 $226,300 $(2,500)$225,100 
(1)The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amount funded.
(2)Related to Cytokinetics Funding Commitments for which related tranches remain available as of respective balance sheet dates. The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements and Financial Instruments
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements and Financial Instruments Fair Value Measurements and Financial Instruments
Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):
As of September 30, 2023As of December 31, 2022
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Money market funds (1)$605,422 $— $— $605,422 $5,068 $— $— $5,068 
Marketable securities
Certificates of deposit— — — — — 11,501 — 11,501 
U.S. government securities— — — — — 12,920 — 12,920 
Available for sale debt securities (2)— — 5,300 5,300 — — 1,300 1,300 
Derivative instruments (3)— — — — — — 86,150 86,150 
Total current assets$605,422 $— $5,300 $610,722 $5,068 $24,421 $87,450 $116,939 
Equity securities140,170 — 4,172 144,342 103,876 — 8,472 112,348 
Available for sale debt securities (2)— — 353,600 353,600 — — 226,300 226,300 
Derivative instruments (3)— — — — — — 10,460 10,460 
Royalty at fair value (4)— — 16,331 16,331 — — 14,500 14,500 
Total non-current assets$140,170 $— $374,103 $514,273 $103,876 $— $259,732 $363,608 
Liabilities:
Funding commitments (5)— — (11,300)(11,300)— — (2,500)(2,500)
Total non-current liabilities$— $— $(11,300)$(11,300)$— $— $(2,500)$(2,500)
(1)Recorded within Cash and cash equivalents on the condensed consolidated balance sheets.
(2)Reflects the fair value of the funded portions of the Development Funding Bonds and the Cytokinetics Commercial Launch Funding.
(3)Reflects the fair value of the Milestone Acceleration Option (defined below) which was recorded within Other current assets and Other assets on the condensed consolidated balance sheets. As of December 31, 2022, the fair value for the current portion of the derivative instruments related to the intranasal indication of zavegepant which settled in March 2023 when the U.S. Food and Drug Administration (“FDA”) approved Zavzpret and the fair value of the non-current portion of the derivative instruments related to the oral indication of zavegepant.
(4)Recorded within Other assets on the condensed consolidated balance sheets. See Note 7–Non-Consolidated Affiliates for additional discussion.
(5)Related to the fair value of the Cytokinetics Funding Commitments recorded within Other liabilities on the condensed consolidated balance sheets.
For the third quarter and first nine months of 2023, we recognized gains of $1.5 million and $32.0 million, respectively, on equity securities still held as of September 30, 2023. For the third quarter and first nine months of 2022, we recognized losses of $0.9 million and $27.7 million, respectively, on equity securities still held as of September 30, 2023.

The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands):

For the Three Months Ended September 30, 2023
Equity SecuritiesDebt SecuritiesFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$5,718 $348,800 $(8,500)$8,680 $16,583 
Losses on equity securities(1,546)— — — — 
Losses on derivative financial instruments— — — (8,680)— 
Gains/(losses) on available for sale debt securities included in earnings
— 10,100 (2,800)— — 
Other non-operating expense
— — — — (252)
Balance at the end of the period$4,172 $358,900 $(11,300)$— $16,331 

For the Three Months Ended September 30, 2022
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 
Purchases— 314,579 — — — — 
Losses on initial recognition (1)— (8,800)— — — — 
Losses on equity securities(10,489)— — — — — 
Gains on derivative financial instruments— — — — 25,790 — 
Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)
— 13,050 — — — — 
Gains/(losses) on available for sale debt securities included in earnings— 14,200 40,643 (1,800)— — 
Other non-operating expense— — — — — (7,278)
Settlement (2)
— 2,427 (2,427)— — — 
Redemptions— (15,625)— — — — 
Balance at the end of the period$18,296 $682,831 $66,316 $(9,900)$97,590 $13,937 
(1)Represents the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million.
(2)Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares.

For the Nine Months Ended September 30, 2023
Equity SecuritiesDebt SecuritiesFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$8,472 $227,600 $(2,500)$96,610 $14,500 
Losses on equity securities(4,300)— — — — 
Losses on derivative financial instruments— — — (2,290)— 
Gains/(losses) on available for sale debt securities included in earnings— 131,300 (8,800)— — 
Other non-operating income— — — — 1,831 
Settlement (1)— — — (94,320)— 
Balance at the end of the period$4,172 $358,900 $(11,300)$— $16,331 
(1)Represents the fair value of the Milestone Acceleration Option (defined below) attributable to the intranasal indication of zavegepant which was settled when the FDA approved Zavzpret in March 2023.
For the Nine Months Ended September 30, 2022
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$43,013 $253,700 $16,700 $— $— $— 
Purchases28,785 393,737 — — — 21,215 
Gains/(losses) on initial recognition (1)— 600 — (9,400)— — 
Losses on equity securities(12,810)— — — — — 
Gains on derivative financial instruments— — — — 97,590 — 
Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)— 24,000 — — — — 
Gains/(losses) on available for sale debt securities included in earnings
— 44,400 62,885 (500)— — 
Other non-operating expense— — — — — (7,278)
Settlements (2)
— 13,269 (13,269)— — — 
Transfer out of Level 3 (3)
(40,692)— — — — — 
Redemptions— (46,875)— — — — 
Balance at the end of the period$18,296 $682,831 $66,316 $(9,900)$97,590 $13,937 
(1)Represents purchase price allocation to arrive at the appropriate fair value on initial recognition. Amounts also reflect the initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million.
(2)Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares.
(3)Related to the expiration of the transfer restriction on BioCryst common stock.

Valuation Inputs for Recurring Fair Value Measurements

Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements as of September 30, 2023 and December 31, 2022 in the fair value hierarchy.

ApiJect Investment

We estimated the fair value of the equity securities and revenue participation right that we acquired from ApiJect Holdings, Inc. (“ApiJect”), a private company, as of September 30, 2023 and December 31, 2022 by utilizing a discounted cash flow calculation using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 7–Non-Consolidated Affiliates for additional discussion.

Cytokinetics Commercial Launch Funding and Cytokinetics Funding Commitments

We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of September 30, 2023 and December 31, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding require significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.
We estimated the fair value of the Cytokinetics Funding Commitments as of September 30, 2023 and December 31, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty’s assumed cost of debt, which would impact Cytokinetics’ decision to exercise its option to draw on each respective tranche. As of September 30, 2023 and December 31, 2022, this methodology incorporates Level 3 fair value measurements and inputs, including an assumed risk-adjusted discount rate of 15.4% and 13.5%, respectively, and an assumed interest rate volatility of 32.5% and 30.0%, respectively. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

MorphoSys Development Funding Bonds

We estimated the fair value of the Development Funding Bonds as of September 30, 2023 and December 31, 2022 based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 fair value inputs. Our estimate of the risk adjusted discount rates could reasonably be different than the discount rates selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

Milestone Acceleration Option

On August 7, 2020, we entered into an expanded funding agreement with Biohaven to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. Following Pfizer’s acquisition of Biohaven on October 2, 2022, which was a change of control event, we elected to accelerate the payment of the zavegepant milestone payments, if triggered, into a lump sum amount (“Milestone Acceleration Option”). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven. In March 2023, the FDA approved Zavzpret (zavegepant), a calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults, which triggered a milestone payment of $475 million that we received in the same month and resulted in a partial settlement of the derivative instrument.

We estimated the fair value of the Milestone Acceleration Option as of December 31, 2022 using the “with-and-without” methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rate which was primarily based on Pfizer’s cost of debt and management’s estimated probabilities of achieving the success-based milestones. Assessing the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate and the probabilities of achieving marketing approval could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

Other Financial Instruments

As of September 30, 2023, we did not have any financial instruments recorded at fair value using Level 2 inputs. As of December 31, 2022, financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consisted of certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that provide quoted market prices in active markets for similar securities or observable inputs for their pricing without applying significant adjustments.
Financial Assets Not Measured at Fair Value

Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products which are estimated using sell-side equity research analysts’ consensus sales forecasts. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments, are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are presented below (in thousands):

As of September 30, 2023As of December 31, 2022
Fair ValueCarrying Value, netFair ValueCarrying Value, net
Financial royalty assets, net$17,356,414 $13,230,474 $17,314,094 $13,493,106 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Royalty Assets
 9 Months Ended
Sep. 30, 2023
Receivables [Abstract]  
Financial Royalty Assets Financial Royalty Assets
Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are as follows (in thousands):
As of September 30, 2023
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,304,675 $— $5,304,675 
Tysabri
(3)
1,557,167 (356,280)1,200,887 
Trelegy2029-20301,237,514 (65,715)1,171,799 
Tremfya2031-2032927,465 (151,563)775,902 
Evrysdi
2030-2035 (4)
772,667 — 772,667 
Xtandi2027-2028939,653 (296,160)643,493 
Other2024-20416,375,151 (2,125,113)4,250,038 
Total$17,114,292 $(2,994,831)$14,119,461 
Less: Cumulative allowance for credit losses (Note 6)(146,827)
Total current and non-current financial royalty assets, net$13,972,634 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key U.S. patents on Evrysdi expire in 2035. Our royalty will end when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

As of September 30, 2023, the balance of $14.0 billion for total current and non-current financial royalty assets, net included $562.1 million in unapproved financial royalty assets held at cost related to olpasiran, pelacarsen, KarXT and seltorexant.
As of December 31, 2022
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (4)
Cystic fibrosis franchise
2037 (2)
$5,333,535 $(10,908)$5,322,627 
Tysabri
(3)
1,683,441 (212,283)1,471,158 
Trelegy2029-20301,284,054 (24,126)1,259,928 
Tremfya2031-2032894,160 — 894,160 
Imbruvica2027-20321,436,969 (660,703)776,266 
Xtandi2027-20281,009,168 (235,625)773,543 
Other2024-20415,134,980 (1,332,815)3,802,165 
Total$16,776,307 $(2,476,460)$14,299,847 
Less: Cumulative allowance for credit losses (Note 6)(115,422)
Total current and non-current financial royalty assets, net$14,184,425 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets
 9 Months Ended
Sep. 30, 2023
Credit Loss [Abstract]  
Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets
The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets on the condensed consolidated balance sheets and includes the following:

•the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products which are estimated by sell-side equity research analysts’ consensus sales forecasts,
•the write-off of cumulative allowance at the end of a royalty asset’s life which only impacts the condensed consolidated balance sheets, and
•the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.

The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):

Activity for the Period
Balance at December 31, 2022 (1)$(2,591,882)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(860,242)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets254,478 
Write-off of cumulative allowance87,393 
Current period provision for credit losses, net (2)(31,405)
Balance at September 30, 2023$(3,141,658)
(1)Includes $115.4 million related to cumulative allowance for credit losses.
(2)The provision expense for credit losses was primarily related to the additions of Adstiladrin and Skytrofa to our portfolio of financial royalty assets with limited protective rights.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Non-Consolidated Affiliates
 9 Months Ended
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Non-Consolidated Affiliates Non-Consolidated Affiliates
We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities over which we have elected the fair value option.

ApiJect

In April 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for such investments. We are also required to purchase additional common stock from ApiJect if certain milestones are achieved. The fair value of our equity investment in ApiJect is recorded within Equity securities and the change in fair value is recorded within (Gains)/losses on equity securities. The fair value of the revenue participation right is recorded within Other assets and the change in fair value is recorded within Other non-operating expense, net. No amounts were due from ApiJect as of September 30, 2023.

The Legacy SLP Interest

In connection with the Exchange Offer, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is accounted for under the equity method as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI and RPI ICAV.

The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. Equity in earnings from the Legacy SLP Interest is recorded within Equity in losses/(earnings) of equity method investees. We recorded a loss allocation of $2.3 million and an income allocation of $0.6 million in the third quarter and first nine months of 2023, respectively. We recorded a loss allocation of $2.1 million and an income allocation of $7.2 million in the third quarter and first nine months of 2022, respectively. We collected cash receipts from the Legacy SLP Interest of $4.8 million and $9.7 million in the third quarter and first nine months of 2023, respectively. We collected cash receipts from the Legacy SLP Interest of $5.8 million and $19.9 million in the third quarter and first nine months of 2022, respectively.

The Avillion Entities

We account for our partnership interests in Avillion Financing I, LP and its related entities (“Avillion I”) and BAv Financing II, LP and its related entities (“Avillion II” and, together with Avillion I, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. Equity in earnings from the Avillion Entities is recorded within Equity in losses/(earnings) of equity method investees. During the third quarter of 2023 and first nine months of 2023, we recorded a loss allocation of $3.0 million and an income allocation of $28.0 million, respectively. We recorded loss allocations of $1.2 million and $9.3 million in the third quarter and first nine months of 2022, respectively.

On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.6 million and $13.4 million in the first nine months of 2023 and 2022, respectively.
In May 2018, RPIFT entered into an agreement with Avillion II, which was amended in July 2021 and June 2022, to fund a total of $150 million over multiple years for a portion of the costs of Phase 2 and 3 clinical trials to advance Airsupra, formerly known as PT027, which was approved by the FDA in January 2023. Avillion II is a party to a co-development agreement with AstraZeneca to develop Airsupra for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments. In January 2023, AstraZeneca notified Avillion II that it elected to pay a fee of $80 million to Avillion II to exercise an option to commercialize Airsupra in the United States. In March 2023, we received our pro rata portion of the exercise fee of $34.8 million from Avillion II.Our maximum exposure to loss at any particular reporting date is limited to the carrying value of our equity method investments plus the unfunded commitments. As of September 30, 2023 and December 31, 2022, we had unfunded commitments related to the Avillion Entities of $18.3 million and $28.8 million, respectively.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Research & Development ("R&D") Funding Expense
 9 Months Ended
Sep. 30, 2023
Research and Development [Abstract]  
Research & Development ("R&D") Funding Expense Research & Development (“R&D”) Funding Expense
R&D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the first nine months of 2023 and 2022, we did not enter into any new ongoing R&D funding arrangements.

We recognized R&D funding expense of $50.5 million and $51.5 million in the third quarter and first nine months of 2023, respectively. We recognized R&D funding expense of $25.5 million and $126.6 million in the third quarter and first nine months of 2022, respectively. The R&D funding expense in 2023 was primarily related to a $50.0 million clinical milestone payment that was triggered under the agreement with Cytokinetics. During the first nine months of 2022, R&D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0 million and $25.0 million to acquire royalties on development-stage product candidates from Cytokinetics and Theravance Biopharma, Inc., respectively.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Borrowings Borrowings
Our borrowings as of September 30, 2023 and December 31, 2022 consisted of the following (in thousands):

Type of BorrowingDate of IssuanceMaturityAs of September 30, 2023As of December 31, 2022
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)
9/20209/2023$— $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)
9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)
9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)
9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)
7/20219/2031600,000 600,000 
$1,000,000, 3.30% (issued at 95.556% of par)
9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)
9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)
7/20219/2051700,000 700,000 
Unamortized debt discount and issuance costs(168,806)(183,678)
Total debt carrying value6,131,194 7,116,322 
Less: Current portion of long-term debt— (997,512)
Total long-term debt$6,131,194 $6,118,810 

Senior Unsecured Notes

Interest on each series of the $1.3 billion senior unsecured notes issued in 2021 (the “2021 Notes”) accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.
Interest on each series of the $6.0 billion senior unsecured notes issued in 2020 (the “2020 Notes”) accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.13% and 2.50%, respectively.

The 2020 Notes and the 2021 Notes (the “Notes”) may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly-owned subsidiary. We are required to comply with certain covenants under our Notes and as of September 30, 2023, we were in compliance with all applicable covenants.

In September 2023, we repaid $1.0 billion of senior unsecured notes upon maturity.

As of September 30, 2023 and December 31, 2022, the fair value of our outstanding Notes using Level 2 inputs was approximately $4.6 billion and $5.7 billion, respectively.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the “Credit Agreement”). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Revolving Credit Facility has a maturity date of October 31, 2027. As of September 30, 2023 and December 31, 2022, there were no outstanding borrowings under the Revolving Credit Facility. In October 2023, we drew $350.0 million on the Revolving Credit Facility to fund a portion of our acquisition of additional royalties on Roche’s Evrysdi.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds rate plus 0.5% and (3) Term SOFR plus 1% or (b) Daily SOFR, Term SOFR, the Alternative Currency Term Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuate during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.

The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. The Credit Agreement includes customary covenants for credit facilities of this type that limit our ability to engage in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of September 30, 2023, RP Holdings was in compliance with these covenants.
Principal Payments on the Notes

The future principal payments for our borrowings as of September 30, 2023 over the next five years and thereafter are as follows (in thousands):

YearPrincipal Payments
Remainder of 2023$— 
2024— 
20251,000,000 
2026— 
20271,000,000 
Thereafter4,300,000 
Total (1)$6,300,000 
(1)Excludes unamortized debt discount and issuance costs of $168.8 million as of September 30, 2023, which are amortized through interest expense over the remaining life of the underlying debt obligations.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
Capital Structure

We have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up. As of September 30, 2023, we have 445,843 thousand Class A ordinary shares and 152,546 thousand Class B ordinary shares outstanding.

An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of September 30, 2023, we have 382,837 thousand deferred shares outstanding.

In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.

Class A Ordinary Share Repurchases

In March 2023, our board of directors authorized a share repurchase program under which we may repurchase up to $1.0 billion of our Class A ordinary shares. The authorization for the share repurchase program expires on June 23, 2027 and repurchases may be made in the open market or in privately negotiated transactions. Amounts paid to repurchase shares in excess of the par value are allocated between Additional paid-in capital and Retained earnings. We began repurchasing our Class A ordinary shares in April 2023. In the first nine months of 2023, we repurchased and retired 8,889 thousand shares at a cost of approximately $278.6 million.
Non-Controlling Interests

The changes in the balances of our four non-controlling interests for the third quarter and first nine months of 2023 and 2022 are as follows (in thousands):

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
June 30, 2023$1,420,864 $(103)$2,111,258 $— $3,532,019 
Contributions1,413 — 1,437 — 2,850 
Distributions(88,112)(848)(31,238)— (120,198)
Other exchanges— — (18,459)— (18,459)
Net income25,623 285 24,055 — 49,963 
September 30, 2023$1,359,788 $(666)$2,087,053 $— $3,446,175 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
June 30, 2022$1,716,186 $8,882 $2,655,870 $— $4,380,938 
Contributions1,570 — 1,400 — 2,970 
Distributions(95,084)(4,175)(38,621)— (137,880)
Other exchanges— — (61,886)— (61,886)
Net income21,432 1,935 54,396 — 77,763 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities2,294 — 2,975 — 5,269 
Reclassification of unrealized gains on available for sale debt securities(1,250)— (1,621)— (2,871)
September 30, 2022$1,645,148 $6,642 $2,612,513 $— $4,264,303 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2022$1,527,887 $(597)$2,369,933 $— $3,897,223 
Contributions6,614 — 3,076 — 9,690 
Distributions(286,674)(4,755)(95,161)— (386,590)
Other exchanges— — (416,156)— (416,156)
Net income111,961 4,686 225,361 — 342,008 
September 30, 2023$1,359,788 $(666)$2,087,053 $— $3,446,175 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2021$1,809,269 $13,528 $2,649,154 $— $4,471,951 
Contributions4,964 — 4,209 — 9,173 
Distributions(302,670)(20,188)(110,964)— (433,822)
Other exchanges— — (124,108)— (124,108)
Net income133,595 13,302 194,281 — 341,178 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities4,218 — 5,520 — 9,738 
Reclassification of unrealized gains on available for sale debt securities(4,228)— (5,579)— (9,807)
September 30, 2022$1,645,148 $6,642 $2,612,513 $— $4,264,303 
The Continuing Investors Partnerships hold a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests held by them. As the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares, the Continuing Investors Partnerships’ ownership in RP Holdings decreases. We operate and control the business affairs of RP Holdings through our ownership of RP Holdings Class A Interests and RP Holdings Class B Interests. In connection with our repurchase of Class A ordinary shares, RP Holdings also began to retire RP Holdings Class A Interests held by us which reduces our ownership in RP Holdings. The change in RP Holdings ownership between the Continuing Investors Partnerships and us as a result of (1) the exchanges of RP Holding Class B Interests for Class A ordinary shares and (2) retirement of RP Holdings Class A Interests is reflected through Other exchanges in the above tables and in our condensed consolidated statements of shareholders’ equity.

As of September 30, 2023, the Continuing Investors Partnerships owned approximately 25% of RP Holdings with the remaining 75% owned by Royalty Pharma plc. As of September 30, 2022, the Continuing Investors Partnerships owned approximately 27% of RP Holdings with the remaining 73% owned by Royalty Pharma plc.

RP Holdings Class C Special Interest Held by EPA Holdings

EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest. We do not expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met. Similarly, we do not expect any material income to be allocated to EPA Holdings until such performance conditions are met.

Dividends

The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the first nine months of 2023, we declared and paid three quarterly cash dividends of $0.20 per Class A ordinary share for an aggregate amount of $269.0 million to holders of our Class A ordinary shares.

2020 Independent Directors Equity Incentive Plan

On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors.

RSU Activity and Share-based Compensation
We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of General and administrative expenses in the condensed consolidated statements of operations. In the third quarter and first nine months of 2023 and 2022, respectively, we did not recognize material share-based compensation expense.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
For the third quarter and first nine months of 2023 and 2022, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.

The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the third quarter and first nine months of 2023 and 2022 (in thousands, except per share amounts):

For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Numerator
Consolidated net income$122,077 $220,414 $982,502 $840,094 
Less: Net income attributable to continuing non-controlling interests24,055 54,396 225,361 194,281 
Less: Net income attributable to legacy non-controlling interests25,908 23,367 116,647 146,897 
Net income attributable to Royalty Pharma plc - basic72,114 142,651 640,494 498,916 
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 24,055 54,396 225,361 194,281 
Net income attributable to Royalty Pharma plc - diluted$96,169 $197,047 $865,855 $693,197 
Denominator
Weighted average Class A ordinary shares outstanding - basic448,439 439,293 448,162 436,542 
Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares152,691 167,927 156,541 170,651 
Unvested RSUs8 6 14 16 
Weighted average Class A ordinary shares outstanding - diluted601,138 607,226 604,717 607,209 
Earnings per Class A ordinary share - basic$0.16 $0.32 $1.43 $1.14 
Earnings per Class A ordinary share - diluted$0.16 $0.32 $1.43 $1.14 
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Indirect Cash Flow
 9 Months Ended
Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]  
Indirect Cash Flow Indirect Cash Flow
Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):
For the Nine Months Ended September 30,
20232022
Cash flow from operating activities:
Consolidated net income$982,502 $840,094 
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from financial royalty assets(1,674,689)(1,578,555)
Provision for changes in expected cash flows from financial royalty assets637,169 595,396 
Amortization of intangible assets— 5,670 
Amortization of debt discount and issuance costs15,658 16,026 
Losses/(gains) on derivative financial instruments2,290 (97,590)
(Gains)/losses on equity securities(31,994)22,970 
Equity in (earnings)/losses of equity method investees(28,614)2,117 
Distributions from equity method investees18,823 33,316 
Share-based compensation1,740 1,587 
Interest income accretion— (24,053)
Gains on available for sale debt securities(122,500)(97,985)
Other3,263 3,443 
Changes in operating assets and liabilities:
Cash collected on financial royalty assets2,454,054 1,843,899 
Accrued royalty receivable470 37,574 
Other royalty income receivable(669)(4,108)
Other current assets(2,412)8,253 
Accounts payable and accrued expenses1,650 10,492 
Interest payable(41,567)(44,497)
Net cash provided by operating activities$2,215,174 $1,574,049 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Cytokinetics Funding Commitments

As of September 30, 2023, $125 million of the optional $200 million remained available under the Cytokinetics Funding Commitments. Additionally, Cytokinetics is required to draw $50 million if a certain contingency is met.

Other Commitments

We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 7–Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments (defined below) over the life of the Management Agreement as described in Note 14–Related Party Transactions.

Indemnifications

In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.
Legal ProceedingsWe are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of September 30, 2023 and December 31, 2022. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
The Manager

The Manager is the investment manager of Royalty Pharma plc and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.

In connection with the Exchange Offer (discussed in Note 1–Organization and Purpose), the Manager entered into the Management Agreement with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. Additionally, we also pay certain costs and expenses of the Manager.

Total operating and personnel payments incurred, including the amounts attributable to Old RPI, are recognized within General and administrative expenses in the condensed consolidated statements of operations. During the third quarter and first nine months of 2023, total operating and personnel payments incurred, including the amounts attributable to Old RPI, were $43.0 million and $154.9 million, respectively. During the third quarter and first nine months of 2022, total operating and personnel payments incurred, including the amounts attributable to Old RPI, were $40.6 million and $117.8 million, respectively.

Distributions Payable to Legacy Non-Controlling Interests

The distributions payable to legacy non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPI ICAV and RPSFT’s non-controlling interest in RPCT. The distributions payable to legacy non-controlling interests include the following (in thousands):

As of September 30, 2023As of December 31, 2022
Payable to Legacy Investors Partnerships
$98,439 $87,522 
Payable to RPSFT
3,272 7,281 
Total distributions payable to legacy non-controlling interests$101,711 $94,803 

Acquisition from Bristol Myers Squibb

In November 2017, RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly-owned subsidiary of BioPharma Credit PLC (“BPCR”), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.
As of September 30, 2023 and December 31, 2022, the financial royalty asset of $82.6 million and $103.4 million, respectively, on the condensed consolidated balance sheets represented only our right to the future payment streams acquired from BMS.

Other Transactions

Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to develop thematic life sciences indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of both September 30, 2023 and December 31, 2022. The financial impact associated with this transaction has not been material to date.

In connection with the Exchange Offer, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI and RPI ICAV. Refer to Note 7–Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.

RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million was recorded as treasury interests, of which $1.6 million and $1.5 million were held by non-controlling interests as of September 30, 2023 and December 31, 2022, respectively.

Each Continuing Investor Partnership pays a pro rata portion based on its ownership percentage of RP Holdings of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events
 9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsIn October 2023, we acquired additional royalties on Roche’s Evrysdi, an approved product for the treatment of spinal muscular atrophy, from PTC Therapeutics, Inc (“PTC”) for $1.0 billion upfront. Until December 31, 2025, PTC has an option to sell its remaining royalties for $500 million less royalties received in five equal tranches. If PTC exercises its options for fewer than three tranches, we have an option to acquire half of PTC’s remaining royalties for $250 million less royalties received until March 31, 2026.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure        
Net Income (Loss) $ 72,114 $ 142,651 $ 640,494 $ 498,916
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2023
shares
Sep. 30, 2023
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the third quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
Name and TitleActionAdoption/ Termination
Date
Scheduled Expiration Date of Trading Plan (1)
Maximum Shares Subject to Trading Plan
Terrance Coyne
Executive Vice President & Chief Financial Officer
TerminationSeptember 12, 2023June 13, 2024
900,000 (2)
Marshall Urist
Executive Vice President, Research and Investments
AdoptionSeptember 29, 2023December 29, 2023
46,667
Rory Riggs
Director
AdoptionSeptember 29, 2023December 31, 2024
470,000
(1)A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2)As of the termination date of this Rule 10b5-1 trading plan, 150,000 Class A ordinary shares had been sold under its terms.
Non-Rule 10b5-1 Arrangement Adopted false  
Non-Rule 10b5-1 Arrangement Terminated false  
Terrance Coyne [Member]    
Trading Arrangements, by Individual    
Name Terrance Coyne  
Title Executive Vice President & Chief Financial Officer  
Rule 10b5-1 Arrangement Terminated true  
Termination Date September 12, 2023  
Aggregate Available 900,000 900,000
Marshall Urist [Member]    
Trading Arrangements, by Individual    
Name Marshall Urist  
Title Executive Vice President, Research and Investments  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date September 29, 2023  
Arrangement Duration 91 days  
Aggregate Available 46,667 46,667
Rory Riggs [Member]    
Trading Arrangements, by Individual    
Name Rory Riggs  
Title Director  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date September 29, 2023  
Arrangement Duration 459 days  
Aggregate Available 470,000 470,000
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Preparation The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2022, included in our Annual Report on Form 10-K.
Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.
Basis of Consolidation
The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interests in our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

In 2022, we became an indirect owner of an 82% economic interest in Royalty Pharma Investments ICAV (“RPI ICAV”), which previously was owned directly by Old RPI.

We report four non-controlling interests: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the “legacy non-controlling interests”). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of RP Holdings Class B Interests (the “continuing non-controlling interests”) and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain performance conditions are met.

All intercompany transactions and balances have been eliminated in consolidation.
Reclassification Certain prior period amounts have been reclassified to conform to the current period presentation.
Concentrations of Credit Risk
Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of September 30, 2023 and December 31, 2022 were held with Bank of America, State Street, Scotiabank, Citibank, TD Bank, DNB Bank and U.S. Bank. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson & Johnson, Merck & Co., Pfizer, Astellas, Novartis and Gilead. As of September 30, 2023 and December 31, 2022, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, represented the largest individual marketer and payor of our royalties, accounting for 31% of our current portion of financial royalty assets.

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Available for Sale Debt Securities (Tables)
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Summary of Available for Sale Debt Securities
The table below summarizes our available for sale debt securities recorded at fair value as of September 30, 2023 and December 31, 2022 (in thousands):

CostUnrealized(Losses)/GainsFair Value Current AssetsNon-Current AssetsNon-Current LiabilitiesTotal
As of September 30, 2023
Debt securities (1)$359,400 $(500)$358,900 $5,300 $353,600 $— $358,900 
Funding commitments (2)(7,300)(4,000)(11,300)— — (11,300)(11,300)
Total available for sale debt securities$352,100 $(4,500)$347,600 $5,300 $353,600 $(11,300)$347,600 
As of December 31, 2022
Debt securities (1)$359,400 $(131,800)$227,600 $1,300 $226,300 $— $227,600 
Funding commitments (2)(9,400)6,900 (2,500)— — (2,500)(2,500)
Total available for sale debt securities$350,000 $(124,900)$225,100 $1,300 $226,300 $(2,500)$225,100 
(1)The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amount funded.
(2)Related to Cytokinetics Funding Commitments for which related tranches remain available as of respective balance sheet dates. The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements and Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Summary of Fair Value Hierarchy
The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):
As of September 30, 2023As of December 31, 2022
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Money market funds (1)$605,422 $— $— $605,422 $5,068 $— $— $5,068 
Marketable securities
Certificates of deposit— — — — — 11,501 — 11,501 
U.S. government securities— — — — — 12,920 — 12,920 
Available for sale debt securities (2)— — 5,300 5,300 — — 1,300 1,300 
Derivative instruments (3)— — — — — — 86,150 86,150 
Total current assets$605,422 $— $5,300 $610,722 $5,068 $24,421 $87,450 $116,939 
Equity securities140,170 — 4,172 144,342 103,876 — 8,472 112,348 
Available for sale debt securities (2)— — 353,600 353,600 — — 226,300 226,300 
Derivative instruments (3)— — — — — — 10,460 10,460 
Royalty at fair value (4)— — 16,331 16,331 — — 14,500 14,500 
Total non-current assets$140,170 $— $374,103 $514,273 $103,876 $— $259,732 $363,608 
Liabilities:
Funding commitments (5)— — (11,300)(11,300)— — (2,500)(2,500)
Total non-current liabilities$— $— $(11,300)$(11,300)$— $— $(2,500)$(2,500)
(1)Recorded within Cash and cash equivalents on the condensed consolidated balance sheets.
(2)Reflects the fair value of the funded portions of the Development Funding Bonds and the Cytokinetics Commercial Launch Funding.
(3)Reflects the fair value of the Milestone Acceleration Option (defined below) which was recorded within Other current assets and Other assets on the condensed consolidated balance sheets. As of December 31, 2022, the fair value for the current portion of the derivative instruments related to the intranasal indication of zavegepant which settled in March 2023 when the U.S. Food and Drug Administration (“FDA”) approved Zavzpret and the fair value of the non-current portion of the derivative instruments related to the oral indication of zavegepant.
(4)Recorded within Other assets on the condensed consolidated balance sheets. See Note 7–Non-Consolidated Affiliates for additional discussion.
(5)Related to the fair value of the Cytokinetics Funding Commitments recorded within Other liabilities on the condensed consolidated balance sheets.
Summary of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation
The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands):

For the Three Months Ended September 30, 2023
Equity SecuritiesDebt SecuritiesFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$5,718 $348,800 $(8,500)$8,680 $16,583 
Losses on equity securities(1,546)— — — — 
Losses on derivative financial instruments— — — (8,680)— 
Gains/(losses) on available for sale debt securities included in earnings
— 10,100 (2,800)— — 
Other non-operating expense
— — — — (252)
Balance at the end of the period$4,172 $358,900 $(11,300)$— $16,331 

For the Three Months Ended September 30, 2022
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 
Purchases— 314,579 — — — — 
Losses on initial recognition (1)— (8,800)— — — — 
Losses on equity securities(10,489)— — — — — 
Gains on derivative financial instruments— — — — 25,790 — 
Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)
— 13,050 — — — — 
Gains/(losses) on available for sale debt securities included in earnings— 14,200 40,643 (1,800)— — 
Other non-operating expense— — — — — (7,278)
Settlement (2)
— 2,427 (2,427)— — — 
Redemptions— (15,625)— — — — 
Balance at the end of the period$18,296 $682,831 $66,316 $(9,900)$97,590 $13,937 
(1)Represents the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million.
(2)Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares.

For the Nine Months Ended September 30, 2023
Equity SecuritiesDebt SecuritiesFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$8,472 $227,600 $(2,500)$96,610 $14,500 
Losses on equity securities(4,300)— — — — 
Losses on derivative financial instruments— — — (2,290)— 
Gains/(losses) on available for sale debt securities included in earnings— 131,300 (8,800)— — 
Other non-operating income— — — — 1,831 
Settlement (1)— — — (94,320)— 
Balance at the end of the period$4,172 $358,900 $(11,300)$— $16,331 
(1)Represents the fair value of the Milestone Acceleration Option (defined below) attributable to the intranasal indication of zavegepant which was settled when the FDA approved Zavzpret in March 2023.
For the Nine Months Ended September 30, 2022
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentsRoyalty at Fair Value
Balance at the beginning of the period$43,013 $253,700 $16,700 $— $— $— 
Purchases28,785 393,737 — — — 21,215 
Gains/(losses) on initial recognition (1)— 600 — (9,400)— — 
Losses on equity securities(12,810)— — — — — 
Gains on derivative financial instruments— — — — 97,590 — 
Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)— 24,000 — — — — 
Gains/(losses) on available for sale debt securities included in earnings
— 44,400 62,885 (500)— — 
Other non-operating expense— — — — — (7,278)
Settlements (2)
— 13,269 (13,269)— — — 
Transfer out of Level 3 (3)
(40,692)— — — — — 
Redemptions— (46,875)— — — — 
Balance at the end of the period$18,296 $682,831 $66,316 $(9,900)$97,590 $13,937 
(1)Represents purchase price allocation to arrive at the appropriate fair value on initial recognition. Amounts also reflect the initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million.
(2)Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares.
(3)Related to the expiration of the transfer restriction on BioCryst common stock.
Summary of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are presented below (in thousands):
As of September 30, 2023As of December 31, 2022
Fair ValueCarrying Value, netFair ValueCarrying Value, net
Financial royalty assets, net$17,356,414 $13,230,474 $17,314,094 $13,493,106 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Royalty Assets (Tables)
 9 Months Ended
Sep. 30, 2023
Receivables [Abstract]  
Summary of Financial Royalty Assets, Net
The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are as follows (in thousands):
As of September 30, 2023
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,304,675 $— $5,304,675 
Tysabri
(3)
1,557,167 (356,280)1,200,887 
Trelegy2029-20301,237,514 (65,715)1,171,799 
Tremfya2031-2032927,465 (151,563)775,902 
Evrysdi
2030-2035 (4)
772,667 — 772,667 
Xtandi2027-2028939,653 (296,160)643,493 
Other2024-20416,375,151 (2,125,113)4,250,038 
Total$17,114,292 $(2,994,831)$14,119,461 
Less: Cumulative allowance for credit losses (Note 6)(146,827)
Total current and non-current financial royalty assets, net$13,972,634 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key U.S. patents on Evrysdi expire in 2035. Our royalty will end when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

As of September 30, 2023, the balance of $14.0 billion for total current and non-current financial royalty assets, net included $562.1 million in unapproved financial royalty assets held at cost related to olpasiran, pelacarsen, KarXT and seltorexant.
As of December 31, 2022
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (4)
Cystic fibrosis franchise
2037 (2)
$5,333,535 $(10,908)$5,322,627 
Tysabri
(3)
1,683,441 (212,283)1,471,158 
Trelegy2029-20301,284,054 (24,126)1,259,928 
Tremfya2031-2032894,160 — 894,160 
Imbruvica2027-20321,436,969 (660,703)776,266 
Xtandi2027-20281,009,168 (235,625)773,543 
Other2024-20415,134,980 (1,332,815)3,802,165 
Total$16,776,307 $(2,476,460)$14,299,847 
Less: Cumulative allowance for credit losses (Note 6)(115,422)
Total current and non-current financial royalty assets, net$14,184,425 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)
 9 Months Ended
Sep. 30, 2023
Credit Loss [Abstract]  
Summary of Cumulative Allowance for Changes in Expected Cash Flows
The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):

Activity for the Period
Balance at December 31, 2022 (1)$(2,591,882)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(860,242)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets254,478 
Write-off of cumulative allowance87,393 
Current period provision for credit losses, net (2)(31,405)
Balance at September 30, 2023$(3,141,658)
(1)Includes $115.4 million related to cumulative allowance for credit losses.
(2)The provision expense for credit losses was primarily related to the additions of Adstiladrin and Skytrofa to our portfolio of financial royalty assets with limited protective rights.
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Summary of Borrowings
Our borrowings as of September 30, 2023 and December 31, 2022 consisted of the following (in thousands):

Type of BorrowingDate of IssuanceMaturityAs of September 30, 2023As of December 31, 2022
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)
9/20209/2023$— $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)
9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)
9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)
9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)
7/20219/2031600,000 600,000 
$1,000,000, 3.30% (issued at 95.556% of par)
9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)
9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)
7/20219/2051700,000 700,000 
Unamortized debt discount and issuance costs(168,806)(183,678)
Total debt carrying value6,131,194 7,116,322 
Less: Current portion of long-term debt— (997,512)
Total long-term debt$6,131,194 $6,118,810 
Summary of Repayments of Debt by Year
The future principal payments for our borrowings as of September 30, 2023 over the next five years and thereafter are as follows (in thousands):

YearPrincipal Payments
Remainder of 2023$— 
2024— 
20251,000,000 
2026— 
20271,000,000 
Thereafter4,300,000 
Total (1)$6,300,000 
(1)Excludes unamortized debt discount and issuance costs of $168.8 million as of September 30, 2023, which are amortized through interest expense over the remaining life of the underlying debt obligations.
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Summary of Balance Of Non-controlling Interests
The changes in the balances of our four non-controlling interests for the third quarter and first nine months of 2023 and 2022 are as follows (in thousands):

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
June 30, 2023$1,420,864 $(103)$2,111,258 $— $3,532,019 
Contributions1,413 — 1,437 — 2,850 
Distributions(88,112)(848)(31,238)— (120,198)
Other exchanges— — (18,459)— (18,459)
Net income25,623 285 24,055 — 49,963 
September 30, 2023$1,359,788 $(666)$2,087,053 $— $3,446,175 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
June 30, 2022$1,716,186 $8,882 $2,655,870 $— $4,380,938 
Contributions1,570 — 1,400 — 2,970 
Distributions(95,084)(4,175)(38,621)— (137,880)
Other exchanges— — (61,886)— (61,886)
Net income21,432 1,935 54,396 — 77,763 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities2,294 — 2,975 — 5,269 
Reclassification of unrealized gains on available for sale debt securities(1,250)— (1,621)— (2,871)
September 30, 2022$1,645,148 $6,642 $2,612,513 $— $4,264,303 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2022$1,527,887 $(597)$2,369,933 $— $3,897,223 
Contributions6,614 — 3,076 — 9,690 
Distributions(286,674)(4,755)(95,161)— (386,590)
Other exchanges— — (416,156)— (416,156)
Net income111,961 4,686 225,361 — 342,008 
September 30, 2023$1,359,788 $(666)$2,087,053 $— $3,446,175 

Legacy Investors PartnershipsRPSFTContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2021$1,809,269 $13,528 $2,649,154 $— $4,471,951 
Contributions4,964 — 4,209 — 9,173 
Distributions(302,670)(20,188)(110,964)— (433,822)
Other exchanges— — (124,108)— (124,108)
Net income133,595 13,302 194,281 — 341,178 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities4,218 — 5,520 — 9,738 
Reclassification of unrealized gains on available for sale debt securities(4,228)— (5,579)— (9,807)
September 30, 2022$1,645,148 $6,642 $2,612,513 $— $4,264,303 
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Summary of Earnings Per Share, Basic and Diluted
The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the third quarter and first nine months of 2023 and 2022 (in thousands, except per share amounts):

For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Numerator
Consolidated net income$122,077 $220,414 $982,502 $840,094 
Less: Net income attributable to continuing non-controlling interests24,055 54,396 225,361 194,281 
Less: Net income attributable to legacy non-controlling interests25,908 23,367 116,647 146,897 
Net income attributable to Royalty Pharma plc - basic72,114 142,651 640,494 498,916 
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 24,055 54,396 225,361 194,281 
Net income attributable to Royalty Pharma plc - diluted$96,169 $197,047 $865,855 $693,197 
Denominator
Weighted average Class A ordinary shares outstanding - basic448,439 439,293 448,162 436,542 
Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares152,691 167,927 156,541 170,651 
Unvested RSUs8 6 14 16 
Weighted average Class A ordinary shares outstanding - diluted601,138 607,226 604,717 607,209 
Earnings per Class A ordinary share - basic$0.16 $0.32 $1.43 $1.14 
Earnings per Class A ordinary share - diluted$0.16 $0.32 $1.43 $1.14 
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Indirect Cash Flow (Tables)
 9 Months Ended
Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures
Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):
For the Nine Months Ended September 30,
20232022
Cash flow from operating activities:
Consolidated net income$982,502 $840,094 
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from financial royalty assets(1,674,689)(1,578,555)
Provision for changes in expected cash flows from financial royalty assets637,169 595,396 
Amortization of intangible assets— 5,670 
Amortization of debt discount and issuance costs15,658 16,026 
Losses/(gains) on derivative financial instruments2,290 (97,590)
(Gains)/losses on equity securities(31,994)22,970 
Equity in (earnings)/losses of equity method investees(28,614)2,117 
Distributions from equity method investees18,823 33,316 
Share-based compensation1,740 1,587 
Interest income accretion— (24,053)
Gains on available for sale debt securities(122,500)(97,985)
Other3,263 3,443 
Changes in operating assets and liabilities:
Cash collected on financial royalty assets2,454,054 1,843,899 
Accrued royalty receivable470 37,574 
Other royalty income receivable(669)(4,108)
Other current assets(2,412)8,253 
Accounts payable and accrued expenses1,650 10,492 
Interest payable(41,567)(44,497)
Net cash provided by operating activities$2,215,174 $1,574,049 
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions (Tables)
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Summary of Related Party Transactions The distributions payable to legacy non-controlling interests include the following (in thousands):
As of September 30, 2023As of December 31, 2022
Payable to Legacy Investors Partnerships
$98,439 $87,522 
Payable to RPSFT
3,272 7,281 
Total distributions payable to legacy non-controlling interests$101,711 $94,803 
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Purpose (Details)
Feb. 11, 2020
Sep. 30, 2023
Dec. 31, 2022
Old RPI      
Subsidiary, Sale of Stock [Line Items]      
Noncontrolling interest (as percent)     82.00%
RPCT      
Subsidiary, Sale of Stock [Line Items]      
Ownership percentage (as a percent) 66.00%    
Legacy Investors Partnerships | Old RPI      
Subsidiary, Sale of Stock [Line Items]      
Noncontrolling interest (as percent)   18.00%  
RPSFT | RPCT      
Subsidiary, Sale of Stock [Line Items]      
Noncontrolling interest (as percent) 34.00%    
Exchange Offer | Old RPI      
Subsidiary, Sale of Stock [Line Items]      
Ownership percentage (as a percent) 82.00%    
Exchange Offer | Legacy Investors Partnerships      
Subsidiary, Sale of Stock [Line Items]      
Exchange offering, ownership percentage 82.00%    
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Details) - noncontrolling_interest
 9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Vertex | Current portion of Financial royalty assets | Customer Concentration Risk    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Concentration risk (as percent) 31.00% 31.00%
Old RPI    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Noncontrolling interest (as percent)   82.00%
Number of noncontrolling interests created 4  
Old RPI | Legacy Investors Partnerships    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Noncontrolling interest (as percent) 18.00%  
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Available for Sale Debt Securities - Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 07, 2022
USD ($)
tranche
payment
Jun. 02, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Debt and Equity Securities, FV-NI [Line Items]            
Long term funding partnership, amount $ 300          
Long term funding partnership, number of tranches | tranche 5          
Long term funding partnership, initial payment $ 50          
Required amount to be drawn 50          
Long term funding partnership, additional payments, aggregate amount 200          
Long term funding partnership, optional amount unavailable $ 75          
Installment repayments, percentage of amount drawn 1.9          
Number of consecutive quarterly payments | payment 34          
Long term funding partnership, expected payment         $ 125  
Development fund bond            
Debt and Equity Securities, FV-NI [Line Items]            
Maximum commitment to fund collaborative arrangement     $ 300     $ 150
Development fund bond | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Debt and Equity Securities, FV-NI [Line Items]            
Payment of capital   $ 350        
Maximum commitment to fund collaborative arrangement       $ 150   $ 150
MorphoSys            
Debt and Equity Securities, FV-NI [Line Items]            
Redemption price, percentage     2.2      
MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Debt and Equity Securities, FV-NI [Line Items]            
Maximum commitment to fund collaborative arrangement   $ 150        
Period of return (in years)     9 years      
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt and Equity Securities, FV-NI [Line Items]    
Cost $ 352,100 $ 350,000
Unrealized(Losses)/Gains (4,500) (124,900)
Fair Value 347,600 225,100
Available for sale debt securities, current 5,300 1,300
Available for sale debt securities, noncurrent 353,600 226,300
Available for sale debt securities, liabilities noncurrent (11,300) (2,500)
Debt securities    
Debt and Equity Securities, FV-NI [Line Items]    
Cost 359,400 359,400
Unrealized(Losses)/Gains (500) (131,800)
Fair Value 358,900 227,600
Available for sale debt securities, current 5,300 1,300
Available for sale debt securities, noncurrent 353,600 226,300
Available for sale debt securities, liabilities noncurrent 0 0
Funding Commitments    
Debt and Equity Securities, FV-NI [Line Items]    
Cost (7,300) (9,400)
Unrealized(Losses)/Gains (4,000)  
Unrealized(Losses)/Gains   6,900
Fair Value (11,300) (2,500)
Available for sale debt securities, current 0 0
Available for sale debt securities, noncurrent 0 0
Available for sale debt securities, liabilities noncurrent $ (11,300) $ (2,500)
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements and Financial Instruments - Summary of Fair Value Hierarchy (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Assets:    
Marketable securities $ 0 $ 24,421
Available for sale debt securities 5,300 1,300
Equity securities 144,342 112,348
Available for sale debt securities 353,600 226,300
Liabilities:    
Available for sale debt securities, liabilities noncurrent $ 11,300 $ 2,500
Fair value asset liability recurring basis still held unrealized gain loss statement of income extensible list not disclosed flag fair value fair value
Fair Value, Recurring    
Assets:    
Derivative instruments, current $ 0 $ 86,150
Total current assets 610,722 116,939
Equity securities 144,342 112,348
Derivative financial instruments 0 10,460
Total non-current assets 514,273 363,608
Liabilities:    
Available for sale debt securities, liabilities noncurrent (11,300) (2,500)
Fair Value, Recurring | Royalty Investments    
Assets:    
Available for sale debt securities 16,331 14,500
Fair Value, Recurring | Cytokinetics Funding Commitment    
Liabilities:    
Available for sale debt securities, liabilities current (11,300) (2,500)
Fair Value, Recurring | Certificates of deposit    
Assets:    
Marketable securities 0 11,501
Fair Value, Recurring | U.S. government securities    
Assets:    
Marketable securities 0 12,920
Fair Value, Recurring | Debt Securities    
Assets:    
Available for sale debt securities 5,300 1,300
Available for sale debt securities 353,600 226,300
Level 1 | Fair Value, Recurring    
Assets:    
Derivative instruments, current 0 0
Total current assets 605,422 5,068
Equity securities 140,170 103,876
Derivative financial instruments 0 0
Total non-current assets 140,170 103,876
Liabilities:    
Available for sale debt securities, liabilities noncurrent 0 0
Level 1 | Fair Value, Recurring | Royalty Investments    
Assets:    
Available for sale debt securities 0 0
Level 1 | Fair Value, Recurring | Cytokinetics Funding Commitment    
Liabilities:    
Available for sale debt securities, liabilities current 0 0
Level 1 | Fair Value, Recurring | Certificates of deposit    
Assets:    
Marketable securities 0 0
Level 1 | Fair Value, Recurring | U.S. government securities    
Assets:    
Marketable securities 0 0
Level 1 | Fair Value, Recurring | Debt Securities    
Assets:    
Available for sale debt securities 0 0
Available for sale debt securities 0 0
Level 2 | Fair Value, Recurring    
Assets:    
Derivative instruments, current 0 0
Total current assets 0 24,421
Equity securities 0 0
Derivative financial instruments 0 0
Total non-current assets 0 0
Liabilities:    
Available for sale debt securities, liabilities noncurrent 0 0
Level 2 | Fair Value, Recurring | Royalty Investments    
Assets:    
Available for sale debt securities 0 0
Level 2 | Fair Value, Recurring | Cytokinetics Funding Commitment    
Liabilities:    
Available for sale debt securities, liabilities current 0 0
Level 2 | Fair Value, Recurring | Certificates of deposit    
Assets:    
Marketable securities 0 11,501
Level 2 | Fair Value, Recurring | U.S. government securities    
Assets:    
Marketable securities 0 12,920
Level 2 | Fair Value, Recurring | Debt Securities    
Assets:    
Available for sale debt securities 0 0
Available for sale debt securities 0 0
Level 3 | Fair Value, Recurring    
Assets:    
Derivative instruments, current 0 86,150
Total current assets 5,300 87,450
Equity securities 4,172 8,472
Derivative financial instruments 0 10,460
Total non-current assets 374,103 259,732
Liabilities:    
Available for sale debt securities, liabilities noncurrent (11,300) (2,500)
Level 3 | Fair Value, Recurring | Royalty Investments    
Assets:    
Available for sale debt securities 16,331 14,500
Level 3 | Fair Value, Recurring | Cytokinetics Funding Commitment    
Liabilities:    
Available for sale debt securities, liabilities current (11,300) (2,500)
Level 3 | Fair Value, Recurring | Certificates of deposit    
Assets:    
Marketable securities 0 0
Level 3 | Fair Value, Recurring | U.S. government securities    
Assets:    
Marketable securities 0 0
Level 3 | Fair Value, Recurring | Debt Securities    
Assets:    
Available for sale debt securities 5,300 1,300
Available for sale debt securities 353,600 226,300
Money market funds | Fair Value, Recurring    
Assets:    
Cash equivalents 605,422 5,068
Money market funds | Level 1 | Fair Value, Recurring    
Assets:    
Cash equivalents 605,422 5,068
Money market funds | Level 2 | Fair Value, Recurring    
Assets:    
Cash equivalents 0 0
Money market funds | Level 3 | Fair Value, Recurring    
Assets:    
Cash equivalents $ 0 $ 0
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements and Financial Instruments - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]            
Gain (loss) on equity securities still held   $ 1.5 $ (0.9) $ 32.0 $ (27.7)  
Fair Value, Recurring            
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]            
Milestone payment received $ 475.0          
Cytokinetics Commercial Launch Funding | Level 3            
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]            
Risk-adjusted discount rate (as percent)       15.40%   13.50%
Interest rate volatility (as percent)       32.50%   30.00%
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Gains (losses) on derivative financial instruments   $ (8,680) $ 25,785 $ (2,290) $ 97,590
Development fund bond          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Maximum commitment to fund collaborative arrangement $ 300,000       150,000
Development fund bond | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Maximum commitment to fund collaborative arrangement     150,000   150,000
Equity Securities | Level 3          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Balance at the beginning of the period   5,718 28,785 8,472 43,013
Purchases     0   28,785
Losses on equity securities   (1,546) (10,489) (4,300) (12,810)
Transfer out of level 3         (40,692)
Balance at the end of the period 18,296 4,172 18,296 4,172 18,296
Debt Securities | Level 3          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Balance at the beginning of the period   348,800 363,000 227,600 253,700
Purchases     314,579   393,737
Gains/(losses) on initial recognition     (8,800)   600
Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)     13,050   24,000
Gains/(losses) on available for sale debt securities included in earnings   10,100 14,200 131,300 44,400
Settlement     2,427   13,269
Redemptions     (15,625)   (46,875)
Balance at the end of the period 682,831 358,900 682,831 358,900 682,831
Forwards | Level 3          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Balance at the beginning of the period     28,100   16,700
Gains/(losses) on available for sale debt securities included in earnings     40,643   62,885
Settlement     (2,427)   (13,269)
Balance at the end of the period 66,316   66,316   66,316
Funding Commitments | Level 3          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Balance at the beginning of the period     (8,100)   0
Balance at the beginning of the period   (8,500)   (2,500)  
Gains/(losses) on initial recognition         (9,400)
Gains/(losses) on available for sale debt securities included in earnings   (2,800)   (8,800)  
Gains/(losses) on available for sale debt securities included in earnings     (1,800)   (500)
Balance at the end of the period (9,900)   (9,900)   (9,900)
Balance at the end of the period   (11,300)   (11,300)  
Derivative Instruments | Level 3          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Balance at the beginning of the period   8,680 71,800 96,610 0
Gains (losses) on derivative financial instruments   (8,680) 25,790 (2,290) 97,590
Settlement       (94,320)  
Balance at the end of the period 97,590 0 97,590 0 97,590
Royalty at Fair Value | Level 3          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Balance at the beginning of the period   16,583 21,215 14,500 0
Purchases     0   21,215
Other non-operating income (expense)   (252) (7,278) 1,831 (7,278)
Balance at the end of the period $ 13,937 $ 16,331 $ 13,937 $ 16,331 $ 13,937
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements and Financial Instruments - Summary of Estimated Fair Values Based on Level 3 Inputs (Details) - Level 3 - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Fair Value    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Financial royalty assets, net $ 17,356,414 $ 17,314,094
Carrying Value, net    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Financial royalty assets, net $ 13,230,474 $ 13,493,106
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value $ 17,114,292 $ 16,776,307
Cumulative allowance for changes in expected cash flows (2,994,831) (2,476,460)
Net carrying value, before cumulative allowance for credit losses 14,119,461 14,299,847
Cumulative allowance for credit losses (146,827) (115,422)
Total current and non-current financial royalty assets, net 13,972,634 14,184,425
Cystic fibrosis franchise    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 5,304,675 5,333,535
Cumulative allowance for changes in expected cash flows 0 (10,908)
Net carrying value, before cumulative allowance for credit losses 5,304,675 5,322,627
Tysabri    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 1,557,167 1,683,441
Cumulative allowance for changes in expected cash flows (356,280) (212,283)
Net carrying value, before cumulative allowance for credit losses 1,200,887 1,471,158
Trelegy    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 1,237,514 1,284,054
Cumulative allowance for changes in expected cash flows (65,715) (24,126)
Net carrying value, before cumulative allowance for credit losses 1,171,799 1,259,928
Tremfya    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 927,465 894,160
Cumulative allowance for changes in expected cash flows (151,563) 0
Net carrying value, before cumulative allowance for credit losses 775,902 894,160
Imbruvica    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value   1,436,969
Cumulative allowance for changes in expected cash flows   (660,703)
Net carrying value, before cumulative allowance for credit losses   776,266
Evrysdi    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 772,667  
Cumulative allowance for changes in expected cash flows 0  
Net carrying value, before cumulative allowance for credit losses 772,667  
Aggregate royalty amount when patents cease 1,300,000  
Xtandi    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 939,653 1,009,168
Cumulative allowance for changes in expected cash flows (296,160) (235,625)
Net carrying value, before cumulative allowance for credit losses 643,493 773,543
Other    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 6,375,151 5,134,980
Cumulative allowance for changes in expected cash flows (2,125,113) (1,332,815)
Net carrying value, before cumulative allowance for credit losses $ 4,250,038 $ 3,802,165
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Royalty Assets - Narrative (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total current and non-current financial royalty assets, net $ 13,972,634 $ 14,184,425
Seltorexant, Olpasiran, Pelacarsen and KarXT    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Financing receivable, unapproved financial assets held at cost $ 562,100  
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Financing Receivable, Allowance for Credit Loss [Roll Forward]    
Beginning balance $ (2,591,882)  
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets (860,242)  
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets 254,478  
Write-off of cumulative allowance 87,393  
Current period provision for credit losses, net (31,405)  
Ending balance (3,141,658)  
Cumulative allowance for credit losses $ 146,827 $ 115,422
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Non-Consolidated Affiliates (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2023
Jan. 31, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Jun. 30, 2022
Feb. 11, 2020
Schedule of Equity Method Investments [Line Items]                  
Equity method investments     $ 378,291   $ 378,291   $ 397,175    
Equity in losses/(earnings) of equity method investees     (5,222) $ (3,251) 28,614 $ (2,117)      
Distributions from equity method investees         39,225 0      
Distributions from equity method investees         18,823 33,316      
Legacy Investors Partnerships                  
Schedule of Equity Method Investments [Line Items]                  
Equity method investments                 $ 303,700
Equity in losses/(earnings) of equity method investees     2,300 (2,100) 600 7,200      
Distributions from equity method investees     4,800 5,800 9,700 19,900      
Avillion Entities                  
Schedule of Equity Method Investments [Line Items]                  
Equity in losses/(earnings) of equity method investees     (3,000) $ (1,200) 28,000 (9,300)      
Equity method investment, unfunded commitments     $ 18,300   18,300   $ 28,800    
Avillion I                  
Schedule of Equity Method Investments [Line Items]                  
Distributions from equity method investees         $ 13,600 $ 13,400      
Avillion II                  
Schedule of Equity Method Investments [Line Items]                  
Proceeds exercise fee   $ 80,000              
Exercise fee, pro rata amount $ 34,800                
Avillion II | Merck Asset - Phase II Clinical Trial                  
Schedule of Equity Method Investments [Line Items]                  
Other commitment               $ 150,000  
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Research & Development ("R&D") Funding Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development funding expense $ 50,500 $ 25,500 $ 51,500 $ 126,606
Cytokinetics        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development funding expense     $ 50,000 100,000
Theravance Biopharma, Inc.        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development funding expense       $ 25,000
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings - Summary of Borrowings (Details) - USD ($)
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Unamortized debt discount and issuance costs $ (168,806,000) $ (183,678,000)
Total debt carrying value 6,131,194,000 7,116,322,000
Less: Current portion of long-term debt 0 (997,512,000)
Total long-term debt $ 6,131,194,000 6,118,810,000
Point Seven Five Percent Senior Notes Due 2023 | Unsecured Debt    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as percent) 0.75%  
Debt issued as a percent of par value (as percent) 99.322%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
One Point Two Zero Percent Senior Notes Due 2025 | Unsecured Debt    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as percent) 1.20%  
Debt issued as a percent of par value (as percent) 98.875%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
One Point Seven Five Percent Senior Notes Due 2027 | Unsecured Debt    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as percent) 1.75%  
Debt issued as a percent of par value (as percent) 98.284%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Two Point Two Zero Percent Senior Notes Due 2030 | Unsecured Debt    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as percent) 2.20%  
Debt issued as a percent of par value (as percent) 97.76%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Two Point One Five Zero Percent Senior Notes Due 2031 | Unsecured Debt    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as percent) 2.15%  
Debt issued as a percent of par value (as percent) 98.263%  
Debt issued, amount $ 600,000,000 600,000,000
Three Point Three Zero Percent Senior Notes Due 2040 | Unsecured Debt    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as percent) 3.30%  
Debt issued as a percent of par value (as percent) 95.556%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Three Point Five Five Percent Senior Notes Due 2050 | Unsecured Debt    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as percent) 3.55%  
Debt issued as a percent of par value (as percent) 95.306%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Three Point Three Five Zero Percent Due 2051 | Unsecured Debt    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as percent) 3.35%  
Debt issued as a percent of par value (as percent) 97.565%  
Debt issued, amount $ 700,000,000 $ 700,000,000
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings - Narrative (Details)
 1 Months Ended
Oct. 31, 2022
USD ($)
Sep. 02, 2020
USD ($)
Oct. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jul. 26, 2021
USD ($)
Senior Notes            
Debt Instrument [Line Items]            
Debt issued, amount           $ 1,300,000,000
Unamortized discount and loan issuance costs on long-term debt           27,500,000
Senior Notes | Senior Notes Due 2051            
Debt Instrument [Line Items]            
Debt issuance costs           $ 12,300,000
Weighted average coupon rate (as percent)           2.80%
Weighted average effective interest rate (as percent)           3.06%
Unsecured Debt | The Notes            
Debt Instrument [Line Items]            
Debt issued, amount   $ 6,000,000,000        
Unamortized discount and loan issuance costs on long-term debt   149,000,000   $ 168,800,000    
Debt issuance costs   $ 40,400,000        
Weighted average coupon rate (as percent)   2.13%        
Weighted average effective interest rate (as percent)   2.50%        
Repayment of debt       1,000,000,000    
Unsecured Debt | The Notes | Level 2            
Debt Instrument [Line Items]            
Fair value of outstanding notes       4,600,000,000 $ 5,700,000,000  
Unsecured Debt | The Notes | Prior to the applicable par call date            
Debt Instrument [Line Items]            
Redemption price (as percent)   100.00%        
Unsecured Debt | The Notes | Upon occurrence of a change of control triggering event            
Debt Instrument [Line Items]            
Redemption price (as percent)   101.00%        
Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility            
Debt Instrument [Line Items]            
Debt instrument, term (in years) 5 years          
Line of credit, maximum borrowing capacity $ 1,500,000,000          
Outstanding borrowings       $ 0 $ 0  
Maximum consolidated leverage ratio 4.00          
Maximum consolidated leverage ratio following qualifying material acquisition 4.50          
Minimum consolidated coverage ratio 2.50          
Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility | Federal Funds Rate            
Debt Instrument [Line Items]            
Basis spread on variable rate (as percent) 0.50%          
Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility | Overnight Bank Funding Rate            
Debt Instrument [Line Items]            
Basis spread on variable rate (as percent) 0.50%          
Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR)            
Debt Instrument [Line Items]            
Basis spread on variable rate (as percent) 1.00%          
Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility | Subsequent Event            
Debt Instrument [Line Items]            
Proceeds from lines of credit     $ 350,000,000      
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings - Summary of Repayments of Debt by Year (Details) - The Notes - Unsecured Debt - USD ($)
$ in Thousands
Sep. 30, 2023
Sep. 02, 2020
Debt Instrument [Line Items]    
Remainder of 2023 $ 0  
2024 0  
2025 1,000,000  
2026 0  
2027 1,000,000  
Thereafter 4,300,000  
Total 6,300,000  
Unamortized discount and loan issuance costs on long-term debt $ 168,800 $ 149,000
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity - Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
vote
noncontrolling_interest
class
shares
$ / shares
Sep. 30, 2022
noncontrolling_interest
$ / shares
shares
Sep. 30, 2023
USD ($)
class
vote
noncontrolling_interest
shares
payment
$ / shares
Sep. 30, 2023
vote
noncontrolling_interest
class
shares
£ / shares
Sep. 30, 2022
USD ($)
noncontrolling_interest
$ / shares
shares
Jun. 30, 2023
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2022
shares
Jun. 30, 2022
shares
Dec. 31, 2021
shares
Jun. 15, 2020
shares
Class of Stock [Line Items]                      
Number of classes of stock | class 2   2 2              
Number of votes per share | vote 1   1 1              
Quarterly conversion basis (in shares) 1   1 1              
Number of noncontrolling interests | noncontrolling_interest 4 4 4 4 4            
Percentage of net economic profit     20.00%                
Number of dividend payments | payment     3                
Dividends declared and paid (in dollars per share) | $ / shares     $ 0.20                
Dividends to shareholders | $     $ 268,989   $ 249,121            
Requisite service period (in years)     1 year                
Deferred Shares                      
Class of Stock [Line Items]                      
Shares, outstanding (in shares) 382,837,000 369,265,000 382,837,000 382,837,000 369,265,000 382,487,000   371,325,000 365,302,000 361,170,000  
Class A Ordinary Shares                      
Class of Stock [Line Items]                      
Common shares outstanding (in shares) 445,843,000   445,843,000 445,843,000       443,166,000      
Stock repurchase program, authorized repurchase amount | $             $ 1,000,000        
Stock repurchased and retired during period (in shares)     8,889,000                
Stock repurchased and retired value during the period | $     $ 278,600                
Dividends declared and paid (in dollars per share) | $ / shares $ 0.20 $ 0.19 $ 0.60   $ 0.57            
Class A Ordinary Shares | 2020 Equity Incentive Plan                      
Class of Stock [Line Items]                      
Shares reserved for future issuance (in shares)                     800,000
Class B Ordinary Shares                      
Class of Stock [Line Items]                      
Common shares outstanding (in shares) 152,546,000   152,546,000 152,546,000       164,058,000      
Class R Redeemable Shares                      
Class of Stock [Line Items]                      
Common shares outstanding (in shares) 50,000   50,000 50,000       50,000      
Shares, outstanding (in shares) 50,000   50,000 50,000              
Redeemable stock, redemption price (in pound per share) | £ / shares       £ 1              
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity - Summary of Noncontrolling Interests (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance $ 9,813,686 $ 10,408,187 $ 9,525,373 $ 10,248,545
Contributions 2,850 2,970 9,690 9,173
Distributions (120,198) (137,880) (386,590) (433,822)
Other exchanges 0 0 0 0
Net income 122,077 220,414 982,502 840,094
Other comprehensive income/(loss):        
Unrealized gains on available for sale debt securities 0 13,050 0 24,000
Reclassification of unrealized gains on available for sale debt securities 0 (7,111) 0 (24,053)
Ending balance $ 9,585,097 $ 10,416,403 $ 9,585,097 $ 10,416,403
Royalty Pharma plc        
Other comprehensive income/(loss):        
Ownership percentage (as a percent) 75.00% 73.00% 75.00% 73.00%
Continuing Investors Partnerships | RP Holdings        
Other comprehensive income/(loss):        
Noncontrolling interest (as percent) 25.00% 27.00% 25.00% 27.00%
Non-Controlling Interests        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance $ 3,532,019 $ 4,380,938 $ 3,897,223 $ 4,471,951
Contributions 2,850 2,970 9,690 9,173
Distributions (120,198) (137,880) (386,590) (433,822)
Other exchanges (18,459) (61,886) (416,156) (124,108)
Net income 49,963 77,763 342,008 341,178
Other comprehensive income/(loss):        
Unrealized gains on available for sale debt securities   5,269   9,738
Reclassification of unrealized gains on available for sale debt securities   (2,871)   (9,807)
Ending balance 3,446,175 4,264,303 3,446,175 4,264,303
Non-Controlling Interests | Legacy Investors Partnerships        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance 1,420,864 1,716,186 1,527,887 1,809,269
Contributions 1,413 1,570 6,614 4,964
Distributions (88,112) (95,084) (286,674) (302,670)
Other exchanges 0 0 0 0
Net income 25,623 21,432 111,961 133,595
Other comprehensive income/(loss):        
Unrealized gains on available for sale debt securities   2,294   4,218
Reclassification of unrealized gains on available for sale debt securities   (1,250)   (4,228)
Ending balance 1,359,788 1,645,148 1,359,788 1,645,148
Non-Controlling Interests | RPSFT        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance (103) 8,882 (597) 13,528
Contributions 0 0 0 0
Distributions (848) (4,175) (4,755) (20,188)
Other exchanges 0 0 0 0
Net income 285 1,935 4,686 13,302
Other comprehensive income/(loss):        
Unrealized gains on available for sale debt securities   0   0
Reclassification of unrealized gains on available for sale debt securities   0   0
Ending balance (666) 6,642 (666) 6,642
Non-Controlling Interests | Continuing Investors Partnerships        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance 2,111,258 2,655,870 2,369,933 2,649,154
Contributions 1,437 1,400 3,076 4,209
Distributions (31,238) (38,621) (95,161) (110,964)
Other exchanges (18,459) (61,886) (416,156) (124,108)
Net income 24,055 54,396 225,361 194,281
Other comprehensive income/(loss):        
Unrealized gains on available for sale debt securities   2,975   5,520
Reclassification of unrealized gains on available for sale debt securities   (1,621)   (5,579)
Ending balance 2,087,053 2,612,513 2,087,053 2,612,513
Non-Controlling Interests | EPA Holdings        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance 0 0 0 0
Contributions 0 0 0 0
Distributions 0 0 0 0
Other exchanges 0 0 0 0
Net income 0 0 0 0
Other comprehensive income/(loss):        
Unrealized gains on available for sale debt securities   0   0
Reclassification of unrealized gains on available for sale debt securities   0   0
Ending balance $ 0 $ 0 $ 0 $ 0
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Numerator        
Consolidated net income $ 122,077 $ 220,414 $ 982,502 $ 840,094
Less: net income attributable to non-controlling interests 49,963 77,763 342,008 341,178
Net income attributable to Royalty Pharma plc - basic 72,114 142,651 640,494 498,916
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 24,055 54,396 225,361 194,281
Net income attributable to Royalty Pharma plc - diluted $ 96,169 $ 197,047 $ 865,855 $ 693,197
Denominator        
Weighted average Class A ordinary shares outstanding - basic (in shares) 448,439 439,293 448,162 436,542
Class B ordinary shares exchangeable for Class A ordinary shares (in shares) 152,691 167,927 156,541 170,651
Unvested RSUs (in shares) 8 6 14 16
Weighted average Class A ordinary shares outstanding - diluted (in shares) 601,138 607,226 604,717 607,209
Earnings per Class A ordinary share - basic (in dollars per share) $ 0.16 $ 0.32 $ 1.43 $ 1.14
Earnings per Class A ordinary share - diluted (in dollars per share) $ 0.16 $ 0.32 $ 1.43 $ 1.14
Continuing non-controlling interests        
Numerator        
Less: net income attributable to non-controlling interests $ 24,055 $ 54,396 $ 225,361 $ 194,281
Legacy non-controlling interests        
Numerator        
Less: net income attributable to non-controlling interests $ 25,908 $ 23,367 $ 116,647 $ 146,897
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Indirect Cash Flow (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Supplemental Cash Flow Elements [Abstract]        
Consolidated net income $ 122,077 $ 220,414 $ 982,502 $ 840,094
Adjustments to reconcile consolidated net income to net cash provided by operating activities:        
Income from financial royalty assets     (1,674,689) (1,578,555)
Provision for changes in expected cash flows from financial royalty assets 277,137 305,061 637,169 595,396
Amortization of intangible assets 0 0 0 5,670
Amortization of debt discount and issuance costs     15,658 16,026
Losses/(gains) on derivative financial instruments     2,290 (97,590)
(Gains)/losses on equity securities (1,541) (5,168) (31,994) 22,970
Equity in (earnings)/losses of equity method investees 5,222 3,251 (28,614) 2,117
Distributions from equity method investees     18,823 33,316
Share-based compensation     1,740 1,587
Interest income accretion     0 (24,053)
Gains on available for sale debt securities $ (7,300) $ (44,243) (122,500) (97,985)
Other     3,263 3,443
Changes in operating assets and liabilities:        
Cash collected on financial royalty assets     2,454,054 1,843,899
Accrued royalty receivable     470 37,574
Other royalty income receivable     (669) (4,108)
Other current assets     (2,412) 8,253
Accounts payable and accrued expenses     1,650 10,492
Interest payable     (41,567) (44,497)
Net cash provided by operating activities     $ 2,215,174 $ 1,574,049
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Details) - USD ($)
$ in Millions
 9 Months Ended
Jan. 07, 2022
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]    
Long term funding partnership, expected payment   $ 125
Long term funding partnership, additional payments, aggregate amount $ 200  
Required amount to be drawn $ 50  
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 16, 2021
Dec. 08, 2017
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]                    
Distributions payable to legacy non-controlling interests     $ 101,711,000   $ 101,711,000   $ 94,803,000      
Total current and non-current financial royalty assets, net     13,972,634,000   13,972,634,000   14,184,425,000      
Shareholders' equity     9,585,097,000 $ 10,416,403,000 9,585,097,000 $ 10,416,403,000 9,525,373,000 $ 9,813,686,000 $ 10,408,187,000 $ 10,248,545,000
Treasury Stock                    
Related Party Transaction [Line Items]                    
Shareholders' equity     (2,624,000) (2,788,000) (2,624,000) (2,788,000) (2,806,000) (2,629,000) (2,752,000) (2,715,000)
Non-Controlling Interests                    
Related Party Transaction [Line Items]                    
Shareholders' equity     3,446,175,000 4,264,303,000 3,446,175,000 4,264,303,000 3,897,223,000 $ 3,532,019,000 $ 4,380,938,000 $ 4,471,951,000
Related Party | Payable to Legacy Investors Partnerships                    
Related Party Transaction [Line Items]                    
Distributions payable to legacy non-controlling interests     98,439,000   98,439,000   87,522,000      
Related Party | Payable to RPSFT                    
Related Party Transaction [Line Items]                    
Distributions payable to legacy non-controlling interests     3,272,000   3,272,000   7,281,000      
Related Party | Bristol-Myers Squibb                    
Related Party Transaction [Line Items]                    
Total current and non-current financial royalty assets, net     $ 82,600,000   $ 82,600,000   103,400,000      
Operating and Personnel Payments | Related Party                    
Related Party Transaction [Line Items]                    
Quarterly payments to affiliates, percent of adjusted cash receipts (as percent)     6.50%   6.50%          
Quarterly payments to affiliates, percent of security investment (as percent)     0.25%   0.25%          
Amount calculated for operating and personal payment         $ 1,000,000          
Percent calculated for operating and personal payment         0.3125%          
Operating and personnel payments incurred     $ 43,000,000   $ 154,900,000          
Former Operating and Personnel Payments | Related Party                    
Related Party Transaction [Line Items]                    
Operating and personnel payments incurred       $ 40,600,000   $ 117,800,000        
Assignment Agreement - Benefit of Payment Stream | Bristol-Myers Squibb                    
Related Party Transaction [Line Items]                    
Related party, rate (as percent)   50.00%                
Assignment Agreement - Funding Obligations | Bristol-Myers Squibb                    
Related Party Transaction [Line Items]                    
Related party, rate (as percent)   50.00%                
Agreement with MSCI                    
Related Party Transaction [Line Items]                    
Initial term (in years) 7 years                  
Amounts of transaction, related parties         $ 0   0      
Acquisition Of Limited Partnership Interests In Affiliate | Related Party                    
Related Party Transaction [Line Items]                    
Number of limited partnership interest acquired (in shares)         27,210          
Acquisition Of Limited Partnership Interests In Affiliate | Related Party | Treasury Stock                    
Related Party Transaction [Line Items]                    
Shareholders' equity     4,300,000   $ 4,300,000          
Acquisition Of Limited Partnership Interests In Affiliate | Related Party | Non-Controlling Interests                    
Related Party Transaction [Line Items]                    
Shareholders' equity     $ 1,600,000   $ 1,600,000   $ 1,500,000      
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events (Details) - Subsequent Event
$ in Thousands
 1 Months Ended
Nov. 30, 2023
USD ($)
Oct. 31, 2023
USD ($)
tranche
PTC Therapeutics, Inc.    
Subsequent Event [Line Items]    
Option to sell retained royalties, amount   $ 500,000
PTC Therapeutics, Inc. | Maximum    
Subsequent Event [Line Items]    
Number of tranches | tranche   5
PTC Therapeutics, Inc. | Minimum    
Subsequent Event [Line Items]    
Number of tranches | tranche   3
PTC Therapeutics, Inc.    
Subsequent Event [Line Items]    
Option to acquire retained royalties, amount   $ 250,000
PTC Therapeutics, Inc. | Roche’s Evrysdi    
Subsequent Event [Line Items]    
Payments for royalties   $ 1,000,000
Teva Pharmaceuticals International GMBH    
Subsequent Event [Line Items]    
Funding agreement amount $ 125,000  
XML 68 rprx-20230930_htm.xml IDEA: XBRL DOCUMENT 0001802768 2023-01-01 2023-09-30 0001802768 us-gaap:CommonClassAMember 2023-11-02 0001802768 us-gaap:CommonClassBMember 2023-11-02 0001802768 2023-09-30 0001802768 2022-12-31 0001802768 us-gaap:CommonClassAMember 2023-09-30 0001802768 us-gaap:CommonClassAMember 2022-12-31 0001802768 us-gaap:CommonClassBMember 2023-09-30 0001802768 us-gaap:CommonClassBMember 2022-12-31 0001802768 rprx:ClassRRedeemableStockMember 2023-09-30 0001802768 rprx:ClassRRedeemableStockMember 2022-12-31 0001802768 rprx:FinancialRoyaltyAssetsMember 2023-07-01 2023-09-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2022-07-01 2022-09-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2023-01-01 2023-09-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2022-01-01 2022-09-30 0001802768 rprx:IntangibleRoyaltyAssetsMember 2023-07-01 2023-09-30 0001802768 rprx:IntangibleRoyaltyAssetsMember 2022-07-01 2022-09-30 0001802768 rprx:IntangibleRoyaltyAssetsMember 2023-01-01 2023-09-30 0001802768 rprx:IntangibleRoyaltyAssetsMember 2022-01-01 2022-09-30 0001802768 rprx:RoyaltyIncomeOtherMember 2023-07-01 2023-09-30 0001802768 rprx:RoyaltyIncomeOtherMember 2022-07-01 2022-09-30 0001802768 rprx:RoyaltyIncomeOtherMember 2023-01-01 2023-09-30 0001802768 rprx:RoyaltyIncomeOtherMember 2022-01-01 2022-09-30 0001802768 2023-07-01 2023-09-30 0001802768 2022-07-01 2022-09-30 0001802768 2022-01-01 2022-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2023-06-30 0001802768 rprx:DeferredSharesMember 2023-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001802768 us-gaap:RetainedEarningsMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2023-06-30 0001802768 us-gaap:TreasuryStockCommonMember 2023-06-30 0001802768 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001802768 us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001802768 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001802768 rprx:DeferredSharesMember 2023-07-01 2023-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-09-30 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2023-09-30 0001802768 rprx:DeferredSharesMember 2023-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001802768 us-gaap:RetainedEarningsMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember 2023-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2023-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2022-06-30 0001802768 rprx:DeferredSharesMember 2022-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001802768 us-gaap:RetainedEarningsMember 2022-06-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2022-06-30 0001802768 us-gaap:TreasuryStockCommonMember 2022-06-30 0001802768 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001802768 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001802768 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001802768 rprx:DeferredSharesMember 2022-07-01 2022-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2022-09-30 0001802768 rprx:DeferredSharesMember 2022-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001802768 us-gaap:RetainedEarningsMember 2022-09-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember 2022-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2022-09-30 0001802768 2022-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2022-12-31 0001802768 rprx:DeferredSharesMember 2022-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001802768 us-gaap:RetainedEarningsMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2022-12-31 0001802768 us-gaap:TreasuryStockCommonMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001802768 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001802768 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001802768 rprx:DeferredSharesMember 2023-01-01 2023-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2021-12-31 0001802768 rprx:DeferredSharesMember 2021-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001802768 us-gaap:RetainedEarningsMember 2021-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2021-12-31 0001802768 us-gaap:TreasuryStockCommonMember 2021-12-31 0001802768 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0001802768 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001802768 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001802768 rprx:DeferredSharesMember 2022-01-01 2022-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-09-30 0001802768 rprx:ExchangeOfferMember rprx:LegacyInvestorsPartnershipsMember 2020-02-11 2020-02-11 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:ExchangeOfferMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember 2020-02-11 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember 2022-12-31 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember 2023-09-30 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:LegacyInvestorsPartnershipsMember 2023-09-30 0001802768 rprx:VertexMember us-gaap:FinanceReceivablesMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001802768 rprx:VertexMember us-gaap:FinanceReceivablesMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001802768 2022-01-07 2022-01-07 0001802768 rprx:DevelopmentFundingBondMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-06-02 2021-06-02 0001802768 rprx:MorphoSysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-06-02 2021-06-02 0001802768 rprx:DevelopmentFundingBondMember 2022-09-01 2022-09-30 0001802768 rprx:DevelopmentFundingBondMember 2022-01-01 2022-09-30 0001802768 rprx:MorphoSysMember 2022-09-01 2022-09-30 0001802768 rprx:MorphoSysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-09-01 2022-09-30 0001802768 us-gaap:PreferredStockMember 2023-09-30 0001802768 rprx:FundingCommitmentsMember 2023-09-30 0001802768 us-gaap:PreferredStockMember 2022-12-31 0001802768 rprx:FundingCommitmentsMember 2022-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001802768 2022-01-01 2022-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001802768 rprx:DevelopmentFundingBondMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-07-01 2022-09-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001802768 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001802768 rprx:DevelopmentFundingBondMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:CytokineticsCommercialLaunchFundingMember 2023-01-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:CytokineticsCommercialLaunchFundingMember 2022-01-01 2022-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2023-03-01 2023-03-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0001802768 rprx:CysticFibrosisFranchiseMember 2023-09-30 0001802768 rprx:TysabriMember 2023-09-30 0001802768 rprx:TrelegyMember 2023-09-30 0001802768 rprx:TremfyaMember 2023-09-30 0001802768 rprx:EvrysdiMember 2023-09-30 0001802768 rprx:XtandiMember 2023-09-30 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2023-09-30 0001802768 rprx:SeltorexantOlpasiranPelacarsenAndKarXTMember 2023-09-30 0001802768 rprx:CysticFibrosisFranchiseMember 2022-12-31 0001802768 rprx:TysabriMember 2022-12-31 0001802768 rprx:TrelegyMember 2022-12-31 0001802768 rprx:TremfyaMember 2022-12-31 0001802768 rprx:ImbruvicaMember 2022-12-31 0001802768 rprx:XtandiMember 2022-12-31 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2022-12-31 0001802768 rprx:LegacyInvestorsPartnershipsMember 2020-02-11 0001802768 rprx:LegacyInvestorsPartnershipsMember 2023-07-01 2023-09-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2023-01-01 2023-09-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2022-07-01 2022-09-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2022-01-01 2022-09-30 0001802768 rprx:AvillionEntitiesMember 2023-07-01 2023-09-30 0001802768 rprx:AvillionEntitiesMember 2023-01-01 2023-09-30 0001802768 rprx:AvillionEntitiesMember 2022-07-01 2022-09-30 0001802768 rprx:AvillionEntitiesMember 2022-01-01 2022-09-30 0001802768 rprx:AvillionIMember 2023-01-01 2023-09-30 0001802768 rprx:AvillionIMember 2022-01-01 2022-09-30 0001802768 rprx:AvillionIIMember rprx:MerckAssetPhaseIIClinicalTrialMember 2022-06-30 0001802768 rprx:AvillionIIMember 2023-01-01 2023-01-31 0001802768 rprx:AvillionIIMember 2023-03-01 2023-03-31 0001802768 rprx:AvillionEntitiesMember 2023-09-30 0001802768 rprx:AvillionEntitiesMember 2022-12-31 0001802768 rprx:CytokineticsMember 2023-01-01 2023-09-30 0001802768 rprx:CytokineticsMember 2022-01-01 2022-09-30 0001802768 rprx:TheravanceBiopharmaIncMember 2022-01-01 2022-09-30 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2023-01-01 2023-09-30 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2023-01-01 2023-09-30 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2023-01-01 2023-09-30 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2023-01-01 2023-09-30 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2023-01-01 2023-09-30 0001802768 rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2023-01-01 2023-09-30 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2023-01-01 2023-09-30 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 rprx:ThreePointThreeFiveZeroPercentDue2051Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:ThreePointThreeFiveZeroPercentDue2051Member us-gaap:UnsecuredDebtMember 2023-01-01 2023-09-30 0001802768 rprx:ThreePointThreeFiveZeroPercentDue2051Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 us-gaap:SeniorNotesMember 2021-07-26 0001802768 rprx:SeniorNotesDue2051Member us-gaap:SeniorNotesMember 2021-07-26 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:UnsecuredDebtMember 2020-09-02 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:UnsecuredDebtMember 2020-09-02 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2023-09-01 2023-09-30 0001802768 rprx:TheNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:TheNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2022-10-31 2022-10-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2022-10-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2022-12-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:SubsequentEventMember 2023-10-01 2023-10-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember rprx:OvernightBankFundingRateMember 2022-10-31 2022-10-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:FederalFundsPurchasedMember 2022-10-31 2022-10-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember rprx:SecuredOvernightFinancingRateSOFRMember 2022-10-31 2022-10-31 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2023-09-30 0001802768 rprx:ClassRRedeemableStockMember 2023-01-01 2023-09-30 0001802768 us-gaap:CommonClassAMember 2023-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-07-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2023-07-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-07-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-07-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-07-01 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-07-01 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-07-01 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-07-01 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-01-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2023-01-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-01-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-01-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-01-01 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-01-01 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-01-01 2022-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-01-01 2022-09-30 0001802768 rprx:RPHoldingsMember rprx:ContinuingInvestorsPartnershipMember 2023-09-30 0001802768 rprx:RoyaltyPharmaPlcMember 2023-09-30 0001802768 rprx:RPHoldingsMember rprx:ContinuingInvestorsPartnershipMember 2022-09-30 0001802768 rprx:RoyaltyPharmaPlcMember 2022-09-30 0001802768 rprx:A2020EquityIncentivePlanMember us-gaap:CommonClassAMember 2020-06-15 0001802768 rprx:ContinuingNonControllingInterestsMember 2023-07-01 2023-09-30 0001802768 rprx:ContinuingNonControllingInterestsMember 2022-07-01 2022-09-30 0001802768 rprx:ContinuingNonControllingInterestsMember 2023-01-01 2023-09-30 0001802768 rprx:ContinuingNonControllingInterestsMember 2022-01-01 2022-09-30 0001802768 rprx:LegacyNonControllingInterestsMember 2023-07-01 2023-09-30 0001802768 rprx:LegacyNonControllingInterestsMember 2022-07-01 2022-09-30 0001802768 rprx:LegacyNonControllingInterestsMember 2023-01-01 2023-09-30 0001802768 rprx:LegacyNonControllingInterestsMember 2022-01-01 2022-09-30 0001802768 rprx:OperatingAndPersonnelPaymentsMember us-gaap:RelatedPartyMember 2023-09-30 0001802768 rprx:OperatingAndPersonnelPaymentsMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001802768 rprx:OperatingAndPersonnelPaymentsMember us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001802768 rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember us-gaap:RelatedPartyMember 2023-09-30 0001802768 rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember us-gaap:RelatedPartyMember 2022-12-31 0001802768 rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember us-gaap:RelatedPartyMember 2023-09-30 0001802768 rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember us-gaap:RelatedPartyMember 2022-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementBenefitOfPaymentStreamMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember us-gaap:RelatedPartyMember 2023-09-30 0001802768 rprx:BristolMyersSquibbMember us-gaap:RelatedPartyMember 2022-12-31 0001802768 rprx:AgreementWithMSCIMember 2021-04-16 2021-04-16 0001802768 rprx:AgreementWithMSCIMember 2022-01-01 2022-12-31 0001802768 rprx:AgreementWithMSCIMember 2023-01-01 2023-09-30 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember us-gaap:RelatedPartyMember us-gaap:TreasuryStockCommonMember 2023-09-30 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember us-gaap:RelatedPartyMember us-gaap:NoncontrollingInterestMember 2023-09-30 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember us-gaap:RelatedPartyMember us-gaap:NoncontrollingInterestMember 2022-12-31 0001802768 rprx:PTCTherapeuticsIncMember rprx:RochesEvrysdiMember us-gaap:SubsequentEventMember 2023-10-01 2023-10-31 0001802768 us-gaap:SubsequentEventMember rprx:PTCTherapeuticsIncMember 2023-10-01 2023-10-31 0001802768 srt:MaximumMember us-gaap:SubsequentEventMember rprx:PTCTherapeuticsIncMember 2023-10-01 2023-10-31 0001802768 srt:MinimumMember us-gaap:SubsequentEventMember rprx:PTCTherapeuticsIncMember 2023-10-01 2023-10-31 0001802768 rprx:PTCTherapeuticsIncMember us-gaap:SubsequentEventMember 2023-10-01 2023-10-31 0001802768 rprx:TevaPharmaceuticalsInternationalGMBHMember us-gaap:SubsequentEventMember 2023-11-01 2023-11-30 0001802768 rprx:TerranceCoyneMember 2023-07-01 2023-09-30 0001802768 rprx:TerranceCoyneMember 2023-09-30 0001802768 rprx:MarshallUristMember 2023-07-01 2023-09-30 0001802768 rprx:MarshallUristMember 2023-09-30 0001802768 rprx:RoryRiggsMember 2023-07-01 2023-09-30 0001802768 rprx:RoryRiggsMember 2023-09-30 shares iso4217:USD iso4217:USD shares iso4217:GBP shares pure rprx:noncontrolling_interest rprx:tranche rprx:payment rprx:class rprx:vote 0001802768 --12-31 2023 Q3 false 125000000 P91D P459D 10-Q true 2023-09-30 false 001-39329 Royalty Pharma plc X0 98-1535773 110 East 59th Street New York NY 10022 212 883-0200 Class A ordinary shares, par value $0.0001 RPRX NASDAQ Yes Yes Large Accelerated Filer false false false 444886039 152546046 936448000 1710751000 0 24421000 742160000 691319000 16360000 16830000 5300000 1300000 21553000 19767000 6784000 90520000 1728605000 2554908000 13230474000 13493106000 144342000 112348000 353600000 226300000 378291000 397175000 20212000 29629000 15855524000 16813466000 101711000 94803000 13627000 7906000 12595000 54162000 0 997512000 0 12400000 127933000 1166783000 6131194000 6118810000 11300000 2500000 6270427000 7288093000 0.0001 0.0001 445843000 445843000 443166000 443166000 45000 44000 0.000001 0.000001 152546000 152546000 164058000 164058000 0 0 1 1 50000 50000 50000 50000 63000 63000 0.000001 0.000001 382837000 382837000 371325000 371325000 0 0 4006758000 3666160000 2134680000 1964689000 3446175000 3897223000 2624000 2806000 9585097000 9525373000 15855524000 16813466000 508657000 551682000 1674689000 1578555000 252000 1073000 597000 37196000 27404000 20708000 83200000 55716000 536313000 573463000 1758486000 1671467000 277137000 305061000 637169000 595396000 50500000 25500000 51500000 126606000 0 0 0 5670000 57234000 50692000 190563000 154075000 384871000 381253000 879232000 881747000 151442000 192210000 879254000 789720000 -5222000 -3251000 28614000 -2117000 46033000 46977000 139932000 141006000 -8680000 25785000 -2290000 97590000 1541000 5168000 31994000 -22970000 7300000 44243000 122500000 97985000 23436000 14034000 65791000 34482000 -1707000 -10798000 -3429000 -13590000 -29365000 28204000 103248000 50374000 122077000 220414000 982502000 840094000 0 0 0 0 122077000 220414000 982502000 840094000 49963000 77763000 342008000 341178000 72114000 142651000 640494000 498916000 0.16 0.32 1.43 1.14 0.16 0.32 1.43 1.14 448439000 439293000 448162000 436542000 601138000 607226000 604717000 607209000 122077000 220414000 982502000 840094000 0 13050000 0 24000000 0 7111000 0 24053000 0 5939000 0 -53000 122077000 226353000 982502000 840041000 49963000 80161000 342008000 341109000 72114000 146192000 640494000 498932000 450352000 46000 152896000 0 50000 63000 382487000 0 4031242000 2252945000 3532019000 -2629000 9813686000 2850000 2850000 120198000 120198000 0.20 89751000 89751000 -350000 350000 -350000 -18454000 18459000 -5000 0 3000 581000 581000 4862000 1000 43519000 100628000 144148000 72114000 49963000 122077000 445843000 45000 152546000 0 50000 63000 382837000 0 4006758000 2134680000 3446175000 -2624000 9585097000 437139000 44000 170081000 0 50000 63000 365302000 0 3570585000 2446132000 13177000 4380938000 -2752000 10408187000 2970000 2970000 137880000 137880000 0.19 83809000 83809000 -3963000 3963000 -3963000 -61736000 -186000 61886000 36000 0 2000 582000 582000 142651000 77763000 220414000 7781000 5269000 13050000 4240000 2871000 7111000 441104000 44000 166118000 0 50000 63000 369265000 0 3632903000 2504974000 16904000 4264303000 -2788000 10416403000 443166000 44000 164058000 0 50000 63000 371325000 0 3666160000 1964689000 3897223000 -2806000 9525373000 9690000 9690000 386590000 386590000 0.60 268989000 268989000 -11512000 -2000 11512000 -11512000 -415972000 416156000 -182000 0 54000 1740000 1740000 8889000 1000 77114000 201514000 278629000 640494000 342008000 982502000 445843000 45000 152546000 0 50000 63000 382837000 0 4006758000 2134680000 3446175000 -2624000 9585097000 432963000 43000 174213000 0 50000 63000 361170000 0 3507533000 2255179000 16491000 4471951000 -2715000 10248545000 9173000 9173000 433822000 433822000 0.57 249121000 249121000 -8095000 -1000 8095000 -8095000 -123783000 -397000 124108000 73000 0 46000 1587000 1587000 498916000 341178000 840094000 14262000 9738000 24000000 14246000 9807000 24053000 441104000 44000 166118000 0 50000 63000 369265000 0 3632903000 2504974000 16904000 4264303000 -2788000 10416403000 2454054000 1843899000 1067000 72406000 84275000 51607000 18823000 33316000 63135000 10556000 1500000 1606000 50000000 125000000 188839000 141653000 165841000 169476000 2215174000 1574049000 39225000 0 10550000 9896000 0 62785000 0 46158000 0 393737000 0 46875000 0 234869000 24391000 676705000 1113283000 1491399000 0 21215000 12400000 0 -1072617000 -1444163000 284637000 322726000 0 2335000 95045000 110964000 268989000 249121000 274559000 0 455000 971000 5915000 4869000 1000000000 0 -1916860000 -679306000 -774303000 -549420000 1710751000 1541048000 936448000 991628000 Organization and Purpose <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the initial public offering (“IPO”) of our Class A ordinary shares. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our condensed consolidated financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management vehicle, and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”). RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”) and Royalty Pharma plc. Prior to the Exchange Offer (defined below), Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the “Manager”), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the “Management Agreement”).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consummated an exchange offer on February 11, 2020 (the “Exchange Offer”) to facilitate the IPO. Through the Exchange Offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. Following the Exchange Offer, we became the indirect owner of an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”). We are entitled to 82% of the economics of Old RPI’s wholly-owned subsidiary RPI Finance Trust, a Delaware statutory trust (“RPIFT”), and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust.</span></div> 0.82 0.82 0.82 0.66 0.34 Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Preparation and Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2022, included in our Annual Report on Form 10-K. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, we became an indirect owner of an 82% economic interest in Royalty Pharma Investments ICAV (“RPI ICAV”), which previously was owned directly by Old RPI.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report four non-controlling interests: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the “legacy non-controlling interests”). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of RP Holdings Class B Interests (the “continuing non-controlling interests”) and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain performance conditions are met. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of September 30, 2023 and December 31, 2022 were held with Bank of America, State Street, Scotiabank, Citibank, TD Bank, DNB Bank and U.S. Bank. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis and Gilead. As of September 30, 2023 and December 31, 2022, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, represented the largest individual marketer and payor of our royalties, accounting for 31% of our current portion of financial royalty assets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div> The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2022, included in our Annual Report on Form 10-K. The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, we became an indirect owner of an 82% economic interest in Royalty Pharma Investments ICAV (“RPI ICAV”), which previously was owned directly by Old RPI.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report four non-controlling interests: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the “legacy non-controlling interests”). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of RP Holdings Class B Interests (the “continuing non-controlling interests”) and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain performance conditions are met. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances have been eliminated in consolidation.</span></div> 0.82 4 0.18 Certain prior period amounts have been reclassified to conform to the current period presentation. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of September 30, 2023 and December 31, 2022 were held with Bank of America, State Street, Scotiabank, Citibank, TD Bank, DNB Bank and U.S. Bank. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis and Gilead. As of September 30, 2023 and December 31, 2022, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, represented the largest individual marketer and payor of our royalties, accounting for 31% of our current portion of financial royalty assets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div> 0.31 0.31 Available for Sale Debt Securities <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, we entered into a long-term funding agreement, which was later amended in 2022, with Cytokinetics, Incorporated (“Cytokinetics”). We agreed to provide funding of up to $300 million (“Cytokinetics Commercial Launch Funding”) in five tranches. The initial tranche of $50 million was funded upon closing. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). Because the regulatory milestones for the second and third tranches were not met, $75 million of the optional funding is no longer available. For tranches one, four and five, we expect to receive a return of 1.9 times the amount drawn over 34 consecutive quarterly payments beginning on the last business day of the seventh quarter following the quarter of the funding date of each tranche. As of September 30, 2023, $125 million of the optional $200 million remained available under the Cytokinetics Funding Commitments.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Cytokinetics Commercial Launch Funding as it most accurately reflects the nature of the funding arrangement. The funded Cytokinetics Commercial Launch Funding is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. The changes in the fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, we announced a long-term strategic funding agreement with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc. which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350 million of capital (“Development Funding Bonds”), of which MorphoSys was required to draw a minimum of $150 million. In September 2022, we funded $300 million of the Development Funding Bonds, which represents $150 million in additional funding above the minimum funding commitment (“Additional Funding”), and settled our forward commitment. We expect to receive a return of 2.2 times the funded amount of the Development Funding Bonds, payable on a quarterly basis over nine years, with the first payment beginning in the fourth quarter of 2024. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Development Funding Bonds as it most accurately reflects the nature of the instruments. The Development Funding Bonds are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. The changes in the fair value of the Development Funding Bonds are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes our available for sale debt securities recorded at fair value as of September 30, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized(Losses)/Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">352,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,500)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">347,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">353,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">347,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">350,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(124,900)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amount funded.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to Cytokinetics Funding Commitments for which related tranches remain available as of respective balance sheet dates. The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.</span></div> 300000000 5 50000000 50000000 200000000 75000000 1.9 34 125000000 200000000 350000000 150000000 300000000 150000000 2.2 P9Y <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes our available for sale debt securities recorded at fair value as of September 30, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized(Losses)/Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">352,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,500)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">347,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">353,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">347,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">350,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(124,900)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amount funded.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to Cytokinetics Funding Commitments for which related tranches remain available as of respective balance sheet dates. The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.</span></div> 359400000 500000 358900000 5300000 353600000 0 358900000 -7300000 4000000 -11300000 0 0 11300000 -11300000 352100000 4500000 347600000 5300000 353600000 11300000 347600000 359400000 131800000 227600000 1300000 226300000 0 227600000 -9400000 6900000 -2500000 0 0 2500000 -2500000 350000000 124900000 225100000 1300000 226300000 2500000 225100000 Fair Value Measurements and Financial Instruments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">605,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">610,722</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">140,170</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">374,103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">514,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">259,732</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the funded portions of the Development Funding Bonds and the Cytokinetics Commercial Launch Funding.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the Milestone Acceleration Option (defined below) which was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. As of December 31, 2022, the fair value for the current portion of the derivative instruments related to the intranasal indication of zavegepant which settled in March 2023 when the U.S. Food and Drug Administration (“FDA”) approved Zavzpret and the fair value of the non-current portion of the derivative instruments related to the oral indication of zavegepant. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. See Note 7–Non-Consolidated Affiliates for additional discussion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the third quarter and first nine months of 2023, we recognized gains of $1.5 million and $32.0 million, respectively, on equity securities still held as of September 30, 2023. For the third quarter and first nine months of 2022, we recognized losses of $0.9 million and $27.7 million, respectively, on equity securities still held as of September 30, 2023.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">348,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,583</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on available for sale debt securities included in earnings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">358,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on available for sale debt securities included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">682,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">97,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares. </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">227,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on available for sale debt securities included in earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">358,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the fair value of the Milestone Acceleration Option (defined below) attributable to the intranasal indication of zavegepant which was settled when the FDA approved Zavzpret in March 2023.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on available for sale debt securities included in earnings</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer out of Level 3 (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">682,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">97,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:8.68pt">Represents purchase price allocation to arrive at the appropriate fair value on initial recognition. Amounts also reflect the initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the expiration of the transfer restriction on BioCryst common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Inputs for Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements as of September 30, 2023 and December 31, 2022 in the fair value hierarchy.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ApiJect Investment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We estimated the fair value of the equity securities and revenue participation right that we acquired from ApiJect Holdings, Inc. (“ApiJect”), a private company, as of September 30, 2023 and December 31, 2022 by utilizing a discounted cash flow calculation using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 7–Non-Consolidated Affiliates for additional discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding and Cytokinetics Funding Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of September 30, 2023 and December 31, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding require significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Cytokinetics Funding Commitments as of September 30, 2023 and December 31, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty’s assumed cost of debt, which would impact Cytokinetics’ decision to exercise its option to draw on each respective tranche. As of September 30, 2023 and December 31, 2022, this methodology incorporates Level 3 fair value measurements and inputs, including an assumed risk-adjusted discount rate of 15.4% and 13.5%, respectively, and an assumed interest rate volatility of 32.5% and 30.0%, respectively. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MorphoSys Development Funding Bonds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Development Funding Bonds as of September 30, 2023 and December 31, 2022 based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 fair value inputs. Our estimate of the risk adjusted discount rates could reasonably be different than the discount rates selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Acceleration Option</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into an expanded funding agreement with Biohaven to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. Following Pfizer’s acquisition of Biohaven on October 2, 2022, which was a change of control event, we elected to accelerate the payment of the zavegepant milestone payments, if triggered, into a lump sum amount (“Milestone Acceleration Option”). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven. In March 2023, the FDA approved Zavzpret (zavegepant), a calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults, which triggered a milestone payment of $475 million that we received in the same month and resulted in a partial settlement of the derivative instrument. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Milestone Acceleration Option as of December 31, 2022 using the “with-and-without” methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rate which was primarily based on Pfizer’s cost of debt and management’s estimated probabilities of achieving the success-based milestones. Assessing the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate and the probabilities of achieving marketing approval could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we did not have any financial instruments recorded at fair value using Level 2 inputs. As of December 31, 2022, financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consisted of certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that provide quoted market prices in active markets for similar securities or observable inputs for their pricing without applying significant adjustments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products which are estimated using sell-side equity research analysts’ consensus sales forecasts. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments, are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are presented below (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,356,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,230,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,314,094 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,493,106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">605,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">610,722</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">140,170</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">374,103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">514,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">259,732</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the funded portions of the Development Funding Bonds and the Cytokinetics Commercial Launch Funding.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the Milestone Acceleration Option (defined below) which was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. As of December 31, 2022, the fair value for the current portion of the derivative instruments related to the intranasal indication of zavegepant which settled in March 2023 when the U.S. Food and Drug Administration (“FDA”) approved Zavzpret and the fair value of the non-current portion of the derivative instruments related to the oral indication of zavegepant. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. See Note 7–Non-Consolidated Affiliates for additional discussion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets.</span></div> 605422000 0 0 605422000 5068000 0 0 5068000 0 0 0 0 0 11501000 0 11501000 0 0 0 0 0 12920000 0 12920000 0 0 5300000 5300000 0 0 1300000 1300000 0 0 0 0 0 0 86150000 86150000 605422000 0 5300000 610722000 5068000 24421000 87450000 116939000 140170000 0 4172000 144342000 103876000 0 8472000 112348000 0 0 353600000 353600000 0 0 226300000 226300000 0 0 0 0 0 0 10460000 10460000 0 0 16331000 16331000 0 0 14500000 14500000 140170000 0 374103000 514273000 103876000 0 259732000 363608000 0 0 -11300000 -11300000 0 0 -2500000 -2500000 0 0 -11300000 -11300000 0 0 -2500000 -2500000 fair value fair value 1500000 32000000 -900000 -27700000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">348,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,583</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on available for sale debt securities included in earnings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">358,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on available for sale debt securities included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">682,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">97,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares. </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">227,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on available for sale debt securities included in earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">358,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11,300)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the fair value of the Milestone Acceleration Option (defined below) attributable to the intranasal indication of zavegepant which was settled when the FDA approved Zavzpret in March 2023.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on available for sale debt securities included in earnings</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer out of Level 3 (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">682,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">97,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:8.68pt">Represents purchase price allocation to arrive at the appropriate fair value on initial recognition. Amounts also reflect the initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150 million. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to our commitment to purchase Series B Biohaven Preferred Shares that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares. Amounts also reflect the fair value attributed to our forward commitment on the Development Funding Bonds which was settled upon funding in September 2022. Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series B Biohaven Preferred Shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the expiration of the transfer restriction on BioCryst common stock.</span></div> 5718000 348800000 8500000 8680000 16583000 -1546000 -8680000 10100000 2800000 -252000 4172000 358900000 11300000 0 16331000 28785000 363000000 28100000 -8100000 71800000 21215000 0 314579000 0 -8800000 -10489000 25790000 13050000 14200000 40643000 -1800000 -7278000 2427000 -2427000 -15625000 18296000 682831000 66316000 -9900000 97590000 13937000 150000000 8472000 227600000 2500000 96610000 14500000 -4300000 -2290000 131300000 8800000 1831000 -94320000 4172000 358900000 11300000 0 16331000 43013000 253700000 16700000 0 0 0 28785000 393737000 21215000 600000 -9400000 -12810000 97590000 24000000 44400000 62885000 -500000 -7278000 13269000 -13269000 40692000 -46875000 18296000 682831000 66316000 -9900000 97590000 13937000 150000000 0.154 0.135 0.325 0.300 475000000 The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are presented below (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,356,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,230,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,314,094 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,493,106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 17356414000 13230474000 17314094000 13493106000 Financial Royalty Assets<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,304,675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,304,675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,557,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(356,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,171,799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(151,563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">939,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,375,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,125,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,250,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,114,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,994,831)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,119,461</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146,827)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,972,634</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key U.S. patents on Evrysdi expire in 2035. Our royalty will end when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the balance of $14.0 billion for total current and non-current financial royalty assets, net included $562.1 million in unapproved financial royalty assets held at cost related to olpasiran, pelacarsen, KarXT and seltorexant.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,333,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,908)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,322,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,683,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,471,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,284,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,259,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,436,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(660,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(235,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,134,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,332,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,802,165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,776,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,476,460)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,299,847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,422)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,184,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of September 30, 2023 and December 31, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,304,675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,304,675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,557,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(356,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,171,799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(151,563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">939,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,375,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,125,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,250,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,114,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,994,831)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,119,461</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146,827)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,972,634</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key U.S. patents on Evrysdi expire in 2035. Our royalty will end when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the balance of $14.0 billion for total current and non-current financial royalty assets, net included $562.1 million in unapproved financial royalty assets held at cost related to olpasiran, pelacarsen, KarXT and seltorexant.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,333,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,908)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,322,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,683,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,471,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,284,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,259,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,436,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(660,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(235,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,134,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,332,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,802,165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,776,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,476,460)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,299,847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,422)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,184,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div> 5304675000 0 5304675000 1557167000 356280000 1200887000 1237514000 65715000 1171799000 927465000 151563000 775902000 772667000 0 772667000 939653000 296160000 643493000 6375151000 2125113000 4250038000 17114292000 2994831000 14119461000 146827000 13972634000 1300000000 14000000000 562100000 5333535000 10908000 5322627000 1683441000 212283000 1471158000 1284054000 24126000 1259928000 894160000 0 894160000 1436969000 660703000 776266000 1009168000 235625000 773543000 5134980000 1332815000 3802165000 16776307000 2476460000 14299847000 115422000 14184425000 Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets and includes the following:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products which are estimated by sell-side equity research analysts’ consensus sales forecasts,</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the write-off of cumulative allowance at the end of a royalty asset’s life which only impacts the condensed consolidated balance sheets, and</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,591,882)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(3,141,658)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $115.4 million related to cumulative allowance for credit losses.</span></div>(2)The provision expense for credit losses was primarily related to the additions of Adstiladrin and Skytrofa to our portfolio of financial royalty assets with limited protective rights. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,591,882)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(3,141,658)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $115.4 million related to cumulative allowance for credit losses.</span></div>(2)The provision expense for credit losses was primarily related to the additions of Adstiladrin and Skytrofa to our portfolio of financial royalty assets with limited protective rights. 2591882000 -860242000 254478000 87393000 31405000 3141658000 115400000 Non-Consolidated Affiliates<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities over which we have elected the fair value option.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ApiJect</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for such investments. We are also required to purchase additional common stock from ApiJect if certain milestones are achieved. The fair value of our equity investment in ApiJect is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the change in fair value is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of the revenue participation right is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the change in fair value is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-operating expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No amounts were due from ApiJect as of September 30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is accounted for under the equity method as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI and RPI ICAV. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. Equity in earnings from the Legacy SLP Interest is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of equity method investees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a loss allocation of $2.3 million and an income allocation of $0.6 million in the third quarter and first nine months of 2023, respectively. We recorded a loss allocation of $2.1 million and an income allocation of $7.2 million in the third quarter and first nine months of 2022, respectively. We collected cash receipts from the Legacy SLP Interest of $4.8 million and $9.7 million in the third quarter and first nine months of 2023, respectively. We collected cash receipts from the Legacy SLP Interest of $5.8 million and $19.9 million in the third quarter and first nine months of 2022, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP and its related entities (“Avillion I”) and BAv Financing II, LP and its related entities (“Avillion II” and, together with Avillion I, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. Equity in earnings from the Avillion Entities is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of equity method investees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023 and first nine months of 2023, we recorded a loss allocation of $3.0 million and an income allocation of $28.0 million, respectively. We recorded loss allocations of $1.2 million and $9.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the third quarter and first nine months of 2022, respectively.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.6 million and $13.4 million in the first nine months of 2023 and 2022, respectively.</span></div>In May 2018, RPIFT entered into an agreement with Avillion II, which was amended in July 2021 and June 2022, to fund a total of $150 million over multiple years for a portion of the costs of Phase 2 and 3 clinical trials to advance Airsupra, formerly known as PT027, which was approved by the FDA in January 2023. Avillion II is a party to a co-development agreement with AstraZeneca to develop Airsupra for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments. In January 2023, AstraZeneca notified Avillion II that it elected to pay a fee of $80 million to Avillion II to exercise an option to commercialize Airsupra in the United States. In March 2023, we received our pro rata portion of the exercise fee of $34.8 million from Avillion II.Our maximum exposure to loss at any particular reporting date is limited to the carrying value of our equity method investments plus the unfunded commitments. As of September 30, 2023 and December 31, 2022, we had unfunded commitments related to the Avillion Entities of $18.3 million and $28.8 million, respectively. 303700000 2300000 600000 -2100000 7200000 4800000 9700000 5800000 19900000 -3000000 28000000 -1200000 -9300000 13600000 13400000 150000000 80000000 34800000 18300000 28800000 Research &amp; Development (“R&amp;D”) Funding Expense <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&amp;D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the first nine months of 2023 and 2022, we did not enter into any new ongoing R&amp;D funding arrangements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized R&amp;D funding expense of $50.5 million and $51.5 million in the third quarter and first nine months of 2023, respectively. We recognized R&amp;D funding expense of $25.5 million and $126.6 million in the third quarter and first nine months of 2022, respectively. The R&amp;D funding expense in 2023 was primarily related to a $50.0 million clinical milestone payment that was triggered under the agreement with Cytokinetics. During the first nine months of 2022, R&amp;D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0 million and $25.0 million to acquire royalties on development-stage product candidates from Cytokinetics and Theravance Biopharma, Inc., respectively.</span></div> 50500000 51500000 25500000 126600000 50000000 100000000 25000000 Borrowings<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings as of September 30, 2023 and December 31, 2022 consisted of the following (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,131,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,116,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997,512)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,131,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,118,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on each series of the $1.3 billion senior unsecured notes issued in 2021 (the “2021 Notes”) accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on each series of the $6.0 billion senior unsecured notes issued in 2020 (the “2020 Notes”) accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.13% and 2.50%, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Notes and the 2021 Notes (the “Notes”) may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly-owned subsidiary. We are required to comply with certain covenants under our Notes and as of September 30, 2023, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we repaid $1.0 billion of senior unsecured notes upon maturity.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the fair value of our outstanding Notes using Level 2 inputs was approximately $4.6 billion and $5.7 billion, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the “Credit Agreement”). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Revolving Credit Facility has a maturity date of October 31, 2027. As of September 30, 2023 and December 31, 2022, there were no outstanding borrowings under the Revolving Credit Facility. In October 2023, we drew $350.0 million on the Revolving Credit Facility to fund a portion of our acquisition of additional royalties on Roche’s Evrysdi.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds rate plus 0.5% and (3) Term SOFR plus 1% or (b) Daily SOFR, Term SOFR, the Alternative Currency Term Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuate during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. The Credit Agreement includes customary covenants for credit facilities of this type that limit our ability to engage in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of September 30, 2023, RP Holdings was in compliance with these covenants. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments for our borrowings as of September 30, 2023 over the next five years and thereafter are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,300,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1)Excludes unamortized debt discount and issuance costs of $168.8 million as of September 30, 2023, which are amortized through interest expense over the remaining life of the underlying debt obligations. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings as of September 30, 2023 and December 31, 2022 consisted of the following (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,131,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,116,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997,512)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,131,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,118,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1000000000 0.0075 0.99322 1000000000 1000000000 0.0120 0.98875 1000000000 1000000000 1000000000 0.0175 0.98284 1000000000 1000000000 1000000000 0.0220 0.97760 1000000000 1000000000 600000000 0.0215 0.98263 600000000 600000000 1000000000 0.0330 0.95556 1000000000 1000000000 1000000000 0.0355 0.95306 1000000000 1000000000 700000000 0.0335 0.97565 700000000 700000000 168806000 183678000 6131194000 7116322000 0 997512000 6131194000 6118810000 1300000000 27500000 12300000 0.0280 0.0306 6000000000 149000000 40400000 0.0213 0.0250 1 1.01 1000000000 4600000000 5700000000 P5Y 1500000000 0 0 350000000 0.005 0.005 0.01 4.00 4.50 2.50 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments for our borrowings as of September 30, 2023 over the next five years and thereafter are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,300,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1)Excludes unamortized debt discount and issuance costs of $168.8 million as of September 30, 2023, which are amortized through interest expense over the remaining life of the underlying debt obligations. 0 0 1000000000 0 1000000000 4300000000 6300000000 168800000 Shareholders’ Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up. As of September 30, 2023, we have 445,843 thousand Class A ordinary shares and 152,546 thousand Class B ordinary shares outstanding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of September 30, 2023, we have 382,837 thousand deferred shares outstanding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Class A Ordinary Share Repurchases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, our board of directors authorized a share repurchase program under which we may repurchase up to $1.0 billion of our Class A ordinary shares. The authorization for the share repurchase program expires on June 23, 2027 and repurchases may be made in the open market or in privately negotiated transactions. Amounts paid to repurchase shares in excess of the par value are allocated between </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We began repurchasing our Class A ordinary shares in April 2023. In the first nine months of 2023, we repurchased and retired 8,889 thousand shares at a cost of approximately $278.6 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of our four non-controlling interests for the third quarter and first nine months of 2023 and 2022 are as follows (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,420,864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,111,258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,532,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,359,788</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(666)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,087,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,446,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,084)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,612,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,264,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,527,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(597)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,369,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,897,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(286,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(386,590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,359,788</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(666)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,087,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,446,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(302,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(433,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,612,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,264,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Continuing Investors Partnerships hold a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests held by them. As the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares, the Continuing Investors Partnerships’ ownership in RP Holdings decreases. We operate and control the business affairs of RP Holdings through our ownership of RP Holdings Class A Interests and RP Holdings Class B Interests. In connection with our repurchase of Class A ordinary shares, RP Holdings also began to retire RP Holdings Class A Interests held by us which reduces our ownership in RP Holdings. The change in RP Holdings ownership between the Continuing Investors Partnerships and us as a result of (1) the exchanges of RP Holding Class B Interests for Class A ordinary shares and (2) retirement of RP Holdings Class A Interests is reflected through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other exchanges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the above tables and in our condensed consolidated statements of shareholders’ equity.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Continuing Investors Partnerships owned approximately 25% of RP Holdings with the remaining 75% owned by Royalty Pharma plc. As of September 30, 2022, the Continuing Investors Partnerships owned approximately 27% of RP Holdings with the remaining 73% owned by Royalty Pharma plc.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RP Holdings Class C Special Interest Held by EPA Holdings</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met. Similarly, we do not expect any material income to be allocated to EPA Holdings until such performance conditions are met. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the first nine months of 2023, we declared and paid three quarterly cash dividends of $0.20 per Class A ordinary share for an aggregate amount of $269.0 million to holders of our Class A ordinary shares.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity and Share-based Compensation</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span> in the condensed consolidated statements of operations. In the third quarter and first nine months of 2023 and 2022, respectively, we did not recognize material share-based compensation expense. 2 1 445843000 152546000 1 382837000 50000 1 1000000000 8889000 278600000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of our four non-controlling interests for the third quarter and first nine months of 2023 and 2022 are as follows (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,420,864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,111,258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,532,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,359,788</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(666)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,087,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,446,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,084)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,612,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,264,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,527,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(597)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,369,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,897,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(286,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(386,590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,359,788</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(666)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,087,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,446,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(302,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(433,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,612,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,264,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4 4 1420864000 -103000 2111258000 0 3532019000 1413000 0 1437000 0 2850000 88112000 848000 31238000 0 120198000 0 0 18459000 0 18459000 25623000 285000 24055000 0 49963000 1359788000 -666000 2087053000 0 3446175000 1716186000 8882000 2655870000 0 4380938000 1570000 0 1400000 0 2970000 95084000 4175000 38621000 0 137880000 0 0 61886000 0 61886000 21432000 1935000 54396000 0 77763000 2294000 0 2975000 0 5269000 1250000 0 1621000 0 2871000 1645148000 6642000 2612513000 0 4264303000 1527887000 -597000 2369933000 0 3897223000 6614000 0 3076000 0 9690000 286674000 4755000 95161000 0 386590000 0 0 416156000 0 416156000 111961000 4686000 225361000 0 342008000 1359788000 -666000 2087053000 0 3446175000 1809269000 13528000 2649154000 0 4471951000 4964000 0 4209000 0 9173000 302670000 20188000 110964000 0 433822000 0 0 124108000 0 124108000 133595000 13302000 194281000 0 341178000 4218000 0 5520000 0 9738000 4228000 0 5579000 0 9807000 1645148000 6642000 2612513000 0 4264303000 0.25 0.75 0.27 0.73 0.20 3 0.20 269000000 800000 P1Y Earnings per Share<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the third quarter and first nine months of 2023 and 2022, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the third quarter and first nine months of 2023 and 2022 (in thousands, except per share amounts):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840,094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to continuing non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to legacy non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">640,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">865,855 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">439,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effects as shown separately below</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class B ordinary shares exchangeable for Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604,717 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.43 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.14 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the third quarter and first nine months of 2023 and 2022 (in thousands, except per share amounts):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840,094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to continuing non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to legacy non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">640,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">865,855 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">439,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effects as shown separately below</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class B ordinary shares exchangeable for Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604,717 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.43 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.14 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 122077000 220414000 982502000 840094000 24055000 54396000 225361000 194281000 25908000 23367000 116647000 146897000 72114000 142651000 640494000 498916000 24055000 54396000 225361000 194281000 96169000 197047000 865855000 693197000 448439000 439293000 448162000 436542000 152691000 167927000 156541000 170651000 8000 6000 14000 16000 601138000 607226000 604717000 607209000 0.16 0.32 1.43 1.14 0.16 0.32 1.43 1.14 Indirect Cash Flow<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840,094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,674,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,578,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (earnings)/losses of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,823 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,454,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,843,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,215,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,574,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840,094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,674,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,578,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (earnings)/losses of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,823 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,454,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,843,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,215,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,574,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 982502000 840094000 1674689000 1578555000 637169000 595396000 0 5670000 15658000 16026000 -2290000 97590000 31994000 -22970000 28614000 -2117000 18823000 33316000 1740000 1587000 0 24053000 122500000 97985000 -3263000 -3443000 2454054000 1843899000 -470000 -37574000 669000 4108000 2412000 -8253000 1650000 10492000 -41567000 -44497000 2215174000 1574049000 Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cytokinetics Funding Commitments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, $125 million of the optional $200 million remained available under the Cytokinetics Funding Commitments. Additionally, Cytokinetics is required to draw $50 million if a certain contingency is met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 7–Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments (defined below) over the life of the Management Agreement as described in Note 14–Related Party Transactions.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote. </span></div>Legal ProceedingsWe are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of September 30, 2023 and December 31, 2022. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations. 125000000 200000000 50000000 Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Manager is the investment manager of Royalty Pharma plc and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer (discussed in Note 1–Organization and Purpose), the Manager entered into the Management Agreement with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. Additionally, we also pay certain costs and expenses of the Manager.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating and personnel payments incurred, including the amounts attributable to Old RPI, are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations. During the third quarter and first nine months of 2023, total operating and personnel payments incurred, including the amounts attributable to Old RPI, were $43.0 million and $154.9 million, respectively. During the third quarter and first nine months of 2022, total operating and personnel payments incurred, including the amounts attributable to Old RPI, were $40.6 million and $117.8 million, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions Payable to Legacy Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distributions payable to legacy non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPI ICAV and RPSFT’s non-controlling interest in RPCT. The distributions payable to legacy non-controlling interests include the following (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payable to Legacy Investors Partnerships</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payable to RPSFT</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to legacy non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101,711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly-owned subsidiary of BioPharma Credit PLC (“BPCR”), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the financial royalty asset of $82.6 million and $103.4 million, respectively, on the condensed consolidated balance sheets represented only our right to the future payment streams acquired from BMS. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to develop thematic life sciences indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of both September 30, 2023 and December 31, 2022. The financial impact associated with this transaction has not been material to date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI and RPI ICAV. Refer to Note 7–Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million was recorded as treasury interests, of which $1.6 million and $1.5 million were held by non-controlling interests as of September 30, 2023 and December 31, 2022, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Continuing Investor Partnership pays a pro rata portion based on its ownership percentage of RP Holdings of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</span></div> 0.065 0.0025 1000000 0.003125 43000000 154900000 40600000 117800000 The distributions payable to legacy non-controlling interests include the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payable to Legacy Investors Partnerships</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payable to RPSFT</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to legacy non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101,711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 98439000 87522000 3272000 7281000 101711000 94803000 0.50 0.50 82600000 103400000 P7Y 0 0 27210 4300000 1600000 1500000 Subsequent EventsIn October 2023, we acquired additional royalties on Roche’s Evrysdi, an approved product for the treatment of spinal muscular atrophy, from PTC Therapeutics, Inc (“PTC”) for $1.0 billion upfront. Until December 31, 2025, PTC has an option to sell its remaining royalties for $500 million less royalties received in five equal tranches. If PTC exercises its options for fewer than three tranches, we have an option to acquire half of PTC’s remaining royalties for $250 million less royalties received until March 31, 2026. 1000000000 500000000 5 3 250000000 false false <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the third quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Action</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adoption/ Termination<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Scheduled Expiration Date of Trading Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maximum Shares Subject to Trading Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Terrance Coyne </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President &amp; Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 12, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 13, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900,000 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marshall Urist</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Research and Investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adoption</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 29, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,667</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rory Riggs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Director</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adoption</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 29, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470,000</span></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of the termination date of this Rule 10b5-1 trading plan, 150,000 Class A ordinary shares had been sold under its terms.</span></div> Terrance Coyne Executive Vice President & Chief Financial Officer true September 12, 2023 900000 Marshall Urist Executive Vice President, Research and Investments true September 29, 2023 46667 Rory Riggs Director true September 29, 2023 470000 EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

2O+CJ<]LMBD61)5P;P& M41B7__W?JA.Q%S :GPA0J@#E(& X.A&@5@'J0_J#HVD4\[XQAG*OP,6/\U9#'9;/' MI<_H,ED%E*5_(?KW39B]D[^27WS&_%P?Y(-&,S]K'07K3SWB=6_*_,K)_*KY$L29\N4Z'% @Y9X31P_ M%<3W^;G8G1!E>T+N%"'PD:X_$56Z(HJDJ.0UR2B)DWC!D[!DQ0N__">,,\I/ M0D86*S]-MZ>D/CLMC9AWSZF<3+=W_D\FTBYIW-='C7SXZ6/5#F%3J[QK_YU_ M F?BQNH_Y@3_^4_R2/U9E-BXY"QO&___G&U3G-#9Q'LM/4FQQ)0O/N,4N?F> MM6!L,4:CBQU&.5T9IWN3!!2W>UWDTQ2O0UWD84&16BF-#P!U]XFH%ECU!'9> M=+KDF3QFR>(;^9?'7R=V1J/TWVT?;R5LT [+YU#7Z=I?T-L>GR2EE+W2WBSO MR=+/;1\32)B&A.E(F(&$F4B8A8392)B#A+E(F >"-<0ZV(EU(*+/?ME$3Y3E M:BW&"EH(-RV$^[_R4)MF2^:P8.:7*:\SY:;_NB]$8=9+A7@VG7ZVA(&LD(F$ M64B8C80Y2)B+A'D@6$,RPYUDAATED\^]^)R./RD&3ZZ8_$B;8(9'_5,^$(PP MYZ6".9M./UO"0%;(1,(L),Q&PAPDS$7"/!"L(9C13C CH6#^MO$9ORA8O1-^ MH?#*KY/SNT=/?AJFY ._^"TGGFTS\KO16=D(,U\JF[/I]+,E#&2%3"3,0L)L M),Q!PEPDS /!&K(9[V0S[CC.-"^QR?82.^4#SHFK[S8QC8_Z[N! 3&=+:&=+ MZ&=+&&=+F,+S/,?Z%%UZ<9 MH;R')U&X(&N6/(>M?5N(O/0F A*FE3!9WNONTJ?#RQ=D1@,),Y$P"PFSD3 ' M"7.1, \$:TAQNI/BM.,(%(2O84#C8'L#.Q]ZJH=M"-;0HBS5"XV24(U:I<&4!'2QXM=, ?$+189! M<1T5\#F@S_;N1WSD(A4N--V),UXJ5"A-JVCY/\'("[9 ^2.JLV24HF562 79ZLFA;R+-8FD:15MM'^??3293J:'JD1F M-=JR#J:RE%IOBE!O#_3[)DS#C)*<'2YH M/AZ&23E$OE,^0+;>:113+U8=DJ:=:;%<-*MMS1E:#0-*,Z$T"TJSH30'2G.A M- ]%:XJU=HK(PK7MF4:?*RJAS7T6EMSE"5E*.B;FM16L,723VEN.GMA?G1% M_$VV3%CX7QKLO^Q'R2;.3B[F09TP4)H&I>E0F@&EF5":5='VER-E23J^XK*A M:1THS872/!2M^87SVAFCB)TQAYHMC3&,9F&^MA!L6#[L[2T#"D8_<:9+!0NE M:15M_P-^,IE,CX=':%H#2C.A- M*LZ$T!TISH30/16L*MC;%*&)3C%BPK_YJ M0[>RS9:[%?P38ZPXU\62A1IFE!;KRG@R.E8LU# #I9E0F@6EV5": Z6Y4)J' MHC456]MJ%+')Y >83ZN,8H/GO+V4?. XT]J+C0YE!C7$M.<1YDVT8)6&:;GP^"I^] M3X0TA\RA- U*TZ$T THSH30+2K.A- =*(2A-A](,*,V$TBPHS8;2'"C-A=(\%*VIVMHSI$ ]0PK4,P2E M:5":#J494)H)I5E0F@VE.5":"Z5Y*%I3N;5G2/E!GB'EV'HB#Y7AX-AZ,A=7 MX6*!=DZL=R]J0.MH0FD6E&:WG9310!I.CCU#T,0NE.:A:$W=U)XA1>P9*D>\ M!_) THC_VE%13-5J"4(2M.@-!U*,Z T$TJSH#0;2G.@-!=*\U"TYN_4U[XA M54+.5%6H-PA*TZ T'4HSH#032K.@-!M*Y"F9)%_$:O< MIFQW=+?/Z>=BM\>#XW?R]5QN.:[)UT:YBVF-+S=5_>*SES!.R8H^\U32IS$? MBEBY3VGY)$O6Q5Z13TF6)5'Q<$G]@+*\ '_].4FR[9,\P6ZWV-GO4$L#!!0 M ( )A(:%>5/#(IA L !]< 9 >&PO=V]R:W-H965T9?3E_KIM?VT59=M''U7+=OITL MNN[AS73:SA?EJFB_K1_*M?[+7=VLBDY_;>ZG[4-3%K>;1JOEE,:QG*Z*:CVY M.-_\=ME/W;):EY=-U#ZN5D7SZ7VYK)_?3LCD\P]7U?VBZW^87IP_%/?E M==E]>+AL]+?IGN6V6I7KMJK745/>O9V\(V]4POH&&\2_JO*Y/?@<]:[#M))]%M>5<\+KNK^OG[0Z/GF];+=_!L][[#Q))H_MEV] MVC765["JUMO_BX^[CCAHH'G@!G37@-H-^$@#MFO CK7 =PWXL1;$KL'&]>G6 M]TW'Y4577)PW]7/4]&C-UG_8]/ZFM>ZO:MW?*-==H_]:Z7;=Q?6B:,I%O;PM MF_9OD?KML>H^16?1]?:^B>J[Z*=Z/:_775,O==O[Z(=U5S9EV[71J[SLBFK9 MOM;X#]=Y].J;U]$W4;6.?EG4CVVQOFW/IYV^Q-[0=+Z[G/?;RZ$CE\.B'[6M M11NI]6UY"[3/\?89TGZJNV;?/_1S_[RG*.%U^?!MQ.*_1S2F#+B>V?'-*>3. MEUE7?]KZH#/8_F9A&SXVQM?5\U_MF^5=US75S6-7W"S+J*O'[I?H/U?ZET@_ MW<]%<_M?Z-;8&N>P\7[$?-,^%//R[40/B6W9/)63B[_^AB[W7 O5ZUM^/_3VJ7TW@H+1M M+@X,TU3$EKL *$LL4.Z",IE9( 6 R$%G#'R4>Q\EZF->M;B/TC%Z1FA,LM1R M$\*Q)$UM3P$<2Z5PG 5PG+&T'Y @?Y.]OPGJ[\_=HFRB\N-\4:SO2]#CQ+%L MA]2+R+T(A2$&GJ5[SU+4LY]T>ECI,70%/IRI8XY0&B?6(S=S81K%";?<T0Q]G6Q#J!W5 ]VBSSV?RIWCTU?+NFU?OX$Z( OY ME@A)EH_+#6JF-9_5[>1O=:;;11G],_Z6QO\Y;7^B1J M"_WAMKSIHK:_S-_4P*@%!]HXX\D.0@229H=UR5 M\V71MM5=-2\V^D;GQ8_ANHCXN\B%G"6$$+N+O$P*8M)])$9>/X2:/J)H'^F, MVY-7[ B&>8!^SV;VX 4 =69!)(^9[?"1E.H8RJ'C)BDF:,9V<55_*I8Z$;[4 M4FI51 _+.>A\T.PV*%L>E$V%8AN&PV2XA+_ 6X6@>?/)X0G)E@=E4Z'8AN$Q MJ3C!<_&?G]=:/2ZJA^BA;.;ENBONR^A5T4;%YQ]>@_'9LA)R.+1]FPA[Y(!A MSK!Q%)ORL@W[P*3J!,_5>SU2K1^W\OA)B^.Z::/+HNEV7=-&?T17E]'W6FEK M#/S.0"V(Q6(AZQ M-*PV59^K3?V(@HXG*?1H4V<\@6%V@>,X-N5E&W:"T5$$50-])YS-H!HMZ'E0 M 164+0_*ID*Q#0O'1D/1^&M62RFJX$Z-8U"V/"B;"L4VC*,1?Q07?T?53'<< MA_J""=;7UZP1!0!REL89L^IP.<289@FE=M448N0)R02!QQ5J)!W%)9VW;KIK M[RF<0BBW<@J@@-(IA!JMG5*CX2BNX;S5TUU[?_D4!$+U4P@(%E A(%9!I48J M47PVX(@:ZHYAZ$[*A7-; SA)4GO.((=P6H83(6VO(<.4DS@=\=HH$(HK$+R^ M2MWB/,\RR6Q_75B2)#8L!V",TSA.;6\A'"')F+-&:E#Y NDK#:HN@K+E0=E4 M*+9A>(RZH/@L1K@Z*V[HY)"YLQJ"RLR^NX,J"MW>+& M3^YV=Z+EC*:)7>8-:E1!1K,T'E$EU*@2BJL2?T%X1S <];@D3ED' '(J.7/J MP<QX* FKU=_AN'7I^L#8+ES!>L<9<'4$XL1-;""4Y4$A*.IE(GC, !D,97) MR PT,Z*%>:9-_%*-N1K"5N)^2.Z'*!0R],_H%(9/B>"BC+F+B*B0=B5D!L$( M9]1VT8410C));#\!'&,B&UF-QDS6SUYB3H$%S?"#LN5!V50HMF%XC&)@N&(( M)\IP0R>'#%K4E3F#55!Q -CDE(R(,F:T <.UP?_<+V!-!D_:@;'E0-A6*;1@=D[1S^C7%%TE<5=&7"6VH/_#$)QIQZ7@[!$V&4["$9CDH[% MTN@/CNN/(_05=^6 $TTO)/=#% H9^F=XVA].6>&&3@Z9 MFVT[SVW0]!XU.-SC9E)[@:?V+ZNI<..G=KCP[N7(@QI4J,%AAQM1(7!1X==2 M MAL(:6]CQ) 21=S0SV3-"U!&7+@[*I4&S#.!JQ(7"Q<92V$JX.H(00*NRL' )*(5)W M/S, 9#++F+T*$63D&1$CTSWB8/,V+D3\N[==44 XLS>5@:C8\1=8B!4GSB@+ M+!*C\<@4GC B1'SA'FX!;;HFU%X[.@-QJ:3V0A((EPGBS(1 .$+BT;D\872) M^.)MW,+5"N 21 @'+4&$<. 21- PL@11&)DBOF2+MP#J_#RVM? ,@ G.,L== M:-9 ,#?&P,[RC--T9!6Q,$F_>(EMWB)H@A^4+0_*ID*Q#8^-,+)!_K^V>N.& M3@V9!/9R9T[=**A-!=@4@HX(!6F$@OR:V\=QXR=W.R SB/OF"&I404:%2$9> MJ-+(%OFE>](EL#0),?RZB.8!RZ;7)^B=?A,;6F+M^A M&TMQZI/OIJ )?5 V%8IM&"23T$O^-8691.7$R7$,R98'95.AV(9Q-/)$XO+D M*&$F_6NS_)#<#U$H9.CAP=$8!-3CL<",9$EPR^)72 MCD B8ZD?DOLA"H5LW9L>''B\*IO[S4G3K1XK']?=]CC;_:_[TZS?;N?M@?O_0&]F>"7_P/4$L#!!0 ( )A(:%>F^H@( MN@4 $$= 9 >&PO=V]R:W-H965T$HLZ M<\@Y)(0X_NU(9WV?M>'Q[U?VWQOG MI3,/F),5+;[GF=A>SL(9R,@:[PMQ2Y_^()U#7LV7TH(W?\%3A[5G(-US0*'>"R;>YM!/+!+,JKS8<[ @#=UO,"#B+ MB6[CFN,MGX:?"\L(0< M9-V5E78#NFX'A$X,R %?:26V'"151C*#?3QN'XW86U*<7B'TJM U&B6\([L+ MX-B? ;*18QC/ZNWFR.3._^L]^7#O S&88%R4 ESY&\2FE)3+/1$OD-47UWHP#;PVNN]]D:]_HMP/C]R%V A6/ZP%_BA($!04-'J2RJW/:.% MM-U(F"!2?&&,/VU?WM$8W2CR'447'14$@8J*=93CRC,Z5&0QP2 ,0K,L?B^+ M/RK+M]."W-(77(@7<"-#=(G!KDAE,)<':IZ:%/%U7Q%4E\!*1T$7^1Y4)-%A MOFN[D<*6Z# W"B/HFR4)>DF"44FNLFP.;@DN"IKB)A.AZX\L'+!FM 1B*RVX MS*'D9I.H1\)X1[DJ9#NX!I1E>243K.XL-(D;:(XBU_8\15P=Y;E.Y"O:&KB0 MY_C*%"0Z#$8N"J%9V[#7-IQTN65YL1?&(_PZU*.)#_U(T41'P2BP726"Q3HL M]+U053C187[D2$*S*%$O2C1Z(,:DHC(M.W4D1E,>B5.2Q5.2)1.1#68 VH<4 MUAY=F-^;:D#N42QWJ*QNNMUYI>Y.( LE+F1:6N_T+AR",YFNMJ_/C,)#=@]'D]>/[J0NTO]4'$?W MW(;0T10RX0*$-)E,.#> @2J5F<^.3LAU2,;A>#8^*)[-4@WB3":S#,Q:>//6 M+%/;:1T!^O':%]!753+"'*2*9(#!"]=1-3+"X(G$'1XR=SB>NK]-HN,%]$:1 MO+>)9(3I(AE@)I&,L),B'?)X.)[(RZI.Y-6^WDSOJF3&:=^;7DS*%D_*EDS% M-IR@0U4!@X]_]H"C)+7S';Y!4'!5G+KNR+0&9-K+VO:Q\$W3474@]4"%HV/[<$ M9X35 /E^3:EX?:@[Z&]-E_\!4$L#!!0 ( )A(:%<,W['WT@8 -LB 9 M >&PO=V]R:W-H965TK"9X\W_B8/:R5 MOC&=76[H [MGZM/F3L#5=(^RS I6RHR72+#5U>0:7\R)KQTJB]\S]B@//B,= MRH+SS_KB_?)JXN@G8CE+E8:@\&_';EF>:R1XCB\-Z&0_IG8\_/R,_JX*'H)9 M4,EN>?Y'ME3KJTDT04NVHMM2//[$FH.H!4Y[+ZB]Z;&R="4JW4O&B<88G M*+*R_D^_-D0<. ".V8$T#J3KX TXN(V#^]H1O,;!>^T(?N-0A3ZM8Z^(2ZBB MLTO!'Y'0UH"F/U3L5][ 5U;J1+E7 K[-P$_-WI?+3,"DH5LJU^@=Y TZ2YBB M62Z_0^?HTWV"SMY\A]Z@K$2_K?E6TG(I+Z<*AM8 T[09YJ8>A@P,XZ(/O%1K MB>;EDBT-_HG=/[;X3R'D?=SD.>X;8@6\9YNWR'6^1\0AKN%Y;E_O3DSA_+_1 MY_]Y]",RW'T2N!6>.X2WW6QR!LM?T?P@$>;U/8G^O%Y()6!-_V6:^1K;,V/K M0G[0Y[[9F#E8>_8+.F;Q1'Q M'7)L-N^;19[CQ"W:4=3^/FK?FI;7R[^A -8IJ#AL2RDOTRQG*#73H8WT5:HS M>"/X+H-:@19/"+950556/M3[4J8R)B],Y/ECIO*88,F88/.1P(XF-=A/:F!- MY??U5*T$+] J*RG,*!0=P9]HKIX0E9(IX_YB13UU:L8$2VHP_R#YSW$0>D$4 M=U:)R= /(]_WS>LDW%,:6BF]TZE>=6[0.*)T3X4E+Y9X(8XZ%+5-_-CWXT#,U'1GJC(2M1U MP87*_J%5B\I70)$"KK(%E)3A^*/>HSB=T%^T2%ZTF/O8 4@P:9>!WR42VHUKU'*PN^%*);;6#&7MFZR"GLCLJ M6M*@':U[$G?3UF!U'H=^/)"Y^$"68"O!9S]6S$[SBFA-,/NRS:!0299N1;6# M&QG%IAKK=:K0K1*3F8OCV.NRT+<#KH:6+R8M"<1*PKP.&2KY&:.B MA ;F@)'5,R,%4VL.:[G<,:G8 "^D7U\((5U:^E8N\;LEW&!U3J*@VSO.#78$ MXW" E%:K8&NG/4LR6%/98JNK6K.=G4+$J&IE5+2D03LJ5E&D!>(QKWTSUW7Q M4$UK-0:VBXS[-17L7)^Z0,/ BPTK9;5U&&FT0IU,XYAH28-V1&/H]2J7PZL8/.->DM T%6R0Q5'UQJAH28-FZUD,)N?$SG.K^3'>VDL*'JHEY81,(>G+T/'2=;MMF,O,\XKG=>F?JVPFH MX!X?!L,XC*.!]AZW_3VV-_B_JC43QDBM?BORJ\5Y7@M5K6%/T*9V\).G:51]@OO2@W@^E,=>GV30*)'G1G%L7@6D52G$ MKE*N8?/9 JO/1 J6,A I4$]-9-K!3B5S5+2$]'6&%W;KK\'(#?UPX!22M%J$ MV+5(57[W)#8;^PM<6A%/YG),M(085$W0.X$Q67G8B0;(;#4-L6N:FDS8O@73 MAQ"#2]L.8162H.R*M ")V 02K6A_@2+2A3U5OI#172G-?9,<]F=)1M0\Q:)_ [ZUP@Y7CQ62 TE;Z$+OTV7?M#:5&]D:5 M/*.B):0O9F"Q^D'8Y<]DYWGQ@.PAK>PA=MGSRVM_=C$R.ZH,&A4M:=".?RC# M/@Z[N[C!$,/> ]G9X79Z\&-]P<1#]9:$1-6:KG^RW=_=OXEQ7;U_T+E_@R]N ML>%^@B_F]7L6+7S]VL<'*AZTLLK9"H9RWH;PS*)^DZ*^4'Q3O2JPX$KQHOJX M9G3)A#: [U>25!U61+Y<(%,;*;>T-LM7-.\T';!3R85R7&!^J:Z MDF;FMRP9+9$K*CA(7$V]\^'9++;GW8'O%#=J;PS6R5*(6SOYDDV]P I"AJFV M#,1\UCA#QBR1D7&WY?3:D!:X/]ZQ?W+>C9 M 8RV@)$SVBASMN9$DV0BQ0:D/6W8[,#EQJ&-&\KM+2ZT-+O4X'0R$V5)M;D6 MK8#P#&:":\ISY"E%!8=SU(0R=03OX&8QA\.#(S@ RN&2,F9N04U\;418*C_= M!IPU <-G I["I0E1*/C(,\S^QOM&?.L@W#FX"'L)OQ(^@.#D&,(@#+OT],,7 M6 U@%#CXJ$?.J$WHR/&-7I70.54I$ZJ6"#_/ETI+\S?^U2'ZH@DR[@YBG_:9 MJDB*4\^\785RC5[R]LTP#CYT9> _D?V5CW&;CW$?>_)-\!PTRA)6-<],)J B M4G.4JJ#5,>!]91XT9F;UP2:M*Q>] 5Z:BX8L=F2VQ*V381A-_'6'Q:BU&/V+ M19)EU)8LPG8FE5G,NRF-]Y+W?A[5;%$F;MFH2"U6IL"V:ZV_>C< ME6'_S_&FF5T2F5.N@.'*0(/!B4F[;!I$,]&B&PO=V]R M:W-H965TQ);,_@Y6..:(/6(O'M/L M>[YBK"!_K.,DOQRLBF+S83C,YRNV#O/S=,.2\B?+-%N'1?DP>QCFFXR%BWK0 M.AYJBC(>KL,H&^1@^K MHGIB.+O8A _LCA6_;VZS\M%PKRRB-4OR*$U(QI:7@ROU0S!2J@'U%O^(V&-^ M\#VI?I7[-/U>/:"+RX%2[1&+V;RHB+#\\I/=L#BNI'(_?C3H8!^S&GCX_;/N MU+]\^-_1HMB=3DP!V3!EN$V+KZFCQYK?J%1Y4>K*-D]S7\HWDA#@:HQBL#M&: =NP O1F@OQPP>F6 T0PP7@X8 MOS)@U P8'1MAW P8'QMAT@R8'#O ; :8Q^[2M!DP/3:"JCS_SRE'#]G_9^\. MNMU14A]B5EB$LXLL?219M7WI5=_4QVD]OCRRHJ1*J;LB*W\:E>.*V5<6AP5; MD-LP*Y[(MRQ,\K ^V'/RSF)%&,7Y;^2,_'YGD7=__NUB6)0QJY'#>>-;.U][ MQ=?)IS0I5CFQDP5;",8[\O'3M\9[\O&J)@&&Y8NU?\6TYU?L6I.*5YOLG*CC M]T13-%6P0S?RX1:;GQ/%K(:K$]'K*1]^QS;G1%?JZ+I@N'W\<$WTO_%KT=U? MB^X=\=+IZJO#J7RXOTVD.^\?/UP4/3A^YU7)8:CO$U>O/;UOXI)_?2PW);1@ MZ_S?@OV\WKF&V*U.X1_R33AGEX/R')VS["<;S/[R)W6L_$UTL",Q"XG92,Q! M8BX2\Y 816(^$@M &)=JQC[5#)D^LZ*\R*+[[>ZTN F?PON8D2(E,7L(YT\D M29.S>7F2R=*X'/I HJ1@Y5X4N2C[I*'Z9A\2LW;8N,:J2OSG3"U/4:JJ*,K% M\.=A:B'#.D>'=9%AO6[8J6$J>B@1VD8$]06!#-0U#&W63 QG81V(!"..28[Q/CK$T.>Y6 M8<96:;Q@6?Y7PGYLH^))=-1+E;Y'/1*SQIUC8#HR1\ITTCWHQX*_WX8Z-@1_ M2YWC6;<'ZXE8;:1/!'_-N^S45/6Q.>YLZ@OW0#%5L[NW@6A;S3!'!I1DC,0F(V$G.0F(O$/"1&D9B/Q (0 MQJ64N4\I\T3OG4UDJB$Q"XG92,Q!8BX2\Y 816(^$@M &)=JTWVJ32&ED%3I MFUA(S)IVBHLS;:P)JG_1AA/3[%9!QXKNL:(GVM!4NC4-%8>>=HL?8>B1UJU\ MA!NJKY<]JM+.3"C20^=S^8;RYN"R"I5=5I%;?0\@J&9!-1NJ.5#-A6H>5*-0 MS8=J 4KC,^U@#E ]43W4P*BT0VH65+.AF@/57*CF034*U7RH%J T/NVT-NTT M2&TD9WHG&5*S&NWP_*\;QEB=="\6VH)M#6ULZ*(K13UK/NZFJVCRLZRBTBROMTG*@V\5;<1%%72J&*I94,V&:@Y4'7VSOGFS )H-/44,V":C94:].3E4%0J?UH9H%U6RHYD U%ZIY4(U"-1^J!2B-3[MV@E^53FJ"JT#HK#]4 MLQJ-NYZE3;I%D0T-ZQP;UH6&]01A)YK9;16FT+ ^5 M0&I\:[82\*I^1?UD" M7F=EKJ3QV:UH?O;W;9EO+(N?JFN#NS-=D9)PN8SBJ,S'L@0L3XSS MJDA,ER1<_&>;5TDZ#_,5R=B<19MRP+LP?]Y*=&.<:_DN]$Y0:!M'HZG&0?FD MG"OCT:O/6B5U+EK'P;%I7GO*AN M1ZPV?SNCH.T84,UJM)?'MJ)U4@K:C7%L6!<:UH-J%*KY4"U :7Q.M0T;FKQA MXVJ=;LO,F(?Q?+NK%)=I1E+N;=NF?ML6QL]I)TP=:!,'5+.@F@W5'$WTR7[A MU0UH?P94HU#-AVH!2N/SJ^W/T.1W5[AMSDB_GF#0=@VH9D$U&ZHYC5;U"W G M,%WMGL*@O1A0C4(U'ZH%*(U/L;870Y/W8GP1Y%)UC7%?)$9)?45>='?/:[G= M.ZV@O1>-QG_F1W1RL*%Q'4%<=61,A6W;?Q2Q2BW>V<>M$D#JMEZM_7" M4$2M%PXTKBN(JZH34Q#8@P:F4,V':@%*XU.F;>30Y8T<5WD>/23U5?2KAXRQ M^KLSJ>5"- M0C4?J@4HC4^DMJ=#E_=TO%)7.MMD4;T_^W(?1P_A[E.6/2I*:!\'5+.@F@W5 M'*CF0C4/JE&HYD.U *7Q&=EVA.CC4U64T!X0J&9!-1NJ.5#-A6H>5*-0S8=J M 4KCTZYM%-'EC2+_5T4)[0EIM+GH)H-U1RHYD(U#ZI1J.9#M0"E\3G5 M]H(8\EZ0W0=@\FH&NVC/8^4;L(/W8Q$3+[4,[02!:A94LZ&:8W3[.SI+,4/O MY6%T[^716849VOH!U0*4QF=(V_IAO-'Z,?^QC?*H+N^^+,G':!T]UW[-X@[M MTEGE=^3J^0.9Q[0/RV/WSB%H\P=4LZ&: ]5957%&#?G MPLW!N?#Y5K\DK,Z;6?G3ZIU:7JW%]: Q!59WEX[>7N)?O3.\J>5"-0C4?J@4HC4^[ MMF/$D'>,'+N\JYSIG630.XTJBZZPP$TK--H@CLKO"P>H3T@4(U"-1^J M!2B-3XVV!\1XHP<$6#Q^3I.SFX.E7*AL*1?Y?O7.-6A7"52SH9H#U5RHYD$U M"M5\J!:@-#YKVZX2XU1=)0:TJP2J65#-AFH.5'.AF@?5*%3SH5J TKBT&[5= M)2-Y+\BQ=:2)1E;5LN8?;C2!L/.\Y;ZP58% MSSOJ![=^?MCRLXM-^, ^A=E#E.0D9LLRE'(^*=_-9-'#:O^@2#>7 W5 [M.B M2-?UMRL6ENE6;5#^?)FFQ?.#*L!CFGVO?YW9_P!02P,$% @ F$AH5T38 M"Q@#! &A4 !D !X;"]W;W)K&ULK9A=;]LV M%(;_"J$610MTD2CY(TEM 8W3K@&6UDC2[6+8!2T=VT0ETB$I.P'VXT=*LF2E M,C$7S(6M#YY'YZ4.F==GLN/BAUP#*/249TQ.O;52FTO?E\D:U#?-W.AS_R&DM(>N<>2F%)BDS=\=T7J 4-#2_AF2P_T:X:.PH]E!12\;P. MUAGDE%7?Y*F>B(. \%A 6 >$+P*BX$A 5 =$I= JLU+6-5$DG@B^0\*,UC1S M4,Y-&:W54&9>X[T2^B[5<2J^+Q82'@M@"GW:ZD^)WEZ#(C23[]!OZ.5=]!I1 MAA[6O)"$I7+B*YV" ?E)_;BKZG'AD<=A=,N96DOTB:60=N-]G7J3?[C/_RJT M K_R[1F*@O!^9OXVQY] MHT;?Z!>*&?V+;LD3S8N\3Y:5>*HL1[".^'$C?NRVK,_6,24'2MB*_%418Y@ M'?$X:/_M!V[+N.8Y$N^*UE5_8'JPTU*VXTX6CW\JYJB_F''8*@H=&0P[Z&0M MCFA=V:VMPI'C,G;JKUS1NNI;AX6M-N; :)#DL: "3O0:=OS)DS'XR6V$P^-N M [=V"MO]U-&M^H[K]?KFU7F(QQ_T3XJM>)8I[17JU%6YHG6GHW5?>.2XYIV: M+U>TKOK6?F&KQXGGY#DO?ZV4^=5TPZK&P<6,XU;6X7MONH!M@3- MUT3D.AE3X"23NL(5"$;,^B89^OWVZDNO1*<>RQ6M.P^M(<,7CNO:J1]S1>NV M,5I#%EHM3_RY8"EE*T16 L!4N&7?KE&=6BRWVJ84ZYZ'4Y?E'W29Q;&N]N'Z%+V=5FZ[%5%W#6R)6E$F4P5(C@[.QWFE%U8BK M3A3?E+VL!5>*Y^7A&D@*P@S0]Y>4#3#HW_ U!+ P04 " "82&A7 M=QX'77P# ";& #0 'AL+W-T>6QEUNVC 4?94H7:=6F@@A M;2 K(&U(E29M4Z7VQ_Y5ACA@R7$R8SKHZ^Q-]F3SM4/XJ"^B_;$V"RJQ[\DY M]]B^3HC:GZL5I[TGM7[P'K'AADG-<&.[X-#/LE48I*<:T[YF(3? )Y5?MN56J'4TE68>?2WQ#, M22<9%S*EA89_3#.Q(-IW!615E *!21:X;*2/30A#C8YEMK9VI8U$WM:&J:65L!_2WU:SVMFSO1;I>R1X*]7FAAR-,'PJ= MWDB:L:7I+[/: *8>XNJD+/GJ$V=3D5,[^*,3#OMDS?-FA62/.AN4RD0'J/2] M!RH5FVQ'?DE2WM&E6I?3,L,]=QKH^=_.\Y0**@G?-JUK_RW/\HL=1]W7LFSN M*ON&G1ZKWSMOW>1E$TS&33#9B)KL-<%DT@"3W5>[:S['9-@$DYTFF(S>OLFH M$?OF;3X5@^K7^=8KP,X+0!WUX$5KX'^'5S>^2>J-%XPK)JK>C*4I%4_> [2\ M(F-.=_7U]2G-R(*KNQH<^)OV-YJR19[45]W 1%17;=I?87AA7+_EZ5Q,I'1) MTU'5E=.Q:7JZH;-6!Q#VD6MSN!&,8S$W AB6!W. <2P+R_,_C:>'CL=BF+>> M$^FAG![*L2P7,C(?+(^;D^C#/=(DB:(XQF9T-'(Z&&'S%L?PYU;#O $#RP.9 MGC?7^&KC%7*X#K U/50AV$CQ2L1&BL\U(.YY T:2N%<;RP,,;!6PVH'\[CQ0 M4VY.%,&J8MZP'8PC28(A4(ON&HUC9'9B^+C7!]LE490D;@0PMX,HPA#8C3B" M.0 /&!)%YCFX]SP*UL^I8//OB.%?4$L#!!0 ( )A(:%>7BKL

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

0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 M" "82&A7$R?LNN\! "E(@ &@ @ ':HP$ >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "82&A78B/G&-@! !((@ M$P @ $!I@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 ..0@!" 42 *J $ ! end XML 70 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 418 319 1 false 108 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://royaltypharma.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY Sheet http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY (Parenthetical) Sheet http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - Organization and Purpose Sheet http://royaltypharma.com/role/OrganizationandPurpose Organization and Purpose Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Available for Sale Debt Securities Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecurities Available for Sale Debt Securities Notes 11 false false R12.htm 0000012 - Disclosure - Fair Value Measurements and Financial Instruments Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments Fair Value Measurements and Financial Instruments Notes 12 false false R13.htm 0000013 - Disclosure - Financial Royalty Assets Sheet http://royaltypharma.com/role/FinancialRoyaltyAssets Financial Royalty Assets Notes 13 false false R14.htm 0000014 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Notes 14 false false R15.htm 0000015 - Disclosure - Non-Consolidated Affiliates Sheet http://royaltypharma.com/role/NonConsolidatedAffiliates Non-Consolidated Affiliates Notes 15 false false R16.htm 0000016 - Disclosure - Research & Development ("R&D") Funding Expense Sheet http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense Research & Development ("R&D") Funding Expense Notes 16 false false R17.htm 0000017 - Disclosure - Borrowings Sheet http://royaltypharma.com/role/Borrowings Borrowings Notes 17 false false R18.htm 0000018 - Disclosure - Shareholders' Equity Sheet http://royaltypharma.com/role/ShareholdersEquity Shareholders' Equity Notes 18 false false R19.htm 0000019 - Disclosure - Earnings per Share Sheet http://royaltypharma.com/role/EarningsperShare Earnings per Share Notes 19 false false R20.htm 0000020 - Disclosure - Indirect Cash Flow Sheet http://royaltypharma.com/role/IndirectCashFlow Indirect Cash Flow Notes 20 false false R21.htm 0000021 - Disclosure - Commitments and Contingencies Sheet http://royaltypharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 0000022 - Disclosure - Related Party Transactions Sheet http://royaltypharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 22 false false R23.htm 0000023 - Disclosure - Subsequent Events Sheet http://royaltypharma.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 9954472 - Disclosure - Available for Sale Debt Securities (Tables) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables Available for Sale Debt Securities (Tables) Tables http://royaltypharma.com/role/AvailableforSaleDebtSecurities 27 false false R28.htm 9954473 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables Fair Value Measurements and Financial Instruments (Tables) Tables http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments 28 false false R29.htm 9954474 - Disclosure - Financial Royalty Assets (Tables) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsTables Financial Royalty Assets (Tables) Tables http://royaltypharma.com/role/FinancialRoyaltyAssets 29 false false R30.htm 9954475 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) Tables http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets 30 false false R31.htm 9954476 - Disclosure - Borrowings (Tables) Sheet http://royaltypharma.com/role/BorrowingsTables Borrowings (Tables) Tables http://royaltypharma.com/role/Borrowings 31 false false R32.htm 9954477 - Disclosure - Shareholders' Equity (Tables) Sheet http://royaltypharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://royaltypharma.com/role/ShareholdersEquity 32 false false R33.htm 9954478 - Disclosure - Earnings per Share (Tables) Sheet http://royaltypharma.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://royaltypharma.com/role/EarningsperShare 33 false false R34.htm 9954479 - Disclosure - Indirect Cash Flow (Tables) Sheet http://royaltypharma.com/role/IndirectCashFlowTables Indirect Cash Flow (Tables) Tables http://royaltypharma.com/role/IndirectCashFlow 34 false false R35.htm 9954480 - Disclosure - Related Party Transactions (Tables) Sheet http://royaltypharma.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://royaltypharma.com/role/RelatedPartyTransactions 35 false false R36.htm 9954481 - Disclosure - Organization and Purpose (Details) Sheet http://royaltypharma.com/role/OrganizationandPurposeDetails Organization and Purpose (Details) Details http://royaltypharma.com/role/OrganizationandPurpose 36 false false R37.htm 9954482 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies 37 false false R38.htm 9954483 - Disclosure - Available for Sale Debt Securities - Narrative (Details) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails Available for Sale Debt Securities - Narrative (Details) Details 38 false false R39.htm 9954484 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) Details 39 false false R40.htm 9954485 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Fair Value Hierarchy (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails Fair Value Measurements and Financial Instruments - Summary of Fair Value Hierarchy (Details) Details 40 false false R41.htm 9954486 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails Fair Value Measurements and Financial Instruments - Narrative (Details) Details http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables 41 false false R42.htm 9954487 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) Details 42 false false R43.htm 9954488 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Estimated Fair Values Based on Level 3 Inputs (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails Fair Value Measurements and Financial Instruments - Summary of Estimated Fair Values Based on Level 3 Inputs (Details) Details 43 false false R44.htm 9954489 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) Details 44 false false R45.htm 9954490 - Disclosure - Financial Royalty Assets - Narrative (Details) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails Financial Royalty Assets - Narrative (Details) Details 45 false false R46.htm 9954491 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Details) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Details) Details http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables 46 false false R47.htm 9954492 - Disclosure - Non-Consolidated Affiliates (Details) Sheet http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails Non-Consolidated Affiliates (Details) Details http://royaltypharma.com/role/NonConsolidatedAffiliates 47 false false R48.htm 9954493 - Disclosure - Research & Development ("R&D") Funding Expense (Details) Sheet http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails Research & Development ("R&D") Funding Expense (Details) Details http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense 48 false false R49.htm 9954494 - Disclosure - Borrowings - Summary of Borrowings (Details) Sheet http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails Borrowings - Summary of Borrowings (Details) Details 49 false false R50.htm 9954495 - Disclosure - Borrowings - Narrative (Details) Sheet http://royaltypharma.com/role/BorrowingsNarrativeDetails Borrowings - Narrative (Details) Details 50 false false R51.htm 9954496 - Disclosure - Borrowings - Summary of Repayments of Debt by Year (Details) Sheet http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails Borrowings - Summary of Repayments of Debt by Year (Details) Details 51 false false R52.htm 9954497 - Disclosure - Shareholders' Equity - Narrative (Details) Sheet http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity - Narrative (Details) Details 52 false false R53.htm 9954498 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details) Sheet http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails Shareholders' Equity - Summary of Noncontrolling Interests (Details) Details 53 false false R54.htm 9954499 - Disclosure - Earnings per Share (Details) Sheet http://royaltypharma.com/role/EarningsperShareDetails Earnings per Share (Details) Details http://royaltypharma.com/role/EarningsperShareTables 54 false false R55.htm 9954500 - Disclosure - Indirect Cash Flow (Details) Sheet http://royaltypharma.com/role/IndirectCashFlowDetails Indirect Cash Flow (Details) Details http://royaltypharma.com/role/IndirectCashFlowTables 55 false false R56.htm 9954501 - Disclosure - Commitments and Contingencies (Details) Sheet http://royaltypharma.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://royaltypharma.com/role/CommitmentsandContingencies 56 false false R57.htm 9954502 - Disclosure - Related Party Transactions (Details) Sheet http://royaltypharma.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://royaltypharma.com/role/RelatedPartyTransactionsTables 57 false false R58.htm 9954503 - Disclosure - Subsequent Events (Details) Sheet http://royaltypharma.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://royaltypharma.com/role/SubsequentEvents 58 false false All Reports Book All Reports rprx-20230930.htm rprx-20230930.xsd rprx-20230930_cal.xml rprx-20230930_def.xml rprx-20230930_lab.xml rprx-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rprx-20230930.htm": { "nsprefix": "rprx", "nsuri": "http://royaltypharma.com/20230930", "dts": { "inline": { "local": [ "rprx-20230930.htm" ] }, "schema": { "local": [ "rprx-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "rprx-20230930_cal.xml" ] }, "definitionLink": { "local": [ "rprx-20230930_def.xml" ] }, "labelLink": { "local": [ "rprx-20230930_lab.xml" ] }, "presentationLink": { "local": [ "rprx-20230930_pre.xml" ] } }, "keyStandard": 234, "keyCustom": 85, "axisStandard": 30, "axisCustom": 0, "memberStandard": 35, "memberCustom": 69, "hidden": { "total": 8, "http://xbrl.sec.gov/ecd/2023": 2, "http://xbrl.sec.gov/dei/2023": 5, "http://royaltypharma.com/20230930": 1 }, "contextCount": 418, "entityCount": 1, "segmentCount": 108, "elementCount": 639, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1028, "http://xbrl.sec.gov/ecd/2023": 20, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://royaltypharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R3": { "role": "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "rprx:DeferredSharesParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "rprx:DeferredSharesParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "rprx:DeferredSharesParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "rprx:DeferredSharesParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-24", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-24", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R6": { "role": "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://royaltypharma.com/role/OrganizationandPurpose", "longName": "0000009 - Disclosure - Organization and Purpose", "shortName": "Organization and Purpose", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecurities", "longName": "0000011 - Disclosure - Available for Sale Debt Securities", "shortName": "Available for Sale Debt Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments", "longName": "0000012 - Disclosure - Fair Value Measurements and Financial Instruments", "shortName": "Fair Value Measurements and Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://royaltypharma.com/role/FinancialRoyaltyAssets", "longName": "0000013 - Disclosure - Financial Royalty Assets", "shortName": "Financial Royalty Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancingReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancingReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets", "longName": "0000014 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://royaltypharma.com/role/NonConsolidatedAffiliates", "longName": "0000015 - Disclosure - Non-Consolidated Affiliates", "shortName": "Non-Consolidated Affiliates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense", "longName": "0000016 - Disclosure - Research & Development (\"R&D\") Funding Expense", "shortName": "Research & Development (\"R&D\") Funding Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://royaltypharma.com/role/Borrowings", "longName": "0000017 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://royaltypharma.com/role/ShareholdersEquity", "longName": "0000018 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://royaltypharma.com/role/EarningsperShare", "longName": "0000019 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://royaltypharma.com/role/IndirectCashFlow", "longName": "0000020 - Disclosure - Indirect Cash Flow", "shortName": "Indirect Cash Flow", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://royaltypharma.com/role/CommitmentsandContingencies", "longName": "0000021 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://royaltypharma.com/role/RelatedPartyTransactions", "longName": "0000022 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://royaltypharma.com/role/SubsequentEvents", "longName": "0000023 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables", "longName": "9954472 - Disclosure - Available for Sale Debt Securities (Tables)", "shortName": "Available for Sale Debt Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables", "longName": "9954473 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)", "shortName": "Fair Value Measurements and Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsTables", "longName": "9954474 - Disclosure - Financial Royalty Assets (Tables)", "shortName": "Financial Royalty Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables", "longName": "9954475 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://royaltypharma.com/role/BorrowingsTables", "longName": "9954476 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://royaltypharma.com/role/ShareholdersEquityTables", "longName": "9954477 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://royaltypharma.com/role/EarningsperShareTables", "longName": "9954478 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://royaltypharma.com/role/IndirectCashFlowTables", "longName": "9954479 - Disclosure - Indirect Cash Flow (Tables)", "shortName": "Indirect Cash Flow (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://royaltypharma.com/role/RelatedPartyTransactionsTables", "longName": "9954480 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://royaltypharma.com/role/OrganizationandPurposeDetails", "longName": "9954481 - Disclosure - Organization and Purpose (Details)", "shortName": "Organization and Purpose (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-120", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-118", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R37": { "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-123", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-123", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "longName": "9954483 - Disclosure - Available for Sale Debt Securities - Narrative (Details)", "shortName": "Available for Sale Debt Securities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-125", "name": "rprx:LongTermFundingPartnershipAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "rprx:LongTermFundingPartnershipAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "longName": "9954484 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)", "shortName": "Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails", "longName": "9954485 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Fair Value Hierarchy (Details)", "shortName": "Fair Value Measurements and Financial Instruments - Summary of Fair Value Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:TradingSecuritiesDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag", "span", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R41": { "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "longName": "9954486 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)", "shortName": "Fair Value Measurements and Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-24", "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "longName": "9954487 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)", "shortName": "Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R43": { "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails", "longName": "9954488 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Estimated Fair Values Based on Level 3 Inputs (Details)", "shortName": "Fair Value Measurements and Financial Instruments - Summary of Estimated Fair Values Based on Level 3 Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-253", "name": "rprx:FinancingReceivablesFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-253", "name": "rprx:FinancingReceivablesFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails", "longName": "9954489 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)", "shortName": "Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:NotesReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:NotesReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails", "longName": "9954490 - Disclosure - Financial Royalty Assets - Narrative (Details)", "shortName": "Financial Royalty Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:NotesReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-264", "name": "rprx:FinancingReceivableUnapprovedFinancialAssetsHeldAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R46": { "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails", "longName": "9954491 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Details)", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "longName": "9954492 - Disclosure - Non-Consolidated Affiliates (Details)", "shortName": "Non-Consolidated Affiliates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-272", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R48": { "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails", "longName": "9954493 - Disclosure - Research & Development (\"R&D\") Funding Expense (Details)", "shortName": "Research & Development (\"R&D\") Funding Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-288", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R49": { "role": "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "longName": "9954494 - Disclosure - Borrowings - Summary of Borrowings (Details)", "shortName": "Borrowings - Summary of Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "longName": "9954495 - Disclosure - Borrowings - Narrative (Details)", "shortName": "Borrowings - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-315", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-315", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails", "longName": "9954496 - Disclosure - Borrowings - Summary of Repayments of Debt by Year (Details)", "shortName": "Borrowings - Summary of Repayments of Debt by Year (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-331", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-331", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "longName": "9954497 - Disclosure - Shareholders' Equity - Narrative (Details)", "shortName": "Shareholders' Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-4", "name": "rprx:NumberOfClassesOfVotingStock", "unitRef": "class", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardCovenantPercentageOfNetEconomicProfit", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R53": { "role": "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "longName": "9954498 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)", "shortName": "Shareholders' Equity - Summary of Noncontrolling Interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-35", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-334", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R54": { "role": "http://royaltypharma.com/role/EarningsperShareDetails", "longName": "9954499 - Disclosure - Earnings per Share (Details)", "shortName": "Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-24", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R55": { "role": "http://royaltypharma.com/role/IndirectCashFlowDetails", "longName": "9954500 - Disclosure - Indirect Cash Flow (Details)", "shortName": "Indirect Cash Flow (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rprx:IncreaseDecreaseInFinancialRoyaltyAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R56": { "role": "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "longName": "9954501 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "rprx:LongTermFundingPartnershipExpectedPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "longName": "9954502 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "rprx:DistributionsPayableToLegacyNonControllingInterestsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-393", "name": "rprx:DistributionsPayableToLegacyNonControllingInterestsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "unique": true } }, "R58": { "role": "http://royaltypharma.com/role/SubsequentEventsDetails", "longName": "9954503 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-408", "name": "rprx:OptionToSellRetainedRoyaltiesAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-408", "name": "rprx:OptionToSellRetainedRoyaltiesAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rprx-20230930.htm", "first": true, "unique": true } } }, "tag": { "rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TwoPointOneFiveZeroPercentSeniorNotesDue2031Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Two Point One Five Zero Percent Senior Notes Due 2031", "label": "Two Point One Five Zero Percent Senior Notes Due 2031 [Member]", "documentation": "Two Point One Five Zero Percent Senior Notes Due 2031" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://royaltypharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r556", "r558" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r214", "r399" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": "rprx_DebtSecuritiesAvailableForSaleAdjustment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized(Losses)/Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r301" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r172" ] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to continuing non-controlling interests", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r41" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-operating expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r111" ] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r15", "r35", "r894", "r895", "r896" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "rprx_ContinuingNonControllingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ContinuingNonControllingInterestsMember", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing non-controlling interests", "label": "Continuing Non Controlling Interests [Member]", "documentation": "Continuing Non Controlling Interests" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r330", "r331", "r333" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r818", "r829", "r839", "r864" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile consolidated net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r470" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt carrying value", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r21", "r131", "r394", "r410", "r773", "r774", "r986" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r551", "r552", "r974" ] }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investments in equity method investees", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": [ "r39" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_PaymentsToAcquireFinanceReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireFinanceReceivables", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions of financial royalty assets", "label": "Payments to Acquire Finance Receivables", "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith." } } }, "auth_ref": [ "r113" ] }, "rprx_NumberOfClassesOfVotingStock": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "NumberOfClassesOfVotingStock", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of classes of stock", "label": "Number Of Classes Of Voting Stock", "documentation": "Number Of Classes Of Voting Stock" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" ], "lang": { "en-us": { "role": { "terseLabel": "Research & Development (\"R&D\") Funding Expense", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": [ "r142", "r460" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r395", "r421", "r422", "r423", "r424", "r425", "r426", "r562", "r563", "r564", "r773", "r774", "r780", "r781", "r782" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0, "order": 1.0 }, "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available for sale debt securities", "verboseLabel": "Available for sale debt securities, noncurrent", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r167", "r295", "r361" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/SubsequentEventsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r282", "r779", "r940", "r987", "r988" ] }, "rprx_ProceedsFromExerciseFeeProRataAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ProceedsFromExerciseFeeProRataAmount", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise fee, pro rata amount", "label": "Proceeds From Exercise Fee, Pro Rata Amount", "documentation": "Proceeds From Exercise Fee, Pro Rata Amount" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains/(losses) on available for sale debt securities included in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r507" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r299", "r361", "r606", "r910" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on available for sale debt securities included in other comprehensive income/(loss)", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r508" ] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]", "label": "Debt and Equity Securities, FV-NI [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income attributable to non-controlling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r5", "r14", "r126", "r185", "r188" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in losses/(earnings) of equity method investees", "terseLabel": "Equity in losses/(earnings) of equity method investees", "negatedLabel": "Equity in (earnings)/losses of equity method investees", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r9", "r104", "r136", "r269", "r329", "r622" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r163", "r209", "r330", "r331", "r333", "r334", "r521" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r209", "r330", "r331", "r333", "r334", "r521" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455" ] }, "rprx_VertexMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "VertexMember", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vertex", "label": "Vertex [Member]", "documentation": "Vertex" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/EarningsperShareDetails", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Consolidated net income", "verboseLabel": "Consolidated net income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r163", "r184", "r187", "r201", "r209", "r219", "r229", "r230", "r265", "r273", "r277", "r279", "r334", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r471", "r474", "r475", "r500", "r521", "r613", "r624", "r668", "r712", "r734", "r735", "r767", "r785", "r786", "r802", "r896", "r936" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r533", "r557" ] }, "rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermFundingPartnershipAdditionalPaymentsAggregateAmount", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term funding partnership, additional payments, aggregate amount", "label": "Long Term Funding Partnership, Additional Payments, Aggregate Amount", "documentation": "Long Term Funding Partnership, Additional Payments, Aggregate Amount" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r160", "r215", "r216", "r217", "r220", "r228", "r230", "r339", "r345", "r456", "r457", "r458", "r464", "r465", "r481", "r484", "r485", "r488", "r498", "r644", "r646", "r669", "r993" ] }, "rprx_ThreePointThreeFiveZeroPercentDue2051Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ThreePointThreeFiveZeroPercentDue2051Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Point Three Five Zero Percent Due 2051", "label": "Three Point Three Five Zero Percent Due 2051 [Member]", "documentation": "Three Point Three Five Zero Percent Due 2051" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Proceeds from Interest Received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": [ "r898" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r34", "r132", "r209", "r334", "r372", "r374", "r375", "r376", "r379", "r380", "r521", "r620", "r693" ] }, "rprx_EPAHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "EPAHoldingsMember", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EPA Holdings", "label": "EPA Holdings [Member]", "documentation": "EPA Holdings" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r790", "r791", "r792", "r794", "r795", "r796", "r797", "r905", "r906", "r972", "r989", "r993" ] }, "rprx_MorphoSysMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "MorphoSysMember", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys", "label": "MorphoSys [Member]", "documentation": "MorphoSys" } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest (as percent)", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r533", "r557" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r847" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of Class A ordinary shares", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r16", "r97", "r98", "r123", "r669", "r736", "r751", "r802" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r69", "r419", "r905", "r906", "r907", "r993" ] }, "rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TwoPointTwoZeroPercentSeniorNotesDue2030Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Two Point Two Zero Percent Senior Notes Due 2030", "label": "Two Point Two Zero Percent Senior Notes Due 2030 [Member]", "documentation": "Two Point Two Zero Percent Senior Notes Due 2030" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r805" ] }, "rprx_RoyaltyInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoyaltyInvestmentsMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Investments", "label": "Royalty Investments [Member]", "documentation": "Royalty Investments" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized discount and loan issuance costs on long-term debt", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r85", "r393", "r409", "r773", "r774" ] }, "rprx_LongTermFundingPartnershipAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermFundingPartnershipAmount", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term funding partnership, amount", "label": "Long Term Funding Partnership, Amount", "documentation": "Long Term Funding Partnership, Amount" } } }, "auth_ref": [] }, "us-gaap_CreditLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossAbstract", "lang": { "en-us": { "role": { "label": "Credit Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r557" ] }, "rprx_LongTermFundingPartnershipInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermFundingPartnershipInitialPayment", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term funding partnership, initial payment", "label": "Long Term Funding Partnership, Initial Payment", "documentation": "Long Term Funding Partnership, Initial Payment" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r85", "r139", "r192", "r268", "r536", "r721", "r801", "r992" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r32", "r160", "r189", "r190", "r191", "r215", "r216", "r217", "r220", "r228", "r230", "r262", "r339", "r345", "r419", "r456", "r457", "r458", "r464", "r465", "r481", "r483", "r484", "r485", "r486", "r488", "r498", "r526", "r528", "r529", "r530", "r531", "r532", "r547", "r644", "r645", "r646", "r669", "r736" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r55", "r798", "r799", "r800", "r995" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value asset liability recurring basis still held unrealized gain loss statement of income extensible list not disclosed flag", "label": "Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag", "documentation": "Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r89", "r614", "r685", "r686", "r803", "r990" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r160", "r189", "r190", "r191", "r215", "r216", "r217", "r220", "r228", "r230", "r262", "r339", "r345", "r419", "r456", "r457", "r458", "r464", "r465", "r481", "r483", "r484", "r485", "r486", "r488", "r498", "r526", "r528", "r529", "r530", "r531", "r532", "r547", "r644", "r645", "r646", "r669", "r736" ] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Losses/(gains) on derivative financial instruments", "terseLabel": "Gains (losses) on derivative financial instruments", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r75" ] }, "rprx_AssetsFairValueDisclosureNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AssetsFairValueDisclosureNoncurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Assets, Fair Value Disclosure, Noncurrent", "documentation": "Assets, Fair Value Disclosure, Noncurrent" } } }, "auth_ref": [] }, "rprx_DistributionsPayableToLegacyNonControllingInterestsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DistributionsPayableToLegacyNonControllingInterestsCurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions payable to legacy non-controlling interests", "label": "Distributions Payable To Legacy Non-Controlling Interests, Current", "documentation": "Distributions Payable To Legacy Non-Controlling Interests, Current" } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchased and retired during period (in shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r16", "r97", "r98", "r123" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r166" ] }, "rprx_EquityMethodInvestmentsUnfundedCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "EquityMethodInvestmentsUnfundedCommitments", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, unfunded commitments", "label": "Equity Method Investments, Unfunded Commitments", "documentation": "Equity Method Investments, Unfunded Commitments" } } }, "auth_ref": [] }, "rprx_CommonStockVotingRightsNumberOfVotes": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CommonStockVotingRightsNumberOfVotes", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of votes per share", "label": "Common Stock, Voting Rights, Number Of Votes", "documentation": "Common Stock, Voting Rights, Number Of Votes" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SubsequentEventsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r48", "r50", "r81", "r82", "r282", "r754" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r123" ] }, "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net carrying value, before cumulative allowance for credit losses", "label": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows", "documentation": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows" } } }, "auth_ref": [] }, "rprx_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SubsequentEventsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 }, "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income attributable to non-controlling interests", "terseLabel": "Less: net income attributable to non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r73", "r127", "r184", "r187", "r229", "r230", "r625", "r896" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification of unrealized gains on available for sale debt securities", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r3", "r102", "r183", "r328" ] }, "rprx_PaymentsToAcquireEquitySecuritiesFNNI": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PaymentsToAcquireEquitySecuritiesFNNI", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of equity securities", "label": "Payments To Acquire Equity Securities, FN-NI", "documentation": "Payments To Acquire Equity Securities, FN-NI" } } }, "auth_ref": [] }, "rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income accretion", "label": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)", "documentation": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary, Sale of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum commitment to fund collaborative arrangement", "label": "Collaborative Arrangement Rights And Obligations, Maximum Commitment To Fund", "documentation": "Collaborative Arrangement Rights And Obligations, Maximum Commitment To Fund" } } }, "auth_ref": [] }, "rprx_RoyalPharmacySelectFinanceTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoyalPharmacySelectFinanceTrustMember", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RPSFT", "label": "Royal Pharmacy Select Finance Trust [Member]", "documentation": "Royal Pharmacy Select Finance Trust" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r48", "r50", "r81", "r82", "r282", "r654", "r754" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r77" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r143", "r150", "r229", "r230", "r270", "r461", "r466", "r634" ] }, "rprx_LongTermFundingPartnershipOptionalAmountUnavailable": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermFundingPartnershipOptionalAmountUnavailable", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term funding partnership, optional amount unavailable", "label": "Long Term Funding Partnership, Optional Amount Unavailable", "documentation": "Long Term Funding Partnership, Optional Amount Unavailable" } } }, "auth_ref": [] }, "rprx_TysabriMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TysabriMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tysabri", "label": "Tysabri [Member]", "documentation": "Tysabri" } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchases of Class A ordinary shares (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r16", "r97", "r98", "r123", "r662", "r736", "r751" ] }, "rprx_AssignmentAgreementBenefitOfPaymentStreamMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AssignmentAgreementBenefitOfPaymentStreamMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assignment Agreement - Benefit of Payment Stream", "label": "Assignment Agreement - Benefit of Payment Stream [Member]", "documentation": "Assignment Agreement - Benefit of Payment Stream" } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage (as a percent)", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "rprx_DebtInstrumentIssuanceAsAPercentOfPar": { "xbrltype": "percentItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtInstrumentIssuanceAsAPercentOfPar", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issued as a percent of par value (as percent)", "label": "Debt Instrument, Issuance As A Percent Of Par", "documentation": "Debt Instrument, Issuance As A Percent Of Par" } } }, "auth_ref": [] }, "rprx_RoyaltyPharmaCollectionTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoyaltyPharmaCollectionTrustMember", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RPCT", "label": "Royalty Pharma Collection Trust [Member]", "documentation": "Royalty Pharma Collection Trust" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Royalty Pharma plc - diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r198", "r235", "r242", "r243", "r244", "r245", "r254", "r257" ] }, "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains/(losses) on initial recognition", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition" } } }, "auth_ref": [] }, "rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AcquisitionOfLimitedPartnershipInterestsInAffiliateMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition Of Limited Partnership Interests In Affiliate", "label": "Acquisition Of Limited Partnership Interests In Affiliate [Member]", "documentation": "Acquisition Of Limited Partnership Interests In Affiliate" } } }, "auth_ref": [] }, "rprx_FundingCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FundingCommitmentsMember", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funding Commitments", "label": "Funding Commitments [Member]", "documentation": "Funding Commitments" } } }, "auth_ref": [] }, "rprx_TrelegyMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TrelegyMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trelegy", "label": "Trelegy [Member]", "documentation": "Trelegy" } } }, "auth_ref": [] }, "us-gaap_MovementInMinorityInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInMinorityInterestRollForward", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "label": "Equity, Attributable to Noncontrolling Interest [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r805" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r77" ] }, "rprx_DerivativeAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DerivativeAssetMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivative Asset [Member]", "documentation": "Derivative Asset" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r557" ] }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value." } } }, "auth_ref": [ "r511" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r847" ] }, "rprx_DebtSecuritiesAvailableForSaleAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtSecuritiesAvailableForSaleAdjustment", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Adjustment", "documentation": "Debt Securities, Available-for-Sale, Adjustment" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "rprx_BristolMyersSquibbMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "BristolMyersSquibbMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bristol-Myers Squibb", "label": "Bristol-Myers Squibb [Member]", "documentation": "Bristol-Myers Squibb" } } }, "auth_ref": [] }, "rprx_OperatingAndPersonnelPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OperatingAndPersonnelPaymentsMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating and Personnel Payments", "label": "Operating and Personnel Payments [Member]", "documentation": "Operating and Personnel Payments" } } }, "auth_ref": [] }, "rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PaymentsToNoncontrollingInterestsRoyaltyReceipts", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to legacy non-controlling interests - royalty receipts", "label": "Payments To Noncontrolling Interests, Royalty Receipts", "documentation": "Payments To Noncontrolling Interests, Royalty Receipts" } } }, "auth_ref": [] }, "rprx_DebtSecuritiesAvailableForSaleAmortizedCostAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAdjustment", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": "rprx_DebtSecuritiesAvailableForSaleAdjustment", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Debt Securities, Available-For-Sale, Amortized Cost, Adjustment", "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Adjustment" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value." } } }, "auth_ref": [ "r511" ] }, "rprx_ProceedsFromExerciseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ProceedsFromExerciseFee", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds exercise fee", "label": "Proceeds From Exercise Fee", "documentation": "Proceeds From Exercise Fee" } } }, "auth_ref": [] }, "rprx_MilestonePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "MilestonePaymentReceived", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment received", "label": "Milestone Payment Received", "documentation": "Milestone Payment Received" } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r942" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r121", "r122", "r123", "r173", "r174", "r175", "r263", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r659", "r660", "r661", "r662", "r777", "r880", "r901" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Royalty Pharma plc", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r105", "r116", "r138", "r163", "r184", "r187", "r191", "r209", "r219", "r223", "r224", "r225", "r226", "r229", "r230", "r253", "r265", "r273", "r277", "r279", "r334", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r500", "r521", "r626", "r712", "r734", "r735", "r767", "r801", "r936" ] }, "rprx_FinancingReceivableUnapprovedFinancialAssetsHeldAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancingReceivableUnapprovedFinancialAssetsHeldAtCost", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing receivable, unapproved financial assets held at cost", "label": "Financing Receivable, Unapproved Financial Assets Held At Cost", "documentation": "Financing Receivable, Unapproved Financial Assets Held At Cost" } } }, "auth_ref": [] }, "rprx_OperatingAndPersonalPaymentCalculationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OperatingAndPersonalPaymentCalculationAmount", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount calculated for operating and personal payment", "label": "Operating and Personal Payment Calculation, Amount", "documentation": "Operating and Personal Payment Calculation, Amount" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r173", "r174", "r175", "r263", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r659", "r660", "r661", "r662", "r777", "r880", "r901" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r847" ] }, "rprx_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, After Year Four", "documentation": "Long-Term Debt, Maturity, After Year Four" } } }, "auth_ref": [] }, "rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoyaltyDistributionPayableToRPSelectFinanceTrustMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payable to RPSFT", "label": "Royalty Distribution Payable to RP Select Finance Trust [Member]", "documentation": "Royalty Distribution Payable to RP Select Finance Trust" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Royalty Pharma plc - basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r198", "r223", "r224", "r225", "r226", "r233", "r234", "r254", "r257", "r265", "r273", "r277", "r279", "r767" ] }, "rprx_NumberOfDividendPayments": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "NumberOfDividendPayments", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of dividend payments", "label": "Number Of Dividend Payments", "documentation": "Number Of Dividend Payments" } } }, "auth_ref": [] }, "rprx_RochesEvrysdiMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RochesEvrysdiMember", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Roche\u2019s Evrysdi", "label": "Roche\u2019s Evrysdi [Member]", "documentation": "Roche\u2019s Evrysdi" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r805" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average Class A ordinary shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r420", "r428", "r452", "r453", "r454", "r565", "r589", "r641", "r681", "r682", "r742", "r743", "r744", "r745", "r747", "r756", "r757", "r768", "r777", "r783", "r789", "r792", "r932", "r938", "r978", "r979", "r980", "r981", "r982" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r43", "r662" ] }, "rprx_MerckAssetPhaseIIClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "MerckAssetPhaseIIClinicalTrialMember", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Merck Asset - Phase II Clinical Trial", "label": "Merck Asset - Phase II Clinical Trial [Member]", "documentation": "Merck Asset - Phase II Clinical Trial" } } }, "auth_ref": [] }, "rprx_MarshallUristMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "MarshallUristMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Marshall Urist [Member]", "documentation": "Marshall Urist" } } }, "auth_ref": [] }, "rprx_ExchangeOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ExchangeOfferMember", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange Offer", "label": "Exchange Offer [Member]", "documentation": "Exchange Offer" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements." } } }, "auth_ref": [ "r460", "r969" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r817", "r828", "r838", "r863" ] }, "us-gaap_USGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentDebtSecuritiesMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government securities", "label": "US Government Debt Securities [Member]", "documentation": "Debt securities issued by the United States government." } } }, "auth_ref": [ "r985" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "rprx_FinancialRoyaltyAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancialRoyaltyAssetsMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Royalty Assets", "label": "Financial Royalty Assets [Member]", "documentation": "Financial Royalty Assets" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r428", "r589", "r641", "r681", "r682", "r742", "r743", "r744", "r745", "r747", "r756", "r757", "r768", "r777", "r783", "r789", "r938", "r977", "r978", "r979", "r980", "r981", "r982" ] }, "rprx_PointSevenFivePercentSeniorNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PointSevenFivePercentSeniorNotesDue2023Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Point Seven Five Percent Senior Notes Due 2023", "label": "Point Seven Five Percent Senior Notes Due 2023 [Member]", "documentation": "Point Seven Five Percent Senior Notes Due 2023" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r460", "r969" ] }, "rprx_RoyaltyIncomeOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoyaltyIncomeOtherMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other Royalty Income", "label": "Royalty Income, Other [Member]", "documentation": "Royalty Income, Other" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r420", "r428", "r452", "r453", "r454", "r565", "r589", "r641", "r681", "r682", "r742", "r743", "r744", "r745", "r747", "r756", "r757", "r768", "r777", "r783", "r789", "r792", "r932", "r938", "r978", "r979", "r980", "r981", "r982" ] }, "rprx_LongTermFundingPartnershipCovenantRequiredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermFundingPartnershipCovenantRequiredAmount", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Required amount to be drawn", "label": "Long Term Funding Partnership, Covenant, Required Amount", "documentation": "Long Term Funding Partnership, Covenant, Required Amount" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of outstanding notes", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/EarningsperShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r212", "r213", "r385", "r414", "r554", "r761", "r763" ] }, "rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OnePointTwoZeroPercentSeniorNotesDue2025Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Point Two Zero Percent Senior Notes Due 2025", "label": "One Point Two Zero Percent Senior Notes Due 2025 [Member]", "documentation": "One Point Two Zero Percent Senior Notes Due 2025" } } }, "auth_ref": [] }, "rprx_LongTermFundingPartnershipNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermFundingPartnershipNumberOfTranches", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term funding partnership, number of tranches", "label": "Long Term Funding Partnership, Number of Tranches", "documentation": "Long Term Funding Partnership, Number of Tranches" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r428", "r589", "r641", "r681", "r682", "r742", "r743", "r744", "r745", "r747", "r756", "r757", "r768", "r777", "r783", "r789", "r938", "r977", "r978", "r979", "r980", "r981", "r982" ] }, "rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple": { "xbrltype": "pureItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Installment repayments, percentage of amount drawn", "label": "Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple", "documentation": "Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple" } } }, "auth_ref": [] }, "rprx_TevaPharmaceuticalsInternationalGMBHMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TevaPharmaceuticalsInternationalGMBHMember", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Teva Pharmaceuticals International GMBH", "label": "Teva Pharmaceuticals International GMBH [Member]", "documentation": "Teva Pharmaceuticals International GMBH" } } }, "auth_ref": [] }, "rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtSecuritiesAvailableForSaleLiabilityCurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": "rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available for sale debt securities, liabilities current", "label": "Debt Securities, Available For Sale, Liability, Current", "documentation": "Debt Securities, Available For Sale, Liability, Current" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized repurchase amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r456", "r457", "r458", "r669", "r905", "r906", "r907", "r972", "r993" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r557" ] }, "rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ThreePointFiveFivePercentSeniorNotesDue2050Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Point Five Five Percent Senior Notes Due 2050", "label": "Three Point Five Five Percent Senior Notes Due 2050 [Member]", "documentation": "Three Point Five Five Percent Senior Notes Due 2050" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r842" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars/pounds per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r98" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Losses on equity securities", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r633", "r927" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r193", "r209", "r266", "r267", "r272", "r275", "r276", "r280", "r281", "r282", "r334", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r521", "r613", "r936" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r152", "r173", "r174", "r175", "r209", "r236", "r241", "r255", "r257", "r263", "r264", "r334", "r372", "r374", "r375", "r376", "r379", "r380", "r412", "r413", "r415", "r416", "r418", "r521", "r659", "r660", "r661", "r662", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r691", "r713", "r736", "r748", "r749", "r750", "r751", "r752", "r880", "r901", "r908" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r166" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r846" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://royaltypharma.com/role/EarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Earnings Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r909" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r865" ] }, "rprx_CysticFibrosisFranchiseMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CysticFibrosisFranchiseMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cystic fibrosis franchise", "label": "Cystic Fibrosis Franchise [Member]", "documentation": "Cystic Fibrosis Franchise" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r48", "r50", "r81", "r82", "r282", "r754" ] }, "rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets", "label": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense", "documentation": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r101", "r133", "r621", "r787", "r903", "r929", "r973" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/EarningsperShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r212", "r213", "r385", "r414", "r554", "r762", "r763" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r854" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gains)/losses on equity securities", "negatedTerseLabel": "(Gains)/losses on equity securities", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r632", "r927" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury interests", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r31", "r66", "r67" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r846" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r846" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r819", "r827", "r837", "r854", "r862", "r866", "r874" ] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableGross", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Value", "label": "Financing Receivable, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r149", "r154", "r155", "r176", "r353", "r358", "r769", "r770", "r891", "r930" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://royaltypharma.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Borrowings", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r28", "r62", "r65", "r83", "r84", "r86", "r91", "r121", "r122", "r773", "r775", "r904" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r19", "r76", "r395", "r773", "r774" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r867" ] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Indirect Cash Flow", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r112" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r868" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Related Party Transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_FinanceReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceReceivablesMember", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of Financial royalty assets", "label": "Financing Receivable [Member]", "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty at Fair Value", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r941" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurpose" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Purpose", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r94", "r125", "r655", "r656" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r854" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r865" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (as percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_ForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForwardContractsMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forwards", "label": "Forward Contracts [Member]", "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date." } } }, "auth_ref": [ "r971" ] }, "rprx_AvillionIMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AvillionIMember", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avillion I", "label": "Avillion I [Member]", "documentation": "Avillion I" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r819", "r827", "r837", "r854", "r862", "r866", "r874" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r815", "r826", "r836", "r861" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r865" ] }, "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-operating income (expense)", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Non-Operating Income (Loss)", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Non-Operating Income (Loss)" } } }, "auth_ref": [] }, "us-gaap_TradingSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradingSecuritiesDebt", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0, "order": 1.0 }, "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Debt Securities, Trading", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r170", "r760", "r910" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payable", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "rprx_PaymentsToNoncontrollingInterestsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PaymentsToNoncontrollingInterestsOther", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to legacy non-controlling interests - other", "label": "Payments To Noncontrolling Interests, Other", "documentation": "Payments To Noncontrolling Interests, Other" } } }, "auth_ref": [] }, "rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RPSFT", "label": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]", "documentation": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r511" ] }, "us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on equity securities still held", "label": "Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held." } } }, "auth_ref": [ "r510" ] }, "rprx_OtherRoyaltyIncomeReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OtherRoyaltyIncomeReceivableCurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other royalty income receivable", "label": "Other Royalty Income Receivable, Current", "documentation": "Other Royalty Income Receivable, Current" } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r865" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for royalties", "label": "Payments for Royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r7" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r853" ] }, "rprx_DeferredSharesParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DeferredSharesParOrStatedValuePerShare", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock, par value (in dollars per share)", "label": "Deferred Shares, Par or Stated Value Per Share", "documentation": "Deferred Shares, Par or Stated Value Per Share" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r17", "r78" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r865" ] }, "rprx_OptionToAcquireRetainedRoyaltiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OptionToAcquireRetainedRoyaltiesAmount", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to acquire retained royalties, amount", "label": "Option To Acquire Retained Royalties, Amount", "documentation": "Option To Acquire Retained Royalties, Amount" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r17", "r78" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the period", "periodEndLabel": "Balance at the end of the period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r817", "r828", "r838", "r863" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r28" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r866" ] }, "rprx_CommonStockQuarterlyConversionBasis": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CommonStockQuarterlyConversionBasis", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly conversion basis (in shares)", "label": "Common Stock, Quarterly Conversion Basis", "documentation": "Common Stock, Quarterly Conversion Basis" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r854" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term (in years)", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r854" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Available for Sale Debt Securities", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r865" ] }, "rprx_NoncontrollingInterestIncreaseFromContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "NoncontrollingInterestIncreaseFromContributions", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions", "label": "Noncontrolling Interest, Increase from Contributions", "documentation": "Noncontrolling Interest, Increase from Contributions" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gains/(losses) on available for sale debt securities included in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r507" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of available for sale debt securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r38", "r199", "r294" ] }, "rprx_NumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "NumberOfTranches", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Number Of Tranches", "documentation": "Number Of Tranches" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r842" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r866" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "rprx_RedeemableStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RedeemableStockRedemptionPricePerShare", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable stock, redemption price (in pound per share)", "label": "Redeemable Stock, Redemption Price Per Share", "documentation": "Redeemable Stock, Redemption Price Per Share" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income/(loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from available for sale debt securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r37", "r199", "r294", "r327" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r30" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r874" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payable", "label": "Increase (Decrease) in Interest Payable, Net", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r8" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r118", "r366", "r367", "r755", "r933" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transfer out of level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r509" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r298", "r361", "r615" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r875" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Ordinary Shares", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r993" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Royalty Pharma plc", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r36", "r186", "r188", "r196", "r611", "r630" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development funding expense", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r93", "r459", "r983" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r876" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r875" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r48", "r50", "r81", "r82", "r282", "r754", "r882" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r812", "r823", "r833", "r858" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r56", "r57" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r877" ] }, "us-gaap_UnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnsecuredDebtMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Debt", "label": "Unsecured Debt [Member]", "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsDomain", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Domain]", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r68", "r97", "r98", "r123" ] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsAxis", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Axis]", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r808", "r878" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares", "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B ordinary shares exchangeable for Class A ordinary shares (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met." } } }, "auth_ref": [ "r238", "r239", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r257" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r808", "r878" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested RSUs (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r237", "r238", "r240", "r257", "r429" ] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Losses/(gains) on derivative financial instruments", "label": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": [ "r9", "r730", "r731", "r732", "r733", "r746" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r808", "r878" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0, "order": 4.0 }, "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available for sale debt securities", "verboseLabel": "Available for sale debt securities, current", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r295", "r361" ] }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units." } } }, "auth_ref": [] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Ordinary Shares", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r993" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r810", "r821", "r831", "r856" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding borrowings", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r21", "r131", "r986" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r98" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "negatedNetLabel": "Less: Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r171" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchased and retired value during the period", "label": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r16", "r97", "r98", "r123" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per Class A ordinary share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r197", "r223", "r224", "r225", "r226", "r227", "r236", "r255", "r256", "r257", "r261", "r499", "r500", "r612", "r631", "r765" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r98", "r618", "r787" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r120", "r124" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r330", "r331", "r333" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r214", "r399" ] }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange offering, ownership percentage", "label": "Sale of Stock, Percentage of Ownership before Transaction", "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r265", "r273", "r277", "r279", "r767" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, outstanding (in shares)", "terseLabel": "Common shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r98", "r691", "r710", "r993", "r994" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r811", "r822", "r832", "r857" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r17" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r214", "r399" ] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliates" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Consolidated Affiliates", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r151", "r332", "r335", "r881" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r11", "r794", "r795", "r796", "r797" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt securities", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r790", "r791", "r794", "r795", "r796", "r797", "r989", "r993" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r812", "r823", "r833", "r858" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r16", "r97", "r98", "r123" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r214", "r399" ] }, "rprx_OptionToSellRetainedRoyaltiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OptionToSellRetainedRoyaltiesAmount", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to sell retained royalties, amount", "label": "Option To Sell Retained Royalties, Amount", "documentation": "Option To Sell Retained Royalties, Amount" } } }, "auth_ref": [] }, "rprx_NumberOfNoncontrollingInterestsCreated": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "NumberOfNoncontrollingInterestsCreated", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of noncontrolling interests created", "label": "Number Of Noncontrolling Interests Created", "documentation": "Number Of Noncontrolling Interests Created" } } }, "auth_ref": [] }, "rprx_DeferredSharesSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DeferredSharesSharesOutstanding", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock, outstanding (in shares)", "label": "Deferred Shares, Shares, Outstanding", "documentation": "Deferred Shares, Shares, Outstanding" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r58" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense/(income)", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "rprx_XtandiMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "XtandiMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Xtandi", "label": "Xtandi [Member]", "documentation": "Xtandi" } } }, "auth_ref": [] }, "rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ProceedsFromIssuanceOfEquitySecuritiesFNNI", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from equity securities", "label": "Proceeds From Issuance Of Equity Securities, FN-NI", "documentation": "Proceeds From Issuance Of Equity Securities, FN-NI" } } }, "auth_ref": [] }, "rprx_OperatingAndPersonalPaymentCalculationPercent": { "xbrltype": "percentItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OperatingAndPersonalPaymentCalculationPercent", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent calculated for operating and personal payment", "label": "Operating and Personal Payment Calculation, Percent", "documentation": "Operating and Personal Payment Calculation, Percent" } } }, "auth_ref": [] }, "rprx_FundingAgreementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FundingAgreementAmount", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funding agreement amount", "label": "Funding Agreement Amount", "documentation": "Funding Agreement Amount" } } }, "auth_ref": [] }, "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition": { "xbrltype": "pureItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum consolidated leverage ratio following qualifying material acquisition", "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition", "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "rprx_ClassRRedeemableStockMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ClassRRedeemableStockMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class R Redeemable Shares", "label": "Class R Redeemable Stock [Member]", "documentation": "Class R Redeemable Stock" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r503", "r504", "r512" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average coupon rate (as percent)", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ProceedsFromNoncontrollingInterestsResearchAndDevelopment", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from legacy non-controlling interests - R&D", "label": "Proceeds From Noncontrolling Interests, Research And Development", "documentation": "Proceeds From Noncontrolling Interests, Research And Development" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "rprx_RoryRiggsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoryRiggsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rory Riggs [Member]", "documentation": "Rory Riggs" } } }, "auth_ref": [] }, "rprx_RoyaltyPharmaInvestmentsOldRPIMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoyaltyPharmaInvestmentsOldRPIMember", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Old RPI", "label": "Royalty Pharma Investments (Old RPI) [Member]", "documentation": "Royalty Pharma Investments (Old RPI)" } } }, "auth_ref": [] }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple": { "xbrltype": "pureItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtSecuritiesAvailableForSaleRedemptionPriceMultiple", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price, percentage", "label": "Debt Securities, Available-For-Sale, Redemption Price, Multiple", "documentation": "Debt Securities, Available-For-Sale, Redemption Price, Multiple" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r117", "r207" ] }, "rprx_AccruedRoyaltyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AccruedRoyaltyReceivable", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalty receivable", "label": "Accrued Royalty Receivable", "documentation": "Accrued Royalty Receivable" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r51", "r52", "r53", "r144", "r145", "r147", "r148" ] }, "us-gaap_CreditLossFinancialInstrumentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossFinancialInstrumentTextBlock", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "label": "Credit Loss, Financial Instrument [Text Block]", "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security." } } }, "auth_ref": [ "r287", "r289", "r347", "r355", "r356", "r357", "r360", "r362", "r363" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r218", "r219", "r220", "r221", "r222", "r225", "r231", "r261", "r291", "r292", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r365", "r456", "r457", "r458", "r462", "r463", "r464", "r465", "r467", "r468", "r469", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r516", "r517", "r522", "r523", "r524", "r525", "r534", "r535", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r591", "r592", "r593", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r657" ] }, "rprx_ImbruvicaMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ImbruvicaMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Imbruvica", "label": "Imbruvica [Member]", "documentation": "Imbruvica" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0, "order": 2.0 }, "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": [ "r518" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average Class A ordinary shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r235", "r257" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r164", "r179", "r209", "r334", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r472", "r476", "r521", "r787", "r936", "r937", "r975" ] }, "us-gaap_FinancingReceivablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivablesTextBlock", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Royalty Assets", "label": "Financing Receivables [Text Block]", "documentation": "The entire disclosure for financing receivable." } } }, "auth_ref": [ "r283", "r286", "r288", "r290", "r768" ] }, "rprx_AvillionEntitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AvillionEntitiesMember", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avillion Entities", "label": "Avillion Entities [Member]", "documentation": "Avillion Entities" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r503", "r504", "r512" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNet", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current and non-current financial royalty assets, net", "terseLabel": "Total current and non-current financial royalty assets, net", "label": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r284", "r358", "r699" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items." } } }, "auth_ref": [ "r45", "r158", "r159", "r160", "r161", "r162", "r218", "r219", "r220", "r221", "r222", "r225", "r231", "r261", "r291", "r292", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r365", "r456", "r457", "r458", "r462", "r463", "r464", "r465", "r467", "r468", "r469", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r516", "r517", "r522", "r523", "r524", "r525", "r534", "r535", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r591", "r592", "r593", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r657" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average Class A ordinary shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r233", "r257" ] }, "rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate royalty amount when patents cease", "label": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents", "documentation": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents" } } }, "auth_ref": [] }, "rprx_SeltorexantOlpasiranPelacarsenAndKarXTMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "SeltorexantOlpasiranPelacarsenAndKarXTMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seltorexant, Olpasiran, Pelacarsen and KarXT", "label": "Seltorexant, Olpasiran, Pelacarsen And KarXT [Member]", "documentation": "Seltorexant, Olpasiran, Pelacarsen And KarXT" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "rprx_IncreaseDecreaseInFinancialRoyaltyAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "IncreaseDecreaseInFinancialRoyaltyAssets", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income from financial royalty assets", "label": "Increase (Decrease) In Financial Royalty Assets", "documentation": "Increase (Decrease) In Financial Royalty Assets" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r347", "r348", "r353", "r354", "r357", "r362", "r363", "r364", "r406", "r417", "r489", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r628", "r771", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r923", "r924", "r925", "r926" ] }, "rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "IncreaseDecreaseInOtherRoyaltyIncomeReceivable", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other royalty income receivable", "label": "Increase (Decrease) In Other Royalty Income Receivable", "documentation": "Increase (Decrease) In Other Royalty Income Receivable" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r210", "r211", "r551", "r552", "r553", "r554", "r684", "r685", "r686", "r687", "r688", "r709", "r711", "r741" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "rprx_TerranceCoyneMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TerranceCoyneMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Terrance Coyne [Member]", "documentation": "Terrance Coyne" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income/(loss):", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r16", "r20", "r185", "r188", "r194", "r526", "r527", "r532", "r609", "r627", "r894", "r895" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements and Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r502" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesRollForward", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "rprx_PaymentsForMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PaymentsForMilestones", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Milestone payments", "label": "Payments For Milestones", "documentation": "Payments For Milestones" } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r76", "r78" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets", "label": "Financing Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss." } } }, "auth_ref": [ "r13", "r351", "r359", "r769" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r395", "r421", "r422", "r423", "r424", "r425", "r426", "r504", "r562", "r563", "r564", "r773", "r774", "r780", "r781", "r782" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Beginning balance", "negatedPeriodEndLabel": "Ending balance", "label": "Financing Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": [ "r12", "r154", "r156", "r157", "r177", "r346", "r349", "r352", "r984" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "IncreaseDecreaseInCashCollectionsOnFinancingReceivables", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash collected on financial royalty assets", "label": "Increase (Decrease) In Cash Collections On Financing Receivables", "documentation": "Increase (Decrease) In Cash Collections On Financing Receivables" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r395", "r421", "r426", "r504", "r563", "r773", "r774", "r780", "r781", "r782" ] }, "rprx_OtherFinancialRoyaltyAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OtherFinancialRoyaltyAssetMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Financial Royalty Asset [Member]", "documentation": "Other Financial Royalty Asset" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Financial royalty assets, net", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gains on available for sale debt securities", "negatedLabel": "Gains on available for sale debt securities", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r915", "r916" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r395", "r421", "r426", "r504", "r562", "r780", "r781", "r782" ] }, "rprx_DevelopmentFundingBondMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DevelopmentFundingBondMember", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development fund bond", "label": "Development Funding Bond [Member]", "documentation": "Development fund bond" } } }, "auth_ref": [] }, "rprx_OvernightBankFundingRateMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OvernightBankFundingRateMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Overnight Bank Funding Rate", "label": "Overnight Bank Funding Rate [Member]", "documentation": "Overnight Bank Funding Rate" } } }, "auth_ref": [] }, "rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other royalty cash collections", "label": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables", "documentation": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r503", "r504", "r505", "r506", "r513" ] }, "rprx_CytokineticsFundingCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CytokineticsFundingCommitmentMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cytokinetics Funding Commitment", "label": "Cytokinetics Funding Commitment [Member]", "documentation": "Cytokinetics Funding Commitment" } } }, "auth_ref": [] }, "rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ThreePointThreeZeroPercentSeniorNotesDue2040Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Point Three Zero Percent Senior Notes Due 2040", "label": "Three Point Three Zero Percent Senior Notes Due 2040 [Member]", "documentation": "Three Point Three Zero Percent Senior Notes Due 2040" } } }, "auth_ref": [] }, "rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cumulative allowance for credit losses", "terseLabel": "Cumulative allowance for credit losses", "label": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)", "documentation": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://royaltypharma.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Repayments of Debt by Year", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r10" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r395", "r421", "r422", "r423", "r424", "r425", "r426", "r504", "r564", "r773", "r774", "r780", "r781", "r782" ] }, "rprx_RateValueOfSecurityInvestments": { "xbrltype": "percentItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RateValueOfSecurityInvestments", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly payments to affiliates, percent of security investment (as percent)", "label": "Rate, Value Of Security Investments", "documentation": "Rate, Value Of Security Investments" } } }, "auth_ref": [] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "terseLabel": "Shares, outstanding (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r816", "r827", "r837", "r854", "r862" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r911" ] }, "rprx_ContinuingInvestorsPartnershipMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ContinuingInvestorsPartnershipMember", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing Investors Partnerships", "label": "Continuing Investors Partnership [Member]", "documentation": "Continuing Investors Partnership" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r872" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r842" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r99", "r787", "r991" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r869" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r168" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r846" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r879" ] }, "rprx_PTCTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PTCTherapeuticsIncMember", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PTC Therapeutics, Inc.", "label": "PTC Therapeutics, Inc. [Member]", "documentation": "PTC Therapeutics, Inc." } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r845" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r892" ] }, "rprx_IntangibleRoyaltyAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "IntangibleRoyaltyAssetsMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Royalty Assets", "label": "Intangible Royalty Assets [Member]", "documentation": "Intangible Royalty Assets" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r152", "r173", "r174", "r175", "r209", "r236", "r241", "r255", "r257", "r263", "r264", "r334", "r372", "r374", "r375", "r376", "r379", "r380", "r412", "r413", "r415", "r416", "r418", "r521", "r659", "r660", "r661", "r662", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r691", "r713", "r736", "r748", "r749", "r750", "r751", "r752", "r880", "r901", "r908" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r844" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r470" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r870" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses, net", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r106" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r843" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r108", "r110" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r871" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r29", "r90", "r617", "r690" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r92", "r146" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r872" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r843" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share." } } }, "auth_ref": [ "r46", "r47", "r236", "r241", "r255" ] }, "rprx_TheNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TheNotesMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Notes", "label": "The Notes [Member]", "documentation": "The Notes" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r844" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "rprx_NumberOfNoncontrollingInterests": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "NumberOfNoncontrollingInterests", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of noncontrolling interests", "label": "Number Of Noncontrolling Interests", "documentation": "Number Of Noncontrolling Interests" } } }, "auth_ref": [] }, "rprx_CytokineticsCommercialLaunchFundingMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CytokineticsCommercialLaunchFundingMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cytokinetics Commercial Launch Funding", "label": "Cytokinetics Commercial Launch Funding [Member]", "documentation": "Cytokinetics Commercial Launch Funding" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions of other financial assets", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r113" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions from equity method investees", "verboseLabel": "Distributions from equity method investees", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r6", "r9", "r104", "r622" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r845" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r874" ] }, "rprx_ProceedsFromNoncontrollingInterestsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ProceedsFromNoncontrollingInterestsOther", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from non-controlling interests - other", "label": "Proceeds From Noncontrolling Interests, Other", "documentation": "Proceeds From Noncontrolling Interests, Other" } } }, "auth_ref": [] }, "rprx_FormerOperatingAndPersonnelPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FormerOperatingAndPersonnelPaymentsMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Former Operating and Personnel Payments", "label": "Former Operating and Personnel Payments [Member]", "documentation": "Former Operating and Personnel Payments" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per Class A ordinary share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r197", "r223", "r224", "r225", "r226", "r227", "r233", "r236", "r255", "r256", "r257", "r261", "r499", "r500", "r612", "r631", "r765" ] }, "rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write-off of cumulative allowance", "label": "Financing Receivable Change In Present Value, Write-off Cumulative Allowance", "documentation": "Financing Receivable Change In Present Value, Write-off Cumulative Allowance" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2023", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r904" ] }, "rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payable to Legacy Investors Partnerships", "label": "Royalty Distribution Payable to Legacy Investors Partnerships [Member]", "documentation": "Royalty Distribution Payable to Legacy Investors Partnerships" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r236", "r241", "r255" ] }, "rprx_A2020EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "A2020EquityIncentivePlanMember", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Equity Incentive Plan", "label": "2020 Equity Incentive Plan [Member]", "documentation": "2020 Equity Incentive Plan" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r427", "r551", "r552", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r684", "r685", "r686", "r687", "r688", "r709", "r711", "r741", "r974" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r845" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r49", "r282" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requisite service period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r784" ] }, "rprx_TremfyaMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TremfyaMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tremfya", "label": "Tremfya [Member]", "documentation": "Tremfya" } } }, "auth_ref": [] }, "rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfCapital", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of capital", "label": "Collaborative Arrangement, Rights and Obligations, Payment of Capital", "documentation": "Collaborative Arrangement, Rights and Obligations, Payment of Capital" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Available for Sale Debt Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r128", "r140", "r141", "r153", "r293", "r296", "r514", "r515" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "rprx_RelatedPartyTransactionInitialTerm": { "xbrltype": "durationItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RelatedPartyTransactionInitialTerm", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial term (in years)", "label": "Related Party Transaction, Initial Term", "documentation": "Related Party Transaction, Initial Term" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_ProvisionForOtherCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForOtherCreditLosses", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for changes in expected cash flows from financial royalty assets", "terseLabel": "Provision for changes in expected cash flows from financial royalty assets", "label": "Provision for Other Credit Losses", "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions." } } }, "auth_ref": [ "r8", "r135" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Concentration risk (as percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r48", "r50", "r81", "r82", "r282" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Class A ordinary share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "rprx_AssignmentAgreementFundingObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AssignmentAgreementFundingObligationsMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assignment Agreement - Funding Obligations", "label": "Assignment Agreement - Funding Obligations [Member]", "documentation": "Assignment Agreement - Funding Obligations" } } }, "auth_ref": [] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r845" ] }, "rprx_DeferredSharesValueIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DeferredSharesValueIssued", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred shares, $0.000001 par value; issued and outstanding: 2023\u2013382,837 and 2022\u2013371,325", "label": "Deferred Shares, Value, Issued", "documentation": "Deferred Shares, Value, Issued" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r807" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r203" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate volatility (as percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r452" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r280", "r590", "r635", "r636", "r637", "r638", "r639", "r640", "r758", "r778", "r788", "r883", "r934", "r935", "r940", "r987" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r406", "r417", "r489", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r628", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r923", "r924", "r925", "r926" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r203" ] }, "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemptions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r846" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-adjusted discount rate (as percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r454" ] }, "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash collections from intangible royalty assets", "label": "Proceeds From Cash Collections From Royalties Received On Intangible Assets", "documentation": "Proceeds From Cash Collections From Royalties Received On Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r271", "r329", "r893", "r928" ] }, "rprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardCovenantPercentageOfNetEconomicProfit": { "xbrltype": "percentItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCovenantPercentageOfNetEconomicProfit", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of net economic profit", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Covenant, Percentage of Net Economic Profit", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Covenant, Percentage of Net Economic Profit" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r114", "r115", "r116" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount and issuance costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r403", "r537", "r775", "r776", "r900" ] }, "us-gaap_ProvisionForLoanLossesExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForLoanLossesExpensed", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Current period provision for credit losses, net", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable." } } }, "auth_ref": [ "r350", "r608" ] }, "rprx_TheravanceBiopharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "TheravanceBiopharmaIncMember", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Theravance Biopharma, Inc.", "label": "Theravance Biopharma, Inc. [Member]", "documentation": "Theravance Biopharma, Inc." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "rprx_RateAdjustedCashReceipts": { "xbrltype": "percentItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RateAdjustedCashReceipts", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly payments to affiliates, percent of adjusted cash receipts (as percent)", "label": "Rate, Adjusted Cash Receipts", "documentation": "Rate, Adjusted Cash Receipts" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r840" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455" ] }, "rprx_FinancingReceivablesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancingReceivablesFairValueDisclosure", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial royalty assets, net", "label": "Financing Receivables, Fair Value Disclosure", "documentation": "Financing Receivables, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r114" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r280", "r590", "r635", "r636", "r637", "r638", "r639", "r640", "r758", "r778", "r788", "r883", "r934", "r935", "r940", "r987" ] }, "rprx_AvillionIIMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AvillionIIMember", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avillion II", "label": "Avillion II [Member]", "documentation": "Avillion II" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r846" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r874" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r44", "r114", "r206" ] }, "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum consolidated leverage ratio", "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio", "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio" } } }, "auth_ref": [] }, "rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtSecuritiesAvailableForSaleLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": -1.0, "order": 3.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Available for sale debt securities, liabilities noncurrent", "totalLabel": "Available for sale debt securities, liabilities noncurrent", "label": "Debt Securities, Available For Sale, Liability, Noncurrent", "documentation": "Debt Securities, Available For Sale, Liability, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://royaltypharma.com/role/EarningsperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r232", "r258", "r259", "r260" ] }, "rprx_SeniorNotesDue2051Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "SeniorNotesDue2051Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes Due 2051", "label": "Senior Notes Due 2051 [Member]", "documentation": "Senior Notes Due 2051" } } }, "auth_ref": [] }, "rprx_LegacyInvestorsPartnershipsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LegacyInvestorsPartnershipsMember", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy Investors Partnerships", "label": "Legacy Investors Partnerships [Member]", "documentation": "Legacy Investors Partnerships" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r849" ] }, "rprx_OnePointSevenFivePercentSeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "OnePointSevenFivePercentSeniorNotesDue2027Member", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Point Seven Five Percent Senior Notes Due 2027", "label": "One Point Seven Five Percent Senior Notes Due 2027 [Member]", "documentation": "One Point Seven Five Percent Senior Notes Due 2027" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r850" ] }, "rprx_DeferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DeferredSharesMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Shares", "label": "Deferred Shares [Member]", "documentation": "Deferred Shares" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issued, amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r84", "r86", "r382", "r538", "r773", "r774" ] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared and paid (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r123" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r814", "r825", "r835", "r860" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://royaltypharma.com/role/Borrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r119", "r208", "r381", "r387", "r388", "r389", "r390", "r391", "r392", "r397", "r404", "r405", "r407" ] }, "us-gaap_DividendsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCash", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends", "label": "Dividends, Cash", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": [ "r4", "r123" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r116" ] }, "rprx_EvrysdiMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "EvrysdiMember", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Evrysdi", "label": "Evrysdi [Member]", "documentation": "Evrysdi" } } }, "auth_ref": [] }, "rprx_LegacyNonControllingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LegacyNonControllingInterestsMember", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy non-controlling interests", "label": "Legacy Non Controlling Interests [Member]", "documentation": "Legacy Non Controlling Interests" } } }, "auth_ref": [] }, "rprx_RoyaltyPharmaPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RoyaltyPharmaPlcMember", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Pharma plc", "label": "Royalty Pharma plc [Member]", "documentation": "Royalty Pharma plc" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r848" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other exchanges", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r71", "r764" ] }, "rprx_IncreaseDecreaseInAccruedRoyaltyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "IncreaseDecreaseInAccruedRoyaltyReceivable", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued royalty receivable", "label": "Increase (Decrease) In Accrued Royalty Receivable", "documentation": "Increase (Decrease) In Accrued Royalty Receivable" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r395", "r773", "r774" ] }, "rprx_NumberOfPartnershipInterestsAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "NumberOfPartnershipInterestsAcquired", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of limited partnership interest acquired (in shares)", "label": "Number of Partnership Interests Acquired", "documentation": "Number of Partnership Interests Acquired" } } }, "auth_ref": [] }, "rprx_DeferredSharesSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DeferredSharesSharesIssued", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock, issued (in shares)", "label": "Deferred Shares, Shares, Issued", "documentation": "Deferred Shares, Shares, Issued" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt discount and issuance costs", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r83", "r86", "r939" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value, net", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r79", "r80" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r519" ] }, "rprx_LongTermFundingPartnershipExpectedPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "LongTermFundingPartnershipExpectedPayment", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term funding partnership, expected payment", "label": "Long Term Funding Partnership, Expected Payment", "documentation": "Long Term Funding Partnership, Expected Payment" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expense/(income), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r109" ] }, "rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cumulative allowance for changes in expected cash flows", "label": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows", "documentation": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows" } } }, "auth_ref": [] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofEstimatedFairValuesBasedonLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r395", "r520", "r773", "r774" ] }, "rprx_PaymentsForOperatingCostsAndProfessionalServices": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PaymentsForOperatingCostsAndProfessionalServices", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for operating and professional costs", "label": "Payments For Operating Costs and Professional Services", "documentation": "Payments For Operating Costs and Professional Services" } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r865" ] }, "rprx_AgreementWithMSCIMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AgreementWithMSCIMember", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement with MSCI", "label": "Agreement with MSCI [Member]", "documentation": "Agreement with MSCI" } } }, "auth_ref": [] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r847" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r214", "r382", "r383", "r384", "r385", "r386", "r388", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r538", "r772", "r773", "r774", "r775", "r776", "r902" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Balance at the beginning of the period", "negatedPeriodEndLabel": "Balance at the end of the period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Treasury Interests", "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r21", "r95", "r96", "r130", "r131", "r214", "r382", "r383", "r384", "r385", "r386", "r388", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r538", "r772", "r773", "r774", "r775", "r776", "r902" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Preparation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "rprx_PaymentsForUpfrontDevelopmentStageFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PaymentsForUpfrontDevelopmentStageFunding", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Development-stage funding payments - upfront and milestone", "label": "Payments For Upfront Development Stage Funding", "documentation": "Payments For Upfront Development Stage Funding" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r502", "r513" ] }, "us-gaap_FederalFundsPurchasedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalFundsPurchasedMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal Funds Rate", "label": "Federal Funds Purchased [Member]", "documentation": "Short term borrowing where a bank borrows, at the federal funds rate, from another bank." } } }, "auth_ref": [ "r134" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r62", "r65", "r83", "r84", "r86", "r91", "r121", "r122", "r214", "r382", "r383", "r384", "r385", "r386", "r388", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r538", "r772", "r773", "r774", "r775", "r776", "r902" ] }, "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn": { "xbrltype": "durationItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturn", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of return (in years)", "label": "Collaborative Arrangement, Rights and Obligations, Period of Return", "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return" } } }, "auth_ref": [] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r847" ] }, "rprx_PaymentsForOngoingDevelopmentStageFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PaymentsForOngoingDevelopmentStageFunding", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Development-stage funding payments - ongoing", "label": "Payments For Ongoing Development Stage Funding", "documentation": "Payments For Ongoing Development Stage Funding" } } }, "auth_ref": [] }, "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash collections from financial royalty assets", "label": "Proceeds From Cash Collections From Royalties Received On Financing Receivables", "documentation": "Proceeds From Cash Collections From Royalties Received On Financing Receivables" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityOtherShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOtherShares", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other exchanges (in shares)", "label": "Stockholders' Equity, Other Shares", "documentation": "Number of increase (decrease) in shares of stock classified as other." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r165", "r209", "r334", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r473", "r476", "r477", "r521", "r787", "r936", "r975", "r976" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r809", "r820", "r830", "r855" ] }, "rprx_AssetsFairValueDisclosureCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "AssetsFairValueDisclosureCurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Fair Value Disclosure, Current", "documentation": "Assets, Fair Value Disclosure, Current" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r847" ] }, "rprx_PaymentOfDividendsToShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "PaymentOfDividendsToShareholders", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends to shareholders", "terseLabel": "Dividends to shareholders", "label": "Payment Of Dividends To Shareholders", "documentation": "Payment Of Dividends To Shareholders" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r21", "r131", "r408" ] }, "rprx_RPHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "RPHoldingsMember", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RP Holdings", "label": "RP Holdings [Member]", "documentation": "RP Holdings" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r215", "r216", "r217", "r262", "r590", "r658", "r680", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r694", "r695", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r705", "r706", "r707", "r708", "r709", "r711", "r714", "r715", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r793" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price (as percent)", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r18" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r813", "r824", "r834", "r859" ] }, "rprx_NumberOfConsecutiveQuarterlyPayments": { "xbrltype": "integerItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "NumberOfConsecutiveQuarterlyPayments", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of consecutive quarterly payments", "label": "Number Of Consecutive Quarterly Payments", "documentation": "Number Of Consecutive Quarterly Payments" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average effective interest rate (as percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r27", "r84", "r411", "r538" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, stated rate (as percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r383" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r215", "r216", "r217", "r262", "r590", "r658", "r680", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r694", "r695", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r705", "r706", "r707", "r708", "r709", "r711", "r714", "r715", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r793" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r18" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r847" ] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information about timing of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r18" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsSummaryofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsSummaryofRepaymentsofDebtbyYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r28", "r214", "r382", "r383", "r384", "r385", "r386", "r388", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r538", "r772", "r773", "r774", "r775", "r776", "r902" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r899" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r841" ] }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement." } } }, "auth_ref": [ "r970" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r851" ] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior to the applicable par call date", "label": "Debt Instrument, Redemption, Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r18" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r809", "r820", "r830", "r855" ] }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodThreeMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upon occurrence of a change of control triggering event", "label": "Debt Instrument, Redemption, Period Three [Member]", "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r18" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r852" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized(Losses)/Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r302" ] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesMember", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities", "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": [ "r55", "r792", "r995" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r852" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r107", "r715" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Consolidated net income before tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r103", "r137", "r265", "r273", "r277", "r279", "r613", "r623", "r767" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r427", "r551", "r552", "r684", "r685", "r686", "r687", "r688", "r709", "r711", "r741" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Royalty Assets, Net", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r33" ] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative instruments, current", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r180" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r200", "r204", "r205" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/SubsequentEventsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r282", "r779", "r940", "r987", "r988" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r33" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrealized gains on available for sale debt securities", "terseLabel": "Unrealized gains on available for sale debt securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r181", "r182", "r328" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r85" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other commitment", "label": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r804" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r178", "r787" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r805" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating and personnel payments incurred", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value Hierarchy", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r503", "r504" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r44", "r166", "r759" ] }, "rprx_CytokineticsMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "CytokineticsMember", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cytokinetics", "label": "Cytokinetics [Member]", "documentation": "Cytokinetics" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r805" ] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Balance Of Non-controlling Interests", "label": "Schedule of Stockholders Equity [Table Text Block]", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": [ "r16" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r100", "r123", "r619", "r648", "r653", "r663", "r692", "r787" ] }, "rprx_SeniorUnsecuredRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "SeniorUnsecuredRevolvingCreditFacilityMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Revolving Credit Facility", "label": "Senior Unsecured Revolving Credit Facility [Member]", "documentation": "Senior Unsecured Revolving Credit Facility" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of debt", "label": "Repayments of Senior Debt", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": [ "r43" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts of transaction, related parties", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r88", "r551" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from lines of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r40", "r902" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r805" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r806" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r805" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales and maturities of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r74", "r126", "r186", "r188", "r195", "r610", "r629" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r23" ] }, "us-gaap_RelatedPartyTransactionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionRate", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party, rate (as percent)", "label": "Related Party Transaction, Rate", "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties." } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsNoncurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails": { "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative financial instruments", "label": "Derivative Asset, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r180" ] }, "rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://royaltypharma.com/20230930", "localname": "DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum consolidated coverage ratio", "label": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio", "documentation": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio" } } }, "auth_ref": [] }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cumulative Allowance for Changes in Expected Cash Flows", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on financing receivable." } } }, "auth_ref": [ "r54", "r931" ] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r87", "r88", "r716", "r717", "r720" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://royaltypharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r548", "r549", "r550", "r552", "r555", "r664", "r665", "r666", "r718", "r719", "r720", "r739", "r740" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r24", "r209", "r334", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r473", "r476", "r477", "r521", "r689", "r766", "r803", "r936", "r975", "r976" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r129", "r169", "r209", "r265", "r274", "r278", "r334", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r472", "r476", "r521", "r616", "r704", "r787", "r803", "r936", "r937", "r975" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r716", "r717", "r720" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25", "r787" ] }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions from equity method investees", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } } }, "auth_ref": [ "r202", "r897" ] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Financial royalty assets", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r284", "r285", "r607" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of Class A ordinary shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r42" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://royaltypharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Shareholders' equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r69", "r70", "r72", "r160", "r161", "r190", "r215", "r216", "r217", "r220", "r228", "r339", "r345", "r419", "r456", "r457", "r458", "r464", "r465", "r481", "r483", "r484", "r485", "r486", "r488", "r498", "r526", "r528", "r532", "r547", "r645", "r646", "r667", "r693", "r710", "r737", "r738", "r753", "r802", "r903", "r929", "r973", "r993" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "11B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//985-730/tableOfContent" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org//323/tableOfContent" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(c)", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "44", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-44" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "48", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-48" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "48", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-48" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-51" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-52" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-53" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "54", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-54" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "44", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-44" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "44", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-44" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-20/tableOfContent" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-20" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-8" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r880": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r881": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "323", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "(a)", "Publisher": "SEC" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" } } } ZIP 76 0001802768-23-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001802768-23-000029-xbrl.zip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ʖ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

  • ;O+J3NV^O[TS$7*>TRJ2]EA$T41%$P)#: M$,HAL&@IR\H84KLG8F^0Q^J$T3"GH:UB3MTHHZ2)O9M>EHNMGVZVN+Z9'F-" M<? (D81),72-5A[AM\9(:X+NYY(0]VU]NGSQYMH>EI1XI5SD#^G MGY>S\+VTE_LV2ZL9W5L0URF$74!63#OO#.SX">G#=3@]E@).QI8LE">P1WDXAPZ,C"%J)I'5NIMS MV&O9UT>,0^3=8CI86GJP?TL3!'V!B-_$'RC[81.&?"E]J";W ?^\=TD>;+ MH.FJ$/F/M!A)@4Y3DF@,J4H@ D/_J2029"&Y]\JKX.KW_]U&<68,&"CFAXK7 MPP+4W>_ZH\,^%-:\4\Y) =-J)]G;QTIWGCC:?S)OQY.9ZE.%+!4A'1HAEO(@A:FIH; MP2 8)QD+SL>.;4^[K'8F1&@CW1WG78-[C%2:/T>-#M*61H62V-+YGH!-R&WXML'\N1=+N!.JGM][S?+Y":229"*H[AB MJ3Y7"7^R3D.*RB=:)CFFV@TJ#@)ZK!S#MDQKKJ)39QH^93^=_3LF5?B<9?$:43'G#7*0I MI&Y=FCLO>38D:"/DVGO F_E\_&VR+$3>9&&^31.4^J(<)BQA?EG,DONQ&9U# MN$!(&93B% 152%OTK4 ))F1P(<;@.Q&BY\)G0XN6 J^=C;(#Z_O+9<7A1W\Q M_K;,C;@A<5(:XS@/U)6L&4DB[FR$@4_$$RY=TK';3M%CT7,F115!5TQ"6>'< MH/NO\>+[[U_>?=B0-$LBE=5EC#9;[6 FR@1.!)ZXB(*%;N>V>Q8X'T57$&#M M))'E^?!\*<^/^;?QC_'ZO;?/D3],WN0\OABC7-:HT0^FS,<,27*D8B06?9B( M87QV609!C*#=;OL.AG ^Q#B*$HZ7'K)U"K.,HK3V4C/M()A<"HV=+%>8!IPJ M6YH.*6V/_&@59NY ]^K/LX9JK$&WI+MXUA]8%T1'.--ZA@=9@_7W"$T&"+_Q M8=8:F5/6&FHL:&)Q$W2!@"'& ?-"6RV)2:SEUO+\CJV.P(8^,F_,@LW(':IB MM!GW71X\NL;2E_TQ@_9&.,\1_WBSIVX.C/4GZ MR+WZ*,I5^?K=BHRM@HQ'9\<3HVDQI5IQ1.Z=!Y.MAIQ$S%HI+;;[4#\^ _$P M&,^U54,OO>X8HG@$I32:E;D3^>=/>R?3$Z=#MNA(:9*6DM+@*&7@ R4Y)!&L M[U9?==CZKXI E=10>R-Z.T.PTXO?KY',7_Z\''N_!J5"4DID"X26(_Z02S>D M+, %&J4@+D3:[2YEWPIGI_TJHFQP@O5E@0YY>>%5@NR[Z8^?TTFY^EW:6>F\ M)5X+T,SH4D^,N!S:62^,-EI)YJK'JX\".O_8IKY>6G1(OH]I_6UT =7HY',G MH-,.( M5'CBX//83.@C[ 8,^#I+;GXYNUY67:QZK6Y,G,\Y&4E :U+N'(-%\XD>C73) M\$QI8*GV*-6]8$XP5&FXLJ8M)-UB1O/. IHUMFR#0&/XVT 5C3\8I3U4 MQ+4/G3[^+%+\.BT]B#Z7[V>2X@VR=1^SZ%46@1'@9>H:^CWH_025P3*>3 FP MA>YV4MEAL1>NYR8RK7U?? [:'"2M^FW]5M1:E^+O8UJ44"LG)J,\M_N7%+; MGSQJN7\3+VNP8$]=Q;_W0AU?/ILHKH$DPX@7W$Z4B\='I9I(@#!5KQP*>@*43^F.]A6O.Z"ZB*_N!>(,?W_X9J:-I*O)4_ M[?W@$DN2.R&!:U\N#)(!ES%*CCP8629+I-QI)O'STODCWMQ15-Y'JO53R!YPHK>&\N(- M=$U1MYBK\Q#69IYP!V"-Y9SD(R53%*7I*N>N7U<0CR5?7E4/O01=WL>K.V6]5X&C%&!81 )0AL$ MA5C0J:'"1IJ8D+HM!TZ5:E=)48^K_P I5_0.8AHOQP=?_#I9C-?]$\KKB%)/ M3Q5'@D>F /^'!.BWB1B2)Q.):=#J<003T \ MI=6\ISXJ3A5:H,<"Z^>@PSWFMID*^XCL:#<>.6NFB2ZS$4NQ7B(.?#06F&8N M.V)\]MTR%D]_XS%,X)TN-?I(JW)3EL]N\FWE[TDC6$HN@>!L67GMP(8LP'(G MF!$R4M^I\=)3-Y:;!5^\33QX(WTG@NLR;V)2CPD4/ENOKK([#J=X#_ M&O^XW/1Y]B2CBP MS&H7T-US^U.(J\*T#Y,XOAK'2W#1 MJ2[)X1*,06YI&:CTWN1LMD[E]N;0/'CX\3ZYI^2_E?(R3 RUJUU^=[/Y=W=Q M\??2E&6S54>2 MSJX_C[]]VS3-\D;0H'P S4, 03G:485A*8:35"-7HM:\DTJV'OQ,U3'D]?<> M1.ZQ/^N_+G]X-T__^W_]?U!+ P04 " "82&A7!R1JC:,: 0"V PP %0 M ')PW/B-WN"&&:#_!U M=F8V9-D^H[UN2R.KS\Q&QXT*O"AQNT3JD"S9FD]_ 3[JH:IB 2B0XIR(X[8E M$LC\@?@AD4AD_M/_^O&T!"^\K+(B_^>?W']T?@(\IP7+\H=__NGW^\\P_NE_ M_'NR_@8T%73SROP57)<NBN?7,GMXK('G>'[_6/_;\B\.#U#"4P?&J>= A+T($NPQZ'A) M&H6)CUR<7CS\Q>4\)@YU(48QAHAR!Y(P<*$7DC!B 8E([#:-+K/\S[_(/PBN M.!#JY57SSW_^Z;&NG__RZZ_?OW__QQ^D7/YC43[\ZCF._VO_]$_=XS_VGO_N M-T^[29+\VOQV_6B5'7I0-.O^^A^_??E&'_D3AEE>U3BGLH,J^TO5_/!+07'= MH'Y2+G#T"?DOV#\&Y8^@ZT'?_<9D5[%N-R_H+)GPII&]:JU^?^3__5&5/STO>_^RQY.GA9I=E MN=.JE#*14KJAE/*_'>OLUS/$MR1OO2^K!>$:=;_:DG$(TZ_6Q+T7#,''%WBK MF[-%;C^H3SF;ZMM==W6VZ.-+;.NS*&J\G."SV'2S)?)2_N"+^%O7C6QH@$R; M?CKJWA*5_ZAYSGC+ECM-@XS]\T_B;XM5!1\P?EY\JPOZY^7S<\EIUE#WG5S6 MJF^7=]]^XT^$EXMZ_?TN> Y__]9WU;2GV=A/&FK51Z9GR:MB5=+-PO:T/+1: MB85*+FWQKSE^XM4S[EX08DLKH-7D7QJ!P;;$H!49_"R$KG[YIU\WJMK 4M\<"!#B:=^,<5?#O3!YXTF]J?<5;^#2]7_#>.JU7)Y6[YW\4F^?>\ M(!4O7V1GU_GSJJ[NN-0F6W8,P^FJ+,6^^P.NLNJ+$$K\IG[]JY#H2U%5USE= MKH2=]+%:/+A>+O&32^ MWM)9/I<_%K?X5;$YC4*[*LCG&JIW$M]IZ'[@S4EX^;3D/8$J/&FV2?C*:\&> MQ1.7/'I9UV5&5K6DX?OBJQ"^R&NAB'C_X3H7.W'1YX+[/(Q#[L#(=P.(?'D2 MQCF%V'-9F(91F,;!XH67I%"U\[5ET/FZMR49[^,6*DC+6^@ \)8"H"Y 7N1P M2P?Q6*N$IE6N/U"4Q-3W20 Y)1@BG$808X=#/R9NZH8X#7U?QX\SZC!-X>;Y MPJOJ+R"?X5"I;81&'8"1%THY05KA^YW'Y1OP=U4 O0[V-B/&\%G:5.CW/^GF MP!B>MT:^>4-Z2QBG3"Z)?ZMN>2GC/&1LHLM";BV^9#F_KOG3*3-3L949 M324A+7BIP):\8",P^$.*#!J9+?AI-=$Y,%,J3O_QH7CY5;3431+*-G-#M?U) M9H*FLOUWK_N:F:%V6Q:44E10I$ *"38R7X"U/E ,!)2/V5OQ3=&SM.!K=S_I>F\*SMOE MWK@=PU.M+!<$*ZR'.TYYUG@,+Y?+XKMD7='?5D!L.G.(9T>C#,?:!SS@CH7]B'\#?_(GE9/'XJR++X+>KC" M8CC%SQ#*(TY)#%R8)(@'(41]:BO%:2GT_G<)G;C\1!["]I( M?P&>6KD!Z04'M)-Q@+3RX.@6UMDEB M@IDE0T2KZTG-#Q-0WAH=1FV<&8NX<8R)?:(P9^K+G*WC.;X6=;<4L-UH&W'C!;&NYXQ<5+CZ+; MC_R%+XMGN0_Y]..9YQ5?,.PF/HI2&/I8[DT# N.8,A@EF":>[Q(4ICIL/]C; MW B\%[:9Y&PC+DA7N;P8#W@KMQXM#P.NQK368!R9/'<0W)(4?#J!G#8%*B%B MB=6&^YJ4J)34?LL]:B_I1P/\GK-R^?K0G3>\_O9G?5MFE%\]Y@^WM%:AB=.M MS(TCA+1K(@"C45M^,G%-\PM3"637($7-:O]R7.*TQEJ/.7=810 M$H<(!ZD//1QY$+E^*K:4L0_#R(V=.(T"!V,](V.XP[EQ2"5US+T<5668AE9<)^*/8T3P0BY%*+(IS!.O BZ#O-9A,,H0%JQ""J=SHUR MN@-/O 1E\8J78L)@N?>L+F1\MF:XM0KF:FQC&\EW"1K J1C XZ$#%V"CB\7@ M:@WD;,53JW0Y;0BU!@A[4=,Z[QK<:KR3T^SV$9=/F+Y^XTM.Z_;SX??EJJJ[ MTVSF1$Z*' <&?B2HB3 7QE%,(*8X(E$4)]0+5*A)O8-!*##J102/SZ3Q"QM^I^OU(Z[A.=%]2 5]+=R>U$!J\ M2ZG6TG1W*[4TV[EKJ?>F"1_?_FNQE$[2Y(TH/4]K;ER9DKR/R[A+5L8<,..GP];SKG)8<5UP&^%_)7\O[?&+H MJT7"B>.(W2Q$J>-"%&-A* ;(A3YU,4V#U L]);^92>=S8[0=X31FL2[F"I0W M(I(C,^*1.\ 7H!>^O4PT%=8:A#HBYA/QK57L]8C9$+Q!WM9MHPZC,,@<1YY=3I^')9]AP9//&IVAO--[/KY!T&C[*IXDB$IS:=P698R M&*!)P/3A=?-,EY3I4M[':OZX%[U>YNQ6#/=7\0%TN8!U$K*/T/_N^Q&9G#-T,R0J[G,;&SE35^#!&G330_(LA[N>G'[$L_ M^J]I]*^B\_HCKODZ6%DU[._(ZW-CSJV(?ES):P"-R$#*K![C=PRJ81*TA-(D M'+9!1>7ZBE8 WPD(C"+WCK4Y6":6V8_5./:I_&?W3WUK]].&NYC;96PDE;5X M*:7!7?43V [/>+N(C3SQ]<'2NLJNAL,9M]M/=##9A7PPH;8SL4('$=+^%A /TXI1 Y"8+$#3P8<2* MN+N]T@Y7&094Y5#5*DQC'[-V 8:MM& C[IE!*L,HZD:H6$-SRO"4XZC:#$U1 M@N9T7,IP,Q,'I2CIM!^1HO::H=^+/G*VD@G<[DLLW6J;O&UBFW93/_*R^T5S M3;3ZL@[E3U$<,^;X,/#E.7#JV%<>>[K8/U",^=>,4HB .(9*W41.2[%SBW,IG9>>SFS+L#1E_2HRNJ@J_';>PWE MR*1H=Q1'*&$]!NZ62-BJ:),R]QB@OJ7[4?HPW&/7N&Y:NTF;RMZ/Q5*\7+7; MDTM2U24^F6-#JZT93?"UO/+4%X#)6O%YU7ZG+@ O08, M^T7H=5XVFQF;TYNF2H#8IK7-;^W<]*:'>H,SFB-;0E^ X]Z+46:*/F"6IHM& MQY/.&7U WDX<@Q;.]=WV%7!O>=G'WF3TP^M5\?14Y%=+7%5-]KX%=R* ;DZ]2K(S$^@4>*BJ:--+P!Y M!:TFH%'EHJN@+6-Y[[\7[0]!>Q3:I=PT]NNJ#J6N/W>$ 1K;=)A^;,[P^6KB M:]W7J]K_._EX->$Y[MO5;<@T>]A+L7R1J;!W$V6W6_; P10SYL+ C0*(/!+" M&(7RUG;D!Z[/">%*T0=*OSPNF\I)!!--V>;3#M_:JYCQJX2"7<9\E$*=N"!%U$$R8 MPR%.$I>D 26^FD&FU>O<&&7GUF)[X?1H468 02%UT(C;41Z,8=(9#>*1R6== MDE'*?*S@LC";;L:"52,H:@QX)PJ-L@.S7J"4+ER#X5+*C4T7-*6KWT[HE/;+ M9I;B?AALL_,7N_[_70C6^IOXQZK4]F-IMCHCNNG<5MV&:TOVQJG52 ]Z\4?Q M:!E"9\DDTNU]4B/)$)JW9I-I,_JWNW[+GS-Y9G^?/7$F2R(63\]_P\O/2_R@ M>L-KH(FYV4&_?;V]WHX0:41N,WEN7;73*S;(,:Z)G$!(_:+(L8;>Z:K(";V.7Q8Y]>*9 M)1VWJ@?+,)K?\X)4O&RR5U_GSZM:9K,6NF;+K/G@[N399RGV7M)=7S7QUTT@ M3BJH\695WZ1?9$D@?\&=P(U0$D _C!R( L^#21R&D$QQ';*5YF+3S<$_X\>9B+RHH5DWXS5(*"WS#>HXCC;C:?G@. SAUY<>+ MG1+=30CDMKJ@U1?L*GP!UBHW!Z3515LRLHNGE'KWG\.7$Y^#>4'(<0?)=I7( MD:1]G]*1XT)_M)[DR-W:+#*IZ8D;;F1&Q'&TZN$83C8U5$:M?/@^+C0UQ=5J M'UIPD(F&^S!-F9?E\D=6J3K&#KPZMTWMEHCBBQ8]/F5YZ\F1$O]%W0=V"*;3 MOJ\S$1I_O@^ (V:]$->2EVL ""/OUJ'V)O-J#2BS[DP_V=%6_-)!Y_FQ M9"K-ETH1YPGA/L0^"2"*?0R)XP4P1BP.O=1#*%%.A72.('.CA_W:/*;$>F6AT8=9*L&0#HS/2+YW5_63)F6R M)VZR4I[[^Y :K,7(A(@)Z(> M=*G/(**-YY]2Z$5^3#R&JS5_4#G#"""68^C -> 11%,0PCIP4AH0Z4>2G M01)[W0!_RME_E>'M19UL<+G8%E(CCY;24_''H'Y>?$F3+XZ M-K@C^NG.2?NZ*7N:%X*$1!+B"4.HY$#_4!8_RAT*<0A]B!&D>^X,7=(XNJES3G: MU]Q<(%NB-GY_NBVL;E*;XPBKT80EW$8FBK>072E!9I XYB08UO+ '.]IXK0N M)U7>S])R^A6#F,'[1]Z45N_"KF(>>;$@ L@=ZD 4)PC&/'1AY&(H#4\V<_$8.3)O5;?)(3O#0X:P7KF>$P4EG?ZL]"+ MO3NL\&"4W9M7IHNG.RSK3N3;G"XP85"EG=B$X2=-TUB7V4N;_[!)CWVU*DLQ@ ON M$0]'+("QQX3Q[+@()IX70P>[**7"E@Y1M'CA)2G4$UD?[$GG8][N;[QO>B,H MR/*J+E==CC;:"JR;W_HPOFI[:PN8C4P 6V!U$<=7)V R2&X]"(*UY-:'>YDX MN?6@JOO)K87;E=F2@U%ZOM8_9\5;SP'.?U'?_[*BLYZRHV MIU'B"4((8!K(XN"R-$C,_ 0FD1/%*7-9&BJYX8QZGYW1T$G750N7:8L)!ZS$ MWW.-':GV&"CLW<=$=F2*D:(W!@7H*VEO22_XII-?'HUVZ&M7(]=&7,-+,";R M$_D1K(^ GMO!%,%!QX1VH].Y+DSUW7%N&#=R7CAZP:NO1=^T/%86-MOKIJR' M093Z<(OS6P$V\=E,B [RH@9E*SSHI3<+83\!K<)N\2T"%V#W/ MK &U7%;%#*RS@^)/=/,NL?)JJA\+H5=\VS 1\JF:Y(,ER1NAJJSFWWCYDE%^ MVX3'N0O.4A9R[$(G2K"P9ST,,4,.3!R'.(R0E#.E4Z-1I9P?ZW5B@JJ5LXLV M!#]G.7CEN*R.!V-,.+9JF^YW'[&1&;41'C;2[R;*V7;@D5>P_5RG)FA4O&C_ M S:CWND*;H=C3/43+8\Y%+:2,8\BX[0)F\>$>2^I\ZB=F2TE]^*UFW1+AN:N M3X(PPJD7PY Y8BD(60KC.,"01 ER$',3'G*=I>!@+W.C\N-EEN3!WO:_FSR* MH'[$^9O:3#H7LH9'0(VPS\9U9,(='U)M8AV$S!(Q'NYC4F(;5/,M,0T_K'_[ M\^9[M^%N/F7.O1@%-(:$, (1\A.( X2@ZSLA"^/(3ZBC>IUSI^6Y$;XK(Z!U9_*@MF=<@MQM;[);C0?5V+ZF>/@!@Z.,ZYR67!@1 M'WG[W^N\H=,#P77)&*_WTE,]J\B#^D6^=C\82S?$$]'BK]D ;>PC,C.\ M],^W3F%AZXSJ:#_3GC.=4G?OK.CD"X91[]E+QGC.JBM3F?IVUC)J1K7OX*/:(/?+G&V9#EUJ&W:SR5HC'OA: MY.5.$INV>C:ACLN12Z 3$PH1B3G$GB]V"HR',4H"PM)09_VW)MG<[(7M+%6; MA%/RM');?K.BY_:&4XUWWF601N8L2^-CGA;,%I:V\X&=+=?[) *S!>?1# M.C LE_FF?/O';+D2%LZ"8Q2Y09I %GD^1-Q+8,+< $:>RP+FX20*M'+X'.EG M;O3:B=5$1S(9YU%6,F 25%)FS4C)8] RAI,PY@'T7;'@B14N@(1X&"9>[(9^ MD@0X2/0N<%H =YH+G+V@#:972UQ5X%)^KEF.R]<69 !FV 0U%8H"\".O-ZL M$14BMG&A%Z"3TF()UV$8;)5J/=++M"59AU7=*[UZXG']*SNWO&BR#SIO7YL:KMY]N0)M$<3>N6>,ZX"%PAF?QF;B,/'/-(-&Z*7-$>:/K,&_; MFNS.RQ$EMB^V''O$(#3IZK6J,_HY(V4A+*S/)<[I8U;Q+@65&P0.#Q(&(\?' M$+F4PH0X8L/J.7Y F9NXOJ]\I7JPJ[E-X%98D';2@K075R/P91C;X;EL%[&1 MIW8'5B\H6$MJD@5M-Z"!KZ$T4#'0414OQ/DIX#(;W#+V2B;[>OKM[J@?[;)Y7'B!F&$$*0L=2%R9"QG$LJ: 1@3A#!U.#7PX^_W M-%-G?B\HR')!UKRJ-;WZ!R!5V\ 8(C11E4:Z"]N9\H_K;NL:Q7X'T]ZA M.*K@W@6*XT^:GN0_/R^;JQC"ZL+5X^=E\?U3^X-*,SQ%I:D9?;3;XC;'4D * M#'J)1XE9T8'(VKFT0I<3'U&K@[!_6JWQKOZ>O4OF>%F6'UZO<]:>@2ANW ^] M.S?CO\\DNG4#J[J0%Y&%P/(X<867ZGOX@V"=WLB?B]/H:]E)B.P=^IS"PVB# M?[#!R7;Y0^IL;_4'GSOS%+NMN-*6.NZV5Y[K<\>)/2CV^S%$V"60!)$'XS#P MD$-YS)S4Z%QZOZ^Y3?I3YYP#VN,I'CU0'7C%CB+Y<]':MZ+Q)DK 2,_%;D=;?&]]_19>%/+C= MI'YBB9^2- PAX01!Y*<,QHY/8,BCT$U<$OMZ_&$LR=S895T=_;_CI^?_N5,? M_>>?[IH??OSIEW56NZYHC1X9F0^;&E5-,A@C$UFOP\7V$%QTA5A:14"O"=BH M8CFMES5$+5>XUY=C4I(\&ZZW%'I^@V8$VR63J>Z+2]ID)/N(G#/DPD@88C7P)XY,G(VH529=[Y4L M()HV,F=B>]'? \=-1)$>5:H,@!HIV@)UHD/83EJ9#[B3%W0";UTPMEB&2@,> M2URFTN.DK*4!P5M^TGE5CXD8S_J]Y;?7)U(L%PGS(]]W$AB14)INH=CU!:D# M6>@'4==%*I\8;^W -L\-9($SDNCFAO_)4/ZKK@%M& MO-/.9?&7S13>;VF2B7I4@7XZ'G_ TO*_7_"^^?TBI@YU413#U">AF),)AL3W M$^A&$4MC'_$@P ;GB*K]S_1T<4M"D.6 -\*#IT9Z\0/Y2ZY[ZUAY2 RM@G,0 M?C_3H)4:M&*#+;E'-!!.(#66E7"LV_./6^_MG/UR*_Y<577ER^ M/#3Q9[1>X>7R]19G3"-^\T0S<[,9A+A0!C!^%?^_?.$E?N!OPA@[^8%40#O. M\Q2HIX^++.(Y,L_8A5+K#$D1)*/CI%-M3W:RI*CD]B&3ZBMFUL[E<]D'<6A:2.=-9!J=M-4PS/V<5DO[)93Y>+MR#3J :E?=U(.1O$QVX#4 MDM%UEBB3&F(V0'MKG%EITR#$_R,G]?6Z?&!?2AE?BNENMDR&Z,[MF.EZ M-4RTV540E'*NHYX6B 2^[WDNI"@15D=(.$R<-(&)'R :(,\5%HE6CLU#OU-JI-@_BJK93.QNMD1=;*1]L*H5*"04WKB,8 M+>;6',+ 5EK-@WU,FU%S2,V]9)J##QLFR1-M?9.I8+IL,4UX+<%^XE%9MR1* M4X@<[$ 2RU!EEF!*$ ]I'.E,_T.=S&WV-V;"1DC= O '4%2;[.=B,X5AO9%O MA(CD(0"LE7T_T,7$-=^/*[E?\'W@6;-9_I77;19]Z199> 'ES$L2Z/' @PC) MZI=N0& 2TB1(O$3,;K*H918$M>F]T[K6O%[W,>*9"*_[4GU9OTNJAI\: [8%.=QO.[K8OPLY=/,DK0+BAH'&N,Q]GF: M,A3:K'=094MTM]OVI#QW4*VW!'?X(0/WZ_'RYU]7DC5OTOLF'0&O%CX-*4]P M"HF'!>?A%,$XYA1B+K8RD1LDB"L==FGV.[?)+24'M33=T^XZQ/-&^ N0-^++ M[4_=*:#AZ=(8#07OY3@83[ S:MQ*Z]LFM]OP?EW#>S\JO!H>P7%@GLBU9P]N M/>>R6#U_SC>17(H1O@--S&W#T8D*I*R@$5:>I1:U/%)1#^(= MPFR8!RS"-3(%#"%E^8ZT(BA&P;I#[4X6J*N@W':0KLKC!A.]^,:735AHEX3_ MJQA]Y2E^Z.793>[BZ1GGKZ 7%72R BFLQNP^")3"O#X7H[%GM!$\>K-X" *S M^7NPQ>EF[I!".W-V\$'38Y+OEY3*2Q%RRUH6N?@K;1-PW90M25SGVT]D. ME[Q-/!;X+$TX32&+/0Q1@B.(.74A=P+7\:GK>TPI5-.*-'.CBHV)W.EQ[N)NYD6@O)7ANQ=2CPR-0JO'<^0"-3&!K;#H)1W#U#6-@B6R. M=#(IBPPK^I8>3CQ]MEO_,F=-LNG'8BG>K]I[UVLW8(ABG*;,AVXJQZ8]4ZW9N+-5++0_ECV9 M,=OM*8Z#&DW91W=DDK(#K'XY 2V<;!444.MTVI("6D#L%170>]N0J"0#WO%G M\3R%*4N])((R<")!";8\2%* QQ[*8\"US/( MB76R8Z5Y-'TRK(W(37K,PT5&-4,L3@^"(D%9P70B;I*R@BUA02LM:,6U7JU' M&1M;?'2ROVFI2%7]/192?M$X]WE=9M)E+].DR&S XC^2\%[P4I+E=ZG!-7]ALL_>7.OLMV_;JZO2A[D92U6PK[<5E-2 MX%"E%(QQ%#G4A4R>Y"$<8TA80J'C!*%/,6'<"_7.],81=&YT=_F"LV5SIU7F MOOLF5AMPUF7VT098]:3Q_8=M]+/*G2S;S6A)(W*C9N_#V[IY_W-C9K:Z@G6- MP$;;7\8OIS/VJ%@[/1U)S(G/7\<%>_\$=^3^SG!8'CYL])F#O3BE,':#$*+ M3R$AA$,_]GP\W2^>Z9Y_D_IQ:U/H_>77OXH%0C<+MI7A4Z.OZ4;C71(U"$X?GX0EVCK3%QX.$0^3$.(D91"YL0-C%#*(>>J%V'6\$&F5+#C5X=R, MOQUY@108K"4V/.LYB;D:G=I$ MQ)S\3\ZNBJJ^9/]WU1[C+GCH$9PB>8G#$7]$'$'"(PSCE#*/.<3Q,=,J&ZHA_KS49?0@TJZ&-.A135C@; M84CT*Y89HWFR"IE^R]-6%C/6?*]:F'E+^BGJ/OT0GBCZ]%3DS>73#YV[.?!3*WPH$>(?L%NHYK;^W(OY5^LNKWO" 5+YORY=?Y\ZH6 MOQ:Z9MQD^T-0([9W'-Z16='Z M<(YZ0#'2.-A.XV])NO?)_&\7VJ/% BQW,VTBXR]9SJ]K_E2)A<1E"0T<&/I! M %'D$IBPV($T#B@)7<\/J%(N"J+0Z3#MG(R\$DHS59DN,]A-\YT?%&GO\2R8[WX+.5\'B_8<-0H.PAS]*, MXKS>ZJ589C3CU<;&'HI!96ZG1L1 M;]GP6PKL3.-.!3+;BQ@+?QV;5.=NK'G#97" MB?9D S RY?7EX+<5 :H#8A)&?M[(:!QT3S9"$QUXGS52EHZ[K6 Z>.Q]7@_3 M'7];06+G&-Q.BV=ZY!OW3/6%O_"EVTVYD 4Q\GP.&8]3>?@FEJS0BZ"? B6W'[X&> MWL>)>USEHP[9@5?T V8,*CG.N'ZC7IE&O>*,\RS):+\"HZVZB^]2;?%$C<7S M*RO*5CX+R8J,@]'\.]+D9%-Q6*7M67GB2<,H,UR6KUG^<,>?B[+FK+W&<* $ M>N_"<4(_08D#"9;).E.9F!T'"?0]A[C,"Q(4:5V;TNQ_;O._%[^W G.N&.EN MBK^:^3PBJF,[8SJ)6T#[V(VG)FF;_0@W,YALA;]I]CYM;)P9-'N! M[&.PK[F1E!2V3RR[%A=(>75R7PS#J^ OM@?:R!QT'"^CI"'#P.FD$+$&X$3^ M6H,/3S._B!(BP]E&AIN8,/>(DBZ[F4C47C'-PHOK9N%M.[@JGIZ%]9G757,9 M)L0.BX+8@[Y/"$3413#Q<0)##W-A"Z:<8*27B'>@M[D1:O=);X0T*BLQ#+": MH6<-MI$I51LQ@_2["DA8R\ [U-?$27@5U-[/PZORDAEM--??4S$)9>U57KYD M5)A_-^GG+,4@9'[ PH!%$#N)8)G8@[ZR\9R^1F "^1X[T',C,! 2__RR751% MW;5_&K_37GZKT(W,:T.H60X2U8+&Z S@=.N3'0NM/ZWRGF=>X14S MMOA2Y _WO'R226U^PW67U.:./^/7]BI-VEV+&(W0#3V?(A3 M%$"4AB'$D2 4'B$4TI"FFOXD$R'FQB_B>POTR,0(>C66&1O0D>E'B@^E_$W5 MO0O0J?!Z :2L0 AKCX#.@0(0D.I"V/&,41<5F-&%,.0!#A@41I[5*L:\XG^YD9=V^?VC9!&'O)3(*LQ MET7H1B8I;=3,8XB'L; =1WRDM_>))1Y6_6@\\8G7#%PNWW')?L]9N7Q]V$K^ M]U0KNUJ.-3 W-A RJ% M+D3(3R%V0A_Z$0VBP NHXJ6A(^W/;8ZW(H)&1M +J3;'CR$X/+LMX#+VH;<6 M),I3^83B Y-8O-E.8O&7S20^UMXDT_>$,OW$/?68F1'_[SQ[>)11B2^\Q _\ MZTIZ/V[2-L?DS:JN:IRS+H4379=)#@.74>)3Z*-(F/9^2B%)Q3^#Q//=B)*8 M.EHIDHRDF-OT_\CSXBG+Y2>K9^.;C8&:Y3\ZLB,32"\_Z!0 K09-RI-&!["E M1%]<9XS:UFFT+B)A23,'(X5\HV?*CQN=%7(Q]H!.PFF;KIL@?<:;OE'#A& M=Y0J(Z%EL1Q3V7,??O3=D% *GA+JF ](2EB,S M@"F,YLY(!5QL>R2'NGP?MZ0""$=]DRKOZCLH^YNF-^FGLI1!PIMNOBCF%%5M M9D:??R]N4\*R+ 6+%ZMJ^0H:OU%31N?IF>=5FQQZ.^CIB\U4H;K &;GNE#J8 MS(NGH^ZV0T_KO=%#&NZXG'5,FNJ?A1QX*<\;%WX2N9SA&":OD-SI:W,/A\5%;R*=$?70S_U@\Q,Y0M+(W M,1+O$A\Q"./TL1*'Q9EKW,0@>&?$4 RW:\:P-_4C;\B[Y(]B=^'5.BR?^ M>UYRO)3%S_ZU6$IWQU]%UU^*JKK)MPYORJP2O_JXDOGV;WF9%>PKKV_2>_QC MD48N9@F/(<(T$LR;X=2U0==M@6>,QSVUXC M\"!TJ60%#=P7IP-I48(*B[\P68>PTCS8'7W@?1H& 8\))+'K090P!C$7 ^^' M+HM9'*4!T[T.;<% M8=L)N!;48CSG+N":+E4[,(Y,QD8(6HKM/(C)J/&=NSW.(,;S( 1J<9Z'7ST[ M%^;'%;\O_I85R\:+>)/^JR##*^FT+5^_X.\:(:"Z[%Z>B(L^'_[17>TSDQS[@&07T*_FG,@P# M:4'5VS SFN2>8I-X0'J,%F$0(3'$&&&(780"1"(W9EK.[?TN MYD9;S<8J6XMX 6KI2?U9[)I>.2ZK7_3,H@.0JEE!YP$U,LLT&%UO823ELV?M M'-?=DG%SH(-);9GC"KXU70:>M#''99;A+M[!92$G,>>0DT1&F80^)&[*( T9 M3DC $A=KA;X>ZVB6\WW[6Y:B&@:6' 779,Z;03;US%=#ZTP*V(=B%"+8ZN8= MZ6!?V6%2./"\08K=+O.03.=+>=84,[X21H?X87U?9@\/7+IHNA2_1?GIQW-6 M=E;(+:[E(=(BD(7H0R2/7QB#*(A2&!,20X=[F%*&J>\DREEXSQ9G;C1S^?!0 M\@XD1Y\?^0Y>&Z%!E1L3Q4S$UD:M6%FFGXLQMX?];J C3(7H%=' M&#)KA;H]$1 J@8U.X"8%G5:3#I-&*N%)AVNB;,-3#)M>>F)K* ]F,#Z_E^F2 M'%M#9"DZF29N5 &/0A> M:T"%-N=1K%5XX7& HX9\1U(D@2 ME$(4AQXDG,4P9^13L^3.I0,('GK8S)IPK 8"7WD;+7D,E/EME^KVN17)A$+ M QZE,*"!!Q&G@L(P83 D&+DD"AC2NP%YNLNY\=6WU=,3;B\N?2C*LO@NEAG- MP$P%G-6HR2YZ(S-2+ZQ$;O=BQ&[6_OLF!-9J/.3)G\_II('J[Y&IDL=)NPEZ,=1!)'C!Q"G MD?BG&Q$2N<*"0EHU,C7[GQLM715+H4TA72XO'&PI W#.=O[=Q(F"^A'G8/34VC?BHW\7G)#?"_\F9W/7*4Z;;DC]EJR?!MLVC5;62,UMZ\JJO MO%X@/^))R"A,<>3+Y. NC 7K0122P*&!B]+ -0^CTI9G;JRXI0!@G08-*RX+ M89!DG?3-H4]S.W$IMVQ-!*:\E'A.-);^4*JQX(0#-#(][L5V;0]6KPWXN=/G MEV;8VG?Z86N4N@!"K;$BP8SQ'25@3%^:=XPK,X9N./S,O%E+46J-\72=BTXK M(4[KH>2TE)%4U7VQ,P& 41!$L)$ M[.A:[?-WC/'G8G(_HL M=F6V[=M.AO2-YUE12M-E05&4<(()=&,OA@@181A@&D*/)@'S$\8;B; MN:WM:RG;RI>Z^ZXC6*IMI\Y':.3%<"-@DZN]$;'9!MG;\@QC8&DG<>-I@._%;MN157>3\MFVX923.%H$O)C[R$20A%QL"GX40ARR" <8X MCG$B,S$K;PB.]3*W:;^6$_33O^PDU;#-CD*J8$C; &KDV;_!J),1W%G$2,," MM8'51#:D 69ZAM\I+ 9-MZ,O3V=\G9)_QWPZ^;"9 =3OYWNSZSJ_>>;R9#A_ M: ^:UO59HMBGS(T#2)@?0<3#!"9!)*C2\S!QO9@0K)5\3[GGN?'EUK%=T4O< MWUYH7-H9)MFR273U%ST+2GTPU(RJ42 >F6E[F<'/O=2_2*37@O?Q\&/4Q-'& MRY)-IM[OI&::-AQO+3?]!DQW<2\\7_%J$44,^ MCWTOU L8[1N>&P7U_%YONE5EO;@M"[:B3=31-UZ^9)3WA5.HYU$:QPG$# G[@"4))!'#,.4L M#&E*'2?U5.;>8"]SFXB=H,VZWTFJ&=DX#.KP3+4&UY+)K:1>/]/5'M9/=MA$C][R,NWN]&CD,SSPZMQF<1L;*V4L MRJ?F +.353\MX2&@AB>Q!8Q&GK[F\&@E$!P P2A'X*'V)DL#.*#,=J:_H@.CU?+:$T\KR]+W&3 M^WTK6OQBIQ#]/H!6)[0"2D83>ZC=R2:X@G+;$UWE<8.3C*LEKJJ[.\XX?Y+C M]ZTNZ)_=W1<719%/.8,.::IEB,UPD@1$&.1^R&+DQE&L9)"?ZFANO-"("N[ M1MBNM+*&JWX(5X43#4MHC

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end

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

    •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